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 ABSTRACT	  
The	  unfolded	  protein	  response	  (UPR)	   is	  a	  cellular	  mechanism	  that	  detects	  the	  accumulation	  
of	  misfolded	  proteins	  within	  the	  endoplasmic	  reticulum	  (ER).	  	  In	  mammalian	  cells,	  the	  UPR	  is	  
mediated	   by	   three	   ER-­‐transmembrane	  proteins:	   PERK,	   IRE1	   and	  ATF6.	   	   Early	   studies	   in	   the	  
field	  provided	  evidence	  for	  the	  role	  of	  BiP,	  the	  major	  ER	  Hsp70	  chaperone,	  in	  UPR	  activation	  
by	   binding	   to	   the	   luminal	   domains	   of	   PERK,	   IRE1	   and	   ATF6	   and	   maintaining	   them	   in	   an	  
inactive	  state.	  	  However	  the	  underlying	  mechanism	  of	  ER	  stress	  sensing	  and	  UPR	  activation	  is	  
not	  yet	  understood.	  	  	  
This	   thesis	   presents	   (i)	   the	   novel	   X-­‐ray	   crystal	   structure	   of	   PERK	   luminal	   domain	   and	   (ii)	   a	  
biochemical	  study	  of	  the	  unconventional	  interaction	  between	  BiP	  chaperone	  and	  the	  luminal	  
domains	  of	  PERK	  and	  IRE1	  in	  vitro.	  	  Firstly,	  the	  structure	  of	  PERK	  luminal	  domain	  was	  solved	  
in	  two	  oligomeric	  states:	  dimers	  and	  tetramers.	  	  Compelling	  evidence	  is	  provided	  for	  a	  role	  of	  
tetramer	   formation	   in	   directing	   downstream	  UPR	   signalling.	   	   Secondly,	   the	   unprecedented	  
and	  unconventional	  direct	  binding	  of	  PERK	  and	  IRE1	  luminal	  domains	  to	  BiP	  is	  demonstrated.	  	  
The	  binding	   surface	  was	  mapped	   to	   the	  nucleotide-­‐binding	  domain	   (NBD)	  of	   BiP.	   	   As	   such,	  
this	  points	  away	  from	  a	  substrate-­‐chaperone	  interaction	  and	  rather	  implies	  BiP	  as	  an	  explicit	  
UPR	  signalling	  component.	  	  Upon	  binding	  to	  CH1	  unfolded	  protein,	  BiP	  is	  released	  from	  PERK	  
and	   IRE1	   luminal	   domains.	   	   BiP	   dissociation	   from	   PERK	   and	   IRE1	   is	   known	   to	   lead	   to	   their	  
activation.	  
Based	  on	  the	  work	  presented	  in	  this	  thesis	  a	  novel	  mechanism	  of	  ER	  stress	  sensing	  and	  UPR	  
activation	   by	   PERK	   and	   IRE1	   is	   proposed.	   	   BiP	   NBD	   normally	   interacts	   with	   the	   luminal	  
domains	   of	   PERK	   and	   IRE1	   and	   represses	   UPR	   signalling.	   	   During	   ER	   stress,	   binding	   of	  
unfolded	  proteins	  to	  BiP’s	  substrate	  binding	  domain	   leads	  to	  the	  dissociation	  of	  BiP-­‐luminal	  
domain	   complexes.	   	   As	   such,	   the	   luminal	   domains	   are	   free	   to	   intertwine,	  mediated	   by	   an	  
extended	  α-­‐helix,	  and	  form	  active	  tetramers	  competent	  for	  cytoplasmic	  UPR	  signalling.	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  trisphosphatase	  
Au	   	   gold	  	  
AUC	   	   analytical	  ultracentrifugation	  
BAG	   	   Bcl2-­‐associated	  athanogene	  	  
BAP	   	   BiP-­‐associated	  protein	  	  
BBF2	   	   box	  B-­‐binding	  factor	  2	  	  
BBF2H7	   	   BBF2	  human	  homolog	  on	  chromosome	  7	  
Bcl2	   	   B-­‐cell	  lymphoma	  2	  
BiP	   	   immunoglobulin	  binding	  protein	  
bZIP	   	   basic	  leucine	  zipper	  
Ca	   	   calcium	  	  
Cam	   	   chloramphenicol	  
CCall	   	   overall	  correlation	  coefficient	  	  
CCanom	   	   anomalous	  correlation	  coefficient	  	  
CCD	   	   charge-­‐coupled	  detector	  
CD4	   	   cluster	  of	  differentiation	  4	  
cDNA	   	   complementary	  DNA	  
CH	   	   immunoglobulin	  heavy	  chains	  
CH1	  	   	   first	  constant	  domain	  of	  immunoglobulin	  heavy	  chain	  
CHOP	   	   CAAT/enhancer-­‐binding	  protein	  homologous	  protein	  
CL	   	   immunoglobulin	  constant	  light	  chain	  	  
CNX	   	   calnexin	  	  
CPY	   	   misfolded	  carboxypeptidase	  Y	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CPY*	   	   constitutively	  misfolded	  CPY	  	  
CREB-­‐H	   	   cyclic	  AMP	  responsive	  element-­‐binding	  protein	  hepatocyte	  specific	  
CRT	   	   calreticulin	  	  
DMSO	   	   dimethyl	  sulphoxide	  
DNA	   	   deoxyribonucleic	  acid	  	  	  
DNase	   	   deoxyribonuclease	  	  
DSF	   	   differential	  scanning	  fluorimetry	  
DTT	   	   dithiothreitol	  
ECL	   	   enhanced	  chemilluminescence	  
EDEM	   	   ER-­‐degradation-­‐enhancing	  a-­‐mannosidase-­‐like	  protein	  
EDTA	   	   ethylenediaminetetraacetic	  acid	  
EGS	   	   elythlene	  glycolbis(succinimidylsuccinate)	  	  
eIF2α	   	   eukaryotic	  Initiation	  Factor	  2α	  
ER	   	   endoplasmic	  reticulum	  
ERAD	   	   ER	  associated	  degradation	  
ERdj	   	   ER	  localised	  DnaJ	  proteins	  	  	  
ERSE	   	   ER	  stress	  response	  element	  
FEM	   	   feature	  enhanced	  maps	  
FL	   	   full-­‐length	  
FOM	   	   figure	  of	  merit	  	  
G1	   	   gap	  1	  	  	  
GADD34	   	   growth	  arrest	  and	  DNA	  damage	  34	  	  
GCN2	   	   general	  control	  non-­‐depressible-­‐2	  
Grp78	   	   glucose-­‐regulated	  protein	  78	  kDa	  
GTP	   	   guanosine	  triphosphate	  	  	  
h	   	   hour	  
H2O2	   	   hydrogen	  peroxide	  
HAC1	   	   homologous	  to	  Atf/Creb1	  
HERP	   	   homocysteine-­‐responsive	  ER-­‐resident	  protein	  
Hg	   	   mercury	  
HRD1	   	   ERAD-­‐associated	  E3	  ubiquitin-­‐protein	  ligase	  
HRI	   	   haem-­‐regulated	  inhibitor	  	  
HRP	   	   horseradish	  peroxidase	  
Hsp	   	   heat	  shock	  protein	  
HspBP1	   	   Hsp	  binding	  protein	  1	  	  
I3C	   	   5-­‐amino-­‐2,4,6-­‐triiodoisophthalic	  acid	  
IPTG	   	   isopropyl	  β-­‐D-­‐1-­‐thiogalactopyranoside	  
IR	   	   infrared	  
IRE1p	   	   inositol	  requiring	  kinase	  1	  	  
ITC	   	   isothermal	  titration	  calorimetry	  
K	   	   potassium	  
Kan	   	   kanamycin	  
Kras2	   	   kirsten	  rat	  sarcomA-­‐2	  viral	  	  
LB	   	   luria-­‐bertani	  	  
LED	   	   light	  emitting	  diode	  
LLG	   	   log-­‐likelihood	  gain	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LS	   	   light	  scattering	  
LSQ	   	   least	  square	  
MAD	   	   multiple	  anomalous	  dispersion	  
MALDI-­‐TOF	   matrix-­‐assisted	  laser	  desorption/ionisation-­‐time	  of	  flight	   	  
MALS	   	   multi-­‐angle	  light	  scattering	  
MEF	   	   mouse	  embryonic	  fibroblast	  
Mg	   	   magnesium	  	  
MHC	   	   major	  histocompatibility	  complexes	  
MIR	   	   multiple	  isomorphous	  replacement	  	  
MIRAS	   	   multiple	  isomorphous	  replacement	  with	  anomalous	  scattering	  
MPD	   	   2-­‐Methyl-­‐2,4-­‐pentanediol	  
MST	   	   microscale	  thermophoresis	  
MW	   	   molecular	  weight	  
NBD	   	   nucleotide-­‐binding	  domain	  
NCS	   	   non-­‐crystallographic	  symmetry	  	  
NEF	   	   nucleotide	  exchange	  factor	  	  
NHS	   	   N-­‐hydrosuccinimide	  
NMR	   	   nuclear	  magnetic	  resonance	  	  
NPS	   	   sodium	  phosphate	  salts	  	  
Nrf2	   	   nuclear	  factor-­‐like	  2	  	  
NTA	   	   nitrilotriacetic	  acid	  
OASIS	   	   old	  astrocyte	  specifically	  induced	  substance	  
OD	   	   optical	  density	  
P58IPK	   	   P58	  inhibitor	  of	  protein	  kinase	  	  
PARP	   	   poly	  ADP	  ribose	  polymerase	  	  
PBS	   	   phosphate	  buffered	  saline	  
PCR	   	   polymerase	  chain	  reaction	  
PDI	   	   protein	  folding	  isomerases	  
PEG	   	   polyethylene	  glycol	  
PEI	   	   polyethylenimine	  
PERK	   	   PKR-­‐like	  ER	  kinase	  
PIC	   	   pre-­‐initiation	  complex	  	  
PKR	   	   double-­‐stranded	  RNA	  activated	  protein	  kinase	  
PPI	   	   peptidyl-­‐prolyl	  cis-­‐trans	  isomerases	  
pQC	   	   pre-­‐emptive	  quality	  control	  	  	  
Pt	   	   platinum	  
R	  factor	   	   residual	  factor	  
RI	   	   refractive	  index	  
RIDD	   	   regulated	  IRE1-­‐dependent	  decay	  
RNA	   	   ribonucleic	  acid	  
RNase	   	   endoribonuclease	  	  
RONN	   	   regional	  order	  neural	  network	  
ROS	   	   reactive	  oxygen	  species	  
RT	   	   room	  temperature	  	  
S1P	   	   site-­‐1	  protease	  
S2P	   	   site-­‐2	  protease	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SAD	   	   single	  anomalous	  dispersion	  
SBD	   	   substrate-­‐binding	  domain	  
SDS-­‐PAGE	   	   sodium	  dodecyl	  sulphate	  polyacrylamide	  gel	  electrophoresis	   	  
Se	   	   selenium	  
SE	   	   standard	  error	  
SEC	   	   size	  exclusion	  chromatography	  
SERp	   	   surface	  entropy	  reduction	  prediction	  
SIR	   	   single	  isomorphous	  replacement	  	  
SIRAS	   	   single	  isomorphous	  replacement	  with	  anomalous	  scattering	  	  
spFRET	   	   single-­‐pair	  Förster	  resonance	  energy	  transfer	  	  
SPR	   	   surface	  plasmon	  resonance	  
SSM	   	   secondary-­‐structure	  matching	  	  
T-­‐coffee	   	   tree	  based	  consistency	  objective	  function	  for	  alignment	  evaluation	  	  
TFZ	   	   translation	  function	  Z-­‐score	  
Tisp40	   	   transcript	  induced	  in	  spermiogenesis-­‐40	  
Tm	   	   melting	  temperature	  
TRAF2	   	   TNF	  receptor	  associated	  factor	  2	  	  
U	   	   units	  
UGT1	   	   UDP-­‐glucuronosyltransferase	  1	  	  	  
uORF	   	   upstream	  open	  reading	  frames	  
UPR	   	   unfolded	  protein	  response	  
UPRE	   	   UPR	  element	  
UV	   	   ultraviolet	  
V0	   	   void	  volume	  	  
Ve	   	   elution	  volume	  	  
Vm	   	   matthews	  coefficient	  
Vs	   	   solvent	  content	  
VSVG	   	   vesicular	  stomatitis	  virus	  G	  
W	   	   tungsten	  
WRS	   	   wolcott-­‐rallison	  syndrome	  
XBP1	   	   bZIP-­‐containing	  X-­‐box-­‐binding	  protein	  1	  	  
XBP1s	   	   spliced	  XBP1	  	  
Zn	   	   zinc	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 AMINO	  ACID	  ABBREVIATIONS	  
Alanine	   Ala	   A	  
Arginine	   Arg	   R	  
Asparagine	   Asn	   N	  
Aspartate	   Asp	   D	  
Cysteine	   Cys	   C	  
Glutamate	   Glu	   E	  
Glutamine	   Gln	   Q	  
Glycine	   Gly	   G	  
Histidine	   His	   H	  
Isoleucine	   Ile	   I	  
Leucine	   Leu	   L	  
Lysine	   Lys	   K	  
Methionine	   Met	   M	  
Phenylalanine	   Phe	   F	  
Proline	   Pro	   P	  
Serine	   Ser	   S	  
Threonine	   Thr	   T	  
Tryptophan	   Trp	   W	  
Tyrosine	   Tyr	   Y	  
Valine	   Val	   V	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1.1 Protein	  folding,	  processing	  and	  quality	  control	  	  
Eukaryotic	   secretory	   and	   membrane	   proteins	   attain	   their	   functional	   and	   assembled	  
conformation	   in	   the	   endoplasmic	   reticulum	   (ER)	   prior	   to	   transit	   to	   the	   Golgi	   apparatus.	  	  
Nascent	   polypeptide	   chains	   co-­‐translationally	   transverse	   the	   ER	   membrane	   though	   the	  
hydrophilic	   interior	   of	   the	   Sec61	   translocon	   complex	   (SecY	   in	   prokaryotes),	   a	   protein	  
conducting	   channel	   [1].	   	   Once	   located	   in	   the	   ER	   lumen,	   a	   complex	   system	   of	   molecular	  
chaperones,	   folding	   enzymes	   and	   co-­‐factors	   assist	   in	   the	   folding,	   post-­‐translational	  
modification,	  quality	  control	  and	  trafficking	  of	  the	  newly	  synthesized	  polypeptide	  chains	  [2].	  	  
The	  cycle	  of	  a	  typical	  misfolded	  protein	  in	  the	  ER	  is	  discussed	  in	  this	  chapter	  and	  summarised	  
in	  Figure	  1-­‐1.	  
1.1.1 Folding	  of	  nascent	  polypeptide	  chains	  
In	   vitro	   studies	   carried	   out	   in	   the	   early	   1960s	   by	   Anfinsen	   and	   co-­‐workers	   revealed	   that	  
protein	  folding	  requires	  solely	  the	  information	  contained	  in	  the	  amino	  acid	  sequence	  [3].	  	  The	  
process	   of	   protein	   folding	   has	   been	   difficult	   to	   study.	   	  Most	   eukaryotic	   proteins	   fold	   on	   a	  
millisecond	  or	  even	  microsecond	  time	  scale,	  which	  makes	  them	  hard	  to	  capture	  and	  examine	  
kinetically	   and/or	   structurally.	   	   Chain	   folding	   is	   often	   started	   by	   the	   burial	   of	   non-­‐polar	  
residues	   or	   patches	   found	   in	   the	   core	   of	   proteins	   as	   a	   means	   of	   minimizing	   free	   surface	  
energies	   [4].	   	  Folding	  occurs	   in	  a	  heterogeneous	  and	  co-­‐operative	   fashion.	   	   It	   is	  directed	  by	  
several	   factors	   including	  predetermined	   folding	  units,	  or	   foldons,	   sequential	   stabilization	  of	  
folding	  intermediates	  and	  misfolding	  errors.	  	  
Although	  nascent	  polypeptide	  chains	  sample	  several	  metastable	  folding	  intermediates,	  some	  
defined	   factors	   limit	   the	   number	   of	   conformations	   available	   for	   them	   to	   trial.	   	   Constraints	  
include	   (i)	   defined	   hydrophilic	   interactions	   (salt	   bridges	   and	   disulphide	   bonds),	   (ii)	   physical	  
restrictions	   (vectorial	   folding	   from	   N-­‐	   to	   C-­‐terminus,	   tethering	   of	   the	   N-­‐terminal	   signal	  
sequence	   to	   the	   ER	  membrane	   and	   the	  width	   of	   the	   ribosomal	   tunnel	   and	   Sec61	   channel	  
which	   can	   accommodate	   limited	   secondary	   structures),	   and	   (iii)	   timing	   of	   events	   (usage	   of	  
rare	   codons	   and	   ribosome	   stalling	   which	   affect	   translation	   speed,	   cleavage	   of	   the	   signal	  
sequence	  and	  disulphide	  bond	  formation	  to	  control	  protein	  maturation	  and	  secretion)	  [5-­‐7].	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Since	   Anfinsen’s	   initial	   studies,	   a	   multitude	   of	   helper	   molecules	   and	   post-­‐translational	  
processes	   that	   edit	   and	   ensure	   the	   folding	   process	   have	   been	   uncovered.	   	   However,	   his	  
thermodynamic	   theory	   stating	   that	   protein	   chains	   will	   always	   fold	   until	   the	   lowest	   energy	  
(native)	  conformation	  is	  achieved	  remains	  undisputed.	  	  Some	  exceptions	  are	  known,	  such	  as	  
amyloids,	  which	   can	   form	  even	   lower	  energy	   conformations	   as	  macromolecular	   aggregates	  
[4].	  	  	  
1.1.2 Processing	  of	  folding	  polypeptides	  
1.1.2.1 Chain	  folding	  and	  post-­‐translational	  modifications	  in	  the	  ER	  
In	   the	   ER	   lumen	   molecular	   chaperones,	   folding	   and	   glycosylation	   enzymes	   assist	   in	   the	  
processing	   of	   the	   nascent	   polypeptide	   chains.	   	   Firstly,	   chaperones	   prevent	   aggregation	   of	  
unfolded	  chains,	  facilitate	  protein	  maturation	  and	  retain	  folding	  proteins	  in	  the	  ER	  until	  they	  
reach	  their	  functional	  and	  assembled	  conformation.	  	  Chaperones	  are	  discussed	  in	  more	  detail	  
in	   Chapter	   1.2.	   	   Secondly,	   folding	   enzymes,	   or	   foldases,	   accelerate	   the	   kinetics	   of	   protein	  
folding.	   	   These	  mainly	   involve	  protein	   folding	   isomerases	   (PDI)	   and	  peptidyl-­‐prolyl	  cis-­‐trans	  
isomerases	   (PPI)	   [2].	   	   PDIs	   catalyse	   the	   formation	   of	   disulphide	   bonds	   between	   Cysteine	  
residues	  of	   proteins.	   	   PPIs	   assist	   in	   the	   interconversion	  of	   cis	  and	   trans	   isomers	   of	   peptide	  
bonds	  with	  Proline	  residues.	  	  Finally,	  protein	  glycosylation	  occurs	  in	  all	  three	  domains	  of	  life,	  
with	   prokaryotic	   glycosylation	   being	   a	   relatively	   recent	   discovery	   [8].	   	   It	   is	   estimated	   that	  
approximately	   half	   of	   all	  mammalian	  proteins	   are	   glycoproteins	   [9].	   	  Glycosylation	   involves	  
the	  attachment	  of	  sugar	  molecules	  via	  glycosidic	  bonds	  to	  the	  nitrogen	  atom	  of	  Asparagine	  
side	   chains	   (N-­‐linked)	   or	   oxygen	   atom	   of	   Serine/Threonine	   side	   chains	   (O-­‐linked).	  	  
Glycosylation	   is	   fundamental	   for	   correct	   protein	   folding	   [9].	   	   Firstly,	   the	   attached	  
oligosaccharides	   occupy	   a	   large	   volume	   on	   the	   surface	   of	   proteins	   and	   can	   shield	   from	  
surrounding	   proteins	   thus	   acting	   as	   chaperones.	   	   Secondly,	   they	   stabilize	   protein	  
conformations	   by	   interacting	  with	   the	   peptide	   backbone	   or	   by	   increasing	   solubility	   due	   to	  
their	   hydrophilic	   nature.	   	   Thirdly,	   the	   sequential	   trimming	  of	   the	   terminal	   glucose	   residues	  
allows	  for	  the	  calnexin	  (CNX)/calreticulin	  (CRT)	  quality-­‐control	  cycle	  [10].	  	  The	  CNX/CRT	  cycle	  
ensures	  that	  only	  proteins	  that	  reach	  their	  fully	  folded	  native	  structure	  and	  macromolecular	  
assembly	   are	   exported	   to	   their	   respective	   cellular	   compartment.	   	   Misfolded	   proteins	   are	  
directed	  towards	  degradation	  pathways.	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1.1.2.2 ER	  associated	  degradation	  	  
Despite	   the	   numerous	   mechanisms	   that	   exist	   to	   ensure	   proper	   folding	   and	   processing,	  
proteins	   may	   fail	   to	   reach	   their	   folded	   and	   functional	   conformation.	   	   Within	   the	   ER,	  
terminally	  misfolded	  or	  unassembled	  N-­‐linked	  glycoproteins	  are	  diverted	  from	  the	  CNX/CRT	  
cycle	  and	  are	  targeted	  for	  ER	  associated	  degradation	  (ERAD)	  [2,11].	  	  The	  main	  mechanism	  by	  
which	  non-­‐glycosylated	  misfolded	  proteins	  are	  directed	  towards	  ERAD	  is	  by	  interaction	  with	  
the	   ER	   chaperone	   Immunoglobulin	   Binding	   Protein	   (BiP),	   which	   recognises	   their	   unfolded	  
regions	   [12].	   	   In	   addition,	   homocysteine-­‐responsive	   ER-­‐resident	   protein	   (HERP)	   and	   ER-­‐
degradation-­‐enhancing	  α-­‐mannosidase-­‐like	  protein	  (EDEM)	  have	  been	  shown	  to	  divert	  non-­‐
glycosylated	  misfolded	  proteins	  towards	  ERAD	  pathways	  [13,14].	  
After	   recognition	   and	   targeting	   for	   ERAD,	   misfolded	   proteins	   are	   retrotranslocated,	   or	  
dislocated,	   from	   the	   ER	   lumen	   to	   the	   cytosol.	   	   At	   the	   cytosolic	   face	   of	   the	   ER	   p97	   protein	  
directs	   the	   dislocation	   of	   the	   misfolded	   substrate	   [15].	   	   p97	   serves	   as	   a	   ratchet	   to	   pull	  
misfolded	  polypeptide	  chains	  across	   the	  ER	  membrane,	  using	  adenosine	  triphosphate	   (ATP)	  
hydrolysis	  as	  the	  driving	  force.	  	  Moreover,	  p97	  also	  acts	  as	  a	  platform	  to	  which	  several	  ERAD-­‐
related	   enzymes	   are	   recruited.	   	   These	   include	   ubiquitin-­‐chain	   modifying	   enzymes,	   chain	  
elongation	   factors	  and	  deubiquitinases	   that	  all	   assist	   in	   the	  polyubiquitination	  of	  misfolded	  
proteins	   [9].	   	   Polyubiquitination	   consists	   in	   the	   successive	   addition	   of	   ubiquitin	   molecules	  
onto	   Lysine	   residues	   by	   ubiquitin-­‐activating,	   -­‐conjugating	   and	   -­‐ligating	   enzymes.	  	  
Polyubiquitinated	  proteins	  are	  transferred	  to	  the	  26S	  proteasome	  by	  shuttle	  proteins	  where	  
peptidases	  proteolytically	  cleave	  the	  unfolded	  substrates	  into	  single	  amino	  acids	  that	  can	  be	  
recycled	  for	  new	  protein	  biosynthesis	  [16].	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Figure	  1-­‐1.	  Protein	  misfolding	  within	  the	  ER	  
After	  translocation	  of	  nascent	  polypeptide	  chains	  through	  the	  Sec61	  channel,	  and	  possible	  modification	  by	  PPI	  and	  
PDI	   enzymes,	   improperly	   folded	   proteins	   are	   recognised	   by	   BiP	  Hsp70	   chaperone.	   	   BiP	   assists	   in	   the	   folding	   of	  
misfolded	   proteins.	   	   Many	   nascent	   chains	   also	   undergo	   N-­‐glycosylation	   (branched	   sugar	   moiety	   shown).	   	   N-­‐
glycosylation	  allows	  proteins	  to	  enter	  the	  CNX/CRT	  cycle.	  	  Removal	  of	  the	  terminal	  glucose	  by	  Glucosidase	  II	  allows	  
exit	   from	   the	  CNX/CRT	   cycle.	   	  Misfolded	   glycoproteins	   can	   re-­‐enter	   the	  CNX/CRT	   cycle	   through	   addition	  of	   the	  
terminal	  glucose	  by	  UDP-­‐glucuronosyltransferase	  1	   	   (UGT1).	  Terminally	  misfolded	  proteins	  are	  directed	  towards	  
ERAD	  pathways	   through	  removal	  of	  a	  mannose	   residue	  by	  EDEM.	   	  Proteins	  are	  dislocated	   from	  the	  ER	   into	   the	  
cytosol	  (putatively	  through	  Sec61,	  HRD1	  and	  Derlin-­‐1	  channels).	  	  In	  the	  cytosol,	  p97	  pulls	  the	  misfolded	  proteins	  
across	   the	  ER	  membrane.	   	  Polyubiquitination	  of	  misfolded	  proteins	   targets	   them	  to	   the	  26S	  proteasome	  where	  
they	   are	   proteolytically	   cleaved	   into	   single	   amino	   acids.	   	   These	   are	   recycled	   and	   used	   in	   the	   synthesis	   of	   new	  
polypeptide	  chains	  by	  the	  translating	  ribosome.	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1.2 Molecular	  chaperones	  of	  the	  ER	  
Cellular	  compartments	   in	  which	  synthesis	  or	  translocation	  of	  proteins	  occurs,	  which	   include	  
the	   ER,	   contain	   a	   high	   concentration	   of	   molecular	   chaperones.	   	   These	   have	   been	   highly	  
conserved	  throughout	  evolution	  and	  mainly	  belong	  to	  the	  heat	  shock	  protein	  (Hsp)	  families	  
but	  also	  include	  lectins	  and	  ribosome-­‐associated	  chaperones	  [10].	  	  Hsps	  are	  found	  in	  all	  living	  
organisms	   from	   prokaryotes	   to	   higher	   eukaryotes	   and	   constitute	   up	   to	   5%	   of	   cellular	  
proteins.	   	   Their	   roles	   vary	   from	   intracellular	   chaperoning	   and	   housekeeping	   functions	   to	  
mediating	  immune	  and	  stress	  responses.	  	  Hsps	  have	  been	  grouped	  into	  families	  according	  to	  
their	   molecular	   weight	   and	   sequence	   similarities:	   small	   Hsp,	   Hsp40,	   Hsp60	   (chaperonins),	  
Hsp70,	  Hsp90,	  and	  Hsp100.	  	  Molecular	  chaperones	  of	  the	  ER	  are	  summarised	  in	  Table	  1-­‐1.	  
1.2.1 Hsp70	  chaperones	  and	  BiP	  	  
Hsp70s	  are	  a	  highly	  conserved	  and	  ubiquitous	  class	  of	  ATP-­‐regulated	  chaperones	  that	  play	  an	  
important	  role	  in	  proteostasis	  [17].	  	  Cellular	  functions	  of	  Hsp70s	  include	  chaperoning	  nascent	  
protein	  chains,	  assisting	  in	  protein	  import	  into	  organelles	  and	  disassembly	  of	  macromolecular	  
complexes	  and	  aggregates.	   	  Hsp70s	  are	  essential	  for	  survival	  during	  stress	  conditions.	   	  Their	  
functions	   are	   mediated	   by	   Hsp70	   interaction	   with	   the	   extended	   hydrophobic	   regions	   of	  
substrate	  misfolded	  proteins.	   	  Sequence	  analysis	  of	  peptides	   identified	  as	  Hsp70	  substrates	  
revealed	   a	   hydrophobic	   binding	   motif	   composed	   of	   a	   heptapeptide	   sequence	   rich	   in	  
Tryptophan,	   Phenylalanine	   and	   Leucine	   residues	   [18].	   	   Protein	   folding	   defects	   are	   thus	  
monitored	   through	   Hsp70	   chaperone	   interaction	   with	   aromatic	   and	   hydrophobic	   residues	  
that	   are	   normally	   found	   in	   the	   core	   of	   correctly	   folded	   and	   assembled	   proteins.	   	   Hsp70s	  
recognise	   and	   transiently	   bind	   to	   these	  misfolded	   or	   non-­‐native	   protein	   substrates.	   	   They	  
assist	  in	  their	  folding	  mainly	  by	  preventing	  their	  irreversible	  aggregation	  thus	  allowing	  folding	  
and	  assembly.	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Table	  1-­‐1.	  Molecular	  chaperones	  of	  the	  ER	  
The	  name	  and	  major	  functions	  of	  the	  yeast	  and	  mammalian	  orthologues	  of	  the	  ER	  chaperones	  are	  listed.	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DnaK	  is	  the	  canonical	  Hsp70	  of	  Escherica	  coli	  and	  has	  been	  used	  for	  a	  large	  part	  of	  functional	  
and	  structural	  studies	  of	  Hsp70s.	  	  Given	  the	  high	  sequence	  conservation	  of	  E.	  coli	  DnaK	  with	  
mammalian	   Hsp70s	   (51%	   sequence	   identity	   between	   DnaK	   and	   Homo	   sapiens	   BiP),	   these	  
studies	  are	  likely	  to	  also	  be	  relevant	  to	  the	  eukaryotic	  orthologues.	  
The	  major	   chaperone	  of	   the	  ER,	  often	   referred	   to	  as	   its	  master	   regulator,	   is	   the	  Hsp70	  BiP	  
(Kar2p	   in	   Saccharomyces	   cerevisiae)	   [12,19].	   	   BiP	   is	   also	   known	   as	   the	   glucose-­‐regulated	  
protein	  78	  kilo	  Dalton	   (kDa)	   (Grp78)	  or	  HspA5.	   	  BiP	  was	   first	   identified	   in	   stable	   complexes	  
with	  unassembled	  immunoglobulin	  heavy	  chains	  (CH),	  hence	  its	  name	  [20].	  	  More	  specifically,	  
the	   first	   constant	   domain	   of	   immunoglobulin	   heavy	   chains	   (CH1)	   represents	   the	   main	   BiP	  
binding	  site.	  	  On	  its	  own,	  CH1	  is	  intrinsically	  unfolded	  and	  it	  becomes	  structured	  upon	  binding	  
of	  its	  cognate	  partner,	  the	  immunoglobulin	  constant	  light	  chain	  (CL)	  [21].	  	  Unfolded	  CH1	  stably	  
binds	   to	   BiP	   in	   the	   presence	   of	   adenosine	   diphosphate	   (ADP)	   with	   an	   affinity	   in	   the	   low	  
micromolar	  range	  [22-­‐26].	  	  In	  the	  assembled	  antibody,	  CL	  and	  CH1	  are	  covalently	  linked	  via	  a	  
disulphide	   bridge	   [25].	   	   Once	   this	   disulphide	   bridge	   is	   formed,	   BiP	   can	   no	   longer	   associate	  
with	  CH1.	   	   Indeed,	  CH1	  oxidation	   inhibits	   its	  association	  with	  BiP.	   	  Additionally,	  BiP	  does	  not	  
cycle	  on	  and	  off	  from	  unassembled	  CH1	  but	  requires	  the	  presence	  of	  CL	  for	  release	  from	  BiP	  
[23].	   	   This	   has	   been	   shown	   in	   vivo	   by	   immunoprecipitation	   experiments,	   which	   used	   BiP	  
adenosine	   trisphosphatase	   (ATPase)	   mutants	   as	   kinetic	   traps.	   	   Together	   these	   results	  
demonstrate	  that	  CH1	  is	  a	  specific	  substrate	  for	  BiP	  chaperoning	  activity.	  	  CH1	  and	  CH1-­‐derived	  
peptides	   have	   been	   used	   for	   many	   studies	   to	   characterise	   the	   interaction	   of	   BiP	   with	  
unfolded	  substrates.	  
In	  addition	  to	  protein	  folding,	  BiP	  also	  plays	  a	  role	   in	  (i)	  entry	  of	  nascent	  chains	   into	  the	  ER	  
lumen,	   (ii)	  homeostasis	   of	   ER	   calcium	   (Ca2+),	   (iii)	   delivery	   of	  misfolded	   substrates	   for	   ERAD	  
and	  (iv)	  mediating	  stress	  responses.	  	  The	  latter	  is	  thoroughly	  discussed	  in	  Chapter	  1.3.	  	  Firstly,	  
BiP	  assists	  in	  the	  entry	  of	  newly	  synthesized	  polypeptides	  into	  the	  ER	  lumen.	  	  This	  is	  achieved	  
by	   opening	   of	   the	   Sec61	   channel,	   co-­‐	   and	   post-­‐translational	   insertion	   of	   the	   nascent	  
polypeptide	  into	  the	  translocation	  complex	  [27].	  	  BiP	  also	  acts	  as	  a	  molecular	  ratchet	  to	  pull	  
the	  growing	  chain	  across	  the	  ER	  membrane.	  	  Secondly,	  BiP	  minimizes	  efflux	  of	  Ca2+	  from	  the	  
ER	  by	  occluding	  the	  Sec61	  pore	  when	  it	  is	  not	  being	  used	  [28].	  	  Finally,	  the	  role	  of	  BiP	  in	  ERAD	  
remains	   somewhat	  elusive.	   	   In	  yeast	  expression	  of	  mutant	  Kar2p	   forms	  has	  been	  shown	   to	  
reduce	  degradation	  of	  ERAD	  substrates	  [29,30].	  	  Thus,	  it	  was	  first	  speculated	  that	  BiP	  plays	  a	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role	   in	   the	   selection	  of	  ERAD	  substrates.	   	   Since,	  hypothesised	   roles	   for	  BiP	   in	  ERAD	   include	  
misfolded	  protein	   ‘solubilisation’,	  or	  prevention	  of	  aggregation,	  which	  would	  allow	  them	  to	  
fit	  through	  the	  retrotranslocation	  channel	  [27,31].	  	  Alternatively	  BiP	  may	  deliver	  substrates	  to	  
the	  Sec61	  channel.	   	  However,	  the	  role	  for	  BiP	  in	  ERAD	  has	  always	  been	  an	  interpretation	  of	  
results	  rather	  than	  a	  direct	  observation.	  	  In	  addition,	  since	  the	  same	  BiP	  regions	  are	  involved	  
in	  binding	  both	  ERAD	  substrates	  and	  the	  Sec61	  channel	  the	  accuracy	  of	  the	  proposed	  models	  
has	  further	  been	  questioned	  [31].	  	  	  
BiP	  knockout	  mice	  exhibit	  severe	  developmental	  defects	  and	  are	  embryonically	  lethal	  at	  day	  
3.5	  [32].	  	  Abnormal	  BiP	  function	  has	  been	  linked	  to	  many	  disease	  states	  including	  infectious	  
diseases,	   inherited	   syndromes,	   neurological	   disorders	   and	   tumours	   [33].	   	   To	   name	   a	   few	  
examples,	   BiP	   is	   fundamental	   for	   the	   initiation	   and	   progression	   of	   cancerous	   cells	   in	  
fibrosarcoma	  and	  mammary	  tumour	  models	  [34,35].	   	  Experimentally,	  BiP	  can	  protect	  breast	  
cancer	  cells	  against	  ER	  stress-­‐induced	  apoptosis,	  whereas	  inhibition	  of	  its	  function	  sensitizes	  
glioma	  cells	   to	  chemotherapy	  treatments	   [36,37].	   	  Clearly	  BiP	   is	  an	  essential	  ER	  component	  
and	   plays	   a	   critical	   role	   in	   cellular	   homeostasis.	   	   Further	   characterising	   its	   mechanism	   of	  
action	   is	   fundamental	   and	   will	   aid	   in	   its	   exploitation	   as	   a	   drug	   development	   target,	   in	  
particular	  for	  chemotherapy.	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1.2.2 Conformational	  cycling	  of	  Hsp70s	  
1.2.2.1 Structure	  of	  Hsp70	  sub-­‐domains	  
Hsp70	  proteins	  are	  composed	  of	  an	  N-­‐terminal	  nucleotide-­‐binding	  domain	  (NBD)	  connected	  
by	  a	  flexible	  hydrophobic	  linker	  to	  a	  C-­‐terminal	  substrate-­‐binding	  domain	  (SBD).	  	  The	  affinity	  
and	  kinetics	  of	  substrate	  binding	  to	  the	  SBD	  is	  modulated	  by	  the	  catalytic	  ATPase	  activity	  of	  
the	  NBD	   [38].	   	   In	   their	   natural	   resting	   state,	  Hsp70s	   exist	   in	   an	  ATP-­‐bound	  open	   form	   and	  
have	   low	  affinity	   for	  unfolded	  substrates.	   	  Upon	  substrate	  binding	  to	  the	  SBD,	  hydrolysis	  of	  
the	  bound	  ATP	  induces	  conformational	  changes	  to	  confer	  high	  affinity	  for	  the	  bound	  peptide.	  	  	  
The	   ATPase	   activity	   of	   Hsp70s	   is	   key	   for	   their	   function.	   	   This	   has	   been	   highlighted	   in	   a	  
multitude	  of	  biochemical	  and	  cellular	  published	  studies,	  only	  some	  of	  which	  are	  mentioned	  
here.	   	   Substrate	   binding	   stimulates	   ATP	   hydrolysis	   by	   DnaK	   approximately	   10-­‐fold;	   similar	  
rates	   have	   been	   measured	   for	   BiP	   [22,39,40].	   	   Indeed,	   BiP	   interaction	   with	   substrates	   is	  
dependent	  on	  the	  presence	  of	  ADP.	  	  Addition	  of	  ATP	  decreases	  affinity	  for	  substrates	  by	  10	  to	  
50-­‐fold	   and	   can	   stimulate	   the	   release	   of	   bound	   substrates	   [18,23,38,41].	   	   Functional	  
mutations	   in	   the	  SBD	  affect	  Hsp70	  ATPase	  activity,	  whereas	  mutations	  of	  key	  catalytic	  NBD	  
residues	  inhibit	  the	  release	  of	  bound	  substrates	  and	  secretion	  of	  assembled	  immunoglobulins	  
[21,42-­‐44].	   	   Although	   the	   functions	   of	   Hsp70s	   are	   biochemically	   well	   defined,	   recent	  
structural	   studies	   have	   been	   key	   to	   understanding	   Hsp70	   allosteric	   cycling	   and	   how	   this	  
affects	   their	   chaperoning	   functions.	   	   Figure	   1-­‐2	   illustrates	   the	   chaperoning	   cycle	   of	   BiP	  
discussed	  in	  detail	  in	  this	  chapter.	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Figure	  1-­‐2.	  BiP	  chaperoning	  cycle	  
(1)	   In	   its	   ‘resting’	   ATP-­‐bound	   substrate-­‐free	   state,	   BiP’s	   NBD	   (pink)	   and	   SBD	   (teal)	   are	   docked	   and	   confer	   low	  
substrate	  affinity.	   	   (2)	  Upon	  binding	  of	  misfolded	  protein	   substrates	   (dark	  purple),	  hydrolysis	  of	   the	  bound	  ATP	  
induces	  a	  conformational	  change	  in	  BiP.	  	  The	  delivery	  of	  misfolded	  proteins	  and	  ATP	  hydrolysis	  can	  be	  facilitated	  
by	  Hsp40	  co-­‐chaperones	  (orange),	  which	  bind	  to	  BiP’s	  SBD.	  	  (3)	  In	  the	  ADP-­‐bound	  state	  the	  SBD	  adopts	  a	  closed	  lid	  
conformation,	  which	   traps	   the	   bound	   peptide	   and	   confers	   high	   substrate	   affinity.	   	   BiP	   assists	   in	   folding	   of	   the	  
misfolded	  protein.	  	  (4)	  Once	  the	  native	  conformation	  is	  reached,	  the	  folded	  protein	  exits	  the	  cycle.	  	  (5)	  Nucleotide	  
exchange	  factors	  (NEF)	  (purple)	  bind	  to	  BiP’s	  NBD	  and	  catalyse	  exchange	  of	  ADP	  for	  ATP	  so	  that	  BiP	  returns	  to	  its	  
‘resting’	  state.	  	  In	  the	  diagram,	  grey	  shading	  of	  BiP	  refers	  to	  its	  conformation	  in	  the	  previous	  step.	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In	  the	  past	  two	  decades,	  many	  structures	  of	  Hsp70	  NBDs	  and	  SBDs	  have	  been	  solved	  by	  X-­‐ray	  
crystallography	   and	   Nuclear	   Magnetic	   Resonance	   (NMR).	   	   These	   have	   been	   captured	   in	  
various	   functional	   conformations.	   	   Overall,	   these	   structures	   are	   consistent	   as	   to	   their	  
structural	   arrangement	   and	   support	   the	   known	  mechanisms	   of	   ATP	   binding/hydrolysis	   and	  
substrate	  capture/release	  of	  Hsp70	  chaperones.	  
Hsp70	  NBD	   consists	   of	   two	   large	   globular	   sub-­‐domains	   (NBD-­‐I	   and	  NBD-­‐II)	   that	   are	   further	  
subdivided	   into	   two	   smaller	   regions	   (A	   and	   B	   for	   each	   sub-­‐domain)	   (Figure	   1-­‐3A)	   [17].	  	  
Nucleotides	   bind	   in	   complex	  with	   one	  magnesium	   (Mg2+)	   and	   two	   potassium	   (K+)	   ions	   in	   a	  
crevice	  formed	  between	  NBD-­‐I	  and	  NBD-­‐II.	  	  The	  structures	  of	  the	  NBD	  in	  the	  apo,	  ATP,	  ADP,	  
and	   adenosine	   5’-­‐(β-­‐γ-­‐imido)triphosphate	   (AMPPNP)	   (a	   non-­‐hydrolysable	   ATP	   analogue)-­‐
bound	  forms	  have	  been	  solved	  [45-­‐47].	  	  Surprisingly,	  they	  are	  all	  very	  similar	  and	  they	  do	  not	  
reveal	  any	  nucleotide-­‐dependent	  conformational	  change.	  	  This	  may	  be	  due	  to	  the	  transiency	  
of	   some	   of	   the	   intermediate	   states	   and/or	   their	   dependence	   on	   the	   adjacent	   SBD	   for	   the	  
correct	  structural	  assembly.	  	  In	  fact,	  the	  NBD	  is	  joined	  to	  the	  SBD	  by	  a	  highly	  conserved	  linker.	  	  
Interestingly,	  when	   the	   SBD	  was	   crystallised	   together	  with	   the	   linker,	   the	   existence	   of	   two	  
structural	  variants	  was	  revealed	  [48].	   	  This	  proposed	  a	  role	   for	   the	  SBD	   in	   the	  ATPase	  cycle	  
and	  allosteric	  regulation	  of	  Hsp70s,	  and	  not	  exclusively	  in	  substrate	  binding,	  for	  the	  first	  time.	  
The	  SBD	  is	  composed	  of	  a	  compact	  β-­‐sandwich	  domain	  (SBD-­‐β)	  that	  contains	  a	  hydrophobic	  
substrate-­‐binding	  cleft	  and	  a	  C-­‐terminal	  α-­‐helical	  domain	  (SBD-­‐α)	  termed	  the	  lid	  (Figure	  1-­‐3B)	  
[17,48].	   	   The	   unfolded	   substrates	   bind	   to	   two	   loops	   of	   SBD-­‐β	   (L1,2	   and	   L3,4)	   through	  
extensive	   hydrogen	   bonding	   and	   van	   der	   Waals	   interactions.	   	   Hydrophobic	   interactions	  
between	  two	  outer	  loops	  of	  SBD-­‐β	  (L1,2	  and	  L5,6)	  and	  the	  helices	  αA	  and	  αB	  of	  SBD-­‐α	  allows	  
for	  movement	  of	  the	  lid,	  which	  opens	  and	  closes	  the	  substrate-­‐binding	  cavity.	  
	   	  
	   	  
	  
	  





Figure	  1-­‐3.	  Structure	  of	  BiP	  sub-­‐domains	  
BiP	   is	   a	   Hsp70	   chaperone	   composed	   of	   an	   N-­‐terminal	   NBD	   and	   a	   C-­‐terminal	   SBD.	   	   A	   highly	   conserved	   linker	  
connects	  the	  two	  domains.	  
(A)	  X-­‐ray	  crystal	  structure	  of	  ATP-­‐bound	  BiP	  NBD	  (PDB:	  3LDL)	  [45].	  	  The	  NBD	  consists	  of	  two	  sub-­‐domains	  (I	  and	  II),	  
which	   are	   both	   further	   divided	   into	   two	   regions	   (A	   and	   B).	   	   Nucleotides	   bind	   between	   NBD-­‐I	   and	   NBD-­‐II	   by	  
coordination	  with	  one	  Mg2+	  and	  two	  K+	  ions	  (no	  density	  for	  these	  observed	  in	  this	  crystal	  structure).	  
(B)	  X-­‐ray	  crystal	  structure	  of	  substrate-­‐bound	  DnaK	  SBD	  (PDB:	  1DKX)	  [48].	  	  The	  SBD	  consists	  of	  a	  substrate	  binding	  
β-­‐sandwich	  (SBD-­‐β)	  and	  an	  α-­‐helical	  lid	  (SBD-­‐α).	  	  Hydrophobic	  interactions	  between	  SBD-­‐αB	  and	  two	  SBD-­‐β	  loops	  
(L3,4	  and	  L5,6)	  mediate	  docking	  of	  the	  two	  sub-­‐domains.	  	  The	  main	  residue	  side	  chains	  involved	  are	  shown.	  	  This	  
closes	  the	  SBD-­‐α	  lid	  to	  trap	  the	  substrate	  between	  two	  SBD-­‐β	  loops	  (L1,2	  and	  L3,4).	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1.2.2.2 Allosteric	  regulation	  
To	   address	   the	   question	   of	   how	   ATP-­‐cycling	   in	   the	   NBD	   and	   substrate	   binding	   to	   the	   SBD	  
confer	  changes	  to	  the	  adjacent	  SBD	  and	  NBD	  respectively,	  studying	  full-­‐length	  Hsp70s	  is	  key.	  	  
Hsp70s	   structures	   comprising	   both	   the	   NBD	   and	   SBD	   have	   been	   reported.	   	   These	   include	  
DnaK	   from	   Thermus	   thermophilus	   and	   Geobacillus	   kaustophilus,	   Bos	   taurus	   Hsc70,	   and	   S.	  
cerevisiae	   Hsp110	   [49-­‐51].	   	   These	   structures	   are	   surprisingly	   incompatible	   amongst	  
themselves	   and	   their	   validity	   has	   been	   somewhat	   disputed.	   	   Firstly,	   Hsp110s	   are	   Hsp70-­‐
related	  proteins	  locked	  in	  the	  ATP-­‐bound	  state.	  	  Thus	  they	  are	  not	  necessarily	  representative	  
of	  Hsp70s,	  despite	   their	   structure	  being	   interpreted	  as	   such.	   	   Secondly,	   the	   location	  where	  
the	   NBD	   and	   SBD	   are	   linked	   varies	   by	  more	   than	   10	   Ångströms	   (Å),	   and	   in	   the	   case	   of	  G.	  
kaustophilus	   DnaK	   they	   are	   not	   even	   docked.	   	   Thirdly,	   the	   oligomers	   formed	   by	   these	  
proteins	   in	   the	   crystal	   lattice	   are	   non-­‐biologically	   relevant.	   	   Finally,	   all	   the	   proteins	   used	  
contained	  truncations,	  mutations	  or	  deletions	  in	  their	  sequences.	  
More	  recently,	  four	  NBD-­‐SBD	  constructs	  of	  E.	  coli	  DnaK	  have	  been	  studied	  by	  crystallography	  
and	   NMR	   [52-­‐55].	   	   These	   studies	   are	   more	   in	   agreement	   as	   to	   their	   findings	   and	   they	  
elegantly	  demonstrate	  how	  the	  conformation	  and	  function	  of	  Hsp70	  NBD	  and	  SBD	  are	  tightly	  
coupled.	   	   In	  the	  ATP-­‐bound	  substrate-­‐free	  state	  the	  NBD	  and	  SBD	  are	  docked	  (Figure	  1-­‐4A).	  	  
Both	  adopt	  an	  open	  conformation	  within	  their	  respective	  sub-­‐domain	  structures.	  	  Binding	  of	  
substrates	  to	  the	  SBD	  promotes	  ATP	  hydrolysis	  in	  the	  NBD	  via	  subtle	  movements	  of	  the	  inter-­‐
domain	   linker	   region.	   	   This	   orients	   residues	   in	   the	   nucleotide-­‐binding	   pocket	   optimally	   for	  
catalysis.	   	   Binding	   of	   substrates	   and	   hydrolysis	   of	   ATP	   reverses	   the	   docking	   of	   the	   two	  
domains	  (Figure	  1-­‐4B).	  	  When	  independent	  from	  the	  NBD,	  the	  substrate-­‐bound	  SBD	  adopts	  a	  
compact	  conformation	  in	  which	  SBD-­‐α	  and	  SBD-­‐β	  are	  compactly	  sandwiched	  together	  closing	  
the	   lid	   and	   conferring	   the	   high	   affinity	   for	   peptides.	   	   These	   results	   illustrate	   how	   the	   sub-­‐
domains	  of	  Hsp70s	   communicate	  by	  an	  allosteric	  mechanism	  during	  nucleotide	  cycling	  and	  






	   	  
	  
	  




Figure	  1-­‐4.	  Allosteric	  regulation	  of	  BiP	  chaperone	  	  
(A)	  X-­‐ray	  crystal	  structure	  of	  ATP-­‐bound	  (PDB:	  4B9Q)	  E.	  coli	  DnaK	  Hsp70	  [54].	   	  Binding	  of	  ATP	  to	  the	  NBD	  brings	  
sub-­‐domains	  IB	  and	  IIB	  closer	  so	  as	  to	  trap	  the	  bound	  substrate	  whereas	  sub-­‐domains	  IA	  and	  IIA	  separate.	   	  This	  
creates	  a	  hydrophobic	  cleft	  to	  which	  the	  linker	  (green)	  binds	  to.	  	  This	  induces	  a	  conformational	  change	  in	  the	  SBD	  
so	  that	  the	  SBD-­‐α	  lid	  is	  docked	  onto	  the	  NBD.	  	  In	  this	  conformation,	  the	  substrate-­‐binding	  cleft	  of	  SBD-­‐β	  is	  exposed	  
and	  BiP	  has	  low	  affinity	  for	  misfolded	  substrates.	  
(B)	  X-­‐ray	  crystal	  structure	  of	  ADP	  plus	  substrate-­‐bound	  (PDB:	  2KHO)	  E.	  coli	  DnaK	  Hsp70	  [53].	  	  Misfolded	  substrates	  
bind	  to	  SBD-­‐β,	  which	  stimulates	  ATP	  hydrolysis.	  	  In	  this	  conformation,	  NBD-­‐IA	  and	  NBD-­‐IIA	  move	  closer	  together	  
so	  that	  the	  linker	  can	  no	  longer	  be	  accommodated.	  	  The	  ‘free’	  linker	  extends	  allowing	  the	  two	  domains	  to	  move	  
independently	  of	  each	  other.	  	  This	  results	  in	  the	  docking	  of	  SBD-­‐α	  lid	  onto	  SBD-­‐β,	  which	  traps	  the	  bound	  substrate	  
and	  confers	  high	  affinity.	  	  Conformational	  changes	  are	  highlighted	  with	  dashed	  red	  arrows.	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The	   conformational	   changes	   that	   BiP	   undergoes	   upon	   binding	   nucleotides	   and	   substrates	  
have	   been	   elegantly	   illustrated	   in	   a	   recent	   single-­‐pair	   Förster	   resonance	   energy	   transfer	  
(spFRET)	  study	  [26].	  	  In	  the	  AMPPNP-­‐bound	  state,	  the	  separation	  between	  the	  NBD	  and	  SBD-­‐
β	  is	  short	  indicating	  the	  two	  domains	  are	  tightly	  coupled,	  as	  expected.	  	  The	  distance	  between	  
SBD-­‐β	  and	  SBD-­‐α	  is	  broad	  indicative	  of	  opening	  of	  the	  lid.	  	  On	  the	  other	  hand,	  in	  the	  apo	  and	  
ADP-­‐bound	  states,	   the	  distance	  between	  the	  NBD	  and	  SBD-­‐β	  widens	  and	   that	  between	  the	  
SBD-­‐α	  and	  SBD-­‐β	  becomes	  narrower.	  	  This	  represents	  a	  closed	  lid	  and	  high	  substrate	  affinity	  
conformation.	  	  These	  results	  are	  in	  agreement	  with	  known	  conformational	  changes	  in	  Hsp70	  
cycling,	  discussed	  more	  in	  detail	  below.	  
1.2.2.3 Hsp70	  ATP-­‐bound	  substrate-­‐free	  state	  
In	   the	  ATP-­‐bound	   state,	   binding	  of	   the	   inter-­‐domain	   linker	   to	   a	  hydrophobic	   cleft	   between	  
Hsp70	  NBD-­‐I	  and	  NBD-­‐II	  compacts	  the	  distance	  between	  the	  NBD	  and	  SBD	  and	  docks	  the	  two	  
domains	   (Figure	   1-­‐4A)	   [52,54,55].	   	   Indeed,	   mutagenesis	   of	   the	   linker	   has	   highlighted	   its	  
importance	  in	  allosteric	  coupling	  of	  the	  NBD	  and	  SBD	  [56].	  	  Docking	  of	  the	  NBD	  and	  SBD	  leads	  
to	  major	   conformational	   changes	   in	   both	   domains.	   	  Most	   importantly,	   at	   least	   in	   terms	   of	  
biological	   function,	   is	   the	  opening	  of	   the	  SBD-­‐α	   lid	   [52,55,57].	   	  This	  confers	  a	   low	  substrate	  
affinity;	  bound	  substrates	  are	  released.	  	  Substrate	  release	  and	  domain	  docking	  also	  induces	  a	  
conformational	  change	  within	  the	  NBD.	  	  Early	  biochemistry	  work	  on	  full-­‐length	  DnaK	  showed	  
that	   nucleotide	   cycling	   affects	   its	   susceptibility	   to	   proteolysis	   and	   alters	   the	   fluorescence	  
signature	   of	   a	   conserved	   Tryptophan	   residue	   (Trp102)	   [58,59].	   	   These	   experiments	   mirror	  
changes	   in	   the	  surrounding	  physical	  and	  chemical	  environment	  of	   the	  NBD	  respectively.	   	   In	  
agreement,	   the	   NMR	   spectra	   for	   the	   ATP-­‐bound	   isolated	   NBD	   comports	   in	   large	   chemical	  
shifts	  when	  compared	  to	  those	  of	  the	  ATP-­‐bound	  NBD-­‐SBD	  construct	  [52].	  
However,	   the	   flexibility	   of	   the	   ATP-­‐bound	   state	   of	   full-­‐length	   Hsp70s	   has	   inhibited	   its	  
structural	   characterisation	   until	   recently.	   	   By	   engineering	   disulphide	   bonds	   Kityk	   and	   co-­‐
workers	   were	   first	   able	   to	   lock	   DnaK	   in	   this	   closed	   ATP-­‐bound	   conformation,	   without	  
affecting	  its	  activity	  [54].	  	  As	  such	  they	  solved	  the	  crystal	  structure	  of	  the	  intermediate	  state.	  	  
Shortly	   after,	   and	   in	   agreement	   with	   Kityk’s	   structure,	   Qi	   and	   co-­‐workers	   crystallised	   full-­‐
length	   wild-­‐type	   DnaK	   in	   the	   presence	   of	   ATP	   [55].	   	   These	   structures	   unveiled	   that	   ATP-­‐
binding	   induces	  rotation	  of	  NBD-­‐II	  and	  results	   in	  the	  closure	  of	  the	  space	  between	  Lobes	   IB	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and	  IIB,	  so	  as	  to	  trap	  the	  bound	  ligand,	  and	  separation	  of	  Lobes	  IA	  and	  IIA.	  	  The	  latter	  creates	  
a	  crevice	  for	  binding	  of	  the	  linker,	  as	  well	  as	  a	  surface	  for	  binding	  of	  SBD-­‐β.	  	  Thus	  SBD-­‐α	  and	  
SBD-­‐β	   become	   separated	   and	   attain	   the	   open	   lid	   conformation	   capable	   of	   accommodating	  
new	  substrates.	  	  
1.2.2.4 Hsp70	  substrate	  binding,	  ATP	  hydrolysis	  and	  the	  ADP-­‐bound	  state	  
Upon	  substrate	  binding,	   the	  ATP-­‐bound	  compact	  conformation	   is	  disrupted	  and	  the	  ATPase	  
activity	  of	  Hsp70s	  is	  increased	  by	  2	  to	  10-­‐fold	  (Figure	  1-­‐4B)	  [17].	  	  Biochemical	  data	  has	  found	  
the	  linker	  domain	  to	  be	  both	  necessary	  and	  sufficient	  to	  stimulate	  the	  ATPase	  activity	  of	  the	  
NBD.	   	   Firstly,	   mutant	   proteins	   in	   which	   a	   short	   conserved	   sequence	   of	   the	   linker	   domain	  
(VLLL)	   is	   either	   deleted	   or	   mutated	   (to	   VDDL)	   results	   in	   full-­‐length	   DnaK	   proteins	   with	  
defective	  ATPase	  activity	  [52].	   	  Secondly,	  truncated	  proteins	  consisting	  only	  of	  the	  NBD	  plus	  
the	  linker	  region	  show	  very	  similar	  ATPase	  activity	  to	  full-­‐length	  DnaK	  [52].	  	  Thirdly,	  mutation	  
studies	  have	  highlighted	  key	  residues	  that	  affect	  NBD-­‐SBD	  communication	  [53].	  	  These	  data,	  
together	  with	  NMR	  spectra	  of	  the	  ATP,	  ADP	  and	  substrate-­‐bound	  domain	  conformations	  have	  
led	   to	  a	  proposed	  mechanism	   in	  which	  substrate	  binding	   loosens	   the	   inter-­‐domain	  contact.	  	  
In	  this	  conformation,	  some	  element	  of	  the	  linker	  and/or	  SBD	  remains	  in	  contact	  with	  the	  NBD	  
to	  stimulate	  its	  catalytic	  activity.	  	  Once	  again,	  the	  transiency	  of	  this	  substrate-­‐bound	  state	  in	  
which	   ATP	   has	   not	   yet	   been	   hydrolysed	   makes	   it	   a	   challenging	   target	   for	   crystallisation	  
studies.	  	  Indeed,	  in	  the	  ADP-­‐bound	  state	  the	  NBD	  and	  SBD	  move	  independently	  of	  each	  other	  
in	  a	  highly	  flexible	  manner	  as	  measured	  using	  NMR	  techniques	  [52,53].	  	  Here,	  the	  SBD	  exists	  
in	   a	   closed	   lid	   conformation	  where	   the	  SBD-­‐α	   domain	   is	  docked	   to	   the	  SBD-­‐β	   binding	   cleft	  
and	   confers	  high	   affinity	   for	   the	   substrate	   [53].	   	   The	  NBD	  of	   the	   full-­‐length	  DnaK	   structure	  
also	  adopts	  a	  closed	  state.	   	  This	  conformation	   is	   identical	   to	   that	  observed	   in	   the	  NBD-­‐only	  
structures	  obtained	  irrespectively	  of	  whether	  ATP,	  ADP	  or	  no	  nucleotide	  is	  bound	  [60-­‐63].	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1.2.3 Hsp70	  co-­‐factors	  
The	  chaperone	  cycle	  of	  Hsp70s	  is	  regulated	  by	  co-­‐factors	  that	  facilitate	  either	  ATP	  hydrolysis	  
or	  the	  exchange	  of	  ADP	  for	  ATP.	  	  These	  belong	  to	  the	  Hsp40	  chaperone	  family	  and	  nucleotide	  
exchange	  factors	  (NEF)	  respectively.	  	  	  
1.2.3.1 Hsp40	  co-­‐chaperones	  
Hsp40s	   are	   more	   abundant	   and	   diverse	   than	   Hsp70s.	   	   A	   single	   Hsp70	   can	   bind	   multiple	  
Hsp40s,	  albeit	  not	  simultaneously,	  to	  drive	  distinct	  cellular	  processes	  [64].	  	  The	  specificity	  of	  
Hsp40s	  is	  dictated	  by	  factors	  such	  as	  their	  sub-­‐domain	  composition,	  their	  localisation	  or	  the	  
specific	  residues	  involved	  in	  binding	  to	  the	  Hsp70	  partner	  [64,65].	  	  All	  Hsp40s	  contain	  a	  highly	  
conserved	  75	  amino	  acid	  N-­‐terminal	  region	  termed	  the	  J-­‐domain.	  	  The	  J-­‐domain	  binds	  at	  the	  
NBD-­‐SBD	   interface	  of	  Hsp70s	   and	   couples	  ATP	  hydrolysis	   and	   substrate	   binding	   [65,66].	   	   A	  
conserved	  HPD	  motif	  within	  the	  J-­‐domain	  is	  involved	  in	  promoting	  ATP	  hydrolysis	  of	  Hsp70s,	  
even	   in	   the	   absence	   of	   substrate	   [66].	   	   Although	   the	   J-­‐domain	   is	   the	   predominant	   site	   of	  
interaction	   with	   Hsp70s,	   Hsp40s	   may	   contain	   additional	   domains:	   a	   disordered	  
Glycine/Phenylalanine	   rich	   region,	   a	   Cysteine-­‐rich	   zinc	   ion	   (Zn2+)-­‐binding	   region	   and	   C-­‐
terminal	   regions	   involved	   in	   binding	   of	   substrates	   and/or	   mediating	   dimerisation	   [64].	  	  
Because	  of	  their	  ability	  to	  associate	  with	  unfolded	  substrates,	  some	  Hsp40s	  are	  considered	  to	  
be	   molecular	   chaperones	   themselves.	   Nonetheless	   it	   is	   not	   clear	   whether	   these	   assist	   in	  
folding	  or	  simply	  function	  to	  deliver	  misfolded	  proteins	  to	  Hsp70s.	  
DnaJ	   is	   the	   canonical	   Hsp40	   in	   E.	   coli.	   	   It	   was	   first	   identified	   as	   a	   co-­‐factor	   for	   DnaK	   that	  
stimulates	  its	  ATPase	  activity	  and	  helps	  replicate	  lambda	  phage	  deoxyribonucleic	  acid	  (DNA)	  
in	  host	  cells	   [67].	   	  Consequently,	   this	   family	  of	  ER-­‐resident	  Hsp40s	  was	   termed	  ER	   localised	  
DnaJ	  proteins	  (ERdj).	  	  Mammalian	  cells	  contain	  at	  least	  seven	  ERdjs,	  named	  in	  order	  of	  their	  
discovery	  [12].	  	  They	  differ	  in	  their	  functions	  and	  have	  varied	  sub-­‐ER	  localisation	  and	  affinity	  
for	  BiP.	  	  ERdj1,	  2,	  3	  and	  6	  have	  been	  linked	  to	  folding	  of	  nascent	  proteins	  whereas	  ERdj4	  and	  
5	  assist	  in	  ERAD	  pathways.	  	  ERdj3	  has	  been	  of	  interest	  in	  studies	  of	  BiP	  chaperoning	  activity.	  	  	  
Initial	  characterisation	   identified	  that	  (i)	  ERdj3	  can	  bind	  to	  unfolded	  proteins	  which	  are	  also	  
BiP	  substrates	  even	   in	   the	  absence	  of	  BiP,	   (ii)	  BiP	  and	  ERdj3	  have	  similar	   tissue	  distribution	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with	  highest	   levels	  expressed	   in	  secretory	   tissues	  such	  as	   the	  placenta,	   liver	  and	  kidneys	  as	  
seen	   in	   expression	   profiles,	   and	   (iii)	  both	   proteins	   are	   transcriptionally	   upregulated	   during	  
conditions	  of	  ER	  stress	  [68].	  	  ERdj3	  stimulates	  the	  ATPase	  activity	  of	  BiP	  by	  approximately	  2-­‐
fold	  and	  accelerates	  binding	  of	  CH1	   [26,68].	   	   spFRET	  experiments	  have	  shown	  that	  whereas	  
ATP	  normally	  induces	  CH1	  dissociation	  from	  BiP,	  this	  is	  inhibited	  by	  the	  addition	  of	  ERdj3	  [26].	  	  
Upon	  recruitment	  of	  BiP	  to	  the	  substrate,	  ATP	  hydrolysis	  must	  occur	  in	  order	  for	  ERdj3	  to	  be	  
released	   [69].	   	   Because	   unlike	   BiP,	   ERdj3	   does	   not	   assist	   in	   the	   folding	   and	   assembly	   of	  
misfolded	  proteins,	  it	  is	  speculated	  to	  play	  a	  role	  in	  delivering	  unfolded	  substrates	  to	  BiP.	  	  	  
Early	   experiments	   that	  used	  Trp	   fluorescence	   to	   follow	   the	   conformational	   cycling	  of	  DnaK	  
found	   that	  DnaJ	  accelerates	   the	   conversion	  of	  DnaK	   from	  an	  ATP	   to	  ADP-­‐bound	   state	   [70].	  	  
More	   recently,	   spFRET	   measurements	   indeed	   have	   demonstrated	   that	   BiP	   assumes	   the	  
substrate-­‐bound	   closed	   conformation	   in	   the	   presence	  of	  ATP	  nucleotide	   and	  CH1	   substrate	  
only	  when	  ERdj3	  is	  also	  present	  [26].	  	  Together,	  these	  studies	  support	  a	  mechanism	  by	  which	  
ERdj3	  binds	  unfolded	  proteins,	  recruits	  ATP-­‐bound	  BiP	  and	  accelerates	  nucleotide	  hydrolysis.	  	  
This	  would	  reorient	  BiP	  so	  that	  the	  misfolded	  proteins	  bind	  to	  the	  SBD	  and	  ERdj3	  is	  released.	  	  
Structural	  studies	  will	  be	  essential	  to	  further	  appreciate	  this	  system.	  	  	  
1.2.3.2 Nucleotide	  Exchange	  Factors	  
The	  release	  of	  substrates	  from	  Hsp70s	  requires	  exchange	  of	  ADP	  to	  ATP.	  	  In	  the	  mammalian	  
ER,	  nucleotide	  exchange	  is	  catalysed	  by	  BiP-­‐associated	  protein	  (BAP)	  and	  Grp170	  [12].	  	  GrpE	  
is	  the	  NEF	  that	  acts	  on	  DnaK	  in	  E.	  coli.	  	  NEFs	  bind	  to	  the	  NBD	  of	  Hsp70s	  and	  actively	  promote	  
the	  release	  of	  ADP	  thus	  stimulating	  the	  release	  of	  bound	  substrates.	   	  BAP	  and	  Grp170	  both	  
bind	   to	   BiP	   in	   the	   ER,	   however	   their	  mechanism	  of	   action	   and	   precise	   roles	   remain	   poorly	  
characterised.	   	   Structural	   studies	   of	   cytosolic	   Hsp	   Binding	   Protein	   1	   (HspBP1)	   and	   B-­‐cell	  
lymphoma	   2	   (Bcl2)-­‐associated	   athanogene	   (BAG)	   proteins,	   that	   are	   homologs	   of	   BAP	   and	  
Grp170	  respectively,	  in	  complex	  with	  their	  partner	  Hsp70s	  have	  allowed	  for	  the	  elucidation	  of	  
their	  role	  in	  promoting	  nucleotide	  exchange	  [57,71,72].	  	  HspBP1	  and	  BAG	  bind	  to	  Lobe	  IB	  of	  
Hsp70s’	  NBD	  and	  induce	  a	  rotation	  of	  Lobe	  IIB.	  	  This	  locks	  the	  NBD	  in	  an	  open	  conformation	  
that	   no	   longer	   confers	   high	   affinity	   for	  ADP.	   	   Although	  not	   definitive,	   these	   studies	   can	  be	  
useful	  to	  suggest	  a	  mechanism	  by	  which	  BAP	  and	  Grp170	  may	  function	  to	  control	  BiP	  cycling.	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1.3 Activation	  of	  the	  Unfolded	  Protein	  Response	  
Conditions	  that	  perturb	  the	  physiological	  state	  of	  the	  ER,	  or	  ER	  stresses,	  can	  compromise	  the	  
processing	  of	  mature	  proteins	   leading	   to	   the	   accumulation	  of	  misfolded	  proteins	   in	   the	   ER	  
lumen	   and	   initiation	   of	   the	   Unfolded	   Protein	   Response	   (UPR)	   [73].	   	   ER	   stresses	   include	  
nutrient	  and	  energy	  deprivation,	  hypoxia,	  alterations	  in	  cell	  redox	  status,	  depletion	  of	  ER	  Ca2+	  
stores,	   elevated	   protein	   trafficking	   though	   the	   ER,	   altered	   post-­‐translational	   modifications	  
and	   pathogen	   infection.	   	   The	   UPR	   is	   a	   cellular	   response	   which	   attempts	   to	   restore	   ER	  
homeostasis	   by	   up-­‐regulating	   specific	   target	   genes	   and	   by	   reducing	   protein	   translation	   to	  
limit	  the	  influx	  of	  newly	  synthesized	  proteins	  in	  the	  already	  stressed	  ER	  lumen.	  	  If	  the	  cells	  are	  
unable	   to	   restore	   ER	   homeostasis	   and	   protein	   folding	   ability,	   apoptotic	   pathways	   are	  
initiated.	  
The	   UPR	   was	   first	   characterised	   in	   yeast	   where	   the	   response	   to	   ER	   stress	   is	   mediated	  
uniquely	  by	  the	  inositol	  requiring	  kinase	  1	  (IRE1p)	  protein	  [74].	  	  In	  mammals,	  UPR	  signalling	  is	  
mediated	   by	   three	   ER-­‐localised	   signal	   transducers:	   IRE1,	   double-­‐stranded	   ribonucleic	   acid	  
(RNA)	  activated	  protein	  kinase	  (PKR)-­‐like	  ER	  kinase	  (PERK)	  and	  activating	  transcription	  factor	  
6	  (ATF6)	  [73].	  	  There	  are	  two	  isoforms	  of	  IRE1:	  α	  and	  β.	  	  IRE1α	  is	  expressed	  in	  most	  cells	  and	  
tissues	  whereas	  IRE1β	  expression	  is	  limited	  to	  intestinal	  epithelial	  cells	  [75].	  	  Throughout	  this	  
report	  IRE1	  will	  refer	  to	  the	  α	  isoform	  unless	  otherwise	  specified.	  	  	  
IRE1,	  PERK	  and	  ATF6	  all	  have	  an	  ER	  luminal	  domain	  that	  senses	  conditions	  of	  ER	  stress,	  an	  ER	  
transmembrane	  domain	  and	  a	  cytosolic	  domain	  that	  transmits	  signals	  to	  transcriptional	  and	  
translational	  machineries	  [73].	  	  In	  the	  stressed	  ER,	  detection	  of	  the	  accumulation	  of	  unfolded	  
proteins	  by	  the	  ER	  luminal	  sensor	  domains	  of	  IRE1,	  PERK	  and	  ATF6	  leads	  to	  initiation	  of	  UPR	  
signalling.	   	   The	   underlying	   mechanism	   of	   ER	   stress	   sensing	   and	   UPR	   activation	   is	   not	   yet	  
clearly	   understood.	   	   The	   three	   UPR	   sensor	   domains	   do	   not	   share	   high	   overall	   sequence	  
similarity.	  	  However	  since	  experimental	  induction	  of	  ER	  stress	  can	  activate	  all	  three	  signalling	  
pathways	   it	   is	   possible	   that	   they	   have	   similar	   mechanism	   of	   sensing	   the	   accumulation	   of	  
unfolded	   proteins	   [76].	   	   Based	   on	   numerous	   biochemical	   and	   structural	   studies	   that	   have	  
addressed	   this	   key	   question,	   different	   mechanisms	   have	   been	   proposed.	   	   These	   can	   be	  
subdivided	   into	   two	  main	  models:	  BiP-­‐dependent	  and	  BiP-­‐independent	   [77].	   	  The	  proposed	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mechanisms	  by	  which	  ER	  stress	  initiates	  UPR	  signalling	  are	  discussed	  in	  detail	  in	  this	  chapter	  
and	   are	   summarised	   in	   Figure	   1-­‐5.	   	   Downstream	   pathways	   that	   result	   from	   active	   UPR	  
signalling	  are	  discussed	  in	  Chapter	  1.4.	  
1.3.1 BiP-­‐dependent	  mechanisms	  
1.3.1.1 BiP	  as	  a	  negative	  regulator	  of	  the	  UPR	  
The	  most	  supported	  mechanism	  of	  ER	  stress	  sensing	   is	  a	  competition	  model	   in	  which	  BiP	   is	  
normally	  bound	  to	  the	  luminal	  domains	  of	  IRE1,	  PERK	  and	  ATF6	  to	  keep	  them	  in	  an	  inactive	  
state	  [76,78].	  	  Upon	  ER	  stress,	  the	  high	  concentrations	  of	  unfolded	  proteins	  compete	  for	  BiP-­‐
binding.	  	  This	  sequesters	  it	  from	  the	  luminal	  domains	  of	  the	  UPR	  mediators	  allowing	  for	  their	  
oligomerisation,	  in	  the	  case	  of	  IRE1	  and	  PERK,	  and	  their	  subsequent	  activation.	  	  Experiments	  
in	  the	  early	  1990s	  first	  observed	  a	  correlation	  between	  BiP	  overexpression	  and	  attenuation	  of	  
the	  UPR	  [79,80].	  	  Later,	  BiP	  was	  shown	  to	  co-­‐immunoprecipitate	  with	  the	  UPR	  transducers	  in	  
the	   absence	   of	   ER	   stress	   in	   transfected	   yeast	   and	  mammalian	   cell	   lines	   [76,81,82].	   	   Upon	  
induction	  of	  ER	  stress,	   the	  reversible	   loss	  of	  BiP	  binding	  to	   IRE1p,	   IRE1,	  PERK	  and	  ATF6	  was	  
observed.	   	   BiP	   dissociation	   leads	   to	   oligomerisation	   and	   activation	   of	   IRE1	   and	   PERK	   and	  
initiation	  of	  UPR	  signalling	  [76].	  	  In	  the	  absence	  of	  BiP,	  ATF6	  is	  also	  free	  to	  translocate	  to	  the	  
Golgi	  for	  activation	  [82].	  	  Interestingly,	  over-­‐expression	  of	  unfolded	  proteins	  that	  do	  not	  bind	  
to	  BiP	  does	  not	  result	  in	  activation	  of	  UPR	  signalling	  [83,84].	  	  This	  illustrates	  the	  specificity	  of	  
BiP	  interaction	  with	  the	  UPR	  luminal	  domains.	  	  
In	  an	  attempt	  to	  identify	  the	  BiP-­‐binding	  region,	  the	  luminal	  domains	  have	  been	  subdivided	  
into	  five	  regions.	   	  Scanning	  deletions	  of	  IRE1p,	  IRE1	  and	  PERK	  luminal	  domains	  were	  carried	  
out	  in	  three	  separate	  studies	  [85-­‐87].	  	  Deletion	  of	  the	  ER-­‐membrane	  proximal	  regions,	  leads	  
to	   loss	  of	  BiP-­‐binding	   in	   co-­‐immunoprecipitation	  experiments.	   	   This	   is	   termed	   region	  V	  and	  
corresponds	   to	   residues	   448-­‐517	   of	   IRE1p,	   389-­‐434	   of	  H.	   sapiens	   IRE1	   and	   411-­‐481	   of	  H.	  
sapiens	   PERK.	   	   Indeed,	   deletion	   of	   region	   V	   of	   mammalian	   IRE1	   and	   PERK	   results	   in	  
constitutively	  active	  proteins	  even	   in	   the	  absence	  of	  ER	  stress	   [86,87].	   	  The	   failure	  of	   these	  
truncated	   proteins	   to	   be	   repressed,	   putatively	   due	   to	   their	   inability	   to	   bind	   BiP,	   points	  
towards	  a	  negative	  regulatory	  role	  for	  BiP	  binding	  to	  region	  V.	  	  	   	  
	   	  
	  
	  









Figure	  1-­‐5.	  Proposed	  mechanisms	  of	  ER	  stress	  sensing	  and	  UPR	  activation	  by	  PERK/IRE1	  
(A)	   BiP-­‐dependent	  mechanism	   (BiP	   SBD	   is	   shown	   in	   teal;	   BiP	  NBD	   is	   shown	   in	  magenta;	   the	   linker	   is	   shown	   in	  
green).	  	  During	  physiological	  conditions,	  BiP	  is	  bound	  to	  the	  luminal	  domains	  of	  PERK/IRE1	  and	  as	  such	  keeps	  them	  
in	  an	  inactive	  (possibly	  monomeric)	  state.	  	  It	  is	  widely	  believed	  that	  it	  is	  BiP	  SBD	  that	  binds	  to	  the	  luminal	  domains.	  	  
Since	  misfolded	  proteins	  are	  also	  substrates	  for	  BiP	  SBD,	  during	  ER	  stress,	  their	  high	  levels	  compete	  for	  binding	  to	  
BiP	   SBD.	   	   As	   such,	   BiP	   dissociates	   from	   the	   luminal	   domains	   of	   PERK/IRE1	   allowing	   for	   their	   activation	   (auto-­‐
phosphorylation	   of	   their	   cytoplasmic	   domains	   and	   oligomerisation).	   	   BiP	  may	  mediate	   PERK/IRE1	   activation	   by	  
physically	  blocking	  the	  dimerisation	  motifs	  of	   the	   luminal	  domains	  so	  that	  they	  cannot	  oligomerise	  and	  become	  
active.	   	   Alternatively,	   BiP	   binding/release	  may	   cause	   a	   conformational	   change	   in	   PERK/IRE1,	   which	   alters	   their	  
cytoplasmic	  activation	  state.	  
(B)	   BiP-­‐independent	   mechanism.	   	   Misfolded	   proteins	   may	   bind	   directly	   to	   the	   luminal	   domains	   and	   as	   such	  
promote	  their	  dimerisation	  and	  activation	  of	  their	  cytosolic	  domains.	  	  Prolonged	  ER	  stress	  may	  lead	  to	  clustering	  
of	  the	  misfolded	  protein-­‐bound	  luminal	  domains	  that	  allows	  for	  co-­‐operativity	  of	  the	  cytosolic	  domains	  and	  more	  
robust	  downstream	  signalling.	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In	   contrast,	   two	   studies	   have	   independently	   reported	   the	   association	   of	   BiP	   to	   IRE1	  
constructs	   that	   lack	   the	   BiP-­‐binding	   region	   V	   [88,89].	   	   In	   addition,	   deletion	   of	   region	   V	   of	  
IRE1p	   was	   reported	   to	   not	   be	   sufficient	   to	   activate	   signalling,	   and	   sensing	   of	   ER	   stress	  
conditions	  required	  a	  core	  region	  that	  is	  independent	  of	  the	  BiP-­‐binding	  site	  [85].	  	  From	  this	  
latter	   study	   it	  was	   suggested	   that	  BiP	   is	  not	   the	  primary	  sensor	  of	  ER	  stress	  but	   rather	   this	  
relies	   on	   the	   core	   sensing	   region	   of	   IRE1p	   luminal	   domain	   (regions	   II-­‐IV)	   that	   then	   in	   turn	  
positively	   functions	   to	   release	  BiP.	   	  What	   is	  clear	   from	  these	  studies	   is	   that	  BiP	  can	  repress	  
IRE1,	  PERK	  and	  ATF6	  activation	  and	  UPR	  signalling.	  	  However	  the	  exact	  model	  of	  BiP	  binding	  
and	   dissociation	   from	   the	   UPR	   sensors	   and	   how	   this	   leads	   to	   their	   activation	   is	   not	   yet	  
understood.	  	  A	  number	  of	  mechanisms	  have	  been	  proposed.	  
1.3.1.2 	  BiP	  repression	  by	  steric	  hindrance	  of	  dimerisation	  motifs	  
BiP-­‐binding	  and	  oligomerisation	  regions	  of	  IRE1	  luminal	  domain	  were	  found	  to	  overlap	  and	  a	  
‘steric	   hindrance’	   inactivation	   mechanism	   was	   proposed	   [88].	   	   Based	   on	   this	   study	   it	   was	  
suggested	  that	  in	  the	  absence	  of	  ER	  stress,	  BiP	  blocks	  the	  IRE1	  oligomerisation	  motif	  and	  thus	  
maintains	   IRE1	   in	   its	   inactive	   monomeric	   state.	   	   Upon	   release	   of	   BiP,	   the	   oligomerisation	  
motifs	   are	   unmasked	   and	   become	   free	   to	   interact	   allowing	   dimerisation	   and	   activation	   of	  
IRE1	  (Figure	  1-­‐5A).	  
This	  mode	  of	  repression	  by	  BiP	  resembles	  a	  mechanism	  suggested	  to	  occur	   in	  ATF6.	   	  An	  ER	  
stress	  responsive	  region	  in	  the	  ATF6	  luminal	  domain	  required	  for	  the	  active	  release	  of	  BiP	  has	  
been	   identified	   [82].	   	  This	   is	   termed	   ‘luminal	  domain	  region	  2’	  and	  corresponds	  to	  residues	  
431-­‐475	   of	   H.	   sapiens	   ATF6.	   	   ATF6	   ‘luminal	   domain	   region	   2’	   also	   contains	   to	   two	   Golgi-­‐
localisation	   sequences	   (residues	   468-­‐475	   and	   468-­‐500).	   	   It	   has	   been	   proposed	   that	  
association	   of	   ATF6	  with	   BiP	  masks	   these	   sequences	   thereby	   retaining	   ATF6	   in	   the	   ER	   and	  
impeding	   its	   transport	   to	   the	  Golgi	   [82].	   	  BiP	  over-­‐expression	  correlates	  with	   reduced	  ATF6	  
translocation	  whereas	   deletion	   of	   the	   BiP-­‐binding	   region	   leads	   to	   constitutive	   activation	   of	  
ATF6	  signalling	  [82].	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1.3.1.3 The	  BiP-­‐release	  model	  
The	   ATPase	   activity	   of	   BiP	   is	   central	   to	   its	   function	   in	   substrate	   binding	   and	   release	   and	  
therefore	  is	  a	  plausible	  factor	  involved	  in	  UPR	  activation.	  	  Indeed,	  Kar2p	  mutants	  deficient	  in	  
their	  ATPase	  activity	  are	  unable	  to	  activate	  the	  UPR	  in	  yeast	  cells	  [78].	  	  Temperature-­‐sensitive	  
Kar2p	  NBD	  (type	  A)	  or	  SBD	  (type	  S)	  mutations	  that	  abolish	  their	  relevant	  functions	  have	  been	  
identified	   [78].	   	   At	   restrictive	   temperatures,	   although	   the	   type	   A	   mutants	   are	   unable	   to	  
activate	  IRE1p	  signalling,	  they	  remain	  bound	  to	  the	  IRE1p	  substrate.	  	  On	  the	  other	  hand,	  type	  
S	   mutations	   completely	   abolish	   Kar2p-­‐IRE1p	   interaction	   and	   lead	   to	   constitutive	   UPR	  
signalling	  in	  vivo	  even	  in	  the	  absence	  of	  ER	  stress	  signals	  [78].	  	  Kar2p	  appears	  to	  associate	  to	  
substrates	  via	   its	  SBD	  and	  serves	  as	  a	  repressor	  of	  the	  UPR,	  whereas	  the	  NBD	  is	  responsible	  
for	  providing	  an	  activation	  signal	   to	   the	  bound	  substrate.	   	  However,	   in	  a	   later	   study	  by	   the	  
same	  group,	   it	  was	  concluded	   that	   the	  constitutive	  activation	  of	   type	  S	  mutants	   in	   the	   first	  
paper	  was	  due	   to	  elevated	   stress	   levels	   rather	   than	   to	   their	   inability	   to	  negatively	   regulate	  
IRE1p	  [85].	  	  This	  second	  study	  concludes	  on	  a	  tuning	  role	  for	  BiP	  rather	  than	  it	  being	  the	  main	  
switch	  for	  UPR	  activation	  as	  discussed	  previously.	  
An	   independent	  study	  has	  suggested	  that	  BiP	  actually	   interacts	  with	  the	  UPR	  sensors	  via	   its	  
NBD	   [90].	   	   Mutations	   that	   lock	   BiP	   in	   the	   ATP-­‐bound	   open	   state,	   but	   not	   the	   ADP-­‐bound	  
state,	  were	  seen	  to	  mitigate	  UPR	  signalling	  consistent	  with	  type	  A	  mutants	  described	  earlier.	  	  
In	   an	   attempt	   to	   identify	   BiP	   regions	   to	   which	   IRE1p	   binds,	   oligosaccharide-­‐shielding	  
experiments	  were	  then	  carried	  out.	  	  Glycosylation	  of	  Lobe	  IB	  of	  BiP	  NBD	  specifically	  disrupted	  
IRE1p	  binding.	  	  Detailed	  analyses	  of	  BiP	  NBD	  sequence	  conservation	  and	  structural	  properties	  
followed	  by	  a	  mutation	  study	  identified	  Gln88	  as	  the	  key	  residue	  involved	  in	  this	  interaction.	  	  
Indeed,	   IRE1p	   did	   not	   co-­‐immunoprecipitate	   with	   Q88E	   mutant	   BiP	   protein,	   despite	   this	  
mutation	   having	   no	   effect	   on	   BiP’s	   chaperoning	   activity.	   	   Based	   on	   these	   results,	   together	  
with	   known	   conformational	   changes,	  which	  occur	   during	  BiP	   substrate	  binding	   and	  ATPase	  
cycle,	  the	  authors	  put	  forward	  a	  BiP-­‐release	  mechanism.	  	  During	  ER	  stress,	  unfolded	  proteins	  
would	  bind	   to	  BiP	  SBD	  and	  such	   induce	  a	  movement	  of	   the	  Lobe	   IB	  on	   the	  NBD	  and	  which	  
would	  trigger	  the	  release	  of	  the	  bound	  UPR	  sensor	  luminal	  domain.	  	  However	  no	  evidence	  is	  
provided	  for	  such	  mechanism.	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Other	   ambiguities	   include	   the	   role	   of	   different	   nucleotides	   in	   the	   interaction.	   	   It	   has	   been	  
reported	   that	  BiP-­‐binding	   to	   IRE1p,	   IRE1	  and	  PERK	   is	  only	  observed	   in	   the	  presence	  of	  ATP	  
and	  not	  ADP	  [89,90].	   	  However	  other	  studies	  observe	  dissociation	  of	  BiP	  in	  the	  UPR	  sensors	  
upon	  the	  addition	  of	  ATP	  [78,91].	  	  ATF6	  binding	  appears	  to	  be	  independent	  of	  BiP	  nucleotide	  
cycling	   [89].	   	   A	   T37G	   BiP	   mutant	   that	   is	   unable	   to	   switch	   from	   an	   ADP	   to	   ATP-­‐bound	  
conformation	   was	   shown	   to	   be	   able	   of	   binding	   to	   ATF6	   similarly	   to	   wild-­‐type	   BiP	   [91].	  	  
Differences	   in	  BiP	   binding	   to	  ATF6	   and	   IRE1	  or	   PERK	   are	   likely	   to	   be	   a	   consequence	  of	   the	  
absence	  of	  homology	  in	  their	  luminal	  domains	  and	  a	  reflection	  of	  the	  different	  mechanism	  of	  
action.	  	  
1.3.1.4 Uncertainties	  regarding	  the	  BiP-­‐dependent	  models	  
So	   far,	   the	  majority	  of	   the	  mechanistic	  understanding	  about	  UPR	  activation	  and	   the	   role	  of	  
BiP	   in	   this	   process	   have	   come	   from	   immunoprecipitation	   experiments	   from	   whole-­‐cell	  
extracts	  and	  activity	  reporter	  assays	  in	  cells.	  	  It	  is	  possible	  that	  bridging	  proteins	  play	  a	  role	  in	  
the	   interaction	   and	   that	   a	   multitude	   of	   other	   factors	   affect	   the	   results	   observed	   in	   these	  
experiments.	  	  Additionally,	  from	  the	  studies	  above	  it	  cannot	  be	  excluded	  that	  IRE1,	  PERK	  and	  
ATF6	  binding	  to	  BiP	  is	  actually	  only	  a	  client	  interaction	  due	  to	  the	  sticky	  nature	  of	  BiP.	  	  Finally,	  
the	   decrease	   in	   UPR	   signalling	   when	   BiP	   is	   over-­‐expressed	   could	   be	   due	   to	   a	   decrease	   in	  
levels	  of	  unfolded	  proteins	  rather	  than	  repression	  of	  IRE1,	  PERK	  and	  ATF6.	  	  In	  fact,	  published	  
papers	   have	   reported	   that	  when	   expression	   of	   IRE1	   and	   PERK	   is	   controlled,	   as	   opposed	   to	  
over-­‐expressed	   as	   is	   the	   case	   in	   most	   of	   the	   biochemical	   studies	   mentioned	   above,	   full	  
activation	   of	   the	  mutants	   that	   lack	   the	   BiP-­‐binding	   domain	   requires	   induction	   of	   ER	   stress	  
[86,92].	   	  Over-­‐expression	  of	   the	  mutants	  possibly	   itself	   acts	   as	   an	   inducer	  of	   ER	   stress	   and	  
therefore	   the	   observations	   seen	   do	   not	   represent	   physiological	   conditions	   of	   ER	   stress.	  	  
Contradictorily,	   it	   has	   been	   shown	   that	   in	   the	   presence	   of	   ER	   stress,	   BiP	   actively	   and	  
specifically	   dissociates	   from	   ATF6	   and	   IRE1	   but	   not	   from	   two	   other	   BiP	   substrates,	   CH	   of	  
immunoglobulins	  and	  a	   temperature-­‐sensitive	  variant	  of	  vesicular	   stomatitis	  virus	  G	   (VSVG)	  
protein	  [91].	  	  This	  supports	  an	  explicit	  repressive	  role	  for	  BiP	  in	  UPR	  signalling.	  	  	  
Finally,	  as	  discussed	  above,	  type	  S	  Kar2p	  mutations	  abolish	  IRE1p-­‐Kar2p	  binding	  and	  leads	  to	  
constitutive	  activation	  of	  IRE1p	  [78].	  	  Although	  this	  may	  be	  attributed	  to	  the	  absence	  of	  the	  
UPR-­‐repressive	  IRE1p-­‐Kar2p	  interaction	  it	  could	  also	  be	  due	  to	  a	  lack	  of	  interaction	  of	  Kar2p	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with	  unfolded	  proteins	  in	  the	  stressed	  ER	  and	  improper	  re-­‐folding	  which	  would	  lead	  to	  severe	  
ER	  stress	  and	  IRE1p	  activation.	  
1.3.2 BiP-­‐independent	  mechanism	  
Kimata	   and	   co-­‐workers	   first	   suggested	   that	   BiP	   is	   not	   the	   principal	   adjustor	   for	   sensing	   ER	  
stress	  by	   the	   luminal	  domains	  of	   IRE1,	  PERK	  and	  ATF6.	   	   IRE1p	  deletion	  mutants	   lacking	   the	  
BiP-­‐binding	  site	  did	  not	  affect	  their	  ability	  to	  respond	  to	  ER	  stress	  [78].	  	  From	  this	  study	  it	  was	  
proposed	  that	  the	  central	  core	  portion	  of	  the	  luminal	  domain	  of	  IRE1p	  detects	  the	  presence	  
of	   unfolded	   proteins	   in	   the	   stressed	   ER	   that	   leads	   to	   its	   activation.	   	   In	   this	   scenario,	   BiP	  
binding	   and	   release	   serves	  merely	   as	   an	   adjustor	  mechanism	   to	   control	   the	   level	   of	   IRE1p	  
signalling.	  	  These	  observations	  have	  led	  to	  the	  BiP-­‐independent	  model	  which	  points	  towards	  
a	   direct	   role	   for	   unfolded	   proteins	   in	   UPR	   activation,	   at	   least	   in	   the	   yeast	   system	   (Figure	  
1-­‐5B).	  
1.3.2.1 	  	  Direct	  binding	  of	  unfolded	  peptides	  to	  IRE1p	  luminal	  domain	  
Since	  Kimata’s	  study,	  the	  direct	  binding	  of	  IRE1p	  to	  unfolded	  proteins	  has	  been	  observed	  and	  
directly	   linked	   to	   its	   oligomerisation	   and	   activation	   [93,94].	   	   Mutations	   of	   the	   putative	  
peptide-­‐binding	   pocket	   (M229A_F285A_Y301A)	   and	   dimerisation	   interface	   (T226F_F247A)	  
decreased	   IRE1p-­‐mediated	   (via	   HAC1)	   activation	   of	   the	   downstream	   UPR	   element	   (UPRE)	  
promoter	  in	  reporter	  assays	  in	  vitro	  [95].	  	  A	  peptide	  array	  screen	  derived	  by	  sequential	  tiling	  
along	  the	  sequence	  of	  a	  constitutively	  misfolded	  carboxypeptidase	  Y	  (CPY)	  mutant	  (CPY*)	  was	  
designed	  [96].	  	  This	  was	  used	  to	  further	  characterise	  peptide	  binding	  to	  IRE1p.	  	  IRE1p	  appears	  
to	   preferentially	   bind	   to	   peptides	   containing	   basic	   and	   hydrophobic	   residues	   rather	   than	  
recognising	  a	  specific	  consensus	  sequence.	  	  These	  residues	  are	  normally	  found	  in	  the	  core	  of	  
folded	  proteins	  but	  become	  exposed	   if	   the	  peptide	   chain	   is	   not	  properly	   folded.	   	  Although	  
this	  resembles	  to	  the	  Kar2p/BiP	  mode	  of	  recognition	  of	  unfolded	  proteins,	   IRE1p	  was	  found	  
to	  bind	  overlapping	  but	  not	  identical	  peptides	  to	  Kar2p.	  	  This	  observation	  probably	  rules	  out	  a	  
peptide-­‐competition	  model	  in	  which	  saturation	  of	  Kar2p	  is	  required	  for	  IRE1p	  activation.	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1.3.2.2 IRE1p	  clustering	  
Sedimentation	   experiments	   have	   shown	   that	   binding	   of	   a	   CPY*-­‐derived	   peptide	   induces	  
formation	   of	   higher	   oligomeric	   species	   and	   therefore	  may	   be	   the	   driving	   force	   for	   cluster	  
formation	  [96].	  	  Clustering	  of	  IRE1p	  has	  been	  suggested	  to	  occur	  by	  a	  helical	  oligomerisation	  
of	  IRE1	  dimeric	  building	  blocks	  that	  interact	  via	  a	  secondary	  interface	  [97,98].	  	  However	  it	  is	  
difficult	  to	  foresee	  this	  model	  occurring	  in	  cells	  given	  that	  IRE1	  is	  a	  transmembrane	  protein.	  	  
Mutations	   affecting	   either	   peptide-­‐binding,	   dimerisation	   or	   at	   the	   secondary	   clustering	  
interface	  disrupt	  formation	  of	  higher	  oligomers	  IRE1p	   in	  vitro	  [93,96].	  	  Since,	  several	  studies	  
have	   also	   demonstrated	   that	   higher	   oligomer	   formation	   is	   essential	   for	   IRE1p	   activation	  
following	  ER	  stress	   in	  vivo,	  pointing	   towards	  a	  biological	   role	  of	   this	  process,	  at	   least	   in	   the	  
yeast	  system	  [93,99].	  	  Clustering	  could	  allow	  for	  co-­‐operativity	  between	  cytoplasmic	  domains	  
of	  active	  IRE1p	  and	  as	  such	  facilitates	  full	  activation	  of	  downstream	  signalling.	  
1.3.3 Two-­‐step	  activation	  mechanism	  
A	  two-­‐step	  mechanism	  for	  UPR	  activation	  in	  which,	  additionally	  to	  the	  release	  of	  BiP,	  direct	  
binding	  of	  unfolded	  polypeptides	   to	   the	  ER	   sensor	   luminal	  domains	   is	   also	   required	   for	   full	  
activation	   of	   UPR	   signalling	   has	   been	   proposed	   [93].	   	   Mutations	   that	   render	   IRE1p	  
constitutively	   clustered	   require	   additional	   extrinsic	   ER	   stress	   signals	   for	   activation	   of	   the	  
UPRE	   reporter.	   	   This	   was	   the	   first	   suggestion	   that	   although	   higher	   oligomer	   formation	   is	  
necessary,	   it	   is	   not	   sufficient	   to	   activate	   IRE1p	   signalling.	   	   Furthermore,	  mutation	   of	   IRE1p	  
regions	   I	   and	   V,	   either	   in	   combination	   or	   separately,	   results	   in	   differing	   ER	   membrane	  
localisation	  patterns	  in	  vivo.	  	  Whereas	  single	  deletion	  of	  either	  region	  (∆I	  and	  ∆V	  constructs)	  
does	   not	   affect	   oligomerisation,	   ∆I∆V	   constructs	   show	   constitutive	   clustering	   on	   the	   ER	  
membrane.	  	  From	  these	  observations	  it	  was	  proposed	  that	  a	  two-­‐step	  regulatory	  mechanism	  
for	  ER	  stress	  sensing	  and	  IRE1p	  activation	  exists.	  	  In	  this	  novel	  and	  more	  complex	  mechanism,	  
during	  ER	  stress	  BiP	  indeed	  recognises	  and	  binds	  to	  unfolded	  proteins.	  	  As	  such,	  it	  is	  released	  
from	   the	   ER	   sensor	   luminal	   domains	   allowing	   for	   their	   dimerisation	   and	   formation	   of	   the	  
dimerisation	   that	   is	   capable	   of	   accommodating	   unfolded	   polypeptides	   [95].	   	   Following	  
binding	   of	   peptides	   to	   the	   luminal	   domains,	   conformational	   changes	   would	   trigger	   the	  
formation	  of	  higher	  oligomers	   [96,100].	   	  As	  such,	   this	   two-­‐step	  activation	  mechanism	  could	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function	  to	  ensure	  the	  tight	  control	  of	  UPR	  signalling.	  	  However,	  further	  evidence	  is	  required	  
to	  sustain	  and	  characterise	  this	  complex	  model.	  
1.3.4 S.	  cerevisiae	  and	  H.	  sapiens	  IRE1	  luminal	  domain	  structures	  
The	  X-­‐ray	  crystal	  structures	  of	  S.	  cerevisiae	  and	  H.	  sapiens	   IRE1	   luminal	  domains	  have	  been	  
solved	   [95,101].	   	  Despite	   the	  structural	  and	   functional	   conservation	  between	   the	   two,	   they	  
support	  distinct	  models	  of	  ER	  stress	  sensing.	  	  S.	  cerevisiae	  and	  H.	  sapiens	  IRE1	  luminal	  domain	  
monomers	  are	  composed	  of	  a	  triangular	  assembly	  of	  β-­‐sheet	  clusters,	  which	  are	  interspaced	  
by	   α-­‐helices	   (Figure	   1-­‐6).	   	   Dimerisation	   occurs	   by	   symmetric	   packing	   of	   two	   monomers	  
through	   polar	   and	   hydrophobic	   interactions	   between	   two	   solvent-­‐exposed	   antiparallel	   β-­‐
strands.	   	  This	  creates	  an	  interface	  groove	  in	  the	  luminal	  domain	  that	  resembles	  the	  peptide	  
binding	   domains	   of	   major	   histocompatibility	   complexes	   (MHCs).	   	   The	   structure	   of	   IRE1p	  
luminal	   domain	   supports	   the	   BiP-­‐independent	   mechanism	   of	   UPR	   activation	   (Figure	   1-­‐6B)	  
[95].	  	  Two	  mechanisms	  of	  unfolded	  peptide	  binding	  to	  the	  MHC-­‐like	  groove	  were	  proposed.	  	  
Firstly,	  hydrophobic	  amino	  acid	  stretches	  present	  on	  the	  unfolded	  peptides	  may	  directly	  bind	  
at	   the	   dimerisation	   interface.	   	   This	   is	   in	   agreement	   with	   the	   previously	   described	   peptide	  
array	   study	   [96].	   	   Alternatively,	   the	   MHC-­‐like	   groove,	   being	   narrow,	   would	   be	   sterically	  
inaccessible	  to	  compactly	  folded	  proteins	  but	  not	  to	  misfolded	  linear	  polypeptide	  chains.	  
However,	   based	  on	   the	   structure	  of	  H.	   sapiens	   IRE	   luminal	   domain,	   it	  was	   argued	   that	   the	  
direct	  binding	  of	  unfolded	  proteins	  is	  neither	  probable	  nor	  necessary	  for	  initiation	  of	  the	  UPR	  
(Figure	   1-­‐6C)	   [101].	   	   The	   MHC-­‐like	   groove	   appears	   to	   be	   too	   narrow	   and	   structurally	  
unfavourable	   to	   accommodate	   peptide	   binding.	   	   Firstly,	   in	  H.	   sapiens	   IRE1,	   the	   conserved	  
Gln105	   residue	   forms	   a	   hydrogen	   bond	   with	   its	   symmetry	   related	   mate	   to	   contribute	   to	  
dimer	   stability,	   and	   in	   doing	   so	   blocks	   access	   to	   the	   proposed	   peptide-­‐binding	   groove.	  	  
Secondly,	  mutagenesis	   of	  Met229,	   Phe285	  and	  Tyr301	   residues	   located	   in	   the	   groove	  of	  S.	  
cerevisiae	   IRE1p	  were	  shown	  to	  affect	   its	  ability	  to	  activate	  the	  UPRE	  reporter	   in	  yeast	  cells	  
[95].	   	  The	  side	  chains	  of	  these	  residues	  point	   into	  the	  groove,	  and	  thus	  would	  contribute	  to	  
peptide	  binding,	  were	  concluded	  to	  be	  key	  for	  IRE1p	  activation.	  	  However	  these	  residues	  are	  
either	   buried	   (Tyr161	   and	   Tyr179)	   or	   not	   conserved	   (Methionine-­‐to-­‐Lysine	   replacement;	  
Lys121)	  in	  the	  H.	  sapiens	  IRE1	  groove	  [101].	  	  Finally,	  projection	  of	  the	  cytoplasmic	  domain	  of	  
IRE1	  would	  suggest	  that	  the	  MHC-­‐like	  groove	  faces	  the	  ER	  membrane	  thus	  it	  is	  unlikely	  that	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protein	   binding	  would	   occur.	   	   Based	  on	   these	   structures	   it	  would	   appear	   that	  S.	   cerevisiae	  
and	  H.	  sapiens	  IRE1	  have	  evolved	  diverse	  mechanisms	  of	  sensing	  ER	  stress.	  	  	  
Nonetheless,	  ER	  stress	  has	  also	  been	  shown	  to	  promote	  clustering	  of	  mammalian	  IRE1α	  and	  
IRE1β	   [98,102].	   	   Disruption	   of	   IRE1α	   dimerisation	   interface	   inhibits	   both	   cluster	   formation	  
and	  splicing	  of	  Basic	  Leucine	  Zipper	   (bZIP)-­‐containing	  X-­‐box-­‐binding	  protein	  1	   (XBP1)	  mRNA.	  	  
Additionally,	  IRE1β,	  but	  not	  hIRE1α,	  has	  been	  shown	  to	  co-­‐immunoprecipitate	  with	  unfolded	  
proteins	  in	  stressed	  cells	  [102].	  	  It	  is	  possible	  that	  the	  two	  proteins	  used	  to	  solve	  IRE1	  luminal	  
domain	  structures	  were	  trapped	  in	  different	  conformations	  and	  represent	  different	  states	  of	  
dimeric	   IRE1	   luminal	   domains.	   	   In	   addition,	   both	   S.	   cerevisiae	   and	  H.	   sapiens	   IRE1	   luminal	  
domain	  crystal	  structures	  lack	  electron	  density	  for	  the	  ER-­‐membrane	  proximal	  region	  that	  is	  
speculated	   to	   be	   key	   for	   BiP-­‐binding.	   	   Therefore	   it	   is	   challenging	   to	   postulate	   on	   the	  
properties	   of	   BiP-­‐binding	   and	   what	   effect	   this	   would	   have	   on	   the	   conformation	   and	  
oligomeric	  state	  of	  IRE1.	  	  
PERK	  and	   IRE1	   luminal	  domains	  are	   functionally	   interchangeable:	  PERK	   luminal	  domain	   can	  
substitute	  for	  IRE1’s	  to	  signal	  the	  UPR	  in	  vitro	  and	  vice	  versa	  [76,103].	  	  This	  supports	  the	  idea	  
that	   the	   luminal	   domains	   function	   solely	   as	   sensors	   for	   ER	   stress	   sensing	   and	   that	  
dimerisation	  is	  the	  key	  signal	  for	  the	  activation	  of	  the	  cytoplasmic	  effector	  domains,	  at	  least	  
for	  IRE1	  and	  PERK.	  	  Additionally,	  secondary	  structure	  prediction	  suggests	  that	  IRE1	  and	  PERK	  
have	  similar	   folds	  and	  share	  topological	  arrangements	   in	  their	   luminal	  domains.	   	  Therefore,	  
given	   the	   apparent	   conservation	   in	   structure	   and	   function	  between	   IRE1	   and	  PERK	   luminal	  
domains,	   it	   is	   likely	   that	   they	   have	   a	   similar	   mechanism	   for	   sensing	   perturbations	   in	   ER	  
protein-­‐folding	   reactions.	   	  Obtaining	   the	   crystal	   structure	  of	  PERK	   luminal	  domain	   is	   key	   to	  
elucidate	  the	  ER	  stress	  sensing	  mechanism	  in	  higher	  eukaryotes.	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Figure	  1-­‐6.	  X-­‐ray	  crystal	  structure	  of	  IRE1	  luminal	  domain	  
The	  N-­‐terminal	  ER	   luminal	  domains	  of	  S.	  cerevisiae	   (residues	  114-­‐449)	   (PDB:	  2BE1)	  and	  H.	  sapiens	   (residues	  24-­‐
390)	  (PDB:	  2HZ6)	  IRE1	  orthologues	  have	  a	  similar	  structure	  [95,101].	  	  	  
(A)	  IRE1	  luminal	  domain	  monomers	  are	  composed	  of	  a	  triangular	  assembly	  of	  β-­‐sheets	  interspaced	  by	  α-­‐helices.	  	  
Two	  monomers	  come	  together	  through	  hydrogen	  bonding	  between	  two	  anti-­‐parallel	  β-­‐strands	  to	  form	  biological	  
dimers.	  	  Dimerisation	  creates	  an	  MHC-­‐like	  groove	  characterised	  by	  a	  bed	  of	  β-­‐sheets	  with	  two	  transverse	  α-­‐helices	  
(cyan).	  	  	  
(B)	  Based	  on	  the	  S.	  cerevisiae	  structure	  this	  was	  postulated	  to	  constitute	  the	  region	  for	  misfolded	  protein	  binding	  
which	  backs	  the	  BiP-­‐independent	  model	  of	  ER	  stress	  sensing.	  
(C)	  The	  H.	  sapiens	  structure	  does	  not	  fit	  with	  these	  observations	  since	  (i)	  the	  width	  of	  between	  the	  groove	  is	  too	  
narrow	  (ii)	  a	  conserved	  Glutamate	  forms	  hydrogen	  bond	  with	  its	  symmetry	  related	  partner	  which	  blocks	  access	  to	  
the	  peptide-­‐binding	  site,	  (iii)	  residues	  essential	  for	  peptide	  binding	  in	  S.	  cerevisiae	  IRE1p	  are	  either	  not	  conserved	  
(Methionine-­‐to-­‐Lysine	  mutation)	  or	  buried	  (aromatic	  Tyrosine).	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1.3.5 Alternative	  mechanisms	  of	  UPR	  activation	  
At	   least	   three	  distinct	   systems	   involved	   in	  detection	  of	  ER	   stress	  and	  activation	  of	   the	  UPR	  
have	   been	   proposed:	   (i)	   ADP-­‐ribosylation,	   (ii)	   N-­‐linked	   glycosylation	   of	   ATF6	   and	   (iii)	  
aberrations	  in	  the	  ER-­‐membrane.	  	  These	  will	  be	  briefly	  discussed	  below.	  
1.3.5.1 PARP16-­‐mediated	  ribosylation	  activates	  IRE1	  and	  PERK	  
Poly	   ADP	   ribose	   polymerase	   (PARP)	   proteins	   are	   known	   to	   regulate	   key	   stress	   response	  
pathways	   including	   DNA	   damage	   repair	   and	   the	   cytoplasmic	   stress	   response	   and	   have	  
recently	  also	  been	  linked	  to	  activation	  of	  IRE1	  and	  PERK	  [104].	  	  PARP16-­‐mediated	  ADP-­‐ribose	  
modification	   is	   sufficient	   for	   activation	   of	   IRE1	   and	   PERK	   signalling	   in	   vivo,	   even	   in	   the	  
absence	   of	   ER	   stress.	   	   In	   PARP16-­‐/-­‐	   cells,	   IRE1	   and	   PERK	   remain	   bound	   to	   BiP	   following	  
induction	  of	  ER	  stress.	   	   Interestingly,	  ATF6	  activation	   is	  not	  affected	   in	  any	  way	  by	  PARP16.	  	  
Together,	   these	   observations	   have	   led	   to	   the	   proposal	   of	   a	   mechanism	   in	   which	   PARP16-­‐
induced	   ribosylation	   could	   induce	   conformational	   changes	   in	   IRE1	   and	   PERK	   and	   as	   such	  
would	  actively	  assist	  in	  the	  release	  of	  BiP.	  	  For	  example,	  ribosylation	  could	  open	  the	  binding	  
groove	  of	  IRE1	  and	  PERK	  similarly	  to	  the	  arrangement	  observed	  in	  the	  IRE1p	  crystal	  structure,	  
so	  that	  it	  can	  accommodate	  unfolded	  peptides	  [95].	  	  Because	  ATF6	  exists	  as	  a	  monomer	  and	  
does	  not	  require	  dimerisation	  or	  formation	  of	  a	  binding	  pocket	  for	  activation,	  it	  reasons	  that	  
PARP16	  does	  not	  play	  a	  role	  in	  its	  activation.	  	  Although	  this	  is	  an	  attractive	  hypothesis	  and	  it	  
is	  consistent	  with	  previous	  work,	  Further	  experimental	  work	  is	  needed	  to	  support	  it.	  
1.3.5.2 Under-­‐glycosylation	  acts	  as	  an	  activating	  signal	  for	  ATF6	  
Glycosylation	  of	  ATF6	  luminal	  domain	  has	  been	  suggested	  to	  serve	  as	  a	  sensor	  for	  ER	  stress	  
and	  mediate	  ATF6	  activation	  [105].	   	  An	  ATF6	  mutant	  with	  aberrant	  glycosylation,	  T645I,	  has	  
impaired	   interaction	   with	   the	   CRT	   chaperone,	   faster	   Golgi	   translocation	   and	   enhanced	  
transcription	  of	  target	  genes.	  	  Since	  ER	  stress	  perturbs	  glycosylation	  pathways	  and	  improper	  
glycosylation	   is	   an	   inducer	   of	   the	   UPR,	   it	   follows	   that	   it	   could	   represent	   a	  mechanism	   for	  
activation	   or	   regulation	   of	   the	   sensor	   domains	   of	   IRE1,	   PERK	   and	   ATF6.	   	   To	   date	   though,	  
glycosylation	  of	  IRE1	  and	  PERK	  luminal	  domains	  have	  not	  been	  linked	  to	  ER	  stress	  sensing	  and	  
the	   role	  of	   their	  N-­‐glycosylation	  are	  not	   known.	   	   In	   addition,	   it	   is	   possible,	   that	   anomalous	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glycosylation	  of	   the	  T654I	  mutant	  actually	   reduced	  ATF6	   function	   rather	   than	  decreased	   its	  
susceptibility	  to	  ER	  stress.	  	  	  
1.3.5.3 Distortion	  of	  the	  ER	  membrane	  can	  activate	  the	  UPR	  
Extrinsic	  factors,	  have	  recently	  been	  suggested	  to	  initiate	  at	  least	  the	  IRE1	  branch	  of	  the	  UPR.	  	  
The	   cytoplasmic	  domain	  of	   IRE1	   is	   composed	  of	   a	   kinase	  domain	   and	  an	  endoribonuclease	  
(RNase)	   domain.	   	  When	   activated,	   the	   latter	   is	   responsible	   for	   splicing	   of	   the	   xbp1	  mRNA	  
(Homologous	   to	   Atf/Creb1	   (hac1)	   mRNA	   in	   S.	   cerevisiae),	   which	   leads	   to	   downstream	  
signalling	  cascades	  [74].	  
In	  addition,	  aberrations	  of	  the	  ER	  membrane	  can	  activate	  IRE1p	  signalling	  and	  thus	  may	  also	  
play	  a	  role	  in	  UPR	  activation	  [106].	  	  Interestingly,	  deletion	  of	  IRE1p	  luminal	  domain	  region	  III	  
(ΔIII)	  compromises	  its	  ability	  to	  bind	  unfolded	  peptides	  and	  activate	  hac1	  mRNA	  in	  response	  
to	  ER	   stress	  but	  has	  no	  effect	  on	   the	   formation	  of	   clusters.	   	  ΔIII	   IRE1p	   is	   actually	   activated	  
similarly	  to	  wild-­‐type	  IRE1p	  following	  modifications	  of	  the	  lipid	  content	  of	  the	  ER	  membrane	  
suggesting	   there	   is	   more	   than	   one	   signal	   capable	   of	   activating	   UPR	   during	   ER	   stress.	  	  
Substitution	  of	  IRE1p	  luminal	  domain	  regions	  I	  to	  V	  with	  a	  dimer-­‐forming	  bZIP	  motif	  has	  been	  
used	   to	  probe	   the	   role	  of	   the	   luminal	  domain	   in	  UPR	  signalling.	   	   Since	  bZIP-­‐IRE1p	  chimeras	  
are	   capable	   of	   splicing	   hac1	   mRNA	   in	   response	   to	   tunicamycin	   treatment	   it	   has	   been	  
suggested	   that	   there	   exists	   a	   mode	   of	   sensing	   ER	   stress	   which	   is	   independent	   of	   luminal	  
domain	  function	  [103].	  	  Indeed,	  bZIP-­‐IRE1p	  and	  wild-­‐type	  IRE1p	  are	  activated	  alike	  following	  
inositol	  depletion	  of	  the	  ER	  membrane	  [106].	  	  Together,	  these	  results	  indicate	  that	  distortions	  
of	  the	  ER	  membrane	  can	  act	  as	  a	  UPR	  activating	  signal	  and	  that	  the	  transmembrane/cytosolic	  
domains	  also	  play	  a	  role	  in	  sensing	  conditions	  of	  ER	  stress.	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1.4 UPR	  signalling	  
An	  overview	  of	  the	  UPR	  is	  illustrated	  in	  Figure	  1-­‐7.	  
1.4.1 UPR	  target	  gene	  transcription	  by	  the	  IRE1	  and	  ATF6	  pathways	  
IRE1	   is	   a	   type	   I	   transmembrane	   protein	   kinase	   whose	   cytoplasmic	   domain	   comprises	   of	   a	  
Serine/Threonine	  kinase	  domain	  and	  a	  site-­‐specific	  RNase	  domain.	  	  Luminal	  activation	  of	  IRE1	  
leads	  to	  its	  dimerisation/oligomerisation	  [76].	  	  As	  such,	  its	  cytoplasmic	  domains	  are	  brought	  
into	   close	   proximity,	   facilitating	   trans-­‐autophosphorylation	   and	   activation	   of	   the	   RNase	  
domain.	  	  The	  importance	  of	  IRE1	  dimerisation	  in	  its	  activation	  has	  been	  highlighted	  in	  several	  
studies.	  	  For	  instance,	  when	  IRE1	  luminal	  region	  is	  substituted	  by	  a	  bZIP	  dimerisation	  domain,	  
the	   chimera	   is	   constitutively	   active	   [103].	   	   Additionally,	   mutation	   of	   conserved	   residues	  
involved	   in	   dimerisation	   (Q105E,	   D123P,	   W125A)	   of	   IRE1	   is	   sufficient	   for	   disrupting	  
phosphorylation	  of	  its	  cytoplasmic	  domain	  and	  downstream	  signalling	  activation	  [101].	  	  	  	  
Active	  IRE1	  RNase	  domain	  excises	  a	  26	  nucleotide	  intron	  from	  the	  xbp1	  mRNA	  (hac1	  mRNA	  in	  
S.	  cerevisiae).	  	  This	  leads	  to	  a	  translational	  frameshift	  and	  conversion	  from	  a	  267	  amino	  acid	  
unspliced	  XBP1	  (XBP1u)	  form	  to	  a	  371	  amino	  acid	  spliced	  XBP1	  (XBP1s)	  version	  [107].	  	  	  XBP1s	  
comprises	   of	   the	   original	   N-­‐terminal	   DNA-­‐binding	   domain	   plus	   an	   additional	   potent	  
transactivation	   domain	   in	   its	   C-­‐terminus	   [107,108].	   	   XBP1s	   binds	   to	   gene	   promoters	  
containing	  the	  ER	  stress	   response	  element	   (ERSE)	   (CCAAT-­‐N9-­‐CCACAG	  consensus	  sequence)	  
and	  activates	  their	  transcription.	  	  ERSEs	  are	  found	  on	  genes	  involved	  in	  processes	  that	  assist	  
in	   restoring	   ER	   homeostasis.	   	   These	   include	   protein	   entry	   into	   the	   ER	   (components	   of	   the	  
Sec61	   channel),	   protein	   folding	   (CNX,	   CRT,	   PDIs,	   glycosylation	   enzymes)	   and	   ERAD	  
components	   (EDEM,	   ERAD-­‐associated	   E3	   ubiquitin-­‐protein	   ligase	   (HRD1)).	   	   Indeed,	   BiP	   and	  
ERdj3	  genes	  are	  also	  highly	  upregulated	  by	  XBP1s	  (and	  the	  active	  ATF6	  p50	  fragment).	  	  XBP1s	  
has	   also	   been	   shown	   to	   enhance	   phospholipid	   biosynthetic	   pathways	   and	   thus	   indirectly	  
regulates	  biogenesis	  of	  the	  ER	  and	  Golgi.	  	  	  
ATF6	  is	  a	  type	  II	  transmembrane	  protein	  whose	  cytosolic	  domain	  contains	  a	  bZIP	  transcription	  
factor.	   	  Upon	  ER	  stress,	  ATF6	  translocates	  to	  the	  Golgi	  apparatus	  where	  the	  site-­‐1	  protease	  
(S1P)	  and	  site-­‐2	  protease	  (S2P)	  cleave	  a	  50	  kDa	  cytosolic	  region	  to	  yield	  the	  ATF6	  p50	  active	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fragment	  [109].	  	  ATF6	  p50	  is	  a	  bZIP	  transcription	  factor	  that	  translocates	  to	  the	  nucleus	  and	  
functions	  mainly	  in	  parallel	  with	  IRE1	  to	  activate	  transcription	  of	  ERSE-­‐containing	  UPR	  target	  
genes	   [110].	   	   Recently,	   a	   number	   of	   ATF6-­‐like	   proteins	   have	   been	   identified	   as	   possible	  
tissue-­‐specific	   ER	   stress	   sensors	   [111].	   	   These	   are	   cyclic	   adenosine	  monophosphate	   (AMP)	  
responsive	   element-­‐binding	   protein	   hepatocyte	   specific	   (CREB-­‐H),	   Luman,	   old	   astrocyte	  
specifically	   induced	  substance	  (OASIS),	  transcript	   induced	  in	  spermiogenesis-­‐40	  (Tisp40)	  and	  
box	  B-­‐binding	  factor	  2	  (BBF2)	  human	  homolog	  on	  chromosome	  7	  (BBF2H7).	  	  All	  these	  ATF6-­‐
related	  bZIP	  factors	  are	  processed	  at	  the	  Golgi	  similarly	  to	  ATF6	  but	  their	  role,	   if	  any,	   in	  the	  
UPR	  is	  not	  yet	  clear.	  
The	   pattern	   of	   genes	   induced	   by	   XBP1s	   and	   ATF6	   p50	   is	   a	   highly	   complex	   and	   dynamic	  
response,	  which	  is	  dictated	  by	  a	  multitude	  of	  factors	  including	  the	  nature	  of	  the	  ER	  stress	  and	  
the	   duration	   of	   UPR	   activation.	   	   Tissue-­‐specific	   variations	   have	   also	   been	   identified.	   	   For	  
example,	   overexpression	   of	   ATF6,	   in	   contrast	   to	   IRE1,	   does	   not	   induce	   the	   transcription	   of	  
ERAD-­‐inducing	   edem,	   herp	   and	   hrd1	   mRNAs	   [110,112].	   	   Immunoprecipitation	   experiments	  
have	  shown	  that	  ATF6	  p50	  can	  heterodimerize	  with	  XBP1s	  to	  bind	  to	  promoter	  elements	  of	  
edem1,	   herp	   and	   hrd1	   genes	   with	   8-­‐fold	   higher	   affinity	   than	   XBP1s	   homodimers	   [110].	  	  
Clearly,	   both	   ATF6	   and	   IRE1-­‐XBP1	   pathways	   must	   be	   simultaneously	   activated	   for	   the	   full	  
execution	  of	  UPR-­‐dependent	  ERAD.	  	  This	  illustrates	  the	  level	  of	  control	  of	  UPR	  signalling	  that	  
exists	  to	  fine	  tune	  outputs	  such	  as	  ERAD.	  
	   	  
	  
	  





Figure	  1-­‐7.	  Overview	  of	  the	  mammalian	  UPR	  
The	  three	  UPR	  mediators,	  PERK,	   IRE1	  and	  ATF6	  are	  ER-­‐transmembrane	  proteins	  with	  an	  ER	  luminal	  domain	  that	  
senses	  conditions	  of	  ER	  stress,	  a	  transmembrane	  region	  and	  cytosolic	  effector	  domains.	  	  During	  ER	  stress,	  the	  UPR	  
is	   activated.	   	   The	   cytosolic	   domains	   of	   PERK	   and	   IRE1	   auto-­‐phosphorylate	   and	   form	   higher	   oligomeric	   species.	  	  
Active	   PERK	   phosphorylates	   eIF2α	   which	   leads	   to	   (i)	   a	   global	   reduction	   in	   protein	   translation	   to	   alleviate	   the	  
folding	  burden	  on	  the	  ER	  and	  (ii)	  specific	  translation	  of	  ATF4	  mRNA.	  	  Active	  IRE1	  mediates	  splicing	  of	  xbp1	  mRNA	  
that	   leads	   to	  expression	  of	  XBP1s	  protein.	   	  Binding	  of	  TRAF2	   to	  active	   IRE1	   cytosolic	  domain	  activates	   the	   JNK-­‐
pathway.	   	   On	   the	   other	   hand,	   active	   ATF6	   translocates	   to	   the	   Golgi	   where	   it	   is	   proteolytically	   cleaved	   into	   an	  
active	  p50	  fragment.	  	  ATF4,	  XBP1s	  and	  ATF6	  p50	  work	  in	  parallel	  to	  induce	  transcription	  of	  UPR	  target	  genes	  and,	  
under	  prolonged	  ER	  stress,	  to	  induce	  apoptotic	  pathways.	  	  JNK	  also	  plays	  an	  important	  role	  in	  apoptosis.	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1.4.2 Translation	  attenuation	  
PERK	   is	   a	   type	   I	   transmembrane	   protein	   with	   a	   cytoplasmic	   domain	   eukaryotic	   Initiation	  
Factor	   2α	   (eIF2α)	   kinase	   domain.	   	   Similarly	   to	   IRE1,	   PERK	   dimerisation	   is	   essential	   for	  
cytoplasmic	  domain	  autophosphorylation	  and	  activation	  of	  downstream	  pathways.	  	  Fusion	  of	  
PERK’s	   cytoplasmic	   domain	   to	   a	   cluster	   of	   differentiation	   4	   (CD4)	   T-­‐lymphocyte	   receptor	  
results	   in	   full	   signal	   response	   following	   chemical	   crosslinking	   of	   the	   receptors	   [76].	   	   Three	  
other	   mammalian	   eIF2α	   kinases	   have	   been	   identified	   and	   each	   sense	   distinct	   stress	  
conditions	   [113].	   	   General	   control	   non-­‐depressible-­‐2	   (GCN2)	   is	   induced	   during	   amino	   acid	  
starvation,	  ultraviolet	   (UV)	   irradiation	  and	  proteasome	  inhibition.	   	  Haem-­‐regulated	   inhibitor	  
(HRI)	   is	   regulated	   by	   heme-­‐deficiency	   and	   oxidative	   stress	   in	   erythroid	   tissues.	   	   PKR	  
participates	   in	   the	   interferon-­‐mediated	   antiviral	   defence.	   	   When	   activated,	   these	   kinases	  
phosphorylate	   Ser51	   on	   eIF2α,	   which	   inhibits	   the	   formation	   of	   the	   pre-­‐initiation	   complex	  
(PIC),	  a	  fundamental	  step	  in	  translation	  initiation	  [113].	   	  The	  common	  downstream	  effect	  of	  
activation	  of	  these	  eIF2α	  kinase	  pathways	  is	  the	  attenuation	  of	  translation.	  	  The	  mechanism	  
involved	  is	  summarised	  in	  Figure	  1-­‐8.	  	  In	  UPR	  signalling,	  the	  reversible	  and	  transient	  reduction	  
of	  mRNA	  translation	  limits	  the	  influx	  of	  newly	  synthesized	  proteins	  in	  the	  already	  stressed	  ER	  
lumen.	   	   Other	   physiological	   effects	   of	   PERK-­‐mediated	   translation	   attenuation	   include	  
inhibition	  of	  cyclin	  D1	  translation	  leading	  to	  Gap	  1	  (G1)	  phase	  cell	  cycle	  arrest,	  and	  targeted	  
ubiquitination	   and	   degradation	   of	   inhibitors	   of	   nuclear	   factor-­‐like	   2	   (Nrf2)	   which	   leads	   to	  
activation	  of	  genes	  involved	  in	  redox	  homeostasis	  [114,115].	  
	   	  
	  
	  





Figure	  1-­‐8.	  Translation	  attenuation	  by	  activated	  PERK	  
eIF2-­‐GTP	  (green)	  binding	  to	  Met-­‐tRNAi	  leads	  to	  the	  recruitment	  of	  additional	  eIFs	  (grey)	  and	  of	  the	  40S	  ribosomal	  
subunit	  (yellow)	  to	  form	  the	  PIC.	  	  PIC	  scans	  the	  mRNA	  to	  be	  translated	  until	  it	  recognises	  the	  AUG	  start	  codon.	  	  At	  
this	  point	  the	  eIFs	  are	  released	  via	  hydrolysis	  of	  the	  GTP-­‐bound	  eIF2.	  	  This	  allows	  for	  the	  recruitment	  of	  the	  60S	  
ribosomal	   subunit	   (blue)	   and	   formation	   of	   the	   80S	   elongation	   complex	   competent	   of	   translation.	   	   The	   guanine	  
nucleotide	  exchange	   factor	  eIF2B	   (grey)	   is	   responsible	   for	  exchanging	  GDP	   for	  GTP	   in	  eIF2	   for	   the	  cycle	   to	  start	  
over.	  	  During	  ER	  stress,	  active	  PERK	  phosphorylates	  eIF2α	  that	  inhibits	  recycling	  of	  eIF2	  from	  a	  GDP-­‐inactive	  form	  
to	  a	  GTP-­‐active	  form.	  	  This	  reduces	  the	  levels	  of	  PIC	  formed	  and	  hence	  decreases	  global	  translation	  levels.	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Two	  additional	  pathways	  for	  ER-­‐selective	  reduction	  of	  substrate	  burden	  have	  been	  described:	  
regulated	   IRE1-­‐dependent	   decay	   (RIDD)	   and	   pre-­‐emptive	   quality	   control	   (pQC).	   	   RIDD	   is	   a	  
relatively	  novel	  and	  poorly	  characterised	  branch	  of	  IRE1	  signalling	  in	  which	  mRNAs	  encoding	  
proteins	  that	  transverse	  the	  secretory	  pathway	  are	  degraded	  [116-­‐121].	  	  Recent	  studies	  have	  
suggested	  that	  at	  physiologically	  low	  levels	  of	  ER	  stress,	  IRE1’s	  RNase	  activity	  is	  very	  specific	  
whereas	   RIDD	   may	   be	   activated	   during	   more	   intensive	   stress	   signalling	   [122,123].	   	   One	  
possibility	   is	   that	   RIDD	  may	   add	   a	   dimension	   to	   the	   tuning	   of	   the	   ER	   stress	   response	   as	   a	  
consequence	   of	   different	   types	   or	   strengths	   of	   ER	   stress	   [122].	   	   Alternatively	   it	   may	   be	   a	  
driving	   force	   towards	   apoptotic	   pathways.	   	   The	   pQC	   pathway	   controls	   the	   efficiency	   of	  
nascent	   chain	   translocation	   into	   the	   ER	   lumen	   by	   preferentially	   allowing	   entry	   of	  
polypeptides	   containing	   a	   specific	   signal	   peptide.	   	   pQC	   is	   a	   thus	   a	   means	   of	   indirectly	  
adapting	   a	   cell’s	   protein	   production	   to	   its	   needs	   and	   is	   especially	   important	   in	   stress	  
responses	   [30].	   	   During	   ER	   stress	   the	   pQC	   has	   been	   shown	   to	   selectively	   degrade	   nascent	  
secretory	   or	   membrane	   proteins,	   but	   it	   directs	   fast	   and	   preferential	   translocation	   of	   BiP	  
chains	  [30].	  
1.4.3 ATF4	  translation	  	  
eIF2α	   phosphorylation	   does	   not	   simply	   result	   in	   a	   static	   change	   in	   the	   composition	   of	  
proteins	  but	  rather	  leads	  to	  a	  coordinated	  change	  the	  translation	  of	  key	  regulatory	  proteins.	  	  
Mainly,	   translation	   of	   mRNA	   encoding	   the	   bZIP	   activating	   transcription	   factor	   4	   (ATF4)	   is	  
activated	   as	   a	   consequence	   of	   PERK-­‐eIF2α	   signalling	   during	   ER	   stress	   in	   a	   mechanism	  
involving	   ribosomal	   re-­‐initiation	   (Figure	  1-­‐9).	   	  ATF4	  synthesis	   is	  controlled	  by	   two	  upstream	  
open	  reading	  frames	  (uORFs)	  on	  the	  5’	  untranslated	  region	  of	  its	  mRNA.	  	  uORF2	  overlaps	  out	  
of	  frame	  with	  atf4’s	  AUG	  codon.	  	  Under	  physiological	  conditions	  expression	  of	  uORF2	  leads	  to	  
the	  bypassing	  of	  that	  encoding	  ATF4.	  	  However,	  during	  stress,	  eIF2α	  phosphorylation	  reduces	  
eIF2-­‐guanosine	  triphosphate	  (GTP)	  levels	  which	  increases	  the	  time	  required	  for	  the	  scanning	  
ribosomes	   to	   become	   competent	   to	   re-­‐initiate	   translation.	   	   This	   delay	  means	   some	   of	   the	  
scanning	   ribosomes	   bypass	   uORF2	   AUG	   codon	   and	   instead	   re-­‐initiate	   translation	   at	   atf4’s	  
AUG	  codon	  [124,125].	  	  Preferential	  translation	  of	  ATF4	  is	  shared	  by	  the	  other	  eIF2α	  kinases	  in	  
response	  to	  their	  relevant	  stress	  signals.	  	  These	  eIF2α-­‐ATF4	  pathways	  have	  been	  collectively	  
referred	  to	  as	  the	  integrated	  stress	  response	  	  [126].	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ATF4,	   similarly	   to	   XBP1s	   and	   ATF6	   p50,	   directs	   transcription	   of	   UPR	   target	   genes	   and	  
specifically	  targets	  genes	  important	  for	  amino	  acid	  biosynthesis	  and	  transport	  functions,	  anti-­‐
oxidative	   stress	   responses	   and	   apoptosis.	   	   These	   include	   Asparagine	   synthetase	   (ASNS),	  
growth	  arrest	   and	  DNA	  damage	  34	   (GADD34),	   CAAT/enhancer-­‐binding	  protein	  homologous	  
protein	   (CHOP),	   activating	   transcription	   factor	   3	   (ATF3)	   and	   ATF6	   [127,128].	   	   The	   direct	  
dependence	  of	  ATF6	  activation	  on	  the	  PERK-­‐eIF2α-­‐ATF4	  pathway	  during	  ER	  stress	  highlights	  
the	  intricacy	  and	  cross-­‐talk	  that	  exists	  between	  the	  various	  UPR	  branches	  [128].	  
	  
	   	  
	   	  
	  
	  





Figure	  1-­‐9.	  Selective	  translation	  of	  atf4	  mRNA	  
eIF2α-­‐P	  increases	  translation	  of	  atf4	  mRNA	  by	  a	  mechanism	  involving	  ribosomal	  re-­‐initiation.	  	  atf4	  mRNA	  contains	  
two	  uORFs	  and	  an	  ATF4	  ORF	  coding	  region.	  	  After	  translation	  of	  the	  5’	  uORF1,	  ribosomes	  resume	  scanning	  along	  
the	  mRNA.	  	  	  
(A)	   During	   physiological	   conditions,	   eIF2-­‐GTP	   (green)	   is	   readily	   available	   so	   that	   the	   80S	   elongation	   complex	   is	  
rapidly	  formed,	  translation	  quickly	  resumes	  and	  uORF2	  is	  expressed.	  	  Since	  uORF2	  overlaps	  out	  of	  frame	  with	  ATF4	  
ORF,	  ATF4	  coding	  region	  is	  bypassed	  and	  the	  protein	  is	  not	  expressed.	  
(B)	  During	  ER	  stress,	  phosphorylation	  of	  eIF2α	  reduces	  the	  levels	  of	  eIF2-­‐GTP,	  which	  increases	  the	  time	  required	  
for	  the	  scanning	  40S	  ribosome	  to	  acquire	  eIF2-­‐GTP	  to	  form	  the	  active	  PIC.	  	  This	  results	  in	  the	  majority	  of	  scanning	  
ribosomes	  to	  bypass	  uORF2.	  	  However	  in	  the	  interval	  between	  uORF2	  and	  ATF4	  ORF,	  eIF2-­‐GTP	  may	  have	  sufficient	  
time	  to	  bind	  to	  the	  40S	  subunit,	  form	  the	  PIC,	  recruit	  the	  60S	  subunit	  and	  allow	  for	  expression	  of	  ATF4.	  
ORFs	  are	   illustrated	  as	  boxes	  and	   shading	   indicates	   their	  encoding	   sequence	   is	   expressed.	   	  Active	  40S-­‐eIF2-­‐GTP	  
(PIC)	  is	  shown	  in	  yellow;	  inactive	  40S	  alone	  is	  shown	  in	  white.	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1.4.4 Apoptosis	  
Usually,	  all	   three	  branches	  of	   the	  UPR	  are	  activated	  by	  any	  given	  ER	  stress.	   	  However	   their	  
timing	  can	  differ,	  which	  affects	  the	  physiological	  effect	  of	  UPR	  signalling	  (pro-­‐survival	  versus	  
apoptosis)	   [129].	   	  Prolonged,	   chronic	  or	  high	   levels	  of	  ER	  stress	   sensitize	  cells	   to	  apoptosis.	  	  
The	  regulation	  of	  this	  switch	  is	  mainly	  coordinated	  by	  IRE1	  and	  PERK	  signalling.	  
Although	  PERK	  signalling	  appears	  to	  be	  constant	  throughout	  the	  UPR,	  translational	  repression	  
is	   transient.	   	   6	   to	   12	   hours	   after	   initiation	   of	   the	   UPR,	   ATF4-­‐dependent	   activation	   of	   the	  
GADD34	   promoter	   leads	   to	   dephosphorylation	   of	   eIF2α	   allowing	   for	   translational	   recovery	  
[130].	   	   GADD34	   also	   results	   in	   increased	   levels	   of	   BiP	   expression,	   which	   inhibits	   PERK	  
activation.	   	   In	   addition,	   GADD34	   plays	   a	   role	   in	   driving	   cells	   towards	   apoptotic	   pathways	  
[131].	   	  GADD34	  leads	  to	  translational	  recovery,	  by	  dephosphorylating	  eIF2α.	   	  If	  the	  cells	  are	  
unable	   to	   cope	  with	   the	   increased	   protein	   synthesis,	   apoptotic	   pathways	   are	   initiated.	   	   In	  
addition,	  P58	  inhibitor	  of	  protein	  kinase	  (P58IPK)	   is	  activated	  during	  ER	  stress	  and	  has	  been	  
shown	  to	  decrease	  PERK	  phosphorylation	  in	  the	  late	  ER	  stress	  response	  [132].	  	  
In	   contrast	   to	  PERK	  signalling,	   levels	  of	   active	   ire1	   and	  xbp1s	  mRNA	   fall	   after	  prolonged	  ER	  
stress	  [98].	  	  This	  may	  serve	  as	  a	  mechanism	  to	  drive	  cells	  towards	  apoptosis	  by	  shutting	  down	  
resolving	   pathways	   (such	   as	   IRE1’s).	   	   Indeed,	   ire1	   -­‐/-­‐	   or	   xbp1	   -­‐/-­‐	   cells	   show	   increased	  
apoptosis	  as	  a	  result	  of	  ER	  stress	  [133].	   	  On	  the	  other	  hand,	  experimentally	  prolonging	  IRE1	  
signalling	  pathways	  enhances	  the	  survival	  of	  cells	  [133].	   	  During	  the	  early	  phase	  of	  the	  UPR,	  
eIF2α	   phosphorylation	   attenuates	   translation	   of	  many	  mRNAs,	   including	   that	   encoding	   for	  
XBP1s	  [134].	  	  When	  translation	  resolves	  during	  the	  later	  phases	  of	  the	  ER	  stress	  response,	  the	  
accumulated	   xbp1s	   mRNA	   is	   translated	   allowing	   transcription	   of	   target	   genes	   including	   its	  
own	  creating	  a	  positive	  feedback	  loop	  [134].	  
It	  is	  clear	  that	  diversion	  from	  survival	  to	  apoptotic	  pathway	  is	  not	  a	  binary	  event	  but	  rather	  a	  
carefully	  coordinated	  outcome	  of	  the	  three	  UPR	  pathways.	  	  Mechanisms	  by	  which	  apoptotic	  
signals	   are	   generated	   following	   prolonged	   ER	   stress	   include	   CHOP,	   IRE1-­‐mediated	   TNF	  
receptor	  associated	  factor	  2	  (TRAF2)	  activation	  and	  caspase	  pathways	  and	  are	  summarised	  in	  
Figure	  1-­‐10	  [142].	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Figure	  1-­‐10.	  UPR-­‐mediated	  apoptosis	  
Prolonged	   conditions	   of	   ER	   stress	   can	   result	   in	   apoptosis.	   	   This	   can	   be	   mediated	   by	   PERK	   (ATF4-­‐CHOP),	   IRE1	  
(XBP1s-­‐CHOP;	   TRAF2-­‐JNK/Bak/Bax;	   Jab1;	   RIDD;	   CD59)	   and	  ATF6	   (CHOP)	   pathways.	   	   CHOP	   leads	   to	   inhibition	   of	  
expression	  of	  anti-­‐apoptotic	  Bcl2	  proteins	  and	  increased	  expression	  of	  genes	  encoding	  pro-­‐apoptotic	  factors.	  	  JNK	  
leads	  to	  activation	  of	  Bim	  and	  Bad	  which	  also	  inhibit	  anti-­‐apoptotic	  Bcl2	  proteins.	  	  Release	  of	  Ca2+	  from	  the	  ER	  (via	  
Bak/Bax	  and	  generation	  of	  ROS)	  and	  mitochondria	  (due	  OMM	  permeabilization)	  leads	  to	  activation	  of	  the	  caspase	  
pathways,	  which	  ultimately	   leads	   to	   apoptosis.	   	   Two	  Ca2+-­‐independent	   caspase	  pathways	  have	  been	   identified:	  
release	  of	  mitochondrial	  Cytc	  and	  caspase	  12-­‐mediated	   in	  M.	  musculus	   cells.	   	   Transcription	   factors	   (purple)	  are	  
shown	  as	  boxes;	  inactive	  (white)	  and	  active	  (blue)	  mediator	  proteins	  are	  shown	  as	  ovals.	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1.5 UPR	  pathologies	  
In	  lower	  eukaryotes,	  ER	  stress	  leads	  to	  perturbations	  in	  cell	  wall	  assembly	  and	  function	  of	  the	  
plasma	  and	  vacuolar	  membranes	  [73].	  	  In	  higher	  eukaryotes,	  perturbations	  of	  ER	  function	  and	  
UPR	  activation	  has	  been	  linked	  to	  several	  human	  diseases	  [135-­‐137].	  	  These	  include	  diabetes,	  
cystic	   fibrosis,	   ischaemia,	   neurodegenerative	   conditions	   and	   cancer.	   	   The	   importance	   of	  
mammalian	   UPR	   pathways	   in	   cellular	   functions,	   especially	   in	   that	   of	   secretory	   organs,	   has	  
been	  highlighted	  in	  knockout	  animal	  models.	  	  	  
perk	   knockout	   mice	   develop	   type	   1	   diabetes	   and	   exocrine	   dysfunction	   after	   birth	   [138].	  	  
These	  mice	  died	  within	  18	  hours	  after	  birth	  due	  to	  hyperglycaemia.	  	  A	  similar	  phonotype	  was	  
observed	  for	  mice	  containing	  a	  homozygous	  eIF2α	  S51A	  mutation	  [139].	  	  39	  PERK	  mutations	  
have	   been	   reported	   in	   patients	   with	   Wolcott-­‐Rallison	   Syndrome	   (WRS),	   a	   rare	   autosomal	  
recessive	   disorder	   in	   humans	   [140].	   	   Similarly	   to	  perk-­‐/-­‐	   and	   eIF2α	   S51A	  mice,	  WRS	   causes	  
defects	  in	  pancreatic	  function,	  metabolism	  and	  skeletal	  development.	  
	  ire1	   and	   xbp1	   knockout	   is	   embryonic	   lethal	   [141-­‐143].	   	   ire1β	   knockout	   allows	   for	   normal	  
development	  provided	  the	  mice	  are	  not	  subjected	  to	  insults	  in	  the	  gut	  [144].	  	  atf6α	  and	  atfβ	  
single	   knockout	   mice	   are	   viable	   and	   develop	   normally	   whereas	   their	   combined	   deletion	  
results	  in	  embryonic	  lethality	  [110].	  	  This	  indicates	  that	  the	  two	  ATF6	  isoforms	  functional	  in	  a	  
combinatorial	  fashion.	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1.5.1 PERK-­‐mediated	  disease	  states	  
The	   number	   of	   studies	   implicating	   components	   of	   the	   UPR	   with	   human	   diseases	   is	   vast	  
(recently	  reviewed	  by	  Yoshida	  and	  co-­‐workers)	   [137].	   	  Only	  the	  major	  discoveries	  regarding	  
PERK	  will	  be	  outlined	  here.	  
1.5.1.1 Diabetes	  
PERK	  is	  essential	  for	  development	  of	  endocrine	  progenitor	  cells	  into	  insulin-­‐expressing	  β-­‐cells	  
and	   glucose	   homeostasis	   during	   the	   early	   neonatal	   period	   and	   can	   cause	   type	   1	   diabetes	  
[145].	  	  Several	  factors	  play	  a	  role	  in	  the	  development	  of	  insulin	  resistance	  and	  β-­‐cell	  death	  as	  
a	   result	  of	   ER	   stress	  which	  ultimately	   causes	   type	  2	  diabetes	   [146].	   	  Diabetes	  may	  develop	  
due	  to	  PERK-­‐mediated	  disruption	  of	  protein	  translation,	  including	  that	  of	  proinsulin,	  or	  from	  
β-­‐cell	  death	  as	  a	  result	  of	  apoptotic	  UPR	  pathways.	  
1.5.1.2 	  Ischaemia	  
Deletion	  of	  perk,	  but	  not	  the	  other	  eIF2α	  kinases,	  blocked	  cerebral	  ischaemia-­‐induced	  eIF2α	  
phosphorylation	  [147].	  	  Activation	  of	  PERK	  can	  lead	  to	  stalling	  of	  PICs	  which	  are	  essential	  for	  
the	   reconfiguration	   of	   stress	   granules	   during	   ischaemia	   [147].	   	   When	   stress	   granules	   are	  
sequestered	   into	   larger	   protein	   aggregates,	   they	   signal	   irreversible	   inhibition	   of	   protein	  
synthesis	  and	  death	  of	  affected	  neuronal	  tissues	  [147].	  
1.5.1.3 Cancer	  
Cancer	  cells	  must	  be	  able	  to	  proliferate	  in	  harsh	  nutrient	  deprived	  and	  hypoxic	  environments.	  	  
These	  conditions	  are	  often	  causative	  of	  ER	  stress.	  	  Activation	  of	  the	  UPR	  is	  a	  mechanism	  for	  
tumour	  cells	   to	  be	  able	   to	  cope	   in	  such	  environments.	   	  Microarray	  analyses	  have	   identified	  
several	  tumerogenic	  genes,	  which	  are	  preferentially	  translated	  in	  a	  PERK-­‐dependent	  manner	  
[148].	   	   In	  fact,	   injection	  of	  perk-­‐/-­‐	  mouse	  embryonic	  fibroblasts	  (MEFs)	  transformed	  with	  the	  
oncogenic	   kirsten	   rat	   sarcomA-­‐2	   viral	   (kras2)	   gene	   into	   nude	   mice	   leads	   to	   substantially	  
slower	  growing	  tumours	  and	  decreased	  microvessel	   formation	  [148].	   	  Loss	  of	  perk	   in	  breast	  
cancer	  mice	  models	  results	  in	  delayed	  metastasis	  and	  tumerogenesis	  [149].	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1.5.2 Targeting	  the	  UPR	  for	  therapies	  
Given	   that	   the	   functionality	   of	   the	   UPR	   is	   critical	   for	  many	   disease	   states,	   its	   components	  
represent	  excellent	  targets	  for	  therapy	  of	  these	  pathologies.	  	  As	  thoroughly	  reviewed	  by	  Hetz	  
and	  co-­‐workers	   these	   include	  compounds	  to	  attenuate	  ER	  stress	   levels	   (enhancers	  of	  eIF2α	  
phosphorylation,	   use	   of	   chemical	   chaperones,	   chemical	   induction	   of	   BiP)	   or	   to	   inhibit	   UPR	  
pro-­‐survival	  effects/promote	  adaptation	   to	  ER	   stress	   	   (inhibitors	  of	   IRE1	  and	  PERK	  cytosolic	  
domains,	   modulators	   of	   chaperones	   and	   ERAD	   components)	   [150].	   	   Gene	   therapy	   using	  
recombinant	  viruses	  to	  deliver	  active	  UPR	  components	  to	  specific	  affected	  tissues	  has	  been	  
successfully	  employed.	   	  For	  example	  use	  of	  adeno-­‐associated	  virus	  (AAV)	  to	  incorporate	  BiP	  
gene	   has	   been	   shown	   to	   restore	   visual	   function	   in	   mutant	   rhodopsin	   transgenic	   rats	   and	  
reduce	   liver	   steatosis	   in	   obese	  mice	   [151].	   	   Inhibition	   of	   PERK	   by	   using	   the	   small	   inhibitor	  
molecuse	  ISRIB	  has	  been	  shown	  to	  reduce	  the	  viability	  of	  cells	  subjected	  to	  chronic	  ER	  stress	  
[152].	   	   ISRIB	   blocks	   the	   activation	   of	   PERK,	   and	   therefore	   eIF2α	   phosphorylation	   and	  
translation	  attenuation,	  so	  that	  cells	  are	  unable	  to	  cope	  with	  their	  protein	  synthesis.	  	  As	  such	  
it	   is	  an	  important	  tool	  that	  can	  be	  employed	  to	  kill	  cancerous	  cells,	  especially	  those	  derived	  
from	  secretory	  lineages	  and	  thus	  have	  increased	  protein	  synthesis	  and	  higher	  basal	  levels	  of	  
ER	   stress.	   	   This	   includes	  myelomas,	   and	  pancreatic	   and	  breast	   cancers.	   	   Finally,	  Guanabenz	  
has	   been	   used	   to	   increase	   the	   viability	   of	   cells	   subjected	   to	   ER	   stress	   [153].	   	   Guanabenz	  
selectively	   inhibits	   GADD34	   which	   delays	   eIF2α	   dephosphorylation	   and	   translational	  
recovery.	  
Structural	   insights	   of	   the	   UPR	   components	   are	   certainly	   fundamental	   for	   the	   efficacy	   and	  
specificity	   of	   drug	   development.	   	   Indeed,	   since	   the	   resolution	   of	   the	   structure	   of	   IRE1’s	  
cytoplasmic	  domain,	   several	   specific	   inhibitors	  of	   IRE1	  RNase	   activity	   have	  been	  developed	  
for	  anti-­‐cancer	  therapies,	  especially	  in	  the	  context	  of	  multiple	  myeloma	  [136,154,155].	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2 X-­‐ray	  crystallography	  theory	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2.1 Protein	  crystallisation	  
Obtaining	  crystals	  of	  a	  protein	  is	  a	  key	  step	  in	  determining	  its	  structure.	  	  For	  crystals	  to	  form,	  
the	  protein	  molecules	  must	   separate	   from	   the	   surrounding	   solution	   and	   self	   assemble	   in	   a	  
three	   dimensional	   periodic	   pattern	   [156].	   	   This	   forms	   the	   crystal	   lattice,	   which	   is	   held	  
together	   by	  weak	   intermolecular	   interactions.	   	   The	   simplest	   building	   block	   from	  which	   the	  
lattice	  can	  be	  constituted,	  by	  successive	  translation	  along	  its	  edges,	  is	  the	  unit	  cell	  [157].	  	  The	  
asymmetric	  unit	  of	  the	  unit	  cell	  is	  its	  part	  that	  can	  be	  used	  to	  generate	  the	  complete	  unit	  cell	  
by	  applying	  the	  symmetry	  operations	  of	  the	  crystal’s	  space	  group	  (Chapter	  6).	  
Protein	   crystallisation	   can	   be	   elegantly	   illustrated	   by	   the	   phase	   diagram	   (Figure	   2-­‐1)	   [158].	  	  
The	   solubility	   curve	   of	   a	   protein	   represents	   the	   thermodynamic	   equilibrium	   between	   the	  
liquid	   and	   solid	   phases.	   	   In	   the	   supersaturated	   metastable	   zone,	   the	   solid	   phase	   is	   more	  
thermodynamically	   stable	   and	   hence	   the	   formation	   of	   protein	   crystals	   is	   favoured.	   	   In	  
solution,	  protien	  molecules	  constantly	  tumble,	  randomly	  collide	  in	  different	  orientations	  and	  
may	   form	   inter-­‐molecuar	   contacts.	   	   However,	   the	   kinetic	   barrier	   that	   exists	   for	   phase	  
separation	  must	  be	  overcome	  to	  allow	  the	  self-­‐assembly	  of	  protein	  molecules	   into	  crystals.	  	  
This	  is	  achieved	  by	  a	  reduction	  in	  the	  net	  Gibbs	  free	  energy	  of	  the	  system	  resulting	  from	  the	  
formation	  of	  favourable	  intermolecular	  contacts,	  accompanied	  by	  a	  gain	  in	  entropy.	  
As	  the	  proteins	  shift	  from	  the	  liquid	  to	  solid	  phase,	  there	  is	  a	  reduction	  in	  entropy	  due	  to	  the	  
loss	   of	   conformational	   freedom.	   	   This	   unfavourable	   effect	   however,	   is	   more	   than	  
compensated	   by	   the	   gain	   in	   entropy	   that	   occurs	   as	   a	   result	   of	   the	   release	   of	   the	   water	  
molecules	   around	   the	   hydrophobic	   and	   polar	   solvent-­‐exposed	   residues	   of	   the	   protein	   in	  
solution.	  	  Overall	  this	  results	  in	  the	  reduction	  in	  the	  net	  Gibbs	  free	  energy	  of	  the	  system.	  	  This	  
overcomes	  the	  kinetic	  barrier	  that	  exists	  for	  phase	  separation	  and	  allows	  the	  self-­‐assembly	  of	  
protein	   molecules	   into	   crystals.	   	   This	   process	   is	   known	   as	   nucleation	   and	   is	   driven	   by	  
superstaruation	   in	   the	   labile	   zone.	   	  Nulceation	   is	   followed	  by	   crystal	   growth	   to	  expand	   the	  
lattice	   (metastable	   zone).	   	   This	   involves	   the	   addition	   of	   protein	   molecules	   following	   the	  
regular	   and	   repeating	   arrangement	   defined	   at	   the	   nucleation	   stage.	   	   The	   gain	   in	   enthalpy	  
provided	  by	  the	  binding	  reactions	  overcomes	  the	  entropic	  loss	  during	  crystal	  growth	  so	  that	  
the	   system	   can	  proceed.	   	  When	   supersaturation	   is	   exhausted,	   due	   to	   the	   concentration	   of	  
free	  protein	  molecules	   in	   the	   solution	  being	  depleted,	   crystallisation	   is	   complete.	   	   The	   size	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and	   rate	   of	   crystal	   formation	   can	   be	   in	   part	   controlled	   by	   varying	   factors	   such	   as	   the	  
composition	  of	   the	   crystallisation	  buffer,	  protein	   concentration,	  pH	  or	   temperature.	   	   These	  
affect	  a	  protein’s	  solubility	  and	  thus	  its	  behaviour	  in	  the	  phase	  diagram.	  
Controlled	  nucleation	  is	  frequently	  difficult	  to	  achieve.	  	  Initial	  hits	  often	  consist	  of	  either	  too	  
many	  nucleation	  events,	  resulting	  in	  showers	  of	  microcrystals,	  or	  too	  few,	  yielding	  very	  poor	  
crystal	  quantities.	  	  Seeding	  is	  a	  technique	  used	  to	  manipulate	  nucleation	  [159].	  	  Crystal	  seeds	  
are	   made	   from	   crushing	   pre-­‐existing	   crystals,	   or	   sometimes	   crystalline	   or	   non-­‐amorphous	  
precipitates.	   	   These	   are	   introduced	   as	   heterogeneous	   nucleation	   sites	   in	   supersaturated	  
protein	  solutions.	  	  When	  optimised	  this	  can	  lead	  to	  the	  growth	  of	  single	  large	  crystals	  of	  high	  
quality.	  
Common	  methods	  employed	  to	  crystallise	  proteins	  include	  vapour	  diffusion,	  sandwich	  drop,	  
microbatch,	  under	  oil,	  dialysis	  and	  free	  interface	  diffusion	  [156].	  	  Vapour	  diffusion	  was	  used	  
throughout	  this	  study.	  	  In	  this	  method,	  the	  protein	  is	  mixed	  with	  the	  crystallisation	  buffer	  and	  
left	   to	  equilibrate	  against	   a	   reservoir	   containing	   the	   same	   crystallisation	  buffer,	   in	   a	   sealed	  
environment.	  	  Owing	  to	  differences	  in	  the	  concentration	  of	  the	  precipitating	  agent	  between	  
the	   crystallisation	   drop	   and	   the	   reservoir,	   water	   vapour	   diffuses	   from	   the	   drop	   to	   the	  
reservoir.	  	  This	  raises	  both	  the	  protein	  and	  precipitant	  concentrations	  of	  the	  drop,	  which	  can	  
result	  in	  supersaturation	  and	  thus	  spontaneous	  nucleation,	  followed	  by	  crystal	  growth.	   	  
	   	  
	  
	  



























Figure	  2-­‐1.	  Crystallisation	  phase	  diagram	  
The	  solubility	  of	  proteins	  can	  be	  represented	  by	  the	  phase	  diagram.	  	  This	  information	  can	  be	  used	  to	  understand	  
protein	  crystallisation	  as	  a	   function	  of	  protein	  and	  precipitant	  concentration.	   	   In	  conditions	  below	  the	  solubility	  
curve,	   in	   the	   undersaturated	   zone,	   proteins	   remain	   in	   solution.	   	   Spontaneous	   nucleation	   can	   occur	   only	   in	   the	  
supersaturated	   labile	   zone.	   	   This	   causes	   the	   protein	   concentration	   in	   solution	   to	   decrease.	   	   Supersaturated	  
metastable	  conditions	  then	  sustain	  growth	  of	  the	  microcrystals.	   	   If	  the	  concentration	  of	  protein	  or	  precipitant	   is	  
too	  high,	  precipitation	  occurs.	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2.2 X-­‐ray	  diffraction	  
2.2.1 X-­‐ray	  scattering	  by	  protein	  crystals	  
Protein	   X-­‐ray	   crystallography	   is	   based	   on	   the	   diffraction	   of	   X-­‐rays	   by	   the	   protein’s	   atoms,	  
primarily	  by	   their	  electrons.	   	  The	  structure,	  or	  arrangement,	  of	   the	   scattering	  atoms	  within	  
the	  crystal	  lattice	  is	  derived	  from	  their	  X-­‐ray	  diffraction	  pattern	  [157].	  	  
In	  order	  for	  an	  object	  to	  diffract	  light,	  the	  wavelength	  must	  be	  in	  the	  order	  of	  the	  size	  of	  the	  
object.	   	   The	   bonded	   atoms	   in	   protein	   molecules	   are	   roughly	   1.5	   Å	   apart.	   	   X-­‐rays	   have	   a	  
wavelength	   between	   0.1	   and	   100	  Å	   and	   therefore	   fall	  within	   the	   required	   range	   to	   record	  
diffraction	   by	   atoms	   in	   a	   protein.	   	   Synchrotron	   radiation	   sources	   are	   used	   to	   accelerate	  
electrons,	  to	  near	  the	  speed	  of	  light,	  through	  a	  magnetic	  field	  around	  the	  booster	  and	  storage	  
rings	   [160].	   	   Bending	   magnets	   are	   used	   to	   deflect	   the	   electrons	   passing	   through	   their	  
magnetic	   field	   to	   give	  off	   electromagnetic	   radiation.	   	   This	  produces	  a	  beam	  of	   synchrotron	  
light	  whose	   intensity	   is	   increased	   by	   insertion	   devices,	   commonly	  wigglers	   and	   undulators.	  	  
Insertion	  devices	  are	  found	  in	  the	  straight	  sections	  of	  synchrotrons	  so	  that	  light	  in	  the	  X-­‐ray	  
range	   reaches	   the	  end	   station	  of	  beamlines.	   	   The	  wavelength	  of	   the	   light	  produced	   can	  be	  
modified	  by	  changing	  the	  gap	  between	  the	  components	  of	  the	  insertion	  devices.	  
2.2.1.1 Bragg’s	  law	  and	  the	  Ewald	  sphere	  
In	   1913	   by	   William	   Lawrence	   Bragg	   and	   his	   father	   William	   Henry	   Bragg	   showed	   that	   a	  
diffracted	   X-­‐ray	   beam	  occurs	  when	   a	   specific	   set	   of	   conditions,	   defined	   by	   Equation	   1,	   are	  
satisfied	  [157,161].	  
Equation	  1	  2𝑑𝑠𝑖𝑛𝜃 = 𝑛𝜆	  
Here	  d	  is	  the	  spacing	  between	  two	  lattice	  planes	  in	  the	  atomic	  lattice,	  λ	  is	  the	  wavelength	  of	  
the	  incident	  wave	  and	  θ	  is	  the	  angle	  between	  the	  incident	  ray	  and	  the	  scattering	  plane.	  	  This	  
is	   known	   as	   Bragg’s	   law	   and	   is	   the	   foundation	   of	   X-­‐ray	   crystallography	   (Figure	   2-­‐2A).	   	   The	  
intensity	  of	   the	  diffracted	  X-­‐ray	   is	  dependent	  on	  how	  many	  atoms,	  or	   electrons,	   lie	  on	   the	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planes	  upon	  which	  it	  impinges.	  	  The	  ‘space’	  occupied	  by	  the	  reflections	  of	  the	  scattered	  X-­‐ray	  
beam	  is	  known	  as	  the	  reciprocal	  lattice	  and	  is	  defined	  by	  the	  coordinates	  hkl	  (Miller	  indices).	  	  
The	  coordinates	  of	  the	  real	  space	  are	  xyz	  and	  define	  the	  locations	  of	  the	  protein’s	  atoms	  in	  
the	  unit	   cell.	   	   The	  vertex	  of	   the	  unit	   cell	   is	   known	  as	   the	  origin,	  which	  has	  xyz	   coordinates	  
000.	  
Another	  geometric	  construct	  which	  can	  be	  used	  to	  demonstrate	  the	  relationship	  between	  the	  
planes	   of	   a	   crystal	   lattice	   and	   its	   reciprocal	   is	   the	   Ewald	   sphere	   (Figure	   2-­‐2B).	   	   The	   Ewald	  
sphere,	   or	   sphere	   of	   reflection,	   introduced	   by	   Paul	   Peter	   Ewald	   in	   1913,	   has	   a	   radius	   of	  
1/wavelength	   (λ)	   and	   passes	   through	   the	   origin	   of	   the	   reciprocal	   lattice	   [157,161].	   	   A	  
reciprocal	   lattice	  point	   is	  recorded	  only	  when	   it	   lies	  on	  the	  Ewald	  sphere.	   	  Therefore	  at	  any	  
one	  orientation	  only	  a	  small	  proportion	  of	  the	  reciprocal	  lattice	  points	  will	  contribute	  to	  the	  
diffraction	   pattern.	   	   By	   rotating	   the	   crystal	   in	   the	   X-­‐ray	   beam,	   different	   points	   of	   the	  
reciprocal	   lattice	   lie	  along	   the	  edge	  of	   the	  Ewald	  sphere	  and	  are	   recorded.	   	  The	  degrees	  of	  
rotation	  of	  the	  crystal	  during	  each	  image,	  phi	  (φ)	  angle,	  and	  throughout	  the	  data	  collection,	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Figure	  2-­‐2.	  Bragg’s	  law	  and	  Ewald	  sphere	  
(A)	  The	  difference	  in	  path	  length	  travelled	  by	  two	  rays	  reflected	  from	  successive	  planes	  (Pn)	  of	  a	  crystal	  
lattice	  (purple),	  R1	  and	  R2,	  is	  equal	  to	  2dhklsinθ.	  	  Bragg’s	  law	  states	  that	  if	  this	  distance,	  2dsinθ,	  equals	  
to	  an	  integral	  multiple	  of	  the	  wavelength	  (nλ),	  then	  the	  two	  rays	  interfere	  constructively	  to	  produce	  a	  
strong	  diffracted	  beam.	  
(B)	  X-­‐rays	  are	  diffracted	  by	  a	  protein	  crystal	  (purple)	  to	  produce	  a	  reciprocal	  lattice	  (grey),	  with	  planes	  
Ln.	   	  The	  diffracted	  X-­‐ray	  diverges	  from	  the	  beam	  by	  the	  angle	  2θ.	   	  The	  sphere	  of	  reflection,	  or	  Ewald	  
sphere,	   is	  an	   imaginary	  sphere	  with	  radius	  1/λ	  and	  which	  passes	  through	  the	  origin	  of	  the	  reciprocal	  
lattice	   (000).	   	   Only	   reciprocal	   lattice	   points	   which	   lie	   on	   the	   surface	   of	   this	   Ewald	   sphere	   (red)	   are	  
recorded	  and	  produce	  diffraction	  spots	  on	  the	  detector.	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2.2.1.2 Electron	  density	  as	  a	  Fourier	  sum	  
Sinusoidal	  waves	  can	  be	  described	  by	  a	  periodic	  function	  defined	  by	  Equation	  2	  and	  Equation	  
3	  where	  ƒ(x)	  specifies	  the	  vertical	  height	  of	  the	  wave	  at	  any	  position	  x	  along	  the	  wave,	  h	   is	  
the	  frequency	  (which	  is	  proportional	  to	  the	  inverse	  of	  the	  wavelength),	  F	  is	  the	  amplitude	  and	  
α	   is	  the	  phase,	  or	  position	  of	  the	  wave	  with	  respect	  to	  the	  origin	  [157,161].	   	  The	  variable	  x	  
and	  the	  constant	  α	  are	  fractions	  of	  the	  wavelength	  expressed	  in	  angles.	  
Equation	  2	    𝒇 𝒙 = 𝑭𝒄𝒐𝒔𝝅(𝒉𝒙+ 𝜶)	  
	  
Equation	  3	  𝑓 𝑥 = 𝐹𝑠𝑖𝑛𝜋(ℎ𝑥 + 𝛼)	  
In	  1822,	  Jean	  Baptiste	  Joseph	  Fourier	  showed	  that	  waves,	  or	  Fourier	  terms,	  can	  be	  added	  to	  
give	  a	  complicated	  function,	  known	  as	  a	  Fourier	  sum.	  	  A	  general	  Fourier	  sum	  of	  waves	  can	  be	  
described	   using	   complex	   numbers	   as	   in	   Equation	   4.	   	   More	   simply,	   replacing	   the	   complex	  
number	   in	  square	  brackets	  using	  Equation	  5	   (derived	  from	  complex	  number	  theory),	  where	  
θ=2π(hx),	  gives	  Equation	  6.	  
	  
Equation	  4	  𝒇 𝒙 = 𝑭𝒉[𝒄𝒐𝒔𝟐𝝅 𝒉𝒙 + 𝒊𝒔𝒊𝒏𝟐𝝅 𝒉𝒙 ]𝒉 	  
Equation	  5	  𝑐𝑜𝑠 𝜃 + 𝑖𝑠𝑖𝑛𝜃 = 𝑒!" 	  
	  
Equation	  6	  𝑓 𝑥 = 𝐹!𝑒!!" !!! 	  
	  
In	   X-­‐ray	   crystallography,	   the	   scattered	   X-­‐rays	   waves	   give	   rise	   to	   the	   recorded	   diffraction	  
pattern.	  	  The	  scattered	  X-­‐rays	  are	  described	  by	  three-­‐dimensional	  waves	  of	  the	  general	  form	  
ƒ(xyz).	   	   Each	   recorded	   reflection,	  or	  diffraction	  spot,	   is	   the	  sum	  of	  diffractive	  contributions	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from	  all	  atoms	  that	  lie	  on	  the	  crystal	  lattice	  plane	  of	  the	  incident	  X-­‐ray.	  	  Diffraction	  spots	  are	  
described	  by	  the	  structure	  factors	  Fhkl.	  	  Each	  structure	  factor	  can	  be	  written	  as	  a	  Fourier	  sum	  in	  
which	  each	  term	  gives	  the	  contribution	  of	  one	  atom	  to	  the	  reflection	  hkl. 	  Therefore,	  Fourier	  
transform	   of	   all	   Fhkl	   terms	   of	   a	   diffraction	   experiment	   can	   be	   used	   to	   derive	   the	   protein’s	  
atomic	  structure.	  	  The	  structure	  factor	  equation	  (Equation	  7)	  is	  used	  to	  calculate	  each	  Fhkl	  from	  
the	  sum	  of	  the	  waves	  scattered	  by	  the	  i	  atoms	  with	  coordinates	  xyz. 
	  
Equation	  7	  𝐹!!" = 𝑓!𝑒!!"(!!!!"!!")! 	  
Since	  it	  is	  the	  electrons	  in	  a	  protein	  that	  mainly	  scatter	  X-­‐rays	  it	  is	  more	  accurate	  to	  refer	  to	  
the	   Fourier	   transform	   of	   Fhkl	   as	   giving	   rise	   to	   the	   electron	   density	   (ρ)	   of	   a	   protein,	   not	   its	  
atomic	   structure	  per	   se.	   	   The	   inverse	  Fourier	   transform	  of	  all	  Fhkl	   terms	  defines	   the	  electron	  
density	  at	  point	  xyz.  This	   is	  denoted	  as	  ρ(xyz).	   	  ρ(xyz)	  can	  be	  derived	  from	  the	  diffraction	  
pattern	  using	  Equation	  8,	  where	  V	  is	  the	  volume	  of	  the	  unit	  cell.	  	  	  
Equation	  8	  𝜌 𝑥𝑦𝑧 = 1𝑉 𝐹!!"𝑒!!!"(!!!!"!!")!!!  
 
Calculation	  of	  ρ(xyz)	  gives	  rise	  to	  the	  electron	  density	  map	  of	  a	  protein.	  	  This	  is	  essentially	  the	  
three-­‐dimensional	  space	  occupied	  by	  the	  orbiting	  electrons	  of	  the	  ordered	  atoms	  of	  a	  protein	  
within	   a	   crystal.	   	   Once	   the	   electron	   density	  map	   is	   obtained,	   one	   can	   proceed	  with	  model	  
building	  and	  refinement.	  
2.2.1.3 Unit	  cell	  symmetry	  and	  space	  groups	  
Unit	  cell	  parameters	  are	  defined	  by	  vectors	  a,	  b,	  c	  with	  angles	  α,	  β,	  λ	  and	  length	  Å	  [157,161].	  	  
The	  operations	  that	  can	  be	  used	  to	  generate	  the	  contents	  of	  all	   the	  unit	  cells	  of	  the	   lattice,	  
known	   as	   crystal	   symmetry,	   are	   described	   by	   space	   groups.	   	   These	   can	   be	   derived	   from	  
symmetry	  and	  systematic	  absences	   in	   the	  diffraction	  patter.	   	  When	  solving	  an	  X-­‐ray	  crystal	  
structure,	  only	  the	  contents	  of	  the	  asymmetric	  unit	  are	  refined.	  	  Crystal	  symmetry	  operators	  
are	  used	  to	  generate	  the	  remainder	  of	  the	  unit	  cell	  and	  crystal	  lattice	  contents.	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In	   total,	  mathematically,	   there	  are	  230	  possible	   space	  groups.	   	   Since	  protein	  molecules	  are	  
chiral	   and	   incompatible	   with	  mirror	   symmetry	   the	   number	   of	   relevant	   space	   groups	   is	   65	  
(Table	  2-­‐1)	  [162].	  	  Based	  on	  their	  minimal	  internal	  symmetry,	  crystals	  are	  classed	  into	  seven	  
lattice	   systems.	   	   These	   are	   triclinic,	   monoclinic,	   orthorhombic,	   tetragonal,	   rhombohedral,	  
hexagonal	  and	  cubic.	  	  Additionally,	  crystals	  have	  one	  of	  the	  six	  lattice	  centrings:	  primitive	  (P),	  
body-­‐centred	   or	   internal	   (I),	   face-­‐centred	   (F)	   and	   A,	   B	   or	   C-­‐face	   centred	   (A,	   B	   or	   C	  
respectively).	  	  Coupling	  of	  a	  lattice	  system	  with	  a	  lattice	  centring	  can	  be	  used	  to	  describe	  the	  
14	   Bravais	   lattices.	   	   Finally,	   point	   groups	   are	   a	   set	   of	   symmetry	   operations	   (rotations	   and	  
reflections),	   which	   move	   all	   the	   positions	   of	   the	   unit	   cell	   around	   a	   fixed	   central	   point	   to	  
superimpose	   them	  onto	   identical	  motifs	   in	   the	   lattice.	   	   There	   are	   32	   crystallographic	   point	  
groups,	  which	  fit	  in	  with	  the	  14	  Bravais	  lattice	  symmetries.	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Table	  2-­‐1.	  Crystal	  space	  groups	  
The	   lattice	  properties,	   internal	   symmetry,	  point	  group	  and	  Bravais	   lattice	   translation	  of	   the	  65	  chiral	  
space	  groups	  of	  protein	  crystals	  are	  shown.	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2.3 The	  phase	  problem	  
Each	   structure	   factor	  Fhkl describes	  a	  diffracted	   ray	   recorded	  as	   reflection	  hkl.	   	  Fhkl terms are	  
dependant	  on	  the	  frequency,	  amplitude	  (|Fhkl|)	  and	  phase	  (αhkl) of	  the	  scattered	  X-­‐ray	  waves	  
[157,161].	  	  	  
The	  hkl	   indices	  of	   the	   set	  of	   parallel	   planes	   that	  produce	   the	   reflections	   are	   the	   frequency	  
terms.	   	   The	   amplitude	   is	   proportional	   to	   the	   square	   root	   of	   the	  measured	   intensity,	   Ihkl,	   for	  
each	  reflection.	  	  However	  the	  phase	  cannot	  be	  derived	  solely	  from	  the	  diffraction	  pattern	  of	  a	  
native	   crystal.	   	   Since	   there	   is	   no	   experimental	   technique	   to	   directly	   measure	   phases,	   this	  
information	   is	   lost	   during	   the	   diffraction	   experiment.	   	   Several	   methods	   for	   obtaining	   the	  
phase,	   or	   ‘phasing’,	   the	   diffraction	   data	   exist:	   molecular	   replacement	   or	   experimental	  
phasing	  by	  isomorphous	  replacement	  or	  anomalous	  scattering	  [163].	  
2.3.1 Molecular	  replacement	  
Molecular	  replacement	  relies	  on	  the	  use	  of	  phases	  from	  the	  structure	  factors	  of	  a	  previously	  
solved	   structure,	   the	   search	   ensemble.	   	   Programs	   compare	   Patterson	  maps	   obtained	   from	  
the	  diffraction	  pattern	  of	  the	  unknown	  protein	  to	  that	  calculated	  from	  the	  search	  ensemble	  
in	   different	   orientations	   [164,165].	   	   These	   are	   obtained	   by	   carrying	   out	   rotation	   and	  
translation	  functions	  of	  the	  search	  ensemble.	  	  Complex	  algorithms	  are	  used	  to	  compute	  the	  
orientation,	   outputted	   in	   Euler	   angles,	   which	   results	   highest	   correlation	   between	   the	   two	  
Patterson	  maps.	  	  As	  such,	  phase	  estimates	  for	  the	  unknown	  protein	  can	  be	  obtained.	  	  Having	  
a	  search	  ensemble	  though	  is	  necessary	  for	  phasing	  by	  molecular	  replacement.	  	  Typically	  this	  
is	   a	   homologous	   protein,	   usually	   with	   at	   least	   20%	   sequence	   similarity,	   a	   protein	   with	   a	  
similar	   fold	   or	   in	   silico	   models.	   	   If	   an	   appropriate	   search	   ensemble	   is	   not	   available,	  
experimental	  phasing	  must	  be	  used.	  	  
2.3.2 Experimental	  phasing	  
The	  scattering	  factor	  of	  atoms	  is	  proportional	  to	  the	  number	  of	  electrons	  it	  has,	  and	  thus	  its	  
atomic	   number.	   	   Experimental	   phasing	   by	   isomorphous	   replacement	   relies	   on	   the	   strong	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scattering	  of	  X-­‐rays	  by	  heavy	  atoms	  compared	  to	  the	  carbon,	  oxygen	  and	  nitrogen	  atoms	  of	  
proteins	  (Figure	  2-­‐3)	  [166].	  	  Single	  Isomorphous	  Replacement	  (SIR)	  and	  Multiple	  Isomorphous	  
Replacement	   (MIR)	   methods,	   respectively,	   make	   use	   of	   one	   or	   multiple	   heavy	   atom	  
derivative	  crystals.	   	  These	  derivative	  crystals	  must	  be	  isomorphous	  in	  terms	  of	  space	  group,	  
cell	  dimensions	  and	  crystal	  packing	  for	  useful	  phasing	  information	  to	  be	  obtained.	  
Additionally,	  some	  heavy	  atoms	  absorb	  X-­‐rays	  at	  the	  energy	  used	  in	  diffraction	  experiments,	  
which	  leads	  to	  the	  breakdown	  of	  Friedel’s	  law	  (Figure	  2-­‐3)	  [166].	  	  Friedel’s	  law,	  named	  after	  
Georges	  Friedel,	  states	  that	  Bragg	  reflections	  related	  by	  inversion	  through	  the	  origin,	  termed	  
+h+k+l and	   -h-k-l,	   have	  an	  equal	   amplitude	  and	  opposite	  phase.	   	   The	  difference	   in	   Friedel	  
pairs	   caused	   by	   X-­‐ray	   absorbance	   by	   heavy	   atoms	   is	   known	   as	   anomalous	   scattering.	   	   The	  
intensity	  of	   the	   individual	   reflections	   is	   also	   affected	  by	   a	   change	   in	   the	  wavelength	  of	   the	  
impinging	  X-­‐ray.	  	  The	  latter	  are	  known	  as	  dispersive	  differences	  [166].	  	  	  
	   	  
	   	  
	  
	  







Figure	  2-­‐3.	  Experimental	  phasing	  
Diagram	  showing	  structure	  factors	  from	  native	  proteins	  (F(P)),	  the	  heavy	  atom	  (F(H))	  and	  heavy	  atom	  derivative	  
proteins	  without	  (F(PH))	  and	  with	  (F”(PH))	  anomalous	  scattering.	  	  These	  are	  shown	  for	  a	  Friedel	  pair	  (+h+k+l	  and	  -
h-k-l).	   	  F(P)+ is	   the	  reflection	  of	  F(P)-­‐	   in	  the	  real	  axis;	  no	  experimental	  phase	   information	  can	  be	  extracted	  from	  
native	  protein	  scattering.	  	  F(PH)	  is	  the	  contribution	  of	  scattering	  from	  the	  native	  structure	  F(P)	  and	  the	  heavy	  atom	  
F(H).	   	  This	  difference	  in	  the	  structure	  factors	  of	  native	  and	  heavy	  atom	  derivative	  crystals	   is	  exploited	  in	  SIR	  and	  
MIR	  experiments.	  	  At	  wavelengths	  near	  the	  heavy	  atom’s	  absorption	  edge	  (λ”),	  an	  imaginary	  component	  known	  as	  
anomalous	  scattering	  (F”)	  is	  added	  to	  the	  structure	  factor	  of	  the	  heavy	  atom	  derivative	  to	  give	  F”(PH).	  	  This	  causes	  
Friedel’s	  law	  to	  break	  down.	  	  Anomalous	  differences	  are	  used	  for	  phasing	  in	  SAD	  and	  MAD	  experiments.	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Single	   Anomalous	   Dispersion	   (SAD)	   experiments	   are	   carried	   out	   by	   collecting	   data	   at	   a	  
wavelength	  near	  the	  heavy	  atom’s	  absorption	  edge.	  	  At	  this	  peak	  wavelength,	  its	  anomalous	  
scattering	  properties	  are	  at	  a	  maximum.	  	  Multiple	  Anomalous	  Dispersion	  (MAD)	  makes	  use	  of	  
wavelength-­‐dependent	  anomalous	  scattering	  differences	  for	  any	  given	  heavy	  atom.	  	  Typically	  
MAD	  datasets	  are	  collected	  at	  the	  peak,	  remote	  and	  sometimes	  inflection	  energy	  points.	  
For	   experimental	   phasing,	   firstly	   heavy	   atoms	   are	   located	   by	   creating	   Patterson	   maps	  
[166,167].	  	  Patterson	  functions	  represent	  Fourier	  sums	  without	  the	  phases	  and	  thus	  depend	  
solely	   on	   the	   intensity	   of	   the	   reflections.	   	   In	   difference	   Patterson	   functions,	   the	   difference	  
between	   the	   native	   and	   derivative	   amplitude	   of	   each	   term	   is	   calculated.	   	   The	   vectors	  
between	   atoms	   are	   plotted	   in	   Patterson	  maps.	   	   Heavy	   atoms	   will	   result	   in	   large	   peaks	   in	  
difference	  Patterson	  maps	  and,	  together	  with	  the	  cell	  symmetry	  of	  the	  crystal,	  can	  be	  used	  to	  
locate	  the	  position	  of	  the	  heavy	  atoms.	   	  Since	  the	  diffractive	  contributions	  of	  all	  atoms	  to	  a	  
reflection	  are	  additive,	  Equation	  9	  can	  be	  used	  to	  phase	  the	  native	  dataset.	  	  FPH,	  FP,	  FH	  refer	  to	  
protein	   plus	   heavy	   atom	   (derivative),	   protein	   (native)	   and	   heavy	   atom	   structure	   factors	  
respectively.	  
	  
Equation	  9	  𝐅!" = 𝐅! + 𝐅! 	  
	  
	  
2.4 Structure	  refinement	  
The	  first	  maps	  obtained	  after	  phasing	  are	  often	  poorly	  informative	  and	  insufficiently	  resolved	  
to	   obtain	   a	   reliable	   structure.	   	   This	   is	   due	   to	   errors	   in	   phase	  measurements.	   	   Refinement	  
involves	  minimization	   of	   differences	   between	   the	  measured	   diffraction	   intensities	   and	   the	  
intensities	  predicted	  by	  a	  model	  [168].	  
In	  real	  space,	  the	  atomic	  coordinates	  of	  a	  model	  are	  adjusted	  by	  manually	  fitting	  it	  into	  to	  the	  
electron	  density	  maps.	  	  In	  reciprocal	  space,	  comparison	  of	  the	  structure	  factors	  derived	  from	  
the	  model	  with	   the	  measured	  experimental	   intensities	   allow	   for	   phase	   improvement.	   	   This	  
involves	  the	  use	  of	  complex	  algorithms	  which	  employ	  least-­‐square	  fitting,	  energy	  refinement	  
and/or	   Bayesian	   methods.	   	   The	   correlation	   between	   real	   and	   reciprocal	   space	   is	   Fourier	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transformation.	  	  Adjustment	  of	  the	  model	  can	  improve	  the	  accuracy	  of	  the	  phases,	  which	  in	  
turn	  leads	  to	  a	  better	  electron	  density	  map	  allowing	  for	  better	  model	  fitting	  and	  so	  on.	  	  	  
The	  observed	  (|Fobs|)	  and	  calculated	  (|Fcalc|)	  structure	  factors	  give	  rise	  to	  the	  Fo	  and	  Fc	  maps	  
respectively	  [168].	  	  Difference	  maps	  are	  generated	  for	  model	  building	  and	  refinement.	  	  An	  Fo-­‐
Fc	   map	   is	   used	   to	   visualize	   differences	   between	   density	   calculated	   from	   the	   measured	  
intensities	  and	  the	  model.	   	   It	  clearly	  emphasizes	  errors	   in	  the	  model	  and	  points	  out	  regions	  
for	  which	  the	  model	  contributes	  to	  too	  much	  or	  too	  little	  density	  compared	  to	  that	  which	  the	  
asymmetric	   unit	   actually	   contains.	   	   A	  more	   easily	   interpreted	  map	   is	   the	   2Fo-­‐Fc	   difference	  
map.	  	  Here	  the	  density	  is	  positive	  everywhere.	  	  The	  influence	  of	  the	  model	  is	  reduced	  but	  still	  
present.	  	  Finally,	  figure	  of	  merit,	  or	  σA,	  weighted	  maps	  are	  given	  by	  mFo-­‐DFc	  where	  m	  is	  the	  
figure	  of	  merit	  for	  each	  model	  phase	  and	  D	   is	  the	  overall	  estimate	  of	  the	  atomic	  coordinate	  
errors	  in	  the	  current	  model.	  
As	   the	   accuracy	   of	   the	   model	   improved,	   |Fobs|	   and	   |Fcalc|	   should	   converge	   [168].	   	   Their	  
differences	  are	  reflected	  in	  residual	  factors	  (R	  factor)	  statistics.	  	  Since	  the	  refinement	  process	  
improves	  the	  atomic	  model	  of	  a	  given	  structure	  to	  make	  it	  fit	  better	  to	  the	  experimental	  data	  
the	   R	   factor	   gradually	   improves.	   	   However	   a	   decrease	   in	   the	   R	   factor	   may	   be	   due	   to	  
overfitting	  of	   the	  model	   to	   the	  data	   rather	   than	  a	  genuine	   improvement	   in	   the	  accuracy	  of	  
the	   model.	   	   R-­‐free	   is	   used	   as	   a	   less	   biased	   way	   to	   judge	   the	   model’s	   accuracy.	   	   Before	  
refinement	  begins,	  5-­‐10%	  of	   the	  experimental	  observations	  are	   removed	   from	   the	  dataset.	  	  
Refinement	  is	  performed	  using	  the	  remaining	  90-­‐95%	  of	  the	  obeservations.	  	  The	  R-­‐free	  value	  
is	   then	   calculated	   by	   seeing	   how	   well	   the	   model	   predicts	   the	   10%	   that	   were	   not	   used	   in	  
refinement.	  
Several	  rounds	  of	  refinement	  are	  often	  required	  to	  obtain	  the	  final	  structure.	  	  Other	  methods	  
such	  as	  solvent	  flattening,	  density	  modification,	  non-­‐crystallographic	  symmetry	  averaging	  and	  
use	  of	  a	  partial	  model	  are	  also	  often	  useful	  during	  refinement.	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3 Perspective	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Over	  the	   last	  thirty	  years,	  the	  UPR	  has	  been	  characterised	   in	   increasing	  detail.	   	  Advances	   in	  
structural	  biology,	  and	  biophysics	  techniques,	  have	  played	  a	  crucial	  role	  in	  providing	  detailed	  
insights	  of	  UPR	  ER	  stress	  sensing	  and	  signal	  transduction	  pathways.	  	  However,	  despite	  intense	  
efforts,	  the	  precise	  modes	  by	  which	  the	  UPR	  mediators	  sense	  the	  accumulation	  of	  unfolded	  
proteins	   and	   how	   this	   leads	   to	   their	   activation	   remains	   poorly	   understood	   and	   structural	  
insights	  are	  limited.	  
In	   this	   thesis,	   the	  work	   involved	   in	  solving	   the	  novel	  X-­‐ray	  crystal	   structure	  of	  PERK	   luminal	  
domain	   in	   two	   different	   states	   is	   described.	   	   Furthermore,	   the	   results	   of	   a	   comprehensive	  
biophysical	  study	  of	  the	  interaction	  between	  BiP	  chaperone	  and	  the	  luminal	  domains	  of	  PERK	  
and	  IRE1,	  and	  how	  this	  is	  disrupted	  by	  CH1	  unfolded	  protein,	  are	  presented.	  	  Together	  these	  
results	  provide	  a	  new	  paradigm	  for	  ER	  stress	  sensing	  and	  activation	  of	  UPR	  signalling.	  
Aberrant	   protein	   folding	   and	   UPR	   signalling	   are	   a	   major	   cause	   for	   disease.	   	   Obtaining	   a	  
detailed	  understanding	  the	  mechanistic	  aspects	  of	  UPR	  activation	  will	  open	  novel	  avenues	  for	  
targeting	  the	  UPR	  to	  develop	  drugs	  against	  many	  important	  human	  pathologies.	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4.1 Cloning	  and	  expression	  
H.	   sapiens	   perk,	   ire1	   and	   bip	   genes	   were	   amplified	   from	   commercial	   complementary	   DNA	  
(cDNA)	   libraries	   (Clonetech).	   	   Mus	   musculus	   perk,	   Drosophila	   melanogaster	   perk	   and	   H.	  
sapiens	   CH1	   sequences	   were	   amplified	   from	   synthetic	   genes	   produced	   by	   GeneArt	   Gene	  
Synthesis	   services	   (Life	   Technologies).	   	   All	   polymerase	   chain	   reaction	   (PCR)	   amplification	  
reactions	  were	  carried	  out	  as	  following:	  1	  µl	  DNA	  template,	  15	  pmol	  forward	  primer,	  15	  pmol	  
reverse	  primer,	  2	  µl	  dimethyl	  sulphoxide	  (DMSO),	  25	  µl	  2X	  Phusion	  Flash	  II	  DNA	  polymerase	  
(ThemoScientific)	   and	  made	   up	   to	   a	   total	   volume	   of	   50	  µl	   with	  water.	   	   The	   following	   PCR	  
protocol	   was	   used:	   2	   minutes	   (‘)	   initial	   denaturation	   at	   95	   °C,	   30	   amplification	   cycles	   (30	  
seconds	  (“)	  denaturation	  at	  95	  °C,	  30”	  annealing	  at	  56	  °C,	  1’	  amplification	  at	  72	  °C)	  followed	  
by	   a	   final	   5’	   amplification	   at	   72	   °C.	   	   Amplified	   DNA	  was	   then	   purified	   using	   QIAquick	   PCR	  
Purification	   Kit	   (Qiagen)	   and	   digested	   overnight	   at	   37	   °C	   with	   the	   appropriate	   restriction	  
enzymes	  (NEB).	  	  Primer	  sequences	  and	  restriction	  enzymes	  used	  for	  cloning	  can	  be	  found	  in	  
Appendix	  Table	  10-­‐1.	  
Genes	   were	   inserted	   into	   the	   appropriate	   expression	   vector.	   	   In	   this	   study	   pTWO-­‐E,	   with	  
Ampicillin	  (Amp)	  resistance	  gene,	  and	  pET-­‐26b,	  with	  Kanamycin	  (Kan)	  resistance	  gene,	  were	  
used	   (Appendix	  Figure	  10-­‐1).	   	  pTWO-­‐E	   is	  a	  modified	  version	  of	   the	  pET-­‐17b	  vector	   (Merck),	  
which	   contains	   an	   additional	   PreScission	   Protease	   cleavable	   N-­‐terminal	   His6-­‐tag	   and	   NheI	  
restriction	  site.	  	  All	  perk,	  ire1	  and	  bip	  genes	  were	  cloned	  into	  pTWO-­‐E.	  	  pET-­‐26b	  was	  used	  for	  
the	  cloning	  of	  untagged	  CH1	  antibody	   segment	  only.	   	  Vectors	  were	  digested	  with	   the	   same	  
restriction	   enzymes	   as	   the	   PCR	   product	   for	   2	   hours	   (h)	   at	   37	   °C.	   	   Subsequently	   the	   5’	  
phosphate	  was	  removed	  from	  the	  digested	  vectors	   to	  avoid	  self-­‐ligation	  by	   incubation	  with	  
Calf	   Intestine	  Alkaline	  Phosphatase	   (NEB)	   for	  1	  h	  at	  37	   °C.	   	   The	  digested	  and	  purified	  gene	  
inserts	   were	   ligated	   into	   cut	   vectors	   using	   T4	   DNA	   ligase	   (NEB).	   	   Ligation	   reactions	   were	  
incubated	   for	  1	  h	  at	   room	  temperature	   (RT)	  after	  which	   they	  were	   transformed	   into	  E.	   coli	  
TOP10	  chemically	  competent	  cells	  (Life	  Technologies).	  	  	  
The	   following	  protocol	  was	  used	   for	   all	   transformations	  of	  DNA	   into	   chemically	   competent	  
cells.	  	  1	  µl	  of	  DNA	  was	  incubated	  with	  50	  µl	  of	  cells	  on	  ice	  for	  20’	  followed	  by	  heat	  shock	  at	  42	  
°C	   for	  30”.	   	  Cells	  were	  transferred	  to	   ice	   for	  a	   further	  2’	  after	  which	  250	  µl	  of	  Luria-­‐Bertani	  
(LB)	  media	  was	  added.	  	  Cells	  were	  shaken	  at	  220	  rpm	  at	  37	  °C	  for	  45’	  and	  then	  plated	  onto	  LB	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agar	  plates	  containing	   the	  appropriate	  antibiotic	   for	  selection.	   	  All	  antibiotic	  concentrations	  
used	  were	   as	   following:	   100	  µg/ml	   Amp,	   30	  µg/ml	   Kan,	   35	  µg/ml	   Chloramphenicol	   (Cam).	  	  
Plates	  were	  incubated	  overnight	  at	  37	  °C.	  
The	   following	   day	   individual	   colonies	   were	   used	   to	   inoculate	   5	   ml	   of	   LB	   containing	   the	  
appropriate	  antibiotic.	  	  After	  overnight	  growth	  at	  37	  °C	  with	  shaking	  at	  220	  rpm,	  the	  plasmid	  
DNA	  was	   extracted	  using	   the	  QIAprep	  Miniprep	  Kit	   (Qiagen).	   	   Test	   restriction	   digests	  were	  
carried	   out	   to	   verify	   the	   presence	   of	   the	   insert	   by	   cutting	  with	   the	   appropriate	   restriction	  
enzymes	  for	  2	  h	  at	  37	  °C.	   	  Digestions	  products	  run	  on	  a	  1%	  agarose	  gel	   for	  1	  h	  at	  75	  V	  and	  
visualized	   using	   GelRed	   stain	   (Life	   Technologies).	   	   Plasmids	   containing	   DNA	   inserts	   of	   the	  
expected	  size	  were	  sequence	  verified	  (Eurofins	  MWG	  Operon).	  
4.2 Site-­‐directed	  mutagenesis	  
For	   site-­‐directed	  mutagenesis,	   Phusion	   Flash	   II	  DNA	  polymerase	  was	  used	  according	   to	   the	  
manufacturer’s	  protocol.	   	  The	  following	  PCR	  protocol	  was	  used:	  5’	   initial	  denaturation	  at	  95	  
°C	  followed	  by	  15	  cycles	  of	  plasmid	  amplification	  (45”	  denaturation	  at	  95	  °C,	  45”	  annealing	  at	  
56	  °C,	  5’	  amplification	  at	  72	  °C).	  	  The	  methylated	  parental	  plasmid	  was	  digested	  by	  incubation	  
with	  DpnI	  enzyme	  for	  1	  h	  at	  37	  °C.	  	  The	  DNA	  was	  purified	  using	  the	  QIAquick	  PCR	  Purification	  
Kit	  (Qiagen).	  	  1	  µl	  of	  DNA	  was	  transformed	  into	  TOP10	  E.	  coli	  chemically	  competent	  cells	  and	  
the	  plasmid	  was	  isolated	  as	  previously	  described.	  	  All	  plasmids	  were	  sequence	  verified.	  
4.3 PERK,	  IRE1	  and	  BiP	  expression	  and	  purification	  
The	   following	   protocol	   was	   used	   for	   expression	   and	   purification	   of	   all	   PERK,	   IRE1	   and	   BiP	  
proteins	  used	  in	  this	  study.	  	  All	  buffers	  used	  are	  summarised	  in	  .	  	  Plasmids	  were	  transformed	  
into	  E.	  coli	  Rosetta2	  (DE3)	  chemically	  competent	  cells	  (Merck)	  and	  plated	  onto	  LB	  (Amp/Cam)	  
agar	  plates.	   	  The	  plates	  were	   incubated	  overnight	  at	  37	   °C	  and	  a	  single	  colony	  was	  used	  to	  
inoculate	   200	  ml	   of	   LB	   (Amp/Cam)	   culture	  media	  which	  was	   incubated	   overnight	   at	   37	   °C	  
with	  shaking	  at	  220	  rpm.	  	  The	  following	  day,	  each	  1	  L	  of	  LB	  (Amp/Cam)	  media	  was	  inoculated	  
with	  10	  ml	  of	   starter	   culture	   and	  grown	  at	   37	   °C	  with	   shaking	  at	   220	   rpm	  until	   the	  optical	  
density	  (OD)	  at	  600	  nm	  (OD600)	  reached	  0.6.	  	  Cells	  were	  induced	  with	  0.5	  mM	  Isopropyl	  β-­‐D-­‐
	   	  
	  
	  
	   85	  
1-­‐thiogalactopyranoside	  (IPTG)	  (Life	  Technologies),	  grown	  overnight	  at	  22	  °C	  with	  shaking	  at	  
220	  rpm	  after	  which	  they	  were	  harvested	  by	  centrifugation	  at	  4000	  g	  for	  15’.	  	  All	  subsequent	  
steps	  were	  carried	  out	  at	  4	  °C	  to	  avoid	  protein	  degradation.	  
Cell	   pellets	   were	   resuspended	   in	   buffer	   A	   supplemented	   with	   Complete	  
ethylenediaminetetraacetic	  acid	  (EDTA)-­‐free	  Protease	  Inhibitor	  Cocktail	  (Roche)	  and	  25	  µg/ml	  
DNase	  (Sigma-­‐Aldrich)	  for	  lysis.	  	  Where	  specified,	  lysis	  buffer	  for	  BiP	  proteins	  also	  contained	  
additional	  0.1%	  polyethylenimine	  (PEI)	  (Sigma-­‐Aldrich)	  or	  5	  mM	  ATP	  (Sigma-­‐Aldrich)	  plus	  10	  
mM	  MgCl2.	   	   Lysis	   was	   carried	   out	   by	   10’	   sonication	   at	   50%	   amplitude.	   	   Cell	   debris	   were	  
pelleted	  by	   centrifugation	  at	  40000	  g	   for	  1	  h	  and	   soluble	  proteins	  were	   further	  purified	  by	  
chromatography	   steps.	   	   The	   quality	   of	   protein	   samples	   was	   visualized	   after	   each	   step	   by	  
Sodium	   Dodecyl	   Sulphate	   Polyacrylamide	   Gel	   Electrophoresis	   (SDS-­‐PAGE).	   	   Samples	   were	  
supplemented	  with	  Laemmli	  2X	  buffer	   (Sigma-­‐Aldrich),	  denatured	  for	  10’	  at	  100	  °C	  and	  run	  
on	  a	  4-­‐12%	  Bis-­‐Tris	  gel	  for	  1	  h	  at	  180	  V	  visualized	  by	  Coomassie	  Blue	  staining.	  	  SeeBlue	  Plus2	  
Pre-­‐Stained	  Standard	  or	  HiMark	  Pre-­‐Stained	  Protein	  Standard	   (Life	  Technologies)	  was	  used;	  
molecular	  weights	  (MW),	  in	  kDa,	  of	  marker	  bands	  are	  indicated	  for	  each	  gel	  shown.	  
For	   affinity	   purification,	   a	   pre-­‐packed	   5	   ml	   HiTrap	   TALON	   crude	   columns	   (GE	   Healthcare),	  
containing	   cobalt	   ions	   (Co2+),	   was	   equilibrated	   with	   buffer	   A.	   	   Soluble	   cell	   lysate	   fractions	  
were	   loaded	   onto	   the	   TALON	   column	   after	   which	   it	   was	   washed	   with	   100	  ml	   of	   buffer	   A	  
containing	  additional	  5	  mM	   imidazole.	   	  Bound	  proteins	  were	  eluted	  with	  30	  ml	  of	  buffer	  A	  
plus	  additional	  250	  mM	  imidazole.	  	  When	  cleavage	  of	  the	  His6-­‐tag	  was	  desired,	  10	  units	  (U)	  of	  
Prescission	  Protease	  (GE	  Healthcare)	  were	  added	  per	  1	  mg	  of	  purified	  protein.	  	  Samples	  were	  
dialyzed	  overnight	  against	  2	  L	  of	  buffer	  B	  at	  4	  °C.	  	  Samples	  in	  which	  the	  His6-­‐tag	  was	  cleaved	  
were	   passed	   through	   a	   pre-­‐equilibrated	   TALON	   column	   as	   previously.	   	   The	   flow-­‐though	  
containing	  only	  untagged	  protein	  species	  was	  collected	  and	  used	  in	  further	  purification	  steps.	  	  	  
Proteins	  were	   then	   purified	   by	   anion-­‐exchange	   chromatography	   using	   a	   5	  ml	   HiTrap	  Q	  HP	  
column	  (GE	  Healthcare).	  	  The	  ion-­‐exchange	  step	  was	  omitted	  for	  BiP	  protein	  samples.	  	  Briefly,	  
protein	  samples	  were	  loaded	  on	  the	  column	  pre-­‐equilibrated	  with	  buffer	  C,	  washed	  with	  30	  
ml	  of	  buffer	  D,	  which	  contains	  additional	  150	  mM	  NaCl.	  	  A	  shallow	  salt	  gradient	  (between	  200	  
mM	  and	   500	  mM	  NaCl)	  was	   applied	   so	   as	   to	   separate	   bound	   protein	   species	   according	   to	  
their	  charge.	  	  This	  was	  achieved	  by	  running	  samples	  in	  buffer	  B	  and	  applying	  a	  gradient	  of	  20-­‐
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50%	  buffer	  E.	  	  Peak	  fractions	  were	  pooled,	  concentrated	  using	  Amicon	  Ultra	  Centrifugal	  Filter	  
Units	  (Merck)	  of	  the	  appropriate	  MW	  cut	  off	  (at	  least	  half	  of	  the	  protein	  size).	  
Samples	  were	  further	  purified	  by	  size	  exclusion	  chromatography	  (SEC).	  	  Samples	  were	  loaded	  
onto	   a	  HiLoad	   16/60	   Superdex	   200	   column	   (GE	  Healthcare)	   pre-­‐equilibrated	  with	   buffer	   F.	  	  
Fractions	   containing	   pure	   protein	   samples	   were	   pooled,	   concentrated	   as	   appropriate	   and	  
flash	  frozen	  in	  liquid	  nitrogen	  for	  subsequent	  studies.	   	  All	   ion-­‐exchange	  and	  SEC	  profiles	  are	  
shown	  as	  normalized	  curves	  to	  allow	  for	  comparison.	  
4.4 	  CH1	  expression	  and	  purification	  
CH1	  antibody	  domain	  was	  expressed	  in	  inclusion	  bodies	  and	  purified	  as	  previously	  published	  
[25].	  	  Briefly,	  the	  protein	  was	  expressed	  in	  BL21	  (DE3)	  chemically	  competent	  cells	  (Merck)	  in	  
LB	  (Kan)	  for	  overnight	  at	  37	  °C,	  similarly	  to	  the	  protocol	  described	  above	  for	  PERK,	  IRE1	  and	  
BiP	   proteins.	   	   The	   harvested	   cell	   pellet	   was	   resuspended	   in	   buffer	   G	   supplemented	   with	  
Complete	   EDTA-­‐free	   Protease	   Inhibitor	   Cocktail,	   25	   µg/ml	   deoxyribonuclease	   (DNase),	   2%	  
triton	  X-­‐100	  (Sigma-­‐Aldrich),	  20	  mM	  EDTA	  for	   lysis.	   	  After	  sonication	  with	  a	  Q125	  Sonicator	  
(Qsonica,	  USA)	  for	  10”	  at	  50%	  amplitude,	  the	  sample	  was	  centrifuged	  at	  40000	  g	  for	  1	  h.	  	  The	  
supernatant	  was	  discarded	  and	  the	  pellet,	  which	  also	  contains	  the	  inclusion	  bodies	  where	  the	  
insoluble	  CH1	  is	  found,	  was	  resuspended	  in	  50	  ml	  of	  buffer	  H	  and	  incubated	  with	  shaking	  for	  
30’	  at	  25	  °C.	  	  The	  insoluble	  cell	  fragments	  were	  removed	  by	  centrifugation	  at	  40000	  g	  for	  1.5	  
h.	  	  The	  resulting	  supernatant	  was	  applied	  to	  a	  5	  ml	  HiTrap	  SP	  HP	  column	  (GE	  Healthcare)	  pre-­‐
equilibrated	  with	  buffer	   I.	   	  CH1	  protein	  did	  not	  bind	  to	  the	  column	  in	  these	  conditions.	   	  The	  
flow	  through	  was	  collected.	   	  Refolding	  was	  carried	  out	  by	  dialyzing	  overnight	  against	  2	  L	  of	  
buffer	  J.	   	  The	  following	  day,	  aggregates	  were	  removed	  by	  centrifugation	  at	  40000	  g	  for	  1	  h,	  
the	  soluble	  protein	  was	  concentrated	  and	  loaded	  on	  a	  HiLoad	  16/60	  Superdex	  75	  column	  (GE	  
Healthcare)	   pre-­‐equilibrated	   with	   buffer	   K.	   	   Fractions	   containing	   pure	   CH1	   protein	   were	  
pooled,	  concentrated	  and	  flash	  frozen	  in	  liquid	  nitrogen.	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Table	  4-­‐1.	  Purification	  buffers	  composition	  
All	  the	  buffers	  used	  in	  this	  study	  are	  listed.	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4.5 Seleno-­‐Met	  labeling	  of	  PERK	  
Incorporation	   of	   Seleno	   (Se)-­‐Methionine	   (SeMet)	   instead	   of	   Methionine	   residues	   in	   PERK	  
recombinant	   proteins	   was	   carried	   out	   using	   a	   modified	   version	   of	   the	   protein	   expression	  
protocol	   described	   above.	   	   Briefly,	   DNA	   plasmids	   were	   transformed	   into	   the	   Methionine	  
auxotroph	  E.	  coli	  B834	  (DE3)	  chemically	  competent	  strain	  (Merck)	  (Amp).	  	  Overnight	  cultures	  
were	  made	  by	  inoculating	  a	  single	  colony	  in	  M9	  minimal	  media	  supplemented	  with	  a	  nutrient	  
mix	   (containing	   glucose,	   vitamins	   and	   essential	   amino	   acids,	   with	   the	   exception	   of	  
Methionine)	  plus	  40	  µg/ml	  Methionine	  (Molecular	  Dimensions)	  (Amp).	  	  The	  overnight	  culture	  
were	  pelleted	  by	   centrifugation	  at	  4000	  g	   for	  15’	   and	   the	   cell	   pellet	  was	  gently	  washed	  by	  
resuspending	   it	  with	  100	  ml	  of	  1X	  phosphate	  buffered	  saline	   (PBS)	   (pH	  7.5).	   	   This	   step	  was	  
repeated	   five	   times	   to	   thoroughly	   remove	   any	  Met	   for	   subsequent	   steps.	   	   After	   the	   final	  
centrifugation	  step,	   the	  cell	  pellet	  was	  resuspended	   in	  10	  ml	  1X	  PBS	   (pH	  7.5)	  and	  1	  ml	  was	  
used	  to	  inoculate	  each	  1	  L	  of	  M9	  minimal	  media	  supplemented	  with	  the	  nutrient	  mix	  plus	  40	  
µg/ml	  SeMet	   (Molecular	  Dimensions)	   (Amp).	   	  The	   remainder	  of	   the	  protein	  expression	  and	  
purification	  protocol	  was	  identical	  to	  that	  of	  wild-­‐type	  proteins.	  
4.6 Calibration	  of	  HiLoad	  16/60	  Superdex	  200	  column	  	  
For	   approximation	   of	   protein	   MW	   from	   SEC	   profiles,	   a	   High	   MW	   Calibration	   Kit	   (GE	  
Healthcare)	  was	   used.	   	   The	   calibration	   protein	   stocks	   provided	   in	   the	   kit	  were	  made	   up	   in	  
buffer	  F	  as	   specified	  by	   the	  manufacturer.	   	   Samples	  were	  mixed	  and	  applied	   to	   the	  HiLoad	  
16/60	  Superdex	  200	  column	  (GE	  Healthcare)	  pre-­‐equilibrated	  with	  buffer	  F.	  	  The	  void	  volume	  
(V0)	  was	  separately	  determined	  by	  measuring	  elution	  volume	  (Ve)	  of	  Blue	  Dextran	  2000.	   	  A	  
calibration	  curve	  was	  calculated	  by	  plotting	  V0	  –	  Ve	  values	  against	  log	  MW	  and	  fitting	  a	  line	  
of	  nonlinear	   regression.	   	  The	   function	  obtained	  was	  used	   to	  estimate	  MW	  of	  samples	   from	  
their	  elution	  volumes	  on	  the	  HiLoad	  16/60	  Superdex	  200	  column	  (Appendix	  Figure	  10-­‐2).	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4.7 Multi-­‐Angle	  Light	  Scattering	  
Multi-­‐Angle	   Light	   Scattering	   (MALS)	   was	   used	   to	   measure	   the	   absolute	   MW	   of	   protein	  
species.	   	  An	  Agilent	  1260	   (Agilent	  Technologies)	   system	  equipped	  with	  a	  miniDAWN	  TREOS	  
(Wyatt	  Technologies)	  Light	  Scattering	  (LS)	  detector	  and	  an	  Optilab	  T-­‐rEX	  (Wyatt	  Technologies)	  
Refractive	  Index	  (RI)	  detector	  was	  used.	   	  A	  Superdex	  200	  PC	  3.2/30	  column	  (GE	  Healthcare)	  
was	  pre-­‐equilibrated	  with	  the	  appropriate	  buffer	  until	  LS	  and	  RI	  readings	  were	  stable.	  	  Buffer	  
F	  was	  used	  for	  analytical	  SEC	  MALS	  of	  single	  protein	  species;	  buffer	  K	  was	  used	  for	  SEC	  MALS	  
of	  protein-­‐protein	  and	  peptide-­‐protein	  samples.	   	  100	  µl	  of	  protein	  at	  100	  µM,	  plus	  500	  µM	  
∆EspP	  where	  relevant,	  were	  injected	  and	  LS	  and	  RI	  values	  were	  recorded.	  	  Peaks	  of	  interest	  
were	   manually	   selected	   and	   the	   data	   was	   analysed	   using	   the	   ASTRA	   software	   (Wyatt	  
Technologies)	  to	  calculate	  MW	  values	  and	  the	  polydispersity	  of	  the	  sample.	  
4.8 Matrix-­‐assisted	  laser	  desorption/ionization-­‐time	  of	  flight	  
In	  gel	  trypsin	  digestion	  samples	  were	  separated	  on	  a	  4-­‐12%	  Bis-­‐Tris	  gel	  for	  1	  h	  at	  180	  V	  and	  
stained	  using	  CuCl2	  negative	  staining.	   	  The	  peptide	  bands	  of	   interest	  were	  excised	  from	  the	  
gel	   under	   sterile	   conditions	   and	   sent	   for	   in	   gel	   trypsin	   digestion	   and	   matrix-­‐assisted	   laser	  
desorption/ionisation-­‐time	   of	   flight	   (MALDI-­‐TOF)	   analysis	   by	   Dr	   Paul	   Hitchens	   at	   the	  Mass	  
Spectrometry	  facility,	  Imperial	  College	  London.	  
MALDI-­‐TOF	   experiments	   of	   SeMet	   derivative	   proteins	  were	   similarly	   carried	   out	   by	   Dr	   Len	  
Packman	   at	   the	   PNAC	   Facility,	   University	   of	   Cambridge	   (with	   the	   omission	   of	   trypsin	  
digestion).	  
4.9 Native	  gel	  shift	  assays	  
Protein	   samples	   were	   prepared	   as	   described	   in	   the	   results	   as	   desired	   (proteins	   alone	   or	  
complexes).	   	   Coomassie	   native	   4X	   loading	   dye	   was	   added	   (1%	   Bromophenol	   Blue	   (Sigma-­‐
Aldrich),	  40%	  glycerol,	  250	  mM	  Tris-­‐HCl	  (pH	  6.8)).	  	  Samples	  were	  run	  on	  a	  3-­‐8%	  Tris-­‐Acetate	  
gel	   for	   2	  h	   at	   150	  V	   at	   4	   °C	   in	   Tris-­‐Glycine	  Native	  Running	  Buffer	   (Life	   Technologies).	   	  Gels	  
were	  visualized	  by	  Coomassie	  Blue	  staining.	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4.10 Chemical	  cross-­‐linking	  
Cross-­‐linking	   is	   used	   to	   capture	   non-­‐covalent	   interactions	   that	   exist	   between	   proteins	   that	  
come	   in	   close	   proximity	   in	   solution.	   	   The	   chemical	   cross-­‐linker	   elythlene	  
glycolbis(succinimidylsuccinate)	  (EGS)	  (ThermoScientific)	  was	  used.	  	  The	  spacing	  between	  the	  
two	   NHS-­‐ester	   moieties	   of	   EGS	   is	   16.1	   Å.	   	   A	   2.5	   mM	   EGS	   stock	   was	   made	   in	   DMSO	  
immediately	   prior	   to	   use	   since	   its	   reactive	  N-­‐hydrosuccinimide	   (NHS)-­‐ester	  moiety	   is	   easily	  
hydrolysed.	  	  1	  µl	  of	  2.5	  mM	  EGS	  was	  thoroughly	  mixed	  with	  9	  µl	  of	  protein	  in	  buffer	  K	  at	  11	  
µM	  so	   as	   to	   have	   approximately	   a	   25-­‐fold	  molar	   excess	   of	   EGS.	   	   1	  µl	   of	  DMSO	  was	   added	  
instead	  of	  EGS	  for	  control	  experiments.	   	  The	  reaction	  was	  allowed	  to	  proceed	  for	  1	  h	  at	  RT	  
after	  which	  it	  was	  quenched	  with	  1	  µl	  of	  1	  M	  Tris-­‐HCl	  (pH	  7.5)	  for	  15’	  at	  RT.	   	  Samples	  were	  
run	  on	  a	  4-­‐12%	  Bis-­‐Tris	  gel	  for	  1	  h	  at	  180	  V	  and	  visualized	  by	  Coomassie	  Blue	  staining.	  
4.11 Western	  blotting	  
Samples	  were	   first	   separated	   by	   running	   on	   a	   4-­‐12%	  Bis-­‐Tris	   gel	   for	   1	   h	   at	   and	  were	   then	  
transferred	   onto	   enhanced	   chemilluminescence	   (ECL)	   Nitrocellulose	   Membrane	   (GE	  
Healthcare)	  at	  200	  mA	  for	  80’	  using	  a	  Tris-­‐glycine	  buffer	  (pH	  8.5).	  	  Blots	  were	  blocked	  for	  2	  h	  
at	   4	   °C	   with	   40	  ml	   of	   a	   solution	   containing	   2%	   powdered	  milk	   in	   PBS/2%	   Tween-­‐20.	   	   The	  
volume	  was	  reduced	  to	  10	  ml	  and	  1	  µl	  of	  mouse-­‐α-­‐His6	  primary	  antibody	  (Life	  Technologies)	  
was	  added	   for	  1	  h	  at	  4	   °C.	   	  Blots	  were	  carefully	  washed	   three	   times	  with	  40	  ml	  of	  PBS/2%	  
Tween-­‐20.	   	   The	   blot	   was	   incubated	   for	   a	   further	   1	   h	   at	   4	   °C	   with	   1	   µl	   of	   horseradish	  
peroxidase	   (HRP)-­‐conjugated	   sheep-­‐α-­‐mouse-­‐IgG	   secondary	   antibody	   (Life	   Technologies)	   in	  
10	  ml	   PBS/2%	   Tween-­‐20.	   	   The	   blot	   was	   washed	   again	   as	   previously.	   	   Amersham	   ECL	   Plus	  
Western	   Blotting	   Detection	   Reagents	   (GE	   Healthcare)	   was	   used	   to	   generate	   the	  
chemiluminescent	   signal	   from	   the	   HRP.	   	   HRP	   catalyses	   the	   oxidation	   of	   the	   Lumigen	   PS-­‐3	  
Acridan	  substrate	   to	  produce	  acridinium	  ester	   intermediates.	   	   These	   react	  with	  peroxide	   in	  
alkaline	   conditions	   to	   produce	   a	   chemiluminescent	   signal	   with	   emission	   at	   450	   nm.	   	   This	  
signal	  is	  detected	  by	  exposing	  the	  blots	  to	  a	  Chemiluminesce	  ECL	  HyperFilm	  (GE	  Healthcare)	  
for	  30”	  and	  then	  developed	  manually	  on	  a	  X-­‐OMAT	  Film	  Developer	  (Kodak,	  Japan).	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4.12 Pull	  down	  experiments	  
All	  pull	  down	  experiments	  were	  carried	  out	   in	  5	  ml	  gravity	  flow	  columns	  (ThermoScientific).	  	  
50	  µl	  of	  TALON	  resin	  (Clonetech)	  pre-­‐equilibrated	  with	  buffer	  K	  was	  incubated	  with	  50	  µl	  of	  
purified	  His6-­‐BiP	  protein	  at	  50	  µM	  for	  1	  h	  at	  RT.	  	  The	  resin	  was	  washed	  with	  1	  ml	  of	  buffer	  K	  
to	  remove	  any	  unbound	  His6-­‐BiP.	   	  His6-­‐BiP	  was	  replaced	  by	  buffer	  K	   in	  control	  experiments.	  	  
50	   µl	   of	   purified	   untagged	   PERK,	   IRE1	   or	   CH1	   proteins	   at	   250	   µM	   were	   then	   added	   and	  
incubated	  for	  1	  h	  at	  RT.	  	  The	  resin	  was	  extensively	  washed	  with	  a	  total	  of	  5	  ml	  of	  buffer	  K	  in	  
500	   µl	   volumes.	   	   For	   competition	   pull-­‐downs,	   50	   µl	   of	   PERK,	   IRE1,	   CH1	   or	   ∆EspP	   as	  
appropriate	  at	  250	  µM	  in	  buffer	  K,	  supplemented	  with	  5	  mM	  ADP	  plus	  10	  mM	  MgCl2,	  were	  
then	  added.	  	  Reactions	  were	  incubated	  for	  a	  further	  1	  h	  at	  RT	  and	  washed	  as	  previously	  with	  
buffer	  K	  plus	  5	  mM	  ADP	  and	  10	  mM	  MgCl2.	  	  Finally,	  the	  resin	  was	  resuspended	  with	  50	  µl	  of	  
buffer,	  spun	  at	  10000	  g	  for	  5’	  and	  the	  resulting	  supernatant	  was	  analysed	  on	  a	  4-­‐12%	  Bis-­‐Tris	  
gel	  for	  1	  h	  at	  180	  V	  and	  visualized	  by	  Coomassie	  Blue	  staining.	  
4.13 Differential	  Scanning	  Fluorimetry	  
Differential	  Scanning	  Fluorimetry	  (DSF)	  is	  used	  to	  determine	  the	  thermal	  stability	  of	  proteins	  
and	   thus	   is	   a	   useful	  method	   to	   screen	   for	   binding	   of	   low-­‐MW	   ligands	   such	   as	   peptides	   or	  
nucleotide.	   	   DSF	   experiments	   were	   carried	   out	   using	   the	   following	   general	   protocol,	   and	  
adapted	  depending	  on	  the	  assay.	  	  These	  comprised	  of	  screening	  for	  peptide	  binding	  to	  PERK	  
and	  IRE1	  versus	  nucleotide	  binding	  to	  BiP	  protein.	  	  The	  500X	  Sypro	  Orange	  stock	  was	  diluted	  
to	  10X	  in	  DMSO.	  	  Each	  reaction	  consisted	  of	  40	  µl	  of	  the	  protein	  plus	  co-­‐factors	  (peptide	  or	  
nucleotides)	  as	  appropriate	  plus	  1	  µl	   of	  10X	  Sypro	  Orange,	  added	   immediately	  prior	   to	   the	  
assay	  measurements	  as	  it	  is	  light-­‐sensitive.	  	  PERK	  and	  IRE1	  plus	  peptide	  reactions	  were	  made	  
by	  mixing	  200	  µM	  protein	  plus	  500	  µM	  peptide	   in	  buffer	  K.	   	  BiP	  plus	  nucleotides	   reactions	  
were	  made	  by	  mixing	  200	  µM	  protein	   in	  buffer	  F	  plus	  5	  mM	  of	   the	  appropriate	  nucleotide	  
(ATP,	  ADP,	  AMPPNP	  or	  buffer	  F	   for	  control	  experiments)	  and	  10	  mM	  MgCl2.	   	  Samples	  were	  
mixed	   thoroughly	   and	   placed	   in	   a	   96-­‐well	   PCR	   plate	   (ThermoScientific).	   	   Buffer	  was	   added	  
instead	  of	  protein	  in	  control	  experiments	  to	  monitor	  Sypro	  Orange	  background	  fluorescence.	  	  
Experiments	  were	  carried	  out	  by	  heating	  samples	  from	  20	  to	  95	  °C	  in	  increments	  of	  2	  °C/min	  
in	  a	  Mastercycler	  Ep	  Realplex	  (Eppendorf,	  Germany).	  	  Fluorescence	  at	  569	  nm	  was	  measured.	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The	  melting	  transition	  curves	  were	  fitted	  with	  a	  Boltzmann	  equation	  and	  the	  inflection	  point	  
was	  calculated	  to	  obtain	  melting	  temperature	  (Tm)	  values.	  	  Each	  experiment	  was	  repeated	  in	  
triplicate	  and	  average	  values	  were	  used.	  
4.14 Microscale	  Thermophoresis	  
Microscale	   Thermophoresis	   (MST)	   was	   used	   to	  measure	   interaction	   between	  molecules	   in	  
solution.	   	   MST	   has	   the	   advantage	   of	   allowing	   quantitative	   measurement	   of	   interactions	  
directly	   in	   solution	  without	   the	   need	   of	   immobilization	   (as	   is	   the	   case	   in	   Surface	   Plasmon	  
Resonance	   (SPR)),	   requires	   relatively	   small	   amounts	   of	   protein	   (compared	   to	   Isothermal	  
Titration	  Calorimetry	  (ITC))	  and	  is	  useful	  particularly	  to	  efficiently	  screen	  many	  variables	  with	  
consistency	  in	  the	  experimental	  setup.	  	  	  
MST	  experiments	  were	  carried	  in	  buffer	  K	  (and	  where	  specified	  additional	  5	  mM	  ATP,	  ADP	  or	  
AMPPNP	   and	   10	   mM	   MgCl2	   was	   included)	   at	   25	   °C	   using	   a	   Monolith	   NT.115	   instrument	  
(NanoTemper	   Technologies).	   	   Proteins	   were	   labelled	   by	   primary	   amine	   coupling	   using	   the	  
Monolith	  NT	  Protein	  labelling	  Kit	  Red-­‐NHS	  (NanoTemper	  Technologies).	  	  The	  concentration	  of	  
labelled	  protein	  was	  adjusted	  so	  as	  to	  obtain	  fluorescence	  readings	  between	  absolute	  values	  
of	  200	  and	  2000	   (the	  range	  of	   the	   instrumentation).	   	  All	   subsequent	  experiments	  with	   that	  
particular	   labelled	   protein	  were	   carried	   out	   using	   the	   corresponding	   dilution.	   	   10	  µl	   of	   the	  
labelled	   protein	   was	   thoroughly	   mixed	   with	   10	   µl	   of	   16	   two-­‐fold	   serial	   dilutions	   of	   the	  
unlabelled	  binding	  partner.	  	  Buffer	  K	  was	  used	  for	  all	  experiments	  and	  supplemented	  with	  5	  
mM	   nucleotides	   and	   10	   mM	  MgCl2	   where	   specified.	   	   All	   experiments	   were	   carried	   out	   in	  
standard	   treated	   capillaries	   with	   100%	   LED	   power	   and	   80%	   infrared	   (IR)-­‐laser	   unless	  
otherwise	  stated.	  	  	  
With	   the	   Monolith	   NT.115	   (NanoTemper	   Technologies,	   Germany)	   set	   up,	   a	   fluorescently	  
labelled	  molecule	  is	  titrated	  with	  an	  unlabelled	  binding	  partner	  in	  a	  series	  of	  capillaries.	  	  The	  
reaction	  is	  allowed	  to	  equilibrate	  (Fluorescence	  ‘cold’	  (Fcold)),	  after	  which	  an	  IR	  laser	  is	  used	  to	  
create	  a	  microscopic	  temperature	  gradient	  that	  initiates	  thermophoresis	  of	  the	  molecules	  in	  
the	  capillaries	  until	  equilibration	   is	   reached	   (Fluorescence	   ‘hot’	   (Fhot)).	   	  When	  the	   IR	   laser	   is	  
switched	  off	  the	  back-­‐diffusion	  of	  the	  molecules	  is	  observed.	  	  A	  Light	  Emitting	  Diode	  (LED)	  is	  
used	   to	   excite	   the	   fluorescent	  molecule	   and	   the	   changes	   in	   fluorescence	   at	   a	   specific	   and	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constant	   point	   in	   the	   capillary	   is	   monitored.	   	   Curves	   are	   normalized	   to	   take	   into	   account	  
differences	  in	  initial	  fluorescence	  values.	  	  Normalised	  Fhot/Fcold	  values	  were	  plotted	  against	  the	  
concentration	   of	   the	   titrant,	   in	   the	   logarithmic	   scale.	   	   The	   NanoTemper	   Analysis	   1.2.101	  
software	   was	   used	   to	   fit	   the	   data	   with	   a	   nonlinear	   solution	   of	   the	   law	   of	   mass	   action	   to	  
determine	   dissociation	   constant	   (KD)	   values.	   	   Each	   measurement	   was	   repeated	   in	   three	  
independent	  experiments	  and	  KD	  values	  were	  averaged	  and	  Standard	  Error	  (SE)	  values	  were	  
calculated.	   	   Fhot/Fcold	   values	   were	   normalized	   for	   each	   experiment	   so	   as	   to	   compare	   them	  
independently	   of	   absolute	   fluorescence	   value.	   	   These	   are	   shown	   as	   fraction	   of	   labelled	  
protein	   A	   bound	   to	   unlabelled	   protein	   B	   (assuming	   this	   to	   be	   0	   and	   1	   at	   minimum	   and	  
maximum	  equilibriums	  respectively).	  
4.15 Isothermal	  Titration	  Calorimetry	  
ITC	   was	   used	   to	   determine	   the	   affinity	   and	   stoichiometry	   of	   protein-­‐protein	   and	   protein-­‐
peptide	   interactions.	   	   For	   ITC	   experiments,	   samples	   were	   dialyzed	   against	   2	   L	   of	   buffer	   K,	  
supplemented	  with	  5	  mM	  ADP	  and	  10	  mM	  MgCl2	  where	  specified,	  overnight	  at	  4	  °C.	  	  Proteins	  
were	   then	   concentrated	   or	   diluted	   to	   the	   appropriate	   concentration:	   syringe	   sample	  
concentrations	   ranged	   from	   10-­‐40	   µM	   and	   cell	   sample	   concentrations	   were	   9-­‐10-­‐fold	   in	  
molar	  excess.	  	  Precise	  sample	  concentrations	  were	  measured	  and	  are	  indicated	  in	  the	  results	  
section	  for	  each	  ITC	  experiment.	   	  Buffer	  and	  protein	  samples	  were	  degassed	  under	  vacuum	  
for	   5’	   with	   gentle	   stirring.	   	   Samples	   were	   loaded	   into	   the	   syringe	   and	   sample	   cell	   as	  
appropriate	   in	   a	   VP-­‐ITC	   MicroCalorlimeter	   (GE	   Healthcare).	   	   Titrations	   consisted	   of	   10	   µl	  
injections	  of	  syringe	  sample,	  for	  a	  total	  of	  30,	  at	  300”	  intervals	  at	  25	  °C.	  	  For	  each	  experiment,	  
the	   heat	   of	   dilution,	   as	   determined	   by	   titrating	   the	   syringe	   sample,	   at	   the	   same	  
concentration,	  into	  dialysis	  buffer	  was	  subtracted	  from	  the	  raw	  titration	  data	  before	  analysis.	  	  
Data	  were	   fit	   by	   least-­‐squares	  procedure	   assuming	  one-­‐site	  binding	  models	   using	  MicroCal	  
Origin	   (version	   7.0).	   	   KD	   values	   were	   averaged	   over	   three	   measurements;	   SE	   values	   are	  
indicated.	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4.16 Analytical	  ultracentrifugation	  
Purified	   protein	   samples	  made	  up	   to	   a	   final	   concentration	   of	   30	  µM,	  dialyzed	   overnight	   in	  
buffer	  K	  at	  4	  °C,	  spun	  for	  10’	  at	  40000	  g	  and	  analysed	  by	  analytical	  ultracentrifugation	  (AUC).	  	  
AUC	  experiments	  were	  carried	  out	  by	  Dr	  Katherine	  Stott	  at	  the	  Biochemistry	  Department	  of	  
the	  University	  of	  Cambridge.	  	  	  
4.17 Crystallisation	  
4.17.1 PERK	  luminal	  domain	  crystallisation	  
Sitting	  drop	  and	  hanging	  drop	  vapour	  diffusion	  setups	  were	  used	  for	  crystallisation	  of	  PERK	  
luminal	  domain	  proteins.	  	  Initial	  sitting	  drop	  nanolitre	  scale	  crystallisation	  experiments	  were	  
set	   up	   using	   an	   automated	   Mosquito	   crystal	   robot	   (TTP	   LabTech,	   UK).	   	   Initial	   protein	  
concentrations	   used	   varied	   between	   5	   and	   25	   mg/ml	   depending	   on	   the	   protein	   and	   are	  
specified	  in	  the	  results	  section.	  	  Drops	  were	  set	  up	  in	  100	  nl	  protein	  plus	  100	  nl	  reservoir,	  200	  
nl	   protein	   plus	   100	   nl	   reservoir	   and	   100	   nl	   protein	   plus	   200	   nl	   reservoir.	   	   The	   following	  
commercially	   available	   crystallisation	   screens	   were	   tested:	   Crystal	   Screen	   1	   and	   2,	   Index,	  
SaltRx	   1	   and	   2	   (Hampton	   Research,	   USA),	   PACT	   premier,	   JCSG+,	   MemGold,	   Proplex,	  
Morpheus,	   PGA	   Screen	   (Molecular	   Dimensions,	   USA)	   and	   Wizard	   1	   and	   2	   (Emerald	  
Biosystems,	   USA).	   	   Plates	   were	   incubated	   at	   4	   or	   18	   °C.	   	   Drops	   were	   screened	   at	   regular	  
intervals	   from	  2	  days	  and	  up	  to	  a	  year	  after	   initial	  setup.	   	  Crystal	  hits	  were	  optimized	   in	  48	  
and	   24-­‐well	   sitting	   drop	   MRC	   plates	   or	   24-­‐well	   hanging	   drop	   plates	   by	   varying	   the	  
concentration	  of	  protein	  and	  components	  of	   the	  crystallisation	  solution,	  drop	  and	  reservoir	  
volumes,	  temperature	  as	  described	  in	  the	  results	  Chapter	  6.	  	  In	  some	  instances,	  the	  Additive	  
Screen	  (Hampton	  Research)	  was	  also	  carried	  out	  on	  pre-­‐optimized	  crystallisation	  conditions.	  
4.17.2 Micro-­‐seeding	  
Micro-­‐seeding	  was	   achieved	  by	   transferring	   a	   single	   crystal	   into	   a	   Seed	  Bead	   kit	   (Hampton	  
Research)	  containing	  50	  µl	  of	  the	  reservoir	  crystallisation	  solution.	   	  The	  crystal	  was	  crushed	  
by	   vortexing	   for	   2’	   and	   the	   original	   seed	   stock	   was	   diluted	   106-­‐fold	   using	   the	   same	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crystallisation	  solution.	  	  This	  diluted	  seed	  solution	  was	  used	  instead	  of	  the	  reservoir	  buffer	  to	  
set	   up	   crystallisation	   trays	   identically	   as	   described	   above.	   	   For	   matrix-­‐microseeding	   the	  
concentrated	  seed	  stock	  was	  added	  to	  the	  protein	  solution	  (1	  to	  50	  ratio)	  immediately	  prior	  
to	   setting	   up	   nanolitre	   scale	   crystallisation	   screens	   as	   above.	   	   All	   seed	   stocks	  were	   freshly	  
made	  and	  not	  stored.	  
4.17.3 Crystal	  dehydration	  
Dehydration	   of	   crystals	   was	   achieved	   by	   a	   serial	   transfer	   of	   the	   coverslip	   holding	   the	  
crystallised	  drop	  over	  reservoirs	  containing	   increasing	  concentrations	  of	  polyethylene	  glycol	  
(PEG)	  3350.	  	  PEG3350	  concentration	  was	  increased	  by	  2%	  w/v	  and	  incubated	  8-­‐12	  h	  at	  each	  
step	  up	  to	  a	  final	  40%	  w/v	  PEG3500	  concentration.	  
4.17.4 Cryoprotection	  and	  crystal	  harvesting	  
Crystals	   grown	   in	   conditions	   which	   were	   not	   cryoprotectant	   were	   transferred	   to	   a	  
cryoprotectant	  solution	  prior	  to	  freezing.	  	  The	  following	  cryoprotectant	  reagents	  were	  added	  
to	   Cryoprotectant	   solutions	  were	  made	  up	  which	   contained	   the	   reservoir	   components	   and	  
additional	  20%	  v/v	  glycerol,	  30%	  w/v	  sucrose,	  30%	  v/v	  ethylene	  glycol,	  30%	  v/v	  2-­‐Methyl-­‐2,4-­‐
pentanediol	   (MPD)	   and	   30%	   w/v	   PEG400.	   	   Gentle	   cryoprotection	   is	   important	   as	   crystal	  
diffraction	   is	   often	   sensitive	   to	   extensive	   handling	   and	   changes	   in	   its	   surrounding	   solution.	  	  
Therefore,	  1	  µl	  of	  the	  cryoprotectant	  was	  first	  added	  to	  the	  crystallisation	  drop	  and	  crystals	  
were	   then	  briefly	   transferred	   to	  1	  µl	   of	  pure	   cryoprotectant	  and	   then	   flash	   frozen	   in	   liquid	  
nitrogen.	   	   Crystals	   that	   did	   not	   require	   cryoprotection	   were	   directly	   flash	   frozen	   in	   liquid	  
nitrogen.	  
4.18 X-­‐ray	  diffraction	  data	  
All	   X-­‐ray	   diffraction	   data	   were	   collected	   at	   Diamond	   Light	   Source	   (Didcot,	   UK)	   on	  
Macromolecular	   Crystallography	   beamlines	   (I-­‐03,	   I04	   and	   I04-­‐1).	   	   Both	   charge-­‐coupled	  
detector	  (CCD)	  and	  Pilatus	  detectors	  were	  used.	  	  Native	  datasets	  were	  collected	  at	  the	  typical	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working	  wavelength	  of	  0.9795	  Å.	  	  Diffraction	  data	  images	  were	  integrated	  using	  iMosflm	  and	  
then	  merged	  and	  scaled	  using	  Scala	  (CCP4)	  [165].	  
4.19 Phasing	  
4.19.1 Heavy	  atom	  native	  gel	  shifts	  
For	   phasing	   by	   heavy	   atom	   derivatization,	   Heavy	   Atom	   Screens	   (Hampton	   Research)	   were	  
used.	  	  To	  screen	  for	  heavy	  atom	  binding,	  a	  native	  gel	  shift	  assay	  was	  used.	  	  Fresh	  heavy	  atom	  
100	   mM	   stocks	   were	   made	   up	   in	   water.	   	   The	   heavy	   atoms	   tested	   for	   each	   crystal	   are	  
described	   in	   the	   results.	   	   Reactions	   containing	   2	  µl	   purified	   protein	   at	   75	  µM,	   2	  µl	   native	  
loading	  buffer,	  5	  µl	  water	  and	  1	  µl	  of	  heavy	  atom	  stock	  at	  100	  mM	  were	  mixed	  and	  incubated	  
at	  RT	  for	  20’.	   	  Samples	  were	  then	  run	  on	  a	  pre-­‐equilibrated	  3-­‐8%	  Tris-­‐Acetate	  gel	  for	  2	  h	  at	  
100	  V	  at	  4	  °C	  in	  Tris-­‐Glycine	  Native	  Running	  Buffer	  (Life	  Technologies).	   	  Gels	  were	  visualized	  
by	  Coomassie	  Blue	  staining.	  
4.19.2 Heavy	  atom	  soaking	  
For	  phasing	  by	  heavy	  atom	  derivatization,	  a	  soaking	  technique	  was	  used.	   	  The	  heavy	  atoms	  
used	   are	   listed	   in	   the	   results	   section.	   	   For	   soaking,	   200	  mM	   stock	   solutions	  were	  made	   in	  
water	  and	  then	  diluted	  to	  50	  mM	  in	  the	  reservoir	  buffer.	  	  The	  appropriate	  volume	  was	  added	  
to	   crystallisation	   drops	   to	   reach	   the	   desired	   final	   heavy	   atom	   concentration.	   	   Final	   heavy	  
atom	  concentrations	  used	  were	  0.5,	  1,	  2,	  5	  and	  10	  mM.	  	  Crystals	  were	  left	  to	  soak	  for	  30’,	  2	  h,	  
5	  h	  or	  overnight	  after	  which	  they	  were	  harvested.	  	  	  
A	  slightly	  different	  protocol	  was	  used	   for	   soaking	  with	  5-­‐amino-­‐2,4,6-­‐triiodoisophthalic	  acid	  
(I3C)	   Phasing	   Kit	   (Hampton	   Research)	   and	   Tantalum	   Cluster	   Derivatization	   Kit	   (Jena	  
Bioscience).	  	  1	  M	  I3C	  stock	  was	  made	  in	  2	  M	  Lithium	  hydroxide	  so	  as	  to	  fully	  deprotonate	  the	  
I3C	  carboxyl	  groups.	  	  This	  was	  diluted	  to	  0.5	  M	  I3C	  with	  the	  crystallisation	  buffer	  and	  added	  
to	  the	  crystallisation	  drop	  as	  appropriate.	  	  Final	  I3C	  concentrations	  tested	  varied	  between	  10	  
to	   250	   mM.	   	   10	   mM	   I3C	   was	   used	   for	   testing	   crystal	   diffraction.	   	   The	   Tantalum	   Bromide	  
Cluster	  was	  either	   added	  directly	   to	   the	   crystallisation	  drop	  as	  powder	  or	  diluted	   to	  2	  mM	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with	  the	  crystallisation	  solution	  and	  crystals	  were	  transferred	  to	  the	  solution	  and	  soaked	  for	  2	  
h.	  	  The	  latter	  method	  was	  used	  for	  soaking	  crystals	  whose	  diffraction	  was	  tested.	  	  	  
All	  crystals	  soaked	   in	  heavy	  atoms	  were	  either	  back-­‐soaked	  to	  remove	  unspecifically	  bound	  
heavy	   atoms	   or	   harvested	   directly.	   	   Back	   soaking	   was	   carried	   out	   by	   briefly	   transferring	   a	  
crystal	  to	  a	  1	  µl	  drop	  containing	  the	  reservoir	  solution	  prior	  to	  freezing.	  
4.19.3 SeMet	  crystal	  oxidation	  and	  reduction	  
Oxidation	  and	   reduction	  of	  SeMet	  was	  achieved	  by	  soaking	  crystals	   for	  1	  h	   in	   the	   reservoir	  
solution	   containing	   additional	   0.1%	   hydrogen	   peroxide	   (H2O2)	   or	   2	   mM	   TCEP	   respectively.	  	  
Crystals	  were	  then	  flash	  frozen	  in	  liquid	  nitrogen.	  
4.19.4 Heavy	  atom	  derivative	  data	  collection	  
SeMet	   and	   heavy-­‐atom	   derivative	   SAD	   datasets	   were	   collected	   at	   the	   peak	   wavelength	  
experimentally	  derived	  from	  fluorescence	  scans.	   	  For	  MAD	  experiments,	  additional	  datasets	  
were	   collected	   at	   the	   inflection	   and	   lower	   remote	   wavelength,	   also	   obtained	   from	   the	  
fluorescence	   scan.	   	   The	   same	   crystal,	   crystal	   orientation	   and	   strategy	   as	   the	   peak	   dataset	  
were	   used	   to	   collect	   inflection	   and	   remote	   datasets.	   	   This	   served	   to	   minimize	   systematic	  
errors	  that	  arise	  from	  differences	  within	  a	  crystal	  lattice	  and	  between	  crystals	  and	  thus	  more	  
accurately	  measure	  anomalous	  signal.	  
4.19.5 Derivative	  data	  processing	  and	  phasing	  
Molecular	   replacement	   was	   carried	   out	   using	  Molrep	   (CCP4),	   MR	   Rosetta	   and	   Phaser	   MR	  
(Phenix)	  programs	  [164,165].	   	  Experimental	  phasing	  was	  carried	  out	  using	  AutoSol	   (Phenix),	  
Crank	  and	  Shelx	  C/D/E,	  using	  the	  AutoSharp	  pipeline,	  (CCP4)	  [164,165,167].	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4.20 Model	  building	  and	  refinement	  
Structure	  refinement	  was	  carried	  out	  using	  Phenix	  Refine	  and	  Feature	  Enhanced	  Maps	  (FEM)	  
(Phenix)	  [164].	  	  Model	  building	  was	  carried	  out	  manually	  using	  Coot	  [169].	  
4.21 Bioinformatics	  programs	  
Multiple	   sequence	   alignment	   was	   carried	   out	   using	   Tree	   based	   Consistency	   Objective	  
Function	   For	   Alignment	   Evaluation	   (T-­‐coffee)	   [170].	   	   Secondary	   structure	   prediction	   was	  
carried	  out	  using	  the	  Jpred3	  server	  [171].	  	  Disorder	  prediction	  was	  carried	  out	  using	  Regional	  
Order	   Neural	   Network	   (RONN)	   [172].	   	   Surface	   Entropy	   Reduction	   prediction	   (SERp)	   server	  
was	   used	   to	   identify	   flexible	   or	   solvent	   exposed	   residues	   of	   PERK	   luminal	   domain	   to	   be	  
replaced	   with	   residues	   with	   lower	   conformational	   entropy	   in	   an	   attempt	   to	   increase	   the	  
efficiency	   of	   crystallisation	   [173].	   	   The	   Phyre	   server	   was	   used	   to	   generate	   PERK	   luminal	  
domain	  models	  to	  be	  used	  as	  molecular	  replacement	  ensembles	  [174].	  	  DALI	  server	  was	  used	  
to	  search	  for	  known	  fold	  motifs	  based	  on	  PERK	  luminal	  structure	  [175].	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5 PERK,	  IRE1	  and	  BiP	  purification	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5.1 Summary	  
In	  this	  chapter,	  the	  cloning,	  expression	  and	  purification	  of	  wild-­‐type	  PERK	  and	  IRE1	  ER	  stress	  
sensing	  luminal	  domains,	  BiP	  chaperone	  and	  CH1	  unfolded	  protein	  is	  presented.	  	  Purification	  
of	  PERK	  derivatives	  and	  mutant	  proteins	  is	  discussed	  in	  Chapters	  0	  and	  7	  as	  appropriate.	  	  All	  
proteins	   used	   are	   summarised	   in	   Table	   5-­‐1.	   	   Hereon,	   H.	   sapiens,	   M.	   musculus	   and	   D.	  
melanogaster	  orthologues	  will	  be	  identified	  by	  ‘h’,	   ‘m’	  and	  ‘d’	  prefixes	  respectively.	   	  The	  ‘p’	  
suffix	  refers	  to	  S.	  cerevisiae	  proteins	  as	  previously	  used.	  
For	   crystallisation	   studies,	   a	   stable	   luminal	   domain	   core	   region	   corresponding	   to	   residues	  
105-­‐403	  of	  hPERK,	  101-­‐399	  of	  mPERK	  and	  182–384	  of	  dPERK	  was	   identified.	   	  Proteins	  were	  
expressed	   in	  E.	  coli,	  as	   for	  all	  other	  proteins	  used	   in	   this	  work,	  and	  dimeric	  oligomers	  were	  
purified	   to	   near	   homogeneity.	   	   For	   biophysical	   characterisation	   experiments,	   hPERK	   and	  
hIRE1	   luminal	   domains	   were	   divided	   into	   five	   sub-­‐regions	   based	   on	   boundaries	   used	   in	  
previous	  studies.	   	  Full-­‐length	   luminal	  domain	  construct	   (regions	   I-­‐V)	  and	   truncated	  proteins	  
(containing	  regions	  I-­‐IV,	  II-­‐V,	  II-­‐IV)	  were	  purified.	  	  	  
A	  protocol	  was	  established	  for	  the	  purification	  of	  BiP	  chaperone	  to	  overcome	  initial	  problems	  
of	   unspecific	  DNA	   contamination	   that	   rendered	   it	   prone	   to	   aggregation.	   	   Full-­‐length	  BiP	   as	  
well	  as	  its	  NBD	  and	  SBD	  in	  isolation	  were	  purified.	  	  The	  immunoglobulin	  constant	  heavy	  chain	  
domain	  CH1	  was	  purified	  from	  inclusion	  bodies	  following	  a	  published	  protocol.	  
	  
	   	  
	   	  
	  
	  






Table	  5-­‐1.	  PERK,	  IRE1,	  BiP	  and	  CH1	  protein	  constructs	  
The	  constructs	  of	  PERK,	   IRE1,	  BiP	  and	  CH1	  proteins	  used	   in	   this	   study	  are	  summarised.	   	  The	  nomenclature	  used	  
throughout	   this	   report	   as	   well	   as	   a	   brief	   description	   of	   each	   construct	   are	   shown.	   	   H.s.,	   M.m.	   and	   D.m.	  
abbreviations	  are	  used	  to	  refer	  to	  H.	  sapiens,	  M.	  musculus	  and	  D.	  melanogaster	  species	  respectively.	   	  N-­‐	  and	  C-­‐	  
refer	   to	   the	   5’	  N-­‐terminal	   starting	   residue	   and	   3’	   C-­‐terminal	   ending	   residue	   of	   the	   construct	   respectively.	   	   The	  
given	  MW	  (kDa)	  corresponds	  to	  the	  size	  of	  untagged	  species;	  tagged	  proteins	  have	  an	  additional	  3	  kDa	  mass	  due	  
to	  the	  His6-­‐tag	  and	  PreScission	  Protease	  cleavage	  site.	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5.2 Purification	  of	  PERK	  luminal	  domain	  for	  crystallisation	  
5.2.1 Identification	  of	  PERK	  luminal	  domain	  core	  region	  
The	   luminal	   domain	   of	   hPERK,	  without	   its	   signal	   sequence,	   spans	   residues	  Ala41	   to	   Ile510.	  	  
PERK	  luminal	  domain	  has	  limited	  sequence	  identity	  to	  hIRE1	  luminal	  domain	  (18%	  and	  below	  
depending	   on	   the	   species).	   	   However,	   secondary	   structure	   prediction	   of	   hPERK	   luminal	  
domain	   suggests	   that	   their	   overall	   secondary	   structure	   composition	   is	   similar.	   	   Similarly	   to	  
hIRE1	   and	   IRE1p,	   hPERK	   luminal	   domain	   is	   suggested	   to	   be	   composed	  mainly	   of	  β-­‐strands	  
interspaced	   by	   several	   α-­‐helices.	   	   Multiple	   sequence	   alignment,	   PERK	   luminal	   domain	  
secondary	  structure	  prediction	  and	  the	  known	  structures	  of	  the	  hIRE1	  (PDB:	  2HZ6)	  and	  IRE1p	  
(PDB:	  2BE1)	  luminal	  domain	  orthologues	  were	  used	  to	  guide	  PERK	  luminal	  domain	  construct	  
design	   for	   crystallisation	   studies	   (Appendix	   Figure	   10-­‐3)	   [95,101].	   	   Figure	   5-­‐1	   summarises	  
hPERK	  luminal	  domain	  constructs	  expressed	  and	  purified	  for	  X-­‐ray	  crystallography	  studies.	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Figure	  5-­‐1.	  hPERK	  luminal	  domain	  constructs	  for	  X-­‐ray	  crystallography	  studies	  
PERK	  and	   IRE1	  are	  composed	  of	  a	  N-­‐terminal	  ER	   luminal	  domain,	  a	  membrane-­‐spanning	  region	  and	  cytosolic	  C-­‐
terminal	   domain.	   The	   constructs	   of	   hPERK	   luminal	   domain	   (purple)	   that	   were	   purified	   for	   structural	  
characterisation	   and	  discussed	   in	  Chapter	   6	   are	   illustrated.	   	   Initially	   all	   protein	  were	  purified	  with	   a	  N-­‐terminal	  
His6-­‐tag	   (magenta).	   	  A	  10	  kDa	   fragment	   spontaneously	  degraded	   from	  the	  C-­‐terminus	  of	  hPERK	  41-­‐510	  and	  54-­‐
510.	   	   hPERK	   54-­‐403,	   which	   does	   not	   contain	   the	   cleavable	   fragment,	   was	   stable	   but	   eluted	   as	   heterogeneous	  
dimers.	   	   hPERK	  105-­‐403	  was	   successfully	  purified	  as	  a	   stable,	   clean,	  homogeneous	  and	  monodispersed	   sample.	  	  
Crystals	  were	  obtained	  only	  when	  using	  the	  untagged	  hPERK	  105-­‐403.	  	  hIRE1	  luminal	  domain	  (blue)	  (PDB:	  2HZ6)	  
was	  used	  to	  guide	  hPERK	  construct	  design	  [95].	   	  The	  positions	  of	  residues	  of	  particular	   interest	  are	  shown.	   	  Red	  
lines	  indicate	  flexible	  or	  unstructured	  regions.	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The	  hIRE1	   luminal	  domain	  construct	  used	   in	  published	  crystallisation	  studies	  spans	  residues	  
Ser24	   to	   Val390	   [101].	   	   This	   corresponds	   to	   residues	   Glu95	   to	   Ile510	   of	   hPERK.	   Secondary	  
structure	   prediction	   of	   hPERK	   luminal	   domain	   suggests	   there	   is	   an	   extended	  α-­‐helix	   from	  
residues	   Tyr54	   to	  Glu76.	   	   This	   region	   is	   not	   conserved	   in	   hIRE1	   and	  was	   included	   in	   initial	  
hPERK	   luminal	   domain	   constructs	   as	   it	   could	   provide	   additional	   structural,	   and	   hence	  
functional,	   insights.	   	   The	   initial	   hPERK	   luminal	   domain	   constructs	   designed	   comprised	  
residues	  Ala41	  to	  Ile510	  (hPERK	  41-­‐510)	  and	  Ala54	  to	  Ile510	  (hPERK	  54-­‐510).	  
Recombinant	  proteins	  were	  expressed	  in	  E.	  coli	  as	  N-­‐terminal	  His6-­‐tagged	  fusion	  proteins	  and	  
initially	  purified	  by	  TALON	  affinity.	   	   SDS-­‐PAGE	  analysis	  of	   the	  elution	   fractions	   revealed	   the	  
presence	  of	  proteins	  of	  the	  expected	  size	  (Figure	  5-­‐2A).	  	  Two	  additional	  bands	  of	  lower	  MW	  
suggestive	   of	   protein	   degradation	   were	   also	   present.	   	   The	   larger	   ∼70	   kDa	   band,	   which	   is	  
removed	   in	  subsequent	  purification	  steps,	   is	  probably	  a	  contaminant	  E.	  coli	  protein.	   	  α-­‐His6	  
western	   blotting	  was	   carried	   out	   on	   the	   TALON	  elution	   fractions.	   	   Both	   samples	   contained	  
two	  His6-­‐containing	  species:	   (i)	   the	   intact	  58	  kDa	  His6-­‐hPERK	  41-­‐510	  and	  56	  kDa	  His6-­‐hPERK	  
54-­‐510,	  and	  (ii)	  a	  species	  ∼15	  kDa	  smaller	  (Figure	  5-­‐2B).	  	  Ion-­‐exchange	  and	  SEC	  were	  used	  in	  
an	  attempt	  to	  separate	  the	  two	  proteins	  in	  His6-­‐hPERK	  41-­‐510	  samples	  (Figure	  5-­‐2C-­‐D).	  	  The	  
58	   kDa	   intact	   protein	   and	   the	   43	   kDa	   degradation	   product	   co-­‐elute	   a	   single	   homogenous	  
species	   during	   both	   ion-­‐exchange	   and	   SEC.	   	   This	   indicates	   the	   two	   proteins	   have	   similar	  
chemical	  and	  physical	  properties,	  and	  possibly	  interact.	  	  Taken	  together	  these	  results	  suggest	  
the	  smaller	  band	  is	  a	  C-­‐terminally	  cleaved	  fragment	  of	  the	  expressed	  hPERK	  41-­‐510	  and	  54-­‐
510	  luminal	  domain	  proteins.	  
	   	  
	   	  
	  
	  






Figure	  5-­‐2.	  C-­‐terminal	  cleavage	  of	  full-­‐length	  hPERK	  luminal	  domain	  
(A)	  hPERK	  41-­‐510	  and	  54-­‐510	  TALON	  affinity	  elution	  fractions	  analysed	  by	  SDS-­‐PAGE.	  	  The	  ∼70	  kDa	  band	  is	  an	  E.	  
coli	   contaminant;	   the	  ∼58	   and	  ∼56	   kDa	   products	   are	   His6-­‐hPERK	   41-­‐510	   and	   54-­‐510	   respectively;	   all	   the	   other	  
bands	  of	  lower	  MW	  are	  His6-­‐hPERK	  degradation	  products.	  	  
(B)	  α-­‐His6	  western	  blot	  of	  samples	  in	  ‘A’.	  	  In	  each	  sample,	  two	  His6-­‐containig	  species	  are	  detected	  of	  ∼56-­‐58	  kDa	  
(intact	  His6-­‐hPERK	  41-­‐510	  and	  54-­‐510	  respectively)	  and	  His6-­‐tagged	  species	  ∼15kDa	  smaller.	  	  
(C)	  His6-­‐hPERK	  41-­‐510	  SEC	  (HiLoad	  16/60	  Superdex	  200).	  His6-­‐hPERK	  41-­‐510	  elutes	  a	  single	  a	  single	  homogenous	  
peak	  at	  58	  ml.	  
(D)	  Peak	  fractions	  (52	  –	  64	  ml	  elution)	  were	  analysed	  by	  SDS-­‐PAGE;	  ‘ml’	  numbers	  refer	  to	  starting	  volume	  of	  the	  
fraction	  collected.	  	  The	  58	  kDa	  (intact	  His6-­‐hPERK	  41-­‐510)	  and	  the	  43	  kDa	  species	  co-­‐elute	  during	  SEC.	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The	   ∼43	   kDa	   bands	   were	   excised	   from	   the	   SDS-­‐PAGE	   gel	   and	   analysed	   by	   in	   gel	   trypsin	  
digestion	   and	  MALDI-­‐TOF.	   	   The	   resulting	   peptides	   confirmed	   the	   identity	   of	   the	   bands	   as	  
truncated	  fragments	  of	  hPERK	  41-­‐510	  and	  61-­‐510	  (Figure	  5-­‐3A).	  	  The	  most	  C-­‐terminal	  hPERK	  
residue	  identified	  was	  Arg392.	  	  Trypsin	  cuts	  at	  the	  C-­‐terminus	  of	  Arginine	  and	  Lysine	  residues,	  
unless	   they	   are	   adjacent	   to	   a	   Proline.	   	   Therefore,	   the	   cleaved	   species	   must	   terminate	  
between	   Arg392	   and	   Arg402,	   the	   next	   trypsin	   cleavage	   site	   downstream	   of	   Arg392.	   	   This	  
region	   corresponds	   to	   β18	   of	   hIRE1	   luminal	   domain,	   its	   penultimate	   secondary	   structure.	  	  
β19	  of	  hIRE1	   is	  a	   small	   three-­‐residue	   feature	   located	  after	  a	  highly	   flexible	   region	  spanning	  
over	   50	   residues	   for	   which	   no	   electron	   density	   was	   observed	   in	   the	   X-­‐ray	   diffraction	   data	  
used	  to	  solve	  the	  structure	  [101].	  	  hPERK	  Ile403,	  which	  corresponds	  to	  the	  terminal	  residue	  of	  
hIRE1	  β18,	  was	  thus	  chosen	  as	  the	  optimized	  C-­‐terminal	  residue	  for	  subsequent	  constructs.	  	  
hPERK	  54-­‐403	  was	  expressed	  and	  purified	  by	  TALON	  affinity,	  ion-­‐exchange	  and	  SEC.	  	  Although	  
this	  new	  construct	  was	  stable	  and	  did	  not	  degrade,	   it	  eluted	  as	  two	  peaks	  during	  SEC	  MALS	  
indicates	  that	  both	  species	  have	  an	  identical	  MW	  of	  79.3	  kDa,	  which	  correspond	  to	  dimers	  of	  
hPERK	   54-­‐403	   (Figure	   5-­‐3B).	   	   This	   suggests	   that	   hPERK	   54-­‐403	   forms	   two	   distinct	   dimer	  
conformations.	   	   Due	   to	   its	   heterogeneity,	   this	   sample	   was	   deemed	   unsuitable	   for	  
crystallisation	  studies.	  
The	   N-­‐terminal	   region	   of	   hPERK	   (Ala41	   to	   Leu105)	   is	   predicted	   to	   be	   highly	   flexible	   and	  
disordered	  based	  on	  bioinformatics	  analysis	  (Appendix	  Figure	  10-­‐4).	  	  Furthermore,	  this	  ∼100	  
residue	  region	  is	  not	  conserved	  in	  IRE1	  sequences.	  	  Leu105	  of	  hPERK	  actually	  corresponds	  to	  
Leu32	   of	   hIRE1,	   its	   first	   ordered	   residue	   [101].	   	   Leu105	   was	   chosen	   as	   a	   new	   N-­‐terminal	  
residue	   for	   the	   optimized	   hPERK	   luminal	   domain	   construct	   to	   be	   used	   in	   crystallisation	  
studies.	   	  The	  optimized	  hPERK	  construct	   thus	  spans	  Leu105	   to	   Ile403.	   	   Identical	  boundaries	  
were	  used	   for	  cloning	  of	  mPERK	   (Leu101	  to	  Val399)	  and	  dPERK	   (Leu182	  to	  Leu384)	   luminal	  
domains	  for	  crystallisation	  studies.	  
hPERK	  105-­‐403,	  mPERK	  101-­‐399	  and	  dPERK	  182-­‐384	  optimized	  constructs	  represent	  the	  core	  
region	   of	   PERK	   luminal	   domain.	   	   Since	   this	   core	   luminal	   domain	   region	   corresponds	   sub-­‐
regions	   II-­‐IV,	  as	  described	   in	  Chapter	  7,	  hereon	  hPERK	  105-­‐403,	  mPERK	  101-­‐399	  and	  dPERK	  
182-­‐384	  will	  be	   referred	   to	  as	  hPERK	   (II-­‐IV),	  mPERK	   (II-­‐IV)	  and	  dPERK	   (II-­‐IV)	   respectively	   for	  
consistency.	   	  
	   	  
	  
	  






Figure	  5-­‐3.	  Identification	  of	  hPERK	  luminal	  domain	  core	  region	  
(A)	  Results	   from	   in	  gel	   trypsin	  digestion	  and	  MALDI-­‐TOF	  analysis	  of	   the	  43	  kDa	  cleaved	  species	   from	  His6-­‐hPERK	  
41-­‐510	  and	  54-­‐510	  purifications.	  	  The	  matched	  peptides	  are	  highlighted	  in	  cyan.	  	  Trypsin	  cleavage	  sites	  are	  shown	  
in	  bold.	   	   The	  chosen	   Ile403	  optimized	  C-­‐terminal	   residue	   is	   shown	   in	   red.	   	  hIRE1	  β18	   is	  aligned	   to	  hPERK	   (PDB:	  
2HZ6)	  [95].	  	  Numbers	  at	  the	  top	  refer	  to	  hPERK	  sequence.	  
(B)	  hPERK	  54-­‐403	  and	  hPERK	  105-­‐403	  SEC	  MALS	  analysis	  (Superdex	  200	  PC	  3.2/30).	  	  hPERK	  54-­‐403	  (purple)	  elutes	  
as	  two	  separate	  dimer	  species	  of	   identical	  79.3	  kDa	  size.	   	  hPERK	  105-­‐403	  (blue)	  elutes	  as	  a	  single	  dimer	  peak	  of	  
67.2	  kDa.	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5.2.2 Purification	   of	   H.	   sapiens,	   M.	   musculus	   and	   D.	   melanogaster	  
orthologues	  of	  PERK	  (II-­‐IV)	  
Proteins	   were	   expressed	   as	   described	   in	   the	  materials	   and	  methods	   section.	   	   Initially,	   the	  
purification	   protocol	  was	   optimized	   for	   hPERK	   (II-­‐IV).	   	   A	   large	   proportion	   of	  E.	   coli	   protein	  
contaminants	   were	   removed	   in	   the	   flow	   through	   and	   wash	   steps	   of	   TALON	   affinity	  
purification	   (Figure	  5-­‐3A).	   	  The	  major	  species	  of	   the	  TALON	  elution	   fraction	  was	  His6-­‐hPERK	  
(II-­‐IV),	   which	  migrates	   with	   an	   apparent	  MW	   of	   40	   kDa.	   	   The	   elution	   fraction	   was	   further	  
purified	  by	  ion-­‐exchange	  (Figure	  5-­‐3B).	  	  The	  peak	  containing	  hPERK	  (II-­‐IV),	  eluting	  from	  400	  to	  
500	  mM	  NaCl	  concentration,	  was	  analysed	  by	  SDS-­‐PAGE	  (Figure	  5-­‐3C).	   	  Fractions	  containing	  
purest	  hPERK	  (II-­‐IV)	  (420	  –	  490	  mM	  NaCl)	  were	  pooled	  and	  run	  on	  a	  SEC	  column.	  
Initially,	  hPERK	  (II-­‐IV)	  was	  purified	  in	  the	  absence	  of	  reducing	  agent.	  	  However	  the	  SEC	  elution	  
profile	   indicates	   hPERK	   (II-­‐IV)	   elutes	   as	   multiple	   overlapping	   peaks	   (Figure	   5-­‐5A).	   	   The	  
heterogeneity	  of	   this	   sample	   renders	   it	   unsuitable	   for	   crystallisation	   studies.	   	  Addition	  of	   2	  
mM	  TCEP	  reducing	  agent	  shifted	  the	  profile	  to	  a	  single	  homogeneous	  peak	  eluting	  at	  70	  ml	  
on	  a	  HiLoad	  16/60	  Superdex	  200	  column.	  	  Fractions	  eluting	  from	  68	  to	  76	  ml	  contained	  pure	  
hPERK	  (II-­‐IV)	  protein	  and	  were	  pooled	  (Figure	  5-­‐5B).	  	  2	  mM	  TCEP	  was	  used	  in	  all	  purification	  
steps	   after	   the	   initial	   TALON	  affinity	   step	   to	   prevent	   unspecific	   disulphide	   bond	   formation.	  	  
TCEP	  was	  chosen	  as	  the	  reducing	  agent	  as	  it	  is	  less	  easily	  oxidized	  and	  is	  considered	  to	  break	  
disulphide	  bonds	  irreversibly.	  	  10%	  glycerol	  was	  included	  in	  all	  buffers	  as	  it	  increases	  protein	  
solubility,	   helps	   prevent	   aggregation	   and	   assists	   in	   controlled	   nucleation	   during	  
crystallisation.	  	  Identical	  TALON	  affinity,	  ion-­‐exchange	  and	  SEC	  purification	  steps	  were	  carried	  
out	  for	  mPERK	  (II-­‐IV)	  and	  dPERK	  (II-­‐IV).	  
	  
	   	  
	  
	  




Figure	  5-­‐4.	  hPERK	  (II-­‐IV)	  TALON	  affinity	  and	  ion-­‐exchange	  chromatography	  
(A)	  hPERK	  (II-­‐IV)	  TALON	  affinity	  purification.	  	  The	  flow-­‐through	  (FT),	  first	  and	  last	  5	  mM	  imidazole	  washes	  (W1	  and	  
W2)	  and	  elution	  (E)	  fractions	  were	  analysed	  by	  SDS-­‐PAGE.	  	  hPERK	  (II-­‐IV)	  is	  soluble,	  stable	  and	  migrates	  as	  ∼40	  kDa	  
species.	  	  	  
(B)	  hPERK	   (II-­‐IV)	   ion-­‐exchange	  chromatography	   (HiTrap	  Q	  HP).	   	   hPERK	   (II-­‐IV)	  elutes	  as	  a	   single	  peak	  at	  430	  mM	  
NaCl.	  
(C)	   Fractions	   eluting	   from	  400	   to	   480	  mM	  NaCl	   (34	   –	   50	  ml	   elution	   volume)	  were	  analysed	  by	   SDS-­‐PAGE.	   	   ‘ml’	  
numbers	  refer	  to	  starting	  volume	  of	  the	  fraction	  collected.	  	  Fractions	  containing	  purest	  hPERK	  (II-­‐IV)	  (38	  –	  50	  ml	  
elution	  volume	  corresponding	  to	  420	  –	  490	  mM	  NaCl)	  were	  pooled.	  
	   	  
	  
	  







Figure	  5-­‐5.	  hPERK	  (II-­‐IV)	  SEC	  
(A)	   hPERK	   (II-­‐IV)	   SEC	   (HiLoad	   16/60	   Superdex	   200).	   	   In	   the	   absence	   of	   reducing	   agent,	   hPERK	   (II-­‐IV)	   elutes	   as	  
multiple	  overlapping	  peaks	  from	  45	  to	  80	  ml.	  	  Upon	  addition	  of	  2	  mM	  TCEP,	  hPERK	  (II-­‐IV)	  elutes	  as	  a	  single	  species	  
at	  70	  ml.	  	  	  
(B)	  hPERK	  (II-­‐IV)	  (+	  2	  mM	  TCEP)	  fractions	  from	  68	  to	  76	  ml	  were	  analysed	  on	  by	  SDS-­‐PAGE.	  	  ‘ml’	  numbers	  refer	  to	  
starting	  volume	  of	  the	  fraction	  collected.	  	  Fractions	  containing	  pure	  hPERK	  (II-­‐IV)	  (68	  –	  76	  ml)	  were	  pooled.	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Protein	  samples	  were	  concentrated	  and	  used	  in	  subsequent	  biochemistry	  and	  crystallisation	  
studies	  (Figure	  5-­‐6A).	  	  Although	  protein	  expression	  levels	  were	  relatively	  low	  (2	  mg	  of	  protein	  
per	   10	   L	   of	   cells)	   the	   final	   samples	   were	   pure,	   stable,	   homogenous	   and	   monodispersed	  
dimers	  and	  therefore	  optimal	  for	  crystallisation	  studies.	   	  MALS	  analyses	  indicate	  that	  hPERK	  
(II-­‐IV),	   mPERK	   (II-­‐IV)	   and	   dPERK	   (II-­‐IV)	   have	   a	   molar	   mass	   of	   66.3,	   67.2	   and	   80.0	   kDa	  
respectively	   (Figure	   5-­‐6B).	   	   This	   corresponds	   to	   dimeric	   oligomeric	   states.	   	   No	   crystal	   hits	  
were	   obtained	   for	   dPERK	   (II-­‐IV);	   since	   this	   protein	   was	   not	   used	   in	   any	   subsequent	  
experiments	  it	  will	  no	  longer	  be	  discussed	  in	  this	  thesis.	  	  	  
All	  PERK	  SeMet	  derivatives	  and	  mutant	  proteins	  were	  purified	  identically	  as	  for	  the	  wild	  type	  
full-­‐length	  hPERK	  (II-­‐IV)	  protein.	  	  
	   	  
	   	  
	  
	  








Figure	  5-­‐6.	  Purification	  of	  PERK	  (II-­‐IV)	  core	  luminal	  domain	  
(A)	  PERK	  (II-­‐IV)	   luminal	  domain	  purified	  samples.	   	  SDS-­‐PAGE	  gel	  of	   the	  purified	  and	  concentrated	  H.	  sapiens,	  M.	  
musculus	  and	  D.	  melanogaster	  orthologues	  of	  PERK	  (II-­‐IV)	  used	  for	  crystallisation.	  	  
(B)	   SEC	   MALS	   analyses	   (Superdex	   200	   PC	   3.2/30)	   of	   PERK	   (II-­‐IV)	   proteins.	   	   hPERK	   (II-­‐IV)	   (blue),	   mPERK	   (II-­‐IV)	  
(purple)	   and	   dPERK	   (II-­‐IV)	   (green)	   elute	   as	   single	   monodispersed	   dimeric	   species	   of	   67.2,	   66.3	   and	   80.0	   kDa	  
respectively.	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5.3 Purification	  of	  hPERK	  and	  hIRE1	  luminal	  domains	  for	  
biophysical	  studies	  
5.3.1 Designation	  of	  hPERK	  and	  hIRE1	  luminal	  domain	  regions	  I-­‐V	  
To	  predict	  the	  boundaries	  of	  hPERK	  and	  hIRE1	  luminal	  domains’	  sub-­‐regions,	  knowledge	  from	  
previous	  studies	  and	  bioinformatics	  analyses	  were	  utilized.	  	  Kimata	  et	  al.	  first	  suggested	  that	  
IRE1p	  luminal	  domain	  can	  be	  divided	  in	  five	  functional	  sub-­‐regions	  designated	  I	  to	  V	  [85].	  	  In	  
their	   study,	   an	   11	   amino	   acid	   scanning	   deletion	   experiment	   was	   carried	   out	   and	   the	  
truncated	   proteins	   were	   tested	   for	   their	   ability	   to	   splice	   Hac1p	   mRNA	   through	   a	   UPRE	  
promoter	   sequence-­‐LacZ	   reporter	   assay.	   	   IRE1p	   luminal	   domain	   shares	   highest	   sequence	  
similarity	  with	  that	  of	  hIRE1.	   	   Initially,	   IRE1p	  and	  hIRE1	  sequence	  alignment	  was	  used	  as	  an	  
indication	  of	   the	   approximate	   location	  of	   sub-­‐regions	   I	   to	  V	   in	   hIRE1	   luminal	   domain.	   	   The	  
known	  structural	  features	  of	  hIRE1	  and	  IRE1p	  luminal	  domains	  were	  then	  used	  to	  modify	  the	  
domain	  boundaries	  slightly	  [95,101].	  	  In	  particular,	  care	  was	  taken	  to	  not	  truncate	  proteins	  in	  
the	  middle	  of	  a	   secondary	   structure	  element	  and	   to	  not	  disrupt	   structural	   features	   such	  as	  
stacked	  β-­‐sheet	  bundles,	  hydrogen	  bonds	  or	  salt	  bridges,	  all	  which	  could	  affect	  the	  protein’s	  
function	  if	  disturbed.	  	  Multiple	  sequence	  alignment	  and	  secondary	  structure	  prediction	  were	  
carried	  out	  to	  extend	  hIRE1	  luminal	  domain	  sub-­‐region	  boundaries	  to	  hPERK	  luminal	  domain.	  	  
The	  chosen	  boundaries	  for	  hPERK	  and	  hIRE1	  regions	  I	  to	  V	  used	  for	  biochemistry	  experiments	  
are	  summarised	  in	  Table	  5-­‐2.	  
	   	  
	   	  
	  
	  





















Table	  5-­‐2.	  hPERK	  and	  hIRE1	  sub-­‐regions	  I	  to	  V	  boundaries	  
The	  boundaries	  of	  IRE1p,	  hIRE1	  and	  hPERK	  luminal	  domain	  regions	  I,	  II,	  III,	  IV	  and	  V	  are	  shown.	  	  Residues	  for	  IRE1p	  
were	  taken	  from	  Kimata	  et	  al.	  2006	  [85].	  	  The	  hIRE1*	  column	  (grey)	  refers	  to	  residues	  designated	  solely	  based	  on	  
IRE1p	   and	   hIRE1	   sequence	   alignment;	   these	   were	   not	   used	   for	   constructs	   of	   expressed	   proteins.	   	   Rather,	  
optimized	  hIRE1	  (blue)	  and	  hPERK	  (purple)	  domain	  boundaries	  were	  used.	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5.3.2 Purification	   of	   hPERK	   and	   hIRE1	   luminal	   domain	   regions	   I-­‐V	  
fragments	  
The	   following	   hPERK	   and	   hIRE1	   luminal	   domain	   constructs	   were	   used	   to	   assess	   the	  
functionality	  of	  regions	  I	  and	  V:	  I-­‐V,	  I-­‐IV,	  II-­‐V	  and	  II-­‐IV.	  	  All	  proteins	  were	  purified	  identically	  to	  
hPERK	  (II-­‐IV)	  (Chapter	  5.2.2).	  	  
Regions	  I	  and	  III	  are	  very	  short	  segments	  compared	  to	  the	  other	  sub-­‐domains.	  	  Additionally,	  
as	  seen	  from	  the	  structure	  of	  hIRE1,	  they	  are	  unstructured	  loop	  regions	  [101].	  	  Region	  V	  was	  
not	  present	  in	  the	  hIRE1	  crystallised	  fragment.	  	  From	  the	  evidence	  provided	  in	  Chapter	  5.2.1,	  
as	  well	  as	  disorder	  prediction	  results,	  region	  V	  is	  likely	  to	  be	  highly	  flexible.	  	  Regions	  I,	  III	  and	  
V	  were	  therefore	  not	  purified	  as	  isolated	  sub-­‐domains.	  	  Regions	  II	  and	  IV	  alone	  were	  cloned	  
to	   further	   characterise	   the	   ER	   stress	   sensing	   luminal	   domain.	   	   However	   attempts	   at	  
expressing	  these	  proteins	  were	  unsuccessful	  and	  will	  not	  be	  further	  discussed	  in	  this	  thesis.	  
5.4 Purification	  of	  BiP	  chaperone	  
The	   human	   orthologue	   of	   full-­‐length	   (FL)	   BiP	   spans	   residues	   Gly28	   to	   Leu654.	   	   BiP	   FL	  was	  
expressed	  and	  purified	  by	  an	  initial	  TALON	  affinity	  step	  followed	  by	  SEC	  (Figure	  5-­‐7).	  	  The	  ion-­‐
exchange	   step	  was	  omitted	   since	  protein	   levels	  obtained	  were	   significantly	  more	  abundant	  
than	   any	   E.	   coli	   contaminant,	   even	   just	   after	   only	   the	   TALON	   affinity	   step.	   	   Some	   BiP	   FL	  
protein	  was	  lost	  in	  the	  5	  mM	  imidazole	  wash	  step.	  	  However	  since	  most	  of	  the	  E.	  coli	  protein	  
contaminants	   were	   also	   removed	   in	   this	   step	   and	   sufficient	   protein	   was	   recovered	   in	   the	  
elution	  fraction	  this	  step	  was	  included.	  	  The	  BiP	  FL	  that	  is	  lost	  on	  the	  wash	  may	  be	  unfolded	  
and	  as	  a	  result	  does	  not	  bind	  the	  column.	  	  Alternatively	  the	  TALON	  resin	  was	  saturated	  with	  
the	  high	  quantity	  of	  BiP	  protein.	  	  The	  TALON	  resin	  elution	  fraction	  were	  pooled	  and	  run	  on	  a	  
Hi	   Load	  16/60	   Superdex	   200	   column.	   	   BiP	   FL	   initially	   eluted	   in	   the	   void	   volume	  during	   SEC	  
(Figure	  5-­‐7C).	   	  On	  this	  column	  this	  is	   indicative	  of	  a	  protein	  species	  larger	  than	  700	  kDa	  and	  
thus	   suggests	   the	   BiP	   FL	   protein	   was	   aggregating.	   	   The	   absorbance	   of	   the	   purified	   BiP	   FL	  
sample	  was	  measured.	  	  Samples	  had	  an	  absorbance	  at	  260	  nm	  (A260)	  to	  absorbance	  at	  280	  
nm	  (A280)	  ratio	  above	  1.8.	  	  Proteins	  absorb	  almost	  exclusively	  at	  280	  nm	  mainly	  due	  to	  their	  
Tryptophan,	   Tyrosine	   and	   Cysteine	   residues	   (with	   their	   molar	   absorption	   coefficients	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decreasing	   in	   that	   order).	   	   Nucleic	   acids	   normally	   absorb	   at	   260	   nm	   due	   to	   the	   aromatic	  
heterocyclic	  ring	  structures	  of	  pyrimidine	  and	  purine	  bases.	   	  Other	  factors	  that	  may	  cause	  a	  
high	   reading	   at	   260	   nm	   include	   the	   presence	   of	   imidazole	   or	   dithiothreitol	   (DTT)	   and	   β-­‐
mercaptoethanol	  reducing	  agents.	   	  Since	  these	  reagents	  were	  not	  present	   in	  the	  BiP	  FL	  SEC	  
buffer,	   the	   contaminating	   species	  was	   suspected	   to	  be	  DNA.	   	   Two	   identical	   BiP	   FL	   samples	  
were	  run	  on	  a	  native	  gel	  and	  stained	  either	  with	  Coomassie	  Blue	  (protein-­‐specific)	  or	  GelRed	  
(DNA-­‐specific)	   stains	   (Figure	   5-­‐7B).	   	   Large	   quantities	   of	   smeared	   DNA	   were	   detected	  
confirming	   the	   cause	   of	   the	   high	   A260	   to	   A280	   ratio.	   	   DNA-­‐contamination	   caused	   BiP	   FL	  
aggregation	   and	   it	  was	   therefore	   essential	   to	   circumvent	   this	   in	   order	   to	   obtain	   functional	  
protein	  for	  subsequent	  studies.	  	  	  
Firstly,	   the	   amount	   and	   incubation	   time	   with	   DNase	   during	   the	   lysis	   step	   were	   increased.	  	  
Additionally,	   a	   1	  M	   NaCl	   wash	   step	  was	   added	   during	   TALON	   affinity	   purification	   so	   as	   to	  
increase	   the	   ionic	   strength	   of	   the	   buffer	   and	   disrupt	   weak	   electrostatic	   interactions.	  	  
However,	   neither	   of	   these	   changes	   prevented	   BiP	   FL	   from	   co-­‐purifying	   with	   DNA.	   	   The	  
cationic	  reagent	  PEI	  has	  been	  published	  as	  an	  effective	  means	  of	  precipitating	  protein-­‐bound	  
nucleic	   acids	  during	  early	   purification	   steps	   [176].	   	   Addition	  of	   PEI	   during	  BiP	   FL	   lysis	   steps	  
resulted	   in	   the	  elution	  of	  peaks	  corresponding	   to	  ∼140	  and	  ∼70	  kDa	  protein	   species	  during	  
SEC,	   as	   approximated	   using	   the	   Hi	   Load	   16/60	   Superdex	   200	   calibration	   equation	   (Figure	  
5-­‐7C).	   	  These	  MW	  are	   indicative	  of	  BiP	  FL	  dimers	  and	  monomers	  respectively.	   	   In	  summary,	  
these	  results	  demonstrate	  that	  (i)	   the	  contaminating	  nucleic	  acid	  was	  responsible	  for	  BiP	  FL	  
aggregation	  and	  (ii)	  that	  this	  can	  be	  overcome	  by	  the	  addition	  of	  PEI.	  	  Nonetheless,	  the	  effect	  
of	   PEI	   on	   the	   functionality	   of	   proteins	   has	   never	   been	   investigated,	   at	   least	   in	   published	  
studies,	   and	   therefore	   an	   alternative	   protocol	   to	   avoid	   BiP	   FL-­‐DNA	   co-­‐purification	   was	  
developed.	  
BiP	  is	  a	  Hsp70	  chaperone	  and	  adopts	  an	  open	  SBD	  conformation	  and	  low	  substrate	  affinity	  in	  
the	  presence	  of	  ATP	  nucleotide.	  	  Following	  this	  reasoning,	  excess	  ATP	  was	  added,	  instead	  of	  
PEI,	  during	  initial	  lysis	  and	  TALON	  affinity	  steps	  of	  BiP	  FL	  purification.	  	  ATP	  was	  not	  added	  in	  
the	  final	  SEC	  step	  to	  ensure	  that	  BiP	  FL	  could	  be	  used	   in	   its	  different	  nucleotide-­‐dependent	  
functional	  conformations	   in	  subsequent	  experiments.	   	  The	  resulting	  BiP	  FL	  sample	  elutes	  as	  
two	   distinct	  monomer	   and	   dimer	   peaks	   in	   SEC	   (Figure	   5-­‐7C-­‐D).	   	   This	   SEC	   elution	   profile	   is	  
similar	   to	   that	  obtained	  when	  BiP	  FL	  was	  purified	  using	  PEI.	   	  When	  BiP	  FL	   samples	  purified	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either	   with	   PEI	   or	   ATP	   were	   stained	   with	   GelRed,	   no	   DNA	   was	   detected	   confirming	   their	  
efficacy	   in	  preventing	  BiP	  FL-­‐DNA	  contamination	  (Figure	  5-­‐7B).	   	  Addition	  of	  ATP	  avoids	  DNA	  
contamination	  and	  BiP	  FL	  aggregation	  and	  was	  used	  to	  purify	  BiP	  FL	  protein.	  	  
The	   sequence	   of	   BiP,	   as	   for	   all	   Hsp70s,	   is	   highly	   conserved	   and	   proteins	   have	   been	   well	  
characterised.	   	   BiP	  NBD	  and	  BiP	   SBD	   constructs	  were	  designed	  based	  on	  published	   studies	  
and	   encompass	   residues	   Gly28	   to	   Leu405	   and	   Leu422	   to	   Leu654	   respectively.	   	   Their	  
purification	   was	   carried	   out	   as	   for	   BiP	   FL	   protein.	   	   BiP	   NBD	   elutes	   as	   a	   single	   40	   kDa	  
monomeric	  peak	  during	  SEC	  (Figure	  5-­‐8A).	  	  BiP	  SBD	  elutes	  as	  two	  peaks	  corresponding	  to	  25	  
kDa	   monomeric	   and	   50	   kDa	   dimeric	   species	   (Figure	   5-­‐8A).	   	   All	   final	   protein	   samples	   are	  
shown	  in	  Figure	  5-­‐8B.	  
	  
5.5 Purification	  of	  CH1	  
The	   immunoglobulin	   constant	   heavy	   chain	   domain	   CH1	   protein	   was	   purified	   as	   previously	  
published	  from	  inclusion	  bodies	  [25].	  	  CH1	  elutes	  in	  the	  void	  volume	  during	  SEC.	  	  Since	  CH1	  is	  
intrinsically	  unfolded	  and	  only	  becomes	  ordered	  upon	  binding	  of	  its	  cognate	  binding	  partner	  
CL,	   this	  was	  expected.	   	   The	  purified	   sample	  used	   for	   subsequent	   studies	   is	   shown	   in	  Figure	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Figure	  5-­‐7.	  BiP	  FL	  purification	  
(A)	  BiP	  FL	  TALON	  affinity	  purification.	  	  The	  flow-­‐through	  (FT),	  first	  and	  last	  5	  mM	  imidazole	  washes	  (W1	  and	  W2)	  
and	  elution	  (E)	  fractions	  were	  analysed	  by	  SDS-­‐PAGE.	  	  BiP	  FL	  is	  present	  in	  the	  elution	  fraction	  and	  migrates	  with	  an	  
apparent	  MW	  of	  70	  kDa.	  	  	  
(B)	  DNA	  contamination	  of	  BiP	  FL.	   	  BiP	  FL	  samples	  purified	  without	  additives,	  +	  0.1%	  PEI	  or	  +	  5	  mM	  ATP/10	  mM	  
MgCl2	  were	  run	  on	  a	  native	  PAGE	  gel	  and	  stained	  either	  with	  Coomassie	  Blue	  or	  GelRed.	  DNA	  was	  detected	  only	  in	  
the	  sample	  purified	  without	  additives.	  	  
(C)	  BiP	  FL	  SEC	  (HiLoad	  16/60	  Superdex	  200).	   	  BiP	  FL	  purified	  without	  additives	  elutes	  as	  a	   large	  aggregate	   in	  the	  
void	   volume.	   	   BiP	   FL	   purified	   in	   the	   presence	   of	   0.1%	   PEI	   or	   5	   mM	   ATP/10	   mM	   MgCl2	   elutes	   as	   dimer	   and	  
monomer	  oligomers.	  	  Fractions	  from	  47	  to	  80	  ml	  were	  analysed	  by	  SDS-­‐PAGE.	  	  Fractions	  containing	  pure	  BiP	  FL	  (50	  
–	  80	  ml)	  were	  pooled.	  
	   	  
	  
	  






Figure	  5-­‐8.	  BiP	  and	  CH1	  purification	  
(A)	  BiP	  NBD	  and	  SBD	  SEC	  (HiLoad	  16/60	  Superdex	  200).	   	  BiP	  NBD	  elutes	  as	  a	  single	  monomeric	  species;	  BiP	  SBD	  
elutes	  as	  dimer	  and	  monomer	  oligomers.	   	  Fractions	  containing	  pure	  protein	  (68	  –	  75	  ml	  for	  NBD;	  65	  –	  83	  ml	  for	  
SBD)	  were	  pooled.	  	  	  
(B)	   BiP	   and	   CH1	   purified	   proteins.	   	   SDS-­‐PAGE	   of	   BiP	   FL,	   BiP	   NBD,	   BiP	   SBD	   and	   CH1	   purified	   proteins	   used	   in	  
subsequent	  experiments.	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5.6 Discussion	  
In	   this	   chapter	   the	   cloning,	   expression	  and	  purification	  of	  PERK,	   IRE1,	  BiP	   and	  CH1	  proteins	  
used	   in	   subsequent	   crystallisation	   and	   biochemical	   characterisation	   experiments	   are	  
described.	  
Firstly,	   a	   stable	   PERK	   luminal	   domain	   core	   fragment	   for	   use	   in	   crystallisation	   studies	   was	  
identified.	   	   Initially,	   two	   complete	   hPERK	   luminal	   domain	   constructs	   (41-­‐510	   and	   54-­‐510)	  
were	  expressed	  and	  purified.	   	  Although	   these	  proteins	  were	  soluble	   they	  sustained	  specific	  
and	  spontaneous	  cleavage	  of	  a	  large	  C-­‐terminal	  fragment.	  	  This	  corresponded	  approximately	  
to	   residues	   Arg396	   to	   Ile510.	   	   Furthermore,	   the	   ∼50	   N-­‐terminal	   residues	   promoted	   the	  
formation	  of	  two	  distinct	  populations	  of	  PERK	  dimer	  oligomers,	  which	  rendered	  the	  sample	  
highly	  heterogeneous.	  	  These	  results	  were	  combined	  with	  bioinformatics	  analyses	  (PERK	  and	  
IRE1	  multiple	   sequence	   alignment,	   PERK	   secondary	   structure	   prediction	   and	   PERK	   disorder	  
prediction)	  and	  knowledge	  from	  the	  published	  hIRE1	  and	  IRE1p	  luminal	  domain	  structures	  to	  
indentify	   a	  PERK	   luminal	  domain	   core	   region.	   	   This	   core	   region	  of	  H.	   sapiens	   (105-­‐403),	  M.	  
musculus	  	  (101-­‐399)	  and	  D.	  melanogaster	  (182-­‐384)	  PERK	  orthologues	  was	  cloned	  expressed	  
and	  purified.	  	  Although	  the	  proteins	  expressed	  in	  low	  abundance,	  the	  final	  samples	  contained	  
pure,	  stable,	  homogenous	  and	  monodispersed	  PERK	  dimers.	  	  These	  samples	  were	  optimal	  for	  
use	  in	  ensuing	  crystallisation	  experiments	  (Chapter	  6).	  
Secondly,	  hPERK	  and	  hIRE1	   luminal	  domains	  were	  subdivided	   into	   five	   regions	  according	   to	  
previously	  published	  IRE1p	  boundaries.	  	  Constructs	  encompassing	  luminal	  domains	  regions	  I-­‐
V	  (complete	  luminal	  domain),	  I-­‐IV,	  II-­‐V	  or	  II-­‐IV	  (core	  luminal	  domain)	  of	  hPERK	  and	  hIRE1	  were	  
cloned,	   expressed	  and	   successfully	  purified.	   	   These	   truncation	  proteins	  provide	  a	  means	   to	  
asses	   the	   significance	   of	   these	   sub-­‐regions	   in	   the	   biological	   function	   of	   hPERK	   and	   hIRE1	  
luminal	  domains	  in	  vitro	  (Chapter	  7).	  
Thirdly,	  a	  protocol	  for	  the	  purification	  of	  BiP	  chaperone	  purification	  was	  developed.	  	  Initially,	  
purifications	  carried	  out	  using	  published	  protocols	  resulted	  in	  aggregation	  of	  BiP	  FL.	  	  Further	  
analysis	   revealed	   this	  was	  due	   to	  co-­‐purification	  of	  contaminating	  DNA	  species	  with	  BiP	  FL.	  	  
Since	   BiP	   FL	   aggregates	   and	   BiP	   FL-­‐DNA	   complexes	   are	   not	   biologically	   significant,	   protein	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samples	   obtained	   following	   the	   initial	   protocol	   were	   unsuitable	   for	   biochemical	  
characterisation	  experiments.	  	  	  
Initially,	   the	   cationic	   reagent	   PEI,	   which	   is	   widely	   used	   in	   cellular	   biology	   to	   promote	  
attachment	   of	   weakly	   anchoring	   cells	   in	   cultures	   as	   well	   as	   a	   powerful	   DNA	   transfection	  
reagent.	  	  However	  it	  has	  also	  been	  reported	  to	  be	  used	  as	  a	  DNA	  precipitant	  during	  protein	  
purification	   [176].	   	   PEI	  promotes	   the	   condensation	  of	  DNA	   into	  positively	   charged	  particles	  
rendering	   it	   less	   prone	   to	   form	  electrostatic	   interactions	  with	   charged	  proteins	   in	   solution.	  	  
Addition	  of	  PEI	  successfully	  avoided	  DNA	  contamination	  during	  BiP	  FL	  purification.	  	  However	  
since	   the	   effect	   of	   PEI	   on	   recombinant	   proteins	   has	   not	   been	   investigated	   in	   published	  
studies,	  an	  alternate	  protocol	  was	  developed	  to	  ensure	  the	  functionality	  of	  BiP	  FL.	  	  	  
BiP	  is	  a	  Hsp70	  chaperone	  and	  in	  the	  ATP-­‐bound	  state	  exists	  in	  an	  open	  SBD	  conformation	  that	  
confers	  low	  affinity	  for	  its	  hydrophobic	  substrates.	  	  BiP	  FL	  purification	  buffers	  were	  therefore	  
supplemented	   with	   ATP	   as	   a	   means	   of	   maintaining	   BiP	   in	   a	   low	   substrate	   affinity	  
conformation	   to	   avoid	   the	   binding	   of	   DNA	   from	   the	   E.	   coli	   cellular	   extracts.	   	   Similarly	   to	  
addition	  of	  PEI,	  ATP	  was	  also	  successful	  in	  preventing	  the	  unspecific	  binding	  of	  DNA	  to	  BiP	  FL.	  	  
Since	   the	   latter	   protocol	   exploits	   a	   biologically	   relevant	   function	   of	   BiP	   it	  was	   chosen	   as	   a	  
means	  of	  preventing	  co-­‐purification	  of	  BiP	  FL	  and	  DNA.	   	  This	  was	  also	  a	  first	   indication	  that	  
the	  purified	  recombinant	  BiP	  FL	  protein	  is	  functionally	  active	  since	  it	  can	  be	  regulated	  by	  ATP	  
nucleotide.	  	  BiP	  FL	  was	  purified	  to	  near	  homogeneity	  as	  monomers	  and	  dimers	  in	  equimolar	  
amounts.	   	   The	   two	   sub-­‐domains	   of	   BiP,	   the	   NBD	   and	   SBD,	   were	   also	   purified	   in	   isolation.	  	  
These	   respectively	   contained	   uniquely	  monomers,	   or	   a	  mixture	   of	  monomeric	   and	   dimeric	  
species,	  with	  the	  equilibrium	  shifted	  towards	  dimers.	  
Finally,	  the	  intrinsically	  unfolded	  protein	  CH1	  was	  successfully	  purified	  from	  inclusion	  bodies	  
following	  the	  previously	  published	  protocol.	  
	   	  
	  
	  
	   122	  
6 X-­‐ray	  crystal	  structure	  of	  PERK	  luminal	  
domain	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6.1 Summary	  
This	   chapter	   describes	   the	   crystallisation	   and	   structure	   determination	   of	   PERK	   luminal	  
domain	   H.	   sapiens	   and	   M.	   musclus	   orthologues,	   solved	   at	   3.1	   Å	   and	   3.3	   Å	   resolution	  
respectively.	  
Crystallisation	  of	  hPERK	  (II-­‐IV)	  and	  mPERK	  (II-­‐IV)	  proteins	  was	  optimized	  and	  diffraction	  was	  
improved	  at	  best	   from	  10	  to	  3.1	  Å	   for	   the	   former.	   	  Phasing	  of	  hPERK	   (II-­‐IV)	  diffraction	  data	  
was	  achieved	  by	  heavy	  atom	  derivatization	  and	  MAD.	  	  The	  refined	  structure	  of	  hPERK	  (II-­‐IV)	  
was	  used	  to	  phase	  mPERK	  (II-­‐IV)	  diffraction	  data	  by	  molecular	  replacement.	  
Overall	  the	  structures	  of	  hPERK	  (II-­‐IV)	  and	  mPERK	  (II-­‐IV)	  are	  very	  similar	  to	  one	  another	  and	  
to	   those	   of	   H.	   sapiens	   and	   S.	   cerevisiae	   IRE1.	   	   Dimerisation	   occurs	   mainly	   by	   antiparallel	  
stacking	  of	  a	  central	  β-­‐strand	  between	  two	  monomers	  (Interface	  1).	   	  This	   is	   identical	  to	  the	  
dimerisation	  interface	  of	  IRE1	  luminal	  domains.	  	  Strikingly,	  hPERK	  (II-­‐IV)	  packed	  as	  tetramers	  
in	  the	  crystal	  lattice.	  	  This	  is	  achieved	  by	  the	  binding	  of	  two	  extended	  C-­‐terminal	  α-­‐helices	  of	  
a	  hPERK	  (II-­‐IV)	  dimer	  with	  a	  hydrophobic	  cleft	  on	  an	  interacting	  hPERK	  (II-­‐IV)	  dimer	  (Interface	  
2).	  	  This	  conformation	  of	  the	  ER	  stress	  sensors	  has	  never	  been	  reported	  in	  published	  studies.	  	  
Mutant	  proteins	  were	  used	  to	  probe	  the	  biological	  relevance	  of	  this	  assembly	  in	  solution	  by	  
disrupting	   Interface	   2.	   	   Indeed,	   tetramerisation	   was	   highly	   compromised	   by	   selected	  
mutations.	  	  Since	  the	  tetramer	  conformation	  is	  also	  observed	  in	  solution,	  it	  is	  likely	  to	  exist	  in	  
vivo	  and	  as	  such	  has	  a	  functional	  role	  in	  the	  activity	  of	  PERK.	  
On	   the	   other	   hand,	  mPERK	   (II-­‐IV)	   only	   formed	   dimers.	   	   No	   electron	   density	   for	   the	   entire	  
region	   that	   mediated	   tetramerization	   in	   hPERK	   (II-­‐IV)	   was	   observed	   suggesting	   this	   region	  
was	  not	  structured.	   	  The	  differences	  between	  the	  oligomeric	   states	  of	   the	   luminal	  domains	  
can	   be	   reconciled	   by	   representing	   differently	   activated	   states.	   	   A	   novel	   model	   for	  
oligomerisation-­‐dependent	  UPR	  activation	  is	  proposed.	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6.2 Introduction	  
To	   date,	   only	   the	   structures	   of	  H.	   sapiens	   IRE1	   (PDB:	   2HZ6)	   and	   S.	   cerevisiae	   IRE1p	   (PDB:	  
2BE1)	  luminal	  domains	  have	  been	  solved	  [95,101].	  	  These	  date	  back	  to	  almost	  a	  decade	  ago.	  
Up	   to	   2005,	   all	   the	   biochemical	   and	   cellular	   studies	   implicated	   BiP	   chaperone	   as	   a	   major	  
regulator	  of	  PERK,	  IRE1	  and	  ATF6	  signalling.	  	  However,	  based	  on	  the	  X-­‐ray	  crystal	  structure	  of	  
IRE1p	  luminal	  domain,	  a	  mechanism	  for	  ER	  stress	  sensing	  which	  is	  completely	  independent	  of	  
BiP	   chaperone	   was	   proposed.	   	   This	   involves	   the	   direct	   binding	   of	   unfolded	   proteins	   to	   an	  
MHC-­‐like	   crevice	   of	   the	   luminal	   domain,	   which	   allows	   for	   oligomerisation/clustering	   and	  
signalling	  activation.	  	  The	  X-­‐ray	  crystal	  structure	  of	  hIRE1	  luminal	  domain	  closely	  resembles	  to	  
that	   of	   IRE1p.	   	   However	   (i)	   the	  MHC-­‐like	   groove	   of	   hIRE1	   is	   too	   narrow	   to	   accommodate	  
peptide	  binding	  and	  (ii)	  conserved	  residues	  speculated	  to	  be	  essential	  for	  peptide	  binding	  in	  
IRE1p	  are	  either	  not	  conserved	  or	  buried	  in	  hIRE1’s	  structure.	  	  The	  structure	  of	  hIRE1	  points	  
away	  from	  a	  direct	  unfolded	  protein	  binding	  model	  and	  backs	  up	  a	  BiP-­‐dependent	  pathway.	  
Although	   the	   luminal	   domains	   of	   hPERK	   and	   hIRE1	   share	   only	   18%	   sequence	   identity,	   a	  
multitude	  of	  biochemical	  studies	  have	  demonstrated	  that	  they	  are	  similarly	  activated	  by	  ER	  
stress	   [76,103].	   	   Moreover	   the	   two	   are	   functionally	   interchangeable	   to	   mediate	   UPR	  
signalling	  by	  their	  cytoplasmic	  domains	   in	  vivo.	   	  Given	  their	  functional	  conservation,	  at	  least	  
with	  respect	  to	  ER	  stress	  sensing,	  it	  is	  reasonable	  to	  assume	  they	  have	  similar	  mechanisms	  for	  
detecting	   the	   presence	   of	   unfolded	   proteins	   and	   as	   a	   result	   allowing	   phosphorylation	   and	  
activation	  of	  their	  cytoplasmic	  effector	  domains.	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6.3 Crystallisation	  of	  PERK	  (II-­‐IV)	  proteins	  
The	   final	  optimized	  crystallisation	  conditions	  of	  hPERK	   (II-­‐IV)	  and	  mPERK	   (II-­‐IV)	  proteins	  are	  
discussed	  in	  this	  section	  and	  summarised	  in	  Table	  6-­‐1.	  	  	  
6.3.1 hPERK	  (II-­‐IV)	  crystallisation	  
6.3.1.1 Optimization	  of	  crystallisation	  buffer	  
hPERK	  (II-­‐IV)	  protein	   is	  highly	  soluble,	  even	  at	  concentrations	  up	  to	  40	  mg/ml.	   	   Initial	  nano-­‐
litre	   scale	   screening	   crystallisation	   trays	   were	   set	   up	   at	   25	   mg/ml	   protein.	   	   Showers	   of	  
bipyramidal	  microcrystals	   appeared	   overnight	   in	   untagged	   hPERK	   (II-­‐IV)	   drops	   equilibrated	  
over	   0.1	   M	   Tris-­‐HCl	   (pH	   8.5),	   0.2	   M	   MgCl2,	   25%	   w/v	   PEG3350	   (Figure	   6-­‐1A).	   	   An	   initial	  
optimization	  screen	  around	  the	  hit	  condition	  was	  set	  up	  and	  screened	  conditions	   from	  15	  -­‐	  
35%	   w/v	   PEG3350,	   0	   -­‐	   0.4	  M	  MgCl2	   and	   3	   -­‐	   25	   mg/ml	   protein	   concentration.	   	   Conditions	  
containing	   at	   least	   18%	   w/v	   PEG3350	   and	   5	   mg/ml	   hPERK	   (II-­‐IV)	   were	   necessary	   for	   the	  
formation	  of	  microcrystals	  and	  therefore	  spontaneous	  nucleation.	   	  These	  were	   identified	  as	  
the	   lower	   limits	   of	   the	   supersaturated	   labile	   region	   of	   crystallisation.	   	   Although	   nucleation	  
was	   reduced,	   it	   was	   still	   too	   high	   to	   sustain	   growth	   of	   crystals	   larger	   than	   5	   µm.	   	   This	   is	  
probably	  because	  most	  of	  the	  protein	  was	  depleted	  to	  form	  the	  high	  quantity	  (over	  100)	  of	  
initial	  microcrystals	   causing	   the	   protein	   concentration	   to	   quickly	   fall	   below	   the	  metastable	  
zone	  into	  under-­‐saturated	  conditions.	  	  	  
The	   following	   variables	   were	   changed	   to	   promote	   the	   growth	   of	   large	   single	   crystals:	   pH,	  
incubation	  temperature,	   reservoir	  volume	  and	  the	  composition	  of	   the	  crystallisation	  buffer.	  	  
The	   pH	   changes	   the	   charge	   of	   proteins,	   which	   in	   turns	   affects	   electrostatic	   and	   polar	  
interactions	   between	   macromolecules	   in	   solution	   and	   could	   help	   control	   nucleation	   and	  
formation	   of	   protein-­‐protein	   contacts	   and	   thus	   the	   crystal	   lattice.	   	   The	   pH	   was	   varied	  
between	  7	  -­‐	  9,	  the	  buffering	  range	  of	  Tris-­‐HCl.	  	  	  
	   	  
	  
	  





Table	  6-­‐1.	  PERK	  luminal	  domain	  crystallisation	  conditions	  
The	   optimized	   conditions	   used	   to	   obtain	   diffracting	   crystals	   of	   H.	   sapiens	   and	   M.	   musculus	   PERK	   (II-­‐IV)	   are	  
summarised.	  	  The	  components	  of	  the	  crystallisation	  buffer,	  protein	  concentration	  (mg/ml)	  protein	  (P)	  to	  reservoir	  
(R)	  ratio	  used	  to	  set	  up	  vapour	  diffusion	  drops	  is	  shown.	  	  Additional	  ‘treatments’	  carried	  out	  such	  as	  seeding	  and	  
stepwise	  dehydration	  are	  indicated	  where	  relevant.	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Lowering	   the	   incubation	   temperature	   slows	   down	   chemical	   processes	   and	   diffusion	   of	  
molecules	  whereas	   increasing	  the	  reservoir	  volume	  decreases	  the	  rate	  of	  equilibration	  with	  
the	  crystallisation	  drop.	  	  Although	  in	  theory	  these	  variables	  should	  control	  rates	  of	  nucleation	  
in	  this	  instance	  they	  had	  no	  effect	  on	  the	  size	  or	  quantity	  of	  crystals	  obtained.	  	  Different	  PEG	  
chain	   lengths,	   buffer	   types,	   and	   commercially	   available	   additives	   were	   tested	   but	   these	  
variables	  all	  inhibited	  crystallisation.	  	  Finally,	  glycerol	  increases	  the	  solubility	  of	  proteins.	  	  By	  
causing	   a	   shift	   in	   a	   protein’s	   solubility	   curve,	   glycerol	   also	   affects	   the	  position	  of	   the	   labile	  
region	   of	   nucleation	   in	   the	   phase	   diagram	   [177].	   	   This	   reduces	   spontaneous	   nucleation	  
occurring	  at	  a	  given	  protein	  concentration.	  	  7%	  glycerol	  resulted	  in	  fewer	  larger	  bipyramidal	  
crystals	  approximately	  10	  µm	  in	  length	  (Figure	  6-­‐1B).	  	  	  
6.3.1.2 Reiterative	  microseeding	  
Microseeding	  was	  used	  to	  introduce	  nucleation	  sites	  into	  metastable	  zone	  conditions,	  which	  
should	  support	  crystal	  growth	  but	  not	  spontaneous	  nucleation.	  	  Addition	  of	  microseeds	  into	  
17%	   w/v	   PEG3350,	   0.1	   M	   Tris-­‐HCl	   (pH	   8.5),	   0.2	   M	   MgCl2	   did	   not	   lead	   to	   crystal	   growth.	  	  
However,	  microseeding	  into	  conditions	  of	  higher	  PEG	  concentrations	  led	  to	  formation	  of	  few	  
crystals	  approximately	  50	  µm	  in	  all	  dimensions	  overnight	  (Figure	  6-­‐1C).	  	  Although	  this	  result	  
was	   unexpected	   it	   suggests	   that	   the	   metastable	   zone	   is	   small	   and	   17%	   w/v	   PEG3350	  
conditions	  actually	  already	  represent	  the	  clear	  undersaturated	  zone.	  	  The	  presence	  of	  seeds,	  
thus	  nucleation	  sites,	  in	  labile	  zone	  conditions	  reduced	  the	  spontaneous	  nucleation	  of	  hPERK	  
(II-­‐IV).	   	   hPERK	   (II-­‐IV)	   favours	   the	   formation	   of	   contacts	  with	   the	   already	   established	   lattice	  
(from	  the	  seeds)	  rather	  than	  with	  protein	  in	  solution	  to	  form	  new	  nucleation	  sites.	   	  Crystals	  
were	   grown	   by	   mixing	   1	   µl	   of	   untagged	   hPERK	   (II-­‐IV)	   at	   5	   mg/ml	   plus	   1	   µl	   of	   fresh	   seed	  
(diluted	   106-­‐fold)	   equilibrated	   over	   1	  ml	   of	   0.1	  M	   Tris-­‐HCl	   (pH	   8.5),	   0.2	  M	  MgCl2,	   25%	  w/v	  
PEG3350	  and	  7%	  glycerol	  in	  24-­‐well	  hanging	  drop	  plates	  at	  18	  °C	  (Condition	  A).	  	  10	  rounds	  of	  
seeding	   yielded	   crystals	   that	   grew	   up	   to	   300	   µm	   in	   length	   after	   1	   week	   (Figure	   6-­‐1D).	  	  
Identical	  conditions	  were	  used	  for	  crystallisation	  of	  SeMet	  hPERK	  (II-­‐IV).	  
	   	  
	  
	  







Figure	  6-­‐1.	  Optimization	  of	  hPERK	  (II-­‐IV)	  crystals	  (Condition	  A)	  
(A)	  Initial	  hit	  containing	  showers	  of	  hPERK	  (II-­‐IV)	  microcrystals	  grown	  in	  0.1	  M	  Tris-­‐HCl	  (pH	  8.5),	  0.2	  M	  MgCl2,	  25%	  
w/v	  PEG3350	  at	  18	  °C.	  
(B)	  Crystals	  were	  grown	  as	  in	  ‘A’	  plus	  7%	  glycerol.	  	  Nucleation	  was	  reduced	  and	  crystals	  grew	  to	  a	  maximum	  size	  of	  
10	  μM	  in	  length.	  
(C)	  Crystals	  from	  ‘B’	  were	  used	  for	  microseeding.	  	  A	  few	  large	  crystals	  (50	  μM	  in	  length)	  appeared	  overnight.	  
(D)	  10	  rounds	  of	  re-­‐iterative	  microseeding	  seeding,	  as	  in	  ‘C’,	  yielded	  large	  single	  crystals	  (300	  μM	  in	  length)	  after	  a	  
week.	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6.3.1.3 hPERK	  (II-­‐IV)	  microseed	  matrix	  screening	  
To	  obtain	  additional	  crystallisation	  conditions,	  microseed	  matrix	  screening	  was	  employed	  as	  a	  
means	   of	   introducing	   nucleation	   sites	   in	   conditions	  where	   crystal	   growth	   is	   supported	   but	  
spontaneous	   nucleation	   does	   not	   occur.	   	   hPERK	   (II-­‐IV)	   Condition	   A	   crystals	   were	   used	   to	  
produce	  microseeds,	  as	  previously,	  added	  to	  hPERK	  (II-­‐IV)	  at	  20	  mg/ml	  and	  used	  to	  screen	  for	  
new	   crystal	   hits.	   	   One	   new	   crystal	   form	   was	   found.	   	   Thin	   needles	   approximately	   3	  µm	   in	  
length	   and	   less	   than	   1	   µm	   in	   width	   were	   observed	   in	   a	   drop	   equilibrated	   over	   20%	   v/v	  
glycerol	  and	  24%	  w/v	  PEG1500	  (Figure	  6-­‐2A).	  	  These	  crystals	  were	  observed	  a	  year	  after	  the	  
drops	  were	  initially	  set	  up.	  	  It	  was	  speculated	  that	  they	  were	  a	  cleavage	  product	  of	  hPERK	  (II-­‐
IV)	   that	   appeared	   over	   time	   due	   to	   spontaneous	   specific	   degradation	   of	   the	   protein.	   	   The	  
crystals	   were	   washed	   in	   the	   reservoir	   solution	   and	   analysed	   by	   SDS-­‐PAGE	   to	   check	   the	  
identity	  of	  the	  protein	  crystallised.	  	  The	  protein	  appeared	  intact	  and	  identical	  to	  the	  purified	  
hPERK	  (II-­‐IV)	  (Figure	  6-­‐2B).	  	  It	   is	  possible	  that	  these	  crystals	  were	  so	  small	  they	  were	  missed	  
during	   initial	   screening.	   	   However,	   since	   these	   appeared	   only	   in	   the	   corner	   of	   the	   drop	  
containing	   a	   2:1	   protein	   to	   reservoir	   ratio	   (the	   1:1	   ratio	   drop	   remained	   clear)	   it	   suggested	  
that	  higher	  protein	  concentration	  may	  be	  key	  to	  support	  their	  growth.	  	  In	  such	  a	  scenario,	  the	  
crystals	  may	  have	  only	  grown	  after	  extensive	  equilibration	  and	  evaporation	  of	  water	  from	  the	  
drop.	   	  All	   subsequent	  experiments	   for	   this	   condition	  were	  set	  up	  with	  25	  mg/ml	  of	  protein	  
and	  a	  2:1	  protein	  to	  reservoir	  volume	  ratio.	  	  Three-­‐dimensional	  crystals	  measuring	  50	  µm	  in	  
length	   were	   observed	   after	   3	   days	   in	   drops	   seeded	   with	   Condition	   A	   microseeds	   and	  
equilibrated	   over	   1	   ml	   reservoir	   of	   20%	   v/v	   glycerol	   and	   26%	   w/v	   PEG1500	   in	   24-­‐well	  
hanging-­‐drop	   plates	   at	   18	   °C	   (Condition	   B)	   (Figure	   6-­‐2C).	   	   Because	   crystal	   formation	   was	  
dependent	   on	   the	   presence	   of	  microseed	   from	   the	   original	   hPERK	   (II-­‐IV)	   crystals	   grown	   in	  
condition	  A	   it	  suggests	  that	  Condition	  B	  does	  not	  support	  spontaneous	  nucleation	  of	  hPERK	  
(II-­‐IV).	   	  
	   	  
	  
	  






Figure	  6-­‐2.	  hPERK	  (II-­‐IV)	  microseeding	  matrix	  screen	  (Condition	  B)	  
(A)	  Thin	  hPERK	  (II-­‐IV)	  protein	  needles	  grown	  in	  drops	  containing	  20	  mg/ml	  protein,	  20%	  v/v	  glycerol	  and	  24%	  w/v	  
PEG1500	  (1:1	  protein	  to	  reservoir	  ratio)	  at	  18	  °C	  plus	  microseeds	  from	  hPERK	  (II-­‐IV)	  condition	  A	  crystals.	  	  	  
(B)	  Crystals	  from	  ‘A’	  were	  washed	  and	  analysed	  by	  SDS-­‐PAGE.	  	  Crystals	  contained	  pure	  and	  undegraded	  hPERK	  (II-­‐
IV)	  protein.	  
(C)	  Optimized	  hPERK	  (II-­‐IV)	  crystals	  grown	  as	  in	  ‘A’	  with	  the	  following	  modifications:	  25	  mg/ml	  protein,	  25%	  w/v	  
PEG1500,	  2:1	  protein	  to	  reservoir	  ratio.	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6.3.2 mPERK	  (II-­‐IV)	  crystallisation	  
Two	  protein	  crystals	  hits	  were	  obtained	  from	  initial	  untagged	  mPERK	  (II-­‐IV)	  screens:	  (i)	  0.1	  M	  
Tris-­‐HCl	  (pH	  8.5),	  0.2	  M	  Li2SO4,	  40%	  w/v	  PEG400	  (Figure	  6-­‐3A)	  and	  (ii)	  0.1	  M	  MES/imidazole	  
(pH	   6.5),	   0.09	   M	   sodium	   phosphate	   salts	   (NPS)	   (mix	   containing	   0.03	   M	   of	   each	   NaN03,	  
Na2HPO4,	  (NH4)2SO4),	  12.5%	  w/v	  PEG1000,	  12.5%	  w/v	  PEG3350,	  12.5%	  v/v	  MPD	  (Figure	  6-­‐3C).	  	  
In	  both	  conditions,	  single	  crystals	  approximately	  20	  µm	  in	  their	  longest	  dimension	  were	  easily	  
reproduced	  using	   conditions	   from	   the	   initial	   hit	   in	  48	  well	   sitting-­‐drop	  MRC	  plates.	   	  Matrix	  
optimization	  screens	  were	  set	  up	  as	   for	  hPERK	  (II-­‐IV)	  but	  varying	  the	  crystallisation	  solution	  
composition	  did	  not	  make	  a	  significant	  difference	   in	  the	  size	  of	   the	  crystals.	   	   It	  was	  noticed	  
that	  the	  size	  of	  these	  crystals	  was	  directly	  proportional	  to	  the	  time	  they	  took	  to	  appear	  with	  
small	  5	  µm	  crystals	  appearing	  after	  2	  days	  and	  reaching	  20	  µm	  after	  5	  days.	  	  Therefore	  it	  was	  
reasoned	   that	   controlling	   the	   speed	   of	   crystal	   growth	   was	   key	   to	   obtaining	   large	   single	  
crystals.	  	  Indeed,	  drops	  set	  up	  with	  a	  higher	  protein	  to	  reservoir	  solution	  ratio	  and	  increased	  
reservoir	   volume	   grew	   slower	   and	   yielded	   larger	   crystals,	   as	   they	   required	   longer	   for	  
equilibration.	  	  Final	  optimized	  conditions	  which	  gave	  few	  crystals	  50	  -­‐	  100	  µm	  in	  size	  after	  5	  
days	  when	  grown	  in	  24-­‐well	  hanging	  drop	  plates	  at	  18	  °C	  were	  as	  following:	  2	  µl	  protein	  plus	  
1	  µl	   reservoir	   solution,	  500	  µl	   reservoir	   volume,	  20	  mg/ml	  of	  untagged	  mPERK	   (II-­‐IV)	  MPD.	  	  
The	  composition	  of	  the	  reservoir	  solution	  was	  identical	  to	  the	  initial	  hits	  except	  that	  PEG400	  
and	  MPD	  concentrations	  were	  increased	  to	  47.5%	  w/v	  and	  20%	  v/v	  respectively	  as	  a	  means	  
of	  cryoprotecting	  the	  crystals	  (Figure	  6-­‐3B,D).	  	  Before	  modifying	  these,	  it	  was	  verified	  that	  it	  
had	  no	  effect	  on	  the	  diffraction	  of	  the	  crystals.	  	  These	  will	  be	  referred	  to	  as	  Conditions	  C	  and	  
D	  respectively.	  	  Once	  again,	  SeMet	  mPERK	  (II-­‐IV)	  crystals	  were	  set	  up	  in	  identical	  conditions.	  
	   	  
	   	  
	  
	  






Figure	  6-­‐3.	  mPERK	  (II-­‐IV)	  crystals	  (Conditions	  C	  and	  D)	  
(A)	  Initial	  hits	  of	  mPERK	  (II-­‐IV)	  crystals	  grown	  in	  0.1	  M	  Tris-­‐HCl	  (pH	  8.5),	  0.2	  M	  Li2SO4,	  40%	  w/v	  PEG400	  at	  18	  °C.	  
(B)	   Optimized	   crystals	   grown	   as	   in	   ‘A’	   except	   with	   47.5%	   w/v	   PEG400	   and	   equilibrated	   over	   higher	   reservoir	  
volume	  (Condition	  C).	  
(C)	  Initial	  hits	  of	  mPERK	  (II-­‐IV)	  crystals	  grown	  in	  0.1M	  MES/imidazole	  (pH	  6.5),	  0.09	  M	  NPS,	  12.5%	  w/v	  PEG1000,	  
12.5%	  w/v	  PEG3350,	  12.5%	  v/v	  MPD	  at	  18	  °C.	  
(D)	  Optimized	   crystals	   grown	  as	   in	   ‘B’	   except	  with	  20%	  v/v	  MPD	  and	  equilibrated	  over	  higher	   reservoir	   volume	  
(Condition	  D).	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6.3.3 Improving	  crystallisation	  by	  surface	  entropy	  reduction	  
To	   increase	   the	   likelihood	   of	   obtaining	   diffracting	   hPERK	   (II-­‐IV)	   crystals,	   a	   surface	   entropy	  
reduction	   mutant	   was	   created.	   	   The	   property	   of	   a	   protein’s	   surface,	   in	   part,	   dictates	   its	  
propensity	  to	  crystallise	  [173].	  	  Flexible	  regions,	  which	  usually	  contain	  Lysine,	  Glutamine	  and	  
Glutamate	  residues,	  must	  be	  buried	  or	  ordered	  for	  crystal	  contacts	   to	  be	   formed.	   	  As	  such,	  
these	   regions	   confer	   high	   surface	   entropy	   and	   increase	   the	   energy	   required	   for	  
crystallisation.	  	  Mutating	  them	  to	  small	  non-­‐polar	  residues,	  usually	  Alanine,	  has	  been	  used	  as	  
a	   strategy	   to	   lower	   the	   energy	   barrier	   required	   for	   crystallisation	   to	   occur.	   	   This	   has	   been	  
successful	   in	  both	   increasing	  the	  number	  of	  crystal	  hits	  obtained	  as	  well	  as	   their	  diffraction	  
limits	   [178].	   	  The	   latter	   is	  probably	  due	  to	  a	  tighter	  packing	  of	  the	  crystal	   lattice	  due	  to	  the	  
decreased	  energy	  required	  for	  it	  to	  form.	  	  	  
The	   sequence	   of	   hPERK	   (II-­‐IV)	   was	   analysed	   using	   the	   SERp	   server	   [173].	   	   Three	   clustered	  
Glutamate	  residues	  (Glu230,	  Glu231	  and	  Glu233)	  gave	  highest	  scores	  for	  coil	  prediction	  and	  
entropy	   values	   indicating	   they	   are	   probably	   highly	   flexible	   and	   disordered.	   	   In	   fact,	   this	  
corresponds	  to	  the	  region	  just	  upstream	  of	  β9	  of	  hIRE1	  luminal	  domain.	  	  No	  electron	  density	  
was	  observed	  for	  this	  region	  in	  the	  crystal	  structure	  indicating	  it	  is	  highly	  flexible.	  	  hPERK	  (II-­‐
IV)	  E230A_E232A_E233A	  mutant	  was	  created,	  expressed	  and	  purified	  as	  for	  wild	  type	  hPERK	  
(II-­‐IV).	  	  Crystal	  screens	  were	  set	  up	  however	  no	  hits	  were	  obtained.	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6.4 PERK	  (II-­‐IV)	  native	  X-­‐ray	  diffraction	  data	  
6.4.1 Native	  hPERK	  (II-­‐IV)	  diffraction	  data	  
Initially,	  only	  hPERK	  (II-­‐IV)	  crystals	  grown	  in	  Condition	  A	  were	  available	  and	  therefore	  most	  of	  
the	  work	  has	  focused	  on	  these.	  	  At	  the	  concentrations	  used,	  the	  reagents	  in	  Condition	  A	  do	  
not	  act	  as	  cryoprotectants.	  	  Avoiding	  the	  formation	  of	  ice	  during	  flash	  freezing	  of	  the	  crystals	  
is	   essential	   for	   accurate	   data	   collection	   therefore	   a	   number	   of	   reagents	   were	   tested	   as	  
cryoprotectants.	   	   	   Solutions	   were	   made	   up	   containing	   the	   reservoir	   components	   and	  
additional	  20%	  v/v	  glycerol,	  30%	  w/v	  sucrose,	  30%	  v/v	  ethylene	  glycol,	  30%	  v/v	  MPD	  or	  30%	  
w/v	   PEG400.	   	   Although	   these	   reagents	  were	   successful	   in	   preventing	   icing	   during	   freezing,	  
the	   maximum	   resolution	   reached	   was	   only	   8.5	   Å	   in	   crystals	   cryoprotected	   with	   20%	   v/v	  
glycerol	   (Figure	  6-­‐4A).	   	   To	   test	  whether	   this	  was	  due	   to	   the	   cryoprotectant,	   crystals	   frozen	  
without	  cryoprotection	  were	  mounted	  onto	  the	  goniometer.	   	  Diffraction	  extending	  to	  4.9	  Å	  
resolution	  was	  achieved	  (Figure	  6-­‐4B).	  	  However,	  as	  expected,	  there	  were	  large	  ice	  rings	  were	  
visible	  and	  analysis	  of	   the	  diffraction	  data	  was	   indicative	  of	  poor	  crystal	  quality	   (Table	  6-­‐2).	  	  
Firstly,	  the	  mosaicity	  was	  very	  high	  (1.54	  °).	  	  Crystal	  mosaicity	  is	  a	  measure	  of	  the	  degree	  of	  
long-­‐range	  order	  of	  the	  unit	  cells	  within	  the	  crystal	  and	  reflects	  the	  quality	  of	  crystal	  packing.	  	  
Secondly,	  the	  Rsym	  was	  high	  (14.4%	  overall	  and	  95.3%	  in	  the	  outer	  shell	  (despite	  I/σ(I)	  =	  2.0	  in	  
the	   latter)).	   	   Rsym	   is	   a	  measure	   of	   the	   error	   of	   the	  measurement	   of	   each	   unique	   reflection	  
throughout	   the	   dataset	   and	   describes	   the	   quality	   of	   the	   data	   collected.	   	   Rsym	   is	   calculated	  
using	  Equation	  10	  where	  I	  is	  the	  intensity	  of	  a	  reflection	  and	  <I>	  is	  the	  mean	  intensity	  of	  the	  
reflection	  throughout	  the	  dataset.	  
Equation	  10	  𝑅!"# = 𝐼−< 𝐼 >𝐼 	  
	  
Finally,	   the	  overall	  B-­‐factor	   (153.5	  Å2)	  was	  very	  high	  and	   the	  Wilson	  Plot	  of	   the	  data	  varies	  
highly	   from	   the	   linear	   ‘optimal’	   line	   (Appendix	   Figure	  10-­‐5A).	   	   ‘B’	   is	   the	  B-­‐	  or	   temperature-­‐
factor	  and	  describes	  the	  relative	  motion	  of	  a	  value,	  the	  atoms	  in	  the	  crystal	  in	  this	  instance.	  	  
Wilson	   Plot	   is	   also	   indicative	   of	   order	   of	   the	   scattering	   atoms	   in	   a	   crystal.	   	   The	   observed	  
intensities	   (Iobs)	   are	   dependant	   on	   experimental	   factors	   such	   as	   the	   intensity	   of	   the	   X-­‐ray	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beam	  impinging	  the	  crystal,	  the	  volume	  of	  the	  crystal	  which	  is	  exposed	  to	  the	  beam	  as	  well	  as	  
how	   long	   it	   is	   exposed.	   	   Thus	   the	  measured	   Iobs	   are	   proportional,	   but	   not	   identical	   to,	   the	  
asbsolute	   intenisites	   (Iabs).	   	   In	   a	  Wilson	   Plot,	   ln	   (<Iobs>)/(<	   Iabs	   >)	   values	   are	   plotted	   against	  
resolution	   and,	   if	   the	   structure	   is	   perfectly	   ordered,	   this	   should	   yield	   a	   straight	   line	   with	  
gradient	   -­‐2B.	   	   Together	   these	   observations	   indicated	   that	   collection	   of	   data	   from	   non-­‐
cryoprotected	  crystals	  was	  not	  an	  option.	  	  As	  addition	  of	  20%	  glycerol	  was	  found	  to	  decrease	  
the	  diffraction	  quality	  of	  the	  crystals,	  a	  different	  means	  of	  cryoprotection	  was	  investigated.	  
Concentrations	  of	  30%	  w/v	  and	  above	  PEG3350	  have	  been	  reported	  to	  act	  as	  cryoprotectant	  
[179].	   	   Increasing	   the	   PEG3350	   concentration	   reduces	   the	   water	   content	   of	   the	   solution.	  	  
Other	  than	  preventing	  the	  formation	  of	  ice	  crystals	  during	  freezing	  (cryoprotection),	  this	  can	  
also	   result	   in	   more	   closely	   packed	   and	   better	   ordered	   crystal	   lattices	   (dehydration).	  	  
Dehydration	  has	  been	  shown	   to	   sometimes	  extend	   the	  X-­‐ray	  diffraction	   resolution.	   	  Gentle	  
cryoprotection	   and	   dehydration	   of	   the	   crystals	   was	   achieved	   by	   a	   serial	   transfer	   of	   the	  
coverslip	  holding	  the	  crystallised	  drop	  over	  reservoirs	  containing	  increasing	  concentrations	  of	  
PEG.	  	  PEG3350	  concentration	  was	  increased	  stepwise	  (by	  2%	  w/v	  and	  8	  -­‐	  12	  h	  incubation	  at	  
each	   step)	   up	   to	   a	   final	   40%	   w/v	   PEG3500	   concentration.	   	   A	   complete	   3.2	   Å	   dataset	   was	  
collected	  (Figure	  6-­‐4C).	  	  Compared	  to	  data	  collected	  without	  cryoprotection/dehydration,	  the	  
processed	  data	  shows	  lower	  mosaicity	  (0.97	  °),	  Rsym	  (8.0%),	  overall	  B-­‐factor	  (80.3	  Å2)	  and	  fit	  of	  
the	  Wilson	  Plot	  (Table	  6-­‐2;	  Appendix	  Figure	  10-­‐5B).	  	  Together	  these	  indicate	  improved	  crystal	  
and	  diffraction	  data	  quality.	   	  A	  Matthews	  coefficient	   (Vm)	  of	  2.44	  A3/Da	  and	  49.5%	  solvent	  
content	   (Vs)	   were	   obtained	   (0.98	   probability).	   	   This	   corresponds	   to	   two	   hPERK	   (II-­‐IV)	  
molecules	  in	  the	  asymmetric	  unit.	  
	  
	   	  
	   	  
	  
	  




Figure	  6-­‐4.	  Native	  hPERK	  (II-­‐IV)	  Condition	  A	  crystal	  diffraction	  
(A-­‐C)	   The	   looped	   crystal	   mounted	   onto	   the	   goinometer	   and	   a	   diffraction	   image	   of	   hPERK	   (II-­‐IV)	   crystals	   (A)	  
cryoprotected	  with	  20%	  glycerol,	   (B)	   frozen	  without	  cryoprotection	  and	  (C)	  dehydrated	  over	  40%	  w/v	  PEG	  3350	  
are	   shown.	   	   The	   resolution	   limit	   is	   indicated.	   	   Glycerol	   cryoprotection	   increases	   the	   resolution	   of	   diffraction	  
compared	  to	  non-­‐cryoprotected	  crystals.	   	  However	   in	  the	  absence	  of	  cryoprotection,	   large	  ice	  rings	  are	  present.	  	  
Gradual	  dehydration	  successfully	  cryoprotects	  the	  crystals	  and	  improves	  their	  diffraction.	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Table	  6-­‐2.	  Native	  hPERK	  (II-­‐IV)	  Condition	  A	  diffraction	  data	  
The	   diffraction	   images	   for	   hPERK	   (II-­‐IV)	   crystals	   collected	   without	   cryoprotection,	   dehydrated	   over	   40%	   w/v	  
PEG3350	   or	   dehydrated	   plus	   10	   rounds	   of	   reiterative	   seeding	  were	   integrated,	  merged	   and	   scaled;	   the	   results	  
obtained	  are	  summarised.	  	  Rsym,	  I/σ(I),	  multiplicity	  and	  completeness	  values	  refer	  to	  values	  in	  the	  overall	  and	  outer	  
shell,	  in	  brackets.	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Crystals	   grown	   with	   and	   without	   reiterative	   seeding	   were	   compared	   and	   although	   the	  
resolution	   limit	   achieved	   was	   not	   improved,	   crystals	   grown	   from	   with	   reiterative	   seeding	  
diffracted	  to	  resolution	  higher	  than	  4	  Å	  more	  consistently.	  	  Defects	  accumulate	  in	  crystals	  as	  
they	  grow	  and	  this	  may	  limit	  the	  size	  of	  the	  crystals	  achieved.	  	  Multiple	  rounds	  of	  reiterative	  
seeding	  thus	  can	  improve	  crystal	  quality.	  	  In	  fact,	  the	  approximate	  ratio	  of	  crystals	  diffracting	  
to	  4	  Å	  or	  higher	  was	  1:30	  for	  seeded	  and	  1:3	  for	  reiteratively	  seeded	  crystals.	  	  This	  difference	  
was	  especially	   important	  for	  the	  collection	  of	  derivative	  datasets	  where	  extensive	  screening	  
of	  heavy	  atom	  type,	  concentration	  and	  soaking	  time	  is	  already	  required	  and	  therefore	  good	  
quality	  crystals	  are	  a	  prerequisite.	  
Although	  native	  Condition	  A	  crystals	  diffracted	  to	  an	  acceptable	  resolution,	  initially	  (prior	  to	  
attempting	   reiterative	   seeding)	   the	   very	   small	   proportion	   of	   crystals	   reaching	   4	   Å	   or	  more	  
was	  a	  bottleneck	  for	  heavy	  atom	  derivatization.	  	  Attempts	  to	  obtain	  alternative	  crystal	  forms	  
included	  matrix	  microseeding,	  which	  gave	  rise	   to	  Condition	  B	  crystals,	  and	  crystallisation	  of	  
murine	   and	   drosophila	   orthologues	   as	   discussed	   below.	   	   Condition	   B	   crystals	   were	  
cryoprotected	   using	   30%	   v/v	   glycerol	   and	   30%	   w/v	   PEG1500.	   	   Since	   these	   reagents	   are	  
present	   in	   the	   original	   condition,	   albeit	   at	   lower	   concentrations,	   it	   was	   a	   reasonable	   and	  
gentle	   cryoprotection	   technique	   to	   try	   in	   a	   first	   instance.	   	   Indeed,	   by	   comparing	   crystals	  
harvested	  with	   and	  without	   cryoprotection,	   the	   resolution	   limit	   achieved	  was	   not	   affected	  
but	  cryoprotection	  did	  avoid	  the	  formation	  of	  ice	  crystals	  as	  seen	  by	  the	  absence	  of	  ice	  rings.	  	  
However,	  the	  maximum	  resolution	  achieved	  was	  only	  8.7	  Å	  (Table	  6-­‐2).	  	  Condition	  B	  crystals	  
were	  unsuitable	  for	  further	  experiments;	  no	  complete	  data	  sets	  were	  collected.	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6.4.2 Native	  mPERK	  (II-­‐IV)	  diffraction	  data	  
mPERK	  (II-­‐IV)	  native	  crystals	   from	  Condition	  C	  and	  D	  were	  tested	  for	  diffraction	  (Table	  6-­‐3).	  	  
These	   crystals	   consistently	   diffracted	  better	   than	  hPERK	   (II-­‐IV)	   crystals.	   	   The	   cell	   dimension	  
and	  space	  group	  of	  two	  mPERK	  (II-­‐IV)	  datasets	  were	  almost	  identical	  suggesting	  both	  crystals	  
represent	  the	  same	  crystal	  form.	  	  Crystals	  grown	  in	  Condition	  D	  diffracted	  better	  than	  those	  
grown	  in	  Condition	  C.	  	  At	  best,	  a	  complete	  3.3	  Å	  dataset	  from	  Condition	  D	  was	  collected.	  	  The	  
statistics	  of	  the	  processed	  diffraction	  data	  were	  within	  typical	  ranges	  of	  low-­‐resolution	  data.	  	  
However	   the	   Rsym	   values	   (8.0%	   overall	   and	   81.9%	   in	   the	   outer	   shell)	   were	   high.	   	   This	   was	  
particularly	  of	  hindrance	  for	  experimental	  phasing	  as	  discussed	  later.	  	  A	  Vm	  of	  2.47	  A3/Da	  and	  
Vs	   of	   50.2%	   were	   obtained	   (1.00	   probability)	   which	   corresponds	   to	   one	   mPERK	   (II-­‐IV)	  
molecule	  in	  the	  asymmetric	  unit.	  
	   	  
	   	  
	  
	  




Table	  6-­‐3.	  Native	  hPERK	  (II-­‐IV)	  Condition	  B	  and	  mPERK	  (II-­‐IV)	  Condition	  C	  and	  D	  diffraction	  data	  
The	   diffraction	   images	  were	   integrated,	  merged	   and	   scaled;	   the	   results	   obtained	   are	   summarised.	   	   Rsym,	   I/σ(I),	  
multiplicity	  and	  completeness	  values	  refer	  to	  values	   in	  the	  overall	  and	  outer	  shell,	   in	  brackets.	  	  No	  data	  set	  was	  
collected	  for	  Condition	  B.	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6.5 Phasing	  
6.5.1 Molecular	  replacement	  
The	   luminal	   domains	   of	   hPERK	   and	   hIRE1	   are	   functionally	   interchangeable	   and	   appear	   to	  
behave	   similarly	   with	   respect	   to	   UPR	   activation	   function	   [76,103].	   	   In	   addition,	   secondary	  
structure	   prediction	   suggests	   they	   share	   overall	   similar	   structural	   folds.	   	   However,	   hPERK	  
(and	  mPERK)	  and	  hIRE1	  luminal	  domains	  only	  share	  18%	  sequence	  identity.	  	  	  
Molecular	  replacement	  was	  attempted	  to	  solve	  the	  structure	  of	  hPERK	  (II-­‐IV)	  [164,165].	  	  The	  
crystal	  structures	  of	  hIRE1	  (PDB:	  2HZ6)	  and	  IRE1p	  (PDB:	  2BE1),	  and	  in	  silico	  models	  generated	  
based	   on	   PERK	   luminal	   domain	   sequences	   using	   the	   Phyre	   server	   were	   all	   used	   as	   search	  
ensembles	   [174].	   	   hIRE1	   and	   	   IRE1p	   coordinates	   were	   inputted	   both	   as	   monomers	   and	  
dimeric	  assemblies.	   	  Regions	  which	  were	  not	  conserved	  or	  highly	  flexible	  were	  truncated	  to	  
generate	  additional	  search	  models.	  	  However,	  the	  translation	  function	  Z-­‐score	  (TFZ)	  (<2)	  and	  
log-­‐likelihood	   gain	   (LLG)	   scores	   (<20)	   of	   any	   solution	   found	   were	   very	   low.	   	   TFZ	   and	   LLG	  
scores	  reflect	  agreement	  between	  the	  Patterson	  maps	  of	  the	  experimental	  data	  and	  those	  of	  
the	   search	   ensemble	   in	   a	   specific	   orientation.	   	   Nonetheless,	   these	   solutions	   were	   not	  
discarded	  outright.	  	  	  
Symmetry	   related	  mates	  were	  generated	  using	   the	  known	  crystal	   symmetry	  operations.	   	   In	  
these	   orientations,	   there	  was	   extensive	   clashing	   and/or	   improbably	   large	   solvent	   channels	  
between	   the	   proteins.	   	   Together	   these	   results	   are	   dissuasive	   of	   correct	   molecular	  
replacement	   solutions.	   	   Experimental	   phasing	  was	   therefore	   used	   to	   solve	   the	   structure	   of	  
PERK	  luminal	  domain.	  
6.5.2 Phasing	  by	  SeMet	  anomalous	  scattering	  
6.5.2.1 hPERK	  (II-­‐IV)	  and	  mPERK	  (II-­‐IV)	  SeMet	  incorporation	  
SeMet-­‐labelled	   proteins	  were	   expressed	   as	   described	   and	   purified	   identically	   to	   the	   native	  
proteins.	   	  MALDI-­‐TOF	   spectrometry	  was	   used	   to	  measure	   the	  precise	  mass	   of	   the	  proteins	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and	  thus	  determine	  the	  quantity	  of	  SeMet	  incorporation	  (Appendix	  Figure	  10-­‐6).	  	  The	  masses	  
obtained	  were	  34.431	  kDa	  for	  SeMet	  hPERK	  (II-­‐IV)	  and	  34.221	  kDa	  for	  SeMet	  mPERK	  (II-­‐IV).	  	  
These	  values	  indicate	  the	  presence	  of	  7.5	  and	  6.9	  Se	  atoms	  respectively	  per	  protein	  molecule.	  	  
Given	  that	  hPERK	  (II-­‐IV)	  and	  mPERK	  (II-­‐IV)	  have	  8	  and	  7	  Methionine	  residues	  respectively	  per	  
monomer,	  the	  obtained	  masses	  indicate	  near	  complete	  SeMet	  incorporation	  (94%	  for	  SeMet	  
hPERK	  (II-­‐IV)	  and	  99%	  for	  SeMet	  mPERK	  (II-­‐IV)).	  
6.5.2.2 SAD	  and	  MAD	  experiments	  
SeMet	  hPERK	  (II-­‐IV)	  Condition	  A	  and	  SeMet	  mPERK	  (II-­‐IV)	  Condition	  D	  crystals	  were	  used	  to	  
collect	  derivative	  datasets.	   	  SAD	  data	  was	  collected	  at	  the	  peak	  wavelength;	  MAD	  data	  was	  
collected	  on	  a	  single	  crystal	  at	  peak,	  inflection	  and	  higher	  energy	  remote	  wavelengths.	  	  These	  
values	   were	   experimentally	   obtained	   by	   carrying	   out	   fluorescence	   scans	   prior	   to	   data	  
collection.	  	  SeMet	  hPERK	  (II-­‐IV)	  Condition	  A	  derivative	  crystals	  diffracted	  too	  poorly	  (5	  Å	  and	  
above)	  for	  use	  in	  phasing.	  
SeMet	  mPERK	  (II-­‐IV)	  Condition	  D	  derivative	  crystals	  reached	  a	  maximum	  of	  3.4	  Å	  resolution.	  	  
The	   scattering	   factors	   were	   ƒ”	   =	   4.85	   and	   ƒ’	   =	   -­‐7.65	   at	   the	   peak	   wavelength	   (0.9789	   Å).	  	  
Crank,	  Shelx	  C,	  Phenix	  AutoSol	  programs	  were	  used	  to	  attempt	  to	  locate	  the	  Se	  scatters	  and	  
obtain	  phases	  [164,165].	  	  However	  no	  solutions	  were	  obtained	  using	  this	  dataset.	  
The	   approximate	   anomalous	   signal	   can	  be	   calculated	  by	   estimating	   the	   ratio	  of	   anomalous	  
scattering	  to	  the	  expected	  total	  scattering	  of	  a	  protein	  (Equation	  11	  and	  Equation	  12	  where	  N	  
is	  the	  number	  of	  anomalous	  scatterers,	  n	  is	  the	  total	  number	  of	  residues,	  ƒ”A	  is	  the	  scattering	  
factor	  of	  the	  anomalous	  data	  set	  and	  FT	  is	  the	  total	  scattering).	  
Equation	  11	  2𝑁 𝑓"!𝑟𝑚𝑠 𝐹! 	  
	  
Equation	  12	  𝑟𝑚𝑠 𝐹! ≈ 346𝑛	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Assuming	  100%	  SeMet	  incorporation,	  and	  that	  these	  residues	  are	  ordered,	  a	  5.7%	  anomalous	  
signal	  is	  expected	  for	  this	  3.4	  Å	  SeMet	  mPERK	  (II-­‐IV)	  dataset.	  	  The	  anomalous	  signal	  is	  below	  
the	  noise	  (overall	  Rsym	  (8.9%)).	  	  Additionally	  the	  limit	  of	  the	  anomalous	  signal,	  determined	  by	  
using	  a	  30%	  anomalous	  correlation	  coefficient	  (CCanom)	  cut-­‐off,	  only	  reached	  a	  maximum	  of	  
5.6	  Å.	  	  Se	  has	  34	  electrons.	  	  Although	  this	  is	  significantly	  different	  from	  nitrogen,	  oxygen	  and	  
carbon	  atoms	  of	  proteins,	  it	  is	  low	  for	  a	  heavy	  atom.	  	  The	  size	  of	  an	  atom	  is	  partly	  dependent	  
on	  the	  number	  of	  electrons	  it	  has.	  	  As	  such,	  the	  more	  electrons	  an	  atom	  has,	  the	  higher	  the	  
minimum	   resolution	   at	   which	   differences	   between	   it	   and	   the	   atoms	   in	   a	   protein	   can	   be	  
discerned.	   	  As	  a	  rule	  of	  thumb,	  anomalous	  signal	  to	  ∼4	  Å	  resolution	  is	  required	  to	   locate	  Se	  
atoms	   for	   phasing.	   	   The	   exact	   number	   depends	   on	   other	   factors	   such	   as	   Se	   incorporation,	  
how	   ordered	   they	   are,	   their	   scattering	   properties	   and	   the	   quality	   of	   the	   dataset.	   	   Taken	  
together,	   these	  observations	   can	  help	  explain	  why	  phases	   could	  not	  be	  obtained	   from	   this	  
dataset.	   	   Finally,	   since	   these	   crystals	   were	   not	   isomorphous	   to	   the	   native	   dataset	   (20.1%	  
overall	  Rmerge),	   SIR	  and	  Single	   Isomorphous	  Replacement	  with	  Anomalous	  Scattering	   (SIRAS)	  
experiments	  were	  not	  attempted.	  	  	  
The	  anomalous	  signal	  of	  scatterers	  is	  highly	  dependent	  on	  its	  redox	  state	  [180].	  	  In	  the	  case	  of	  
SeMet,	  this	  affects	  both	  the	  magnitude	  and	  energy	  of	  the	  anomalous	  signal.	  	  The	  presence	  of	  
a	   mixture	   of	   SeMet	   oxidation	   states	   in	   the	   crystal	   thus	   results	   in	   a	   heterogeneous	   and	  
dispersed	   absorption	   peak.	   	   This	   reduces	   the	   overall	   anomalous	   signal	   and	   also	   makes	   it	  
difficult	  to	  determine	  precise	  peak	  and	  inflection	  absorbance	  energies.	  	  SeMet	  mPERK	  (II-­‐IV)	  
Condition	   D	   crystals	   were	   oxidized	   or	   reduced	   immediately	   prior	   to	   freezing.	   	   The	   better	  
diffracting	  dataset	  was	  obtained	  with	  reduced	  SeMet	  mPERK	  (II-­‐IV)	  Condition	  D	  crystals.	  	  The	  
absorbance	  peak	  (0.9794	  Å)	  was	  shifted,	  significantly	  more	  sharp	  and	  homogenous	  compared	  
to	  that	  of	  untreated	  crystals	  (Figure	  6-­‐5).	   	   In	  addition,	  the	  scattering	  factors	  were	   increased	  
(ƒ”=7.59	  and	  ƒ’	  =	  -­‐8.91).	   	  This	  amounts	  approximately	  to	  9.3%	  anomalous	  signal.	   	  This	  time,	  
the	   anomalous	   signal	   was	   measured	   up	   to	   4.3	   Å.	   	   Although	   reduction	   of	   the	   SeMet	  
significantly	   improved	   the	   anomalous	   signal,	   no	   phases	   could	   be	   obtained	   in	   this	   instance	  
either.	  	  Heavy	  atom	  derivatization	  was	  attempted	  next	  for	  phasing.	  
	   	  
	   	  
	  
	  




Figure	  6-­‐5.	  SeMet	  mPERK	  (II-­‐IV)	  Condition	  D	  anomalous	  signal	  
(A)	  (i)	  Fluorescence	  scan	  of	  untreated	  SeMet	  mPERK	  (II-­‐IV)	  Condition	  D	  crystals.	  	  The	  absorbance	  peak	  at	  12666.2	  
eV	  (0.9789	  Å)	  is	  wide.	  	  Scattering	  factors	  were	  ƒ”	  =	  4.85	  and	  ƒ’	  =	  -­‐7.65.	  	  (ii)	  The	  CCanom	  falls	  below	  30%	  at	  5.61	  Å.	  
(B)	  (i)	  Fluorescence	  scan	  of	  reduced	  SeMet	  mPERK	  (II-­‐IV)	  Condition	  D	  crystals.	  	  The	  absorbance	  peak	  at	  12659.5	  eV	  
(0.9794	  Å)	  is	  sharper	  than	  in	  ‘Ai’.	  	  The	  scattering	  factors	  (ƒ”	  =	  7.59	  and	  ƒ’	  =	  -­‐8.91)	  are	  higher	  than	  in	  ‘Ai’.	  	  (ii)	  The	  
CCanom	  falls	  below	  30%	  at	  4.27	  Å.	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6.5.3 Heavy	  atom	  derivatization	  
Crystals	  were	  soaked	  with	  numerous	  heavy	  atom	  salts	  for	  derivatization.	  	  Owing	  to	  the	  large	  
number	  of	  Cysteine,	  Methionine	  and	  Histidine	  residues,	  Mercury	  (Hg),	  Platinum	  (Pt)	  and	  Gold	  
(Au)	   were	  mainly	   used.	   	   The	   sulphur	   atom	   of	   Cysteine	   and	   imidazole	   ring	   of	   Histidine	   are	  
most	   reactive	   at	   pH	  above	  7	   and	  6,	   respectively.	   	   The	   crystallisation	  buffer	  of	   hPERK	   (II-­‐IV)	  
and	   mPERK	   (II-­‐IV)	   was	   compatible	   with	   that.	   	   The	   results	   obtained	   are	   summarised	   in	  
Appendix	   Table	   10-­‐2	   and	   Appendix	   Table	   10-­‐3.	   	   The	   data	   can	   be	   grouped	   into	   three	  
categories:	  	  (i)	  no	  heavy	  atom	  binding,	  (ii)	  binding	  but	  not	  adequate	  diffraction	  or	  (iii)	  binding	  
and	  diffraction.	   	   For	  derivatives	   in	   the	   latter	  group	   (iii),	   SAD	  datasets	  were	   collected	  at	   the	  
experimentally	   derived	   peak	   wavelength.	   	   Where	   crystal	   quality	   and	   radiation	   damage	  
permitted,	   MAD	   experiments	   were	   also	   collected	   at	   peak,	   inflection	   and	   higher	   energy	  
remote	  wavelengths.	  	  Where	  the	  derivative	  and	  native	  datasets	  were	  isomorphous,	  SIR,	  MIR,	  
SIRAS	  and/or	  Multiple	   Isomorphous	  Replacement	  with	  Anomalous	   Scattering	   (MIRAS)	  were	  
also	  attempted.	   	  Crank,	  Shelx	  C,	  Phenix	  AutoSol	  programs	  were	  used	  for	  phasing	  [164,165].	  	  
However,	   in	  a	   first	   instance,	  all	  derivative	  datasets	  were	  unsuccessful	   in	  yielding	  any	  phase	  
information.	  	  A	  number	  of	  factors	  including	  poor	  diffraction	  and	  outer	  limit	  of	  the	  anomalous	  
signal,	   non-­‐specific	   or	   insufficient	   binding	   of	   the	   heavy	   atoms,	   disorder	   in	   the	   regions	   of	  
heavy	  atom	  binding,	  poor	  merging	  data	  statistics	  (higher	  noise	  than	  anomalous	  signal)	  might	  
be	  responsible	  for	  this.	  
A	  wide	  range	  of	  heavy	  atom	  salts,	  concentrations,	  times	  of	  soaking	  and	  method	  (or	  absence	  
of)	   backsoaking	   were	   tested.	   	   This	   extensive	   number	   of	   variables	   limited	   the	   number	   of	  
crystals	  that	  could	  be	  tested	  for	  each	  condition.	  	  Native	  gel	  shift	  assays	  were	  thus	  carried	  out	  
to	  screen	  more	  efficiently	  for	  heavy	  atom	  binding	  (Appendix	  Figure	  10-­‐7).	  	  This	  was	  done	  on	  
hPERK	   (II-­‐IV)	   at	   first	   since	   the	   quality	   of	   these	   crystals	   and	   the	   native	   dataset	  were	   better	  
compared	   to	   those	   of	   mPERK	   (II-­‐IV).	   	   Soaking	   of	   hPERK	   (II-­‐IV)	   with	   a	   Tungsten	   (W)	   salt	  
(Na2WO4)	  caused	  a	  large	  shift	  of	  the	  protein	  compared	  to	  unbound	  hPERK	  (II-­‐IV).	  	  hPERK	  (II-­‐
IV)	  Condition	  A	  crystals	  were	  then	  soaked	  with	  0.5	  -­‐	  10	  mM	  Na2WO4	  for	  0.5	  -­‐	  24	  h	  and	  were	  
frozen	  with	  and	  without	  backsoaking	   in	  the	  mother	   liquor.	   	  A	  three-­‐wavelength	  MAD	  set	  of	  
datasets	  was	  collected	  on	  a	  hPERK	  (II-­‐IV)	  Condition	  A	  crystal	  soaked	  with	  2	  mM	  Na2WO4	  for	  5	  
h	  (no	  backsoaking).	  	  The	  data	  were	  integrated,	  merged	  and	  scaled	  (Table	  6-­‐4).	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Phasing	  was	  carried	  out	  using	  Shelx	  C/D/E	  via	  the	  AutoSharp	  pipeline	  [167].	  	  Two	  W	  atoms	  (1	  
and	   0.93	   occupancy)	   were	   located	   within	   the	   asymmetric	   unit	   with	   an	   overall	   correlation	  
coefficient	  (CCall)	  of	  47%	  (Appendix	  Figure	  10-­‐8).	  	  These	  appear	  to	  be	  mainly	  coordinated	  by	  
the	   aromatic	   ring	   of	   a	   solvent	   exposed	   Trp175	   residue.	   	   The	   figure	   of	  merit	   (FOM)	   of	   the	  
original	  hand	  (P41212)	  (0.46)	  was	  significantly	  higher	  compared	  to	  that	  of	  the	   inverted	  hand	  
(P43212)	  (0.21)	  indicative	  of	  a	  correct	  solution	  for	  the	  former.	  
	   	  
	   	  
	  
	  




Table	  6-­‐4.	  Na2WO4	  derivative	  hPERK	  (II-­‐IV)	  Condition	  A	  MAD	  diffraction	  data	  
The	   diffraction	   images	  were	   integrated,	  merged	   and	   scaled;	   the	   obtained	   results	   are	   summarised.	   	   Rsym,	   I/σ(I),	  
multiplicity,	   completeness,	   anomalous	   completeness	   (Anom	  compl.),	   anomalous	  multiplicity	   (Anom	  multiplicity)	  
and	  CCanom	  refer	  to	  values	  in	  the	  overall	  and	  outer	  shell,	  in	  brackets.	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6.6 Model	  building	  and	  structure	  refinement	  
6.6.1 hPERK	  (II-­‐IV)	  
The	   two	  W	  atoms	  were	  used	   to	  phase	   the	   reflections	  of	   the	  MAD	  peak	  dataset.	   	  Since	   this	  
was	   the	  best	  data	  obtained	   it	  was	  used	  as	   the	  native	  dataset	   for	   structure	   solution.	   	   Initial	  
electron	   density	   maps	   were	   very	   poorly	   defined	   (Figure	   6-­‐6A).	   	   Density	   modification	   was	  
carried	   out	   to	   improve	   solvent	   boundaries	   [167].	   	   From	   this	   map,	   polyAla	   chains	   were	  
threaded	  where	  electron	  density	   continuity	   could	  be	   seen.	   	   Eight	   extended	  β-­‐strands	  were	  
apparent;	  this	  feature	  is	  also	  present	  in	  IRE1	  luminal	  domain	  (Figure	  6-­‐6B).	  	  The	  hIRE1	  luminal	  
domain	   structure	  was	   superimposed,	   using	   secondary-­‐structure	  matching	   (SSM)	   alignment,	  
uniquely	  based	  on	  this	  β-­‐sheet	  region	  to	  help	  with	  initial	  assignment	  of	  residues.	  
The	  use	  of	  the	  FEMs	  as	  implemented	  by	  Phenix	  was	  of	  particular	  help	  during	  model	  building	  
in	  poorly	  defined	  areas	  [164].	   	   In	  FEMs	  a	  Hoppe-­‐Gassmann	  (polynomial)	  distribution	  is	  used	  
during	  density	  modification	  to	  reduce/remove	  noise	  and	  enhance	  weak	  signals.	  	  Additionally,	  
local	  map	  scaling	  (as	  opposed	  to	  a	  global	  refinement)	  avoids	  obscuring	  weak	  signal	  (such	  as	  
that	  by	  partially	  occupied	  sites)	  by	  strong	  signal	   (such	  as	  heavy	  atom	  signals).	   	  This	  allowed	  
for	  model	  building	  and	  map	  improvement	  in	  areas	  for	  which	  initial	  density	  was	  very	  poor	  or	  
in	  flexible	  regions	  at	  the	  end	  of	  chain	  fragments	  (Figure	  6-­‐6C).	  	  	  
	   	  
	   	  
	  
	  




Figure	  6-­‐6.	  hPERK	  (II-­‐IV)	  structure	  refinement	  
(A)	  Initial	  electron	  density	  map	  of	  phased	  hPERK	  (II-­‐IV)	  diffraction	  data.	  	  The	  map	  shows	  poor	  connectivity	  and	  few	  
solvent	  boundaries.	  
(B)	   Improved	   electron	   density	   map	   after	   density	   modification.	   	   Solvent	   boundaries	   and	   secondary	   structural	  
features	  (eight	  β-­‐strands)	  are	  discernable.	  
(C)	  Electron	  density	  (2Fo-­‐Fc	  map)	  around	  (i)	  an	  α-­‐helix	  and	  (ii)	  a	  β-­‐strand	  of	  hPERK	  (II-­‐IV)	  (a)	  before	  and	  (b)	  after	  
refinement.	  	  The	  density	  was	  significantly	  improved.	  	  This	  is	  reflected	  in	  the	  R-­‐factors:	  39.3%	  R-­‐work	  and	  43.7%	  R-­‐
free	  before	  refinement	  and	  24.2%	  R-­‐work	  and	  29.3%	  R-­‐free	  after	  completion	  of	  refinement.	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Two	   hPERK	   (II-­‐IV)	   monomers	   were	   present	   in	   the	   asymmetric	   unit.	   	   These	   have	   identical	  
structural	   features	   and	   when	   they	   are	   superimposed	   by	   residue-­‐based	   least	   square	   (LSQ)	  
alignment,	  the	  central	  β-­‐sheets	  overlay	  perfectly.	  	  However	  there	  is	  a	  shift	  of	  ∼2	  -­‐	  4	  Å	  in	  the	  
position	   of	   the	   remainder	   of	   the	   structure.	   	   Since	   there	   was	   a	   lack	   of	   perfect	   symmetry	  
between	   two	  monomers	  within	   the	   asymmetric	   unit,	   non-­‐crystallographic	   symmetry	   (NCS)	  
could	  not	  be	  applied.	   	   Several	   rounds	  of	  model	   improvement	   and	   refinement	  were	   carried	  
out	  until	  the	  model	  could	  not	  be	  improved	  further.	  	  Final	  refined	  statistics	  are	  summarised	  in	  
Table	  6-­‐5.	  
6.6.2 mPERK	  (II-­‐IV)	  
The	   refined	   structure	   of	   hPERK	   (II-­‐IV)	   was	   used	   as	   a	   model	   for	   molecular	   replacement	   to	  
phase	  mPERK	   (II-­‐IV)	   Condition	   D	   native	   diffraction	   data	   (LLG	   =	   416;	   TFZ	   =20.2)	   [165].	   	   The	  
poor	  quality	  of	  the	  diffraction	  data	  and	  low	  resolution	  made	  it	  challenging	  to	  achieve	  a	  well-­‐
refined	  structure.	  	  The	  final	  statistics	  are	  summarised	  in	  Table	  6-­‐5.	  
	   	  
	  
	  
	   151	  
	  
	  
Table	  6-­‐5.	  hPERK	  (II-­‐IV)	  and	  mPERK	  (II-­‐IV)	  refinement	  
The	  final	   refinement	  statistics	  are	  summarised.	   	  Resolution	  values	  refer	   to	  outer	  and	   inner	  diffraction	   limits.	   	  R-­‐
work	  and	  R-­‐free	  values	  refer	  to	  the	  overall	  and	  outer	  shell,	  in	  brackets,	  data.	  	  Protein	  residues	  present	  in	  chain	  A	  /	  
chain	  B	  of	  the	  final	  dimer	  models	  (298	  residues	  expected	  per	  monomer).	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6.7 PERK	  luminal	  domain	  structure	  
6.7.1 hPERK	  (II-­‐IV)	  
6.7.1.1 Monomers	  
The	  overall	  fold	  of	  hPERK	  (II-­‐IV)	  luminal	  domain	  is	  very	  similar	  to	  that	  of	  IRE1	  (3.8	  Å	  and	  4.2	  Å	  
rmsd	   values	   between	   hPERK	   (II-­‐IV)	   and	   IRE1p	   or	   hIRE1	   luminal	   domain	   monomers	  
respectively).	   	   hPERK	   (II-­‐IV)	   monomer	   comprises	   of	   a	   triangular	   assembly	   of	   β-­‐sheet	  
sandwiches	  (19	  β-­‐strands	  in	  total)	  interspersed	  by	  two	  α-­‐helices	  (Figure	  6-­‐7).	  	  The	  amino	  acid	  
chain	  zigzags	  back	  and	  forth	  between	  these	  structural	  elements.	  	  These	  features	  therefore	  do	  
not	  fold	  independently	  and	  linearly	  based	  on	  the	  amino	  acid	  sequence.	  	  hPERK	  (II-­‐IV)	  contains	  
a	  central	  bed	  of	  extended	  β-­‐strands	  (β8,	  β11,	  β12)	  with	  a	  transverse	  short	  α-­‐helix	  (α1)	  and	  
two	   flanking	   short	  β-­‐strands	   (β9,	  β10).	   	   This	   central	  β-­‐sheet/α-­‐helix	   core	   is	   flanked	  by	   two	  
Lobes	  of	  β-­‐sheets	  (Lobe	  1:	  β1-­‐3,	  β13-­‐17;	  Lobe	  2:	  β4-­‐7,	  β18,	  β19,	  α2).	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Figure	  6-­‐7.	  hPERK	  (II-­‐IV)	  monomer	  
(A)	   Cartoon	   diagram	   of	   hPERK	   (II-­‐IV)	   monomer	   comprising	   regions	   II	   to	   IV.	   	   hPERK	   (II-­‐IV)	   is	   composed	   of	   a	  
triangular	  assembly	  of	  β-­‐sheets	  interspaced	  by	  two	  α-­‐helices	  (core	  =	  magenta;	  Lobe	  1	  =	  blue;	  Lobe	  2	  =	  cyan).	  
(B)	   Topology	   diagram	   of	   hPERK	   (II-­‐IV).	   	   β-­‐strands	   are	   shown	   as	   arrows;	   α-­‐helices	   are	   shown	   as	   cylinders.	  	  
Continuous	  black	  lines	  indicate	  resolved	  residues	  without	  secondary	  structure;	  dotted	  grey	  lines	  indicate	  flexible	  
regions	  for	  which	  no	  electron	  density	  was	  observed.	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6.7.1.2 Dimers	  
Two	   hPERK	   (II-­‐IV)	   monomers	   come	   together	   via	   zippering-­‐up	   of	   two	   adjacent	   monomers	  
(Figure	   6-­‐8).	   	   hPERK	   (II-­‐IV)	   dimerisation	   interface	   is	   referred	   to	   as	   Interface	   1.	   	   Interface	   1	  
involves	   38	   amino	   acids	   and	  buries	   a	   total	   solvent-­‐exposed	   surface	   area	  of	   ~2300	  Å2	   of	   an	  
otherwise	  solvent-­‐exposed	  surface	  of	  each	  monomer.	  	  It	  is	  stabilized	  mainly	  by	  five	  hydrogen	  
bonds	   between	   two	   antiparallel	   β8	   strands	   of	   adjacent	   molecules	   (Figure	   6-­‐9A;	   Appendix	  
Table	  10-­‐4).	   	  Compared	  to	   IRE1	   luminal	  domains,	  hPERK	  (II-­‐IV)	  has	  two	  additional	  β-­‐strands	  
(β9	  and	  β10).	  	  These	  are	  closely	  associated	  with	  the	  central	  β-­‐barrel	  core	  and	  also	  contribute	  
to	   Interface	  1.	   	  β9	  and	  β10	  form	  four	  hydrogen	  bonds	  with	  β11	  and	  the	   loop	  between	  β11	  
and	  β12	  of	  two	  interacting	  monomers	  (Figure	  6-­‐9B;	  Appendix	  Table	  10-­‐4).	  	  Finally,	  Glu184	  in	  
helix	  α1	  forms	  a	  salt	  bridge	  with	  Lys198	  in	  strand	  β8	  of	  an	  adjacent	  monomer	  (Figure	  6-­‐9C).	  	  
A	  point	  mutation	  was	  designed	  to	  disrupt	  dimer	  formation	  based	  on	  previous	  work	  on	  hIRE1	  
luminal	  domain	  [101].	  	  The	  hIRE1	  L194P	  mutant	  shifted	  the	  equilibrium	  towards	  a	  monomeric	  
population	   in	   sedimentation	   equilibrium	   experiments.	   	   Leu196	   of	   hIRE1	   corresponds	   to	  
Leu200	  of	  hPERK.	   	  hPERK	  (II-­‐IV)	  L200P	  was	  expressed	  and	  purified	  similarly	  to	  the	  wild	  type	  
protein.	  	  Its	  oligomeric	  state	  was	  analysed	  by	  MALS	  (Figure	  6-­‐9D).	  	  Whereas	  wild	  type	  hPERK	  
(II-­‐IV)	   eluted	   as	   a	   homogenous	   67.8	   kDa	   dimer,	   hPERK	   (II-­‐IV)	   L200P	   eluted	   as	   a	   single	  
homogenous	   species	   of	   33.5	   kDa,	   corresponding	   to	   monomers.	   	   This	   confirms	   the	   dimer	  
observed	   in	   the	  crystal	   structure	   is	  also	  present	   in	  solution	  and	  thus	   likely	   to	   represent	   the	  
true	  in	  vivo	  dimeric	  assembly.	  
	  
	   	  
	   	  
	  
	  




Figure	  6-­‐8.	  	  hPERK	  (II-­‐IV)	  dimers	  
(A)	   Schematic	   representation	   of	   two	   hPERK	   (II-­‐IV)	   monomers	   coming	   together	   to	   form	   dimers.	   	   Each	   luminal	  
domain	  sub-­‐region	  is	  coloured	  differently	  according	  to	  	  
(B)	  Cartoon	  (left)	  and	  surface	  (right)	  diagram	  of	  hPERK	  (II-­‐IV)	  dimer.	  	  Each	  monomer	  is	  coloured	  differently	  (yellow	  
and	  purple).	  
	   	  
	  
	  




Figure	  6-­‐9.	  hPERK	  (II-­‐IV)	  Interface	  1	  
(A-­‐C)	   Interface	  1	  between	  hPERK	   (II-­‐IV)	  monomer	  A	   (yellow)	  and	  monomer	  B	   (purple)	   is	   stabilized	  by	  extensive	  
hydrogen	  bonding	  between	  (A)	  two	  interacting	  β8,	  (B)	  β9-­‐β10	  and	  β11	  and	  the	  loop	  between	  β11	  and	  β12,	  and	  
(C)	  a	  salt	  bridge	  between	  α1	  and	  β8.	  	  Residues	  involved	  and	  atom	  distances	  (Å)	  are	  annotated.	  
(D)	  SEC	  MALS	  analysis	  (Superdex	  200	  PC	  3.2/30)	  of	  hPERK	  (II-­‐IV)	  (100	  μM)	  and	  hPERK	  (II-­‐IV)	  L200P	  (100	  μM).	  	  The	  
calculated	  MW	   (kDa)	   of	   the	   peaks	   obtained	   is	   indicated.	   	   The	   two	   species	   elute	   as	   homogeneous	   dimeric	   and	  
monomeric	  species	  respectively.	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6.7.1.3 Tetramers	  
The	  crystal	  lattice	  of	  hPERK	  (II-­‐IV)	  is	  stabilized	  by	  the	  packing	  of	  helix	  α2	  of	  a	  dimer	  A	  against	  
the	  β-­‐sheets	  and	   loops	  of	  Lobe	  2	   (β4-­‐7,	  β18,	  β19)	  of	  a	  dimer	  B	   (Figure	  6-­‐10;	  Figure	  6-­‐11A).	  	  
This	  is	  referred	  to	  as	  Interface	  2.	  	  As	  such,	  ‘swapping’	  of	  helices	  α2	  mediates	  intertwining	  of	  
two	   hPERK	   (II-­‐IV)	   dimers	   to	   form	   a	   circular	   tetramer.	   	   All	   four	   α2	   helices	   participate	   in	  
tetramer	  formation.	  
Interface	  2	  involves	  38	  residues	  and	  buries	  a	  total	  solvent	  exposed	  surface	  area	  of	  ~2500	  Å2.	  	  
This	  area	  is	  solvent-­‐accessible	  in	  the	  dimer	  assembly.	  	  Interface	  2	  is	  strongly	  hydrophobic	  (∆G	  
=	  -­‐17.9	  kcal/mol)	  (Figure	  6-­‐11B).	   	   	  The	  main	  contributors	  to	  the	  hydrophobic	  core	  are	  found	  
on	   helix	  α2	   (Ile374,	   Val375,	   Ala377,	   Ala378,	   Gly380,	   Ala381,	   Ser385,	   Val386),	  β18	   (Tyr387,	  
Leu388,	  Gly389,	  Met390),	  β19	  (Gly393,	  Leu395,	  Try396,	  Leu397,	  Ser399,	  Ser400)	  and	  the	  loop	  
between	   β6	   and	   β7	   (Trp165,	   Met172)	   from	   two	   interacting	   molecules.	   	   Seven	   hydrogen	  
bonds,	  which	  mainly	  involve	  interaction	  of	  the	  side	  chains	  of	  Lobe	  2	  (β5-­‐7,	  β19-­‐20)	  residues	  
with	   the	   backbone	   oxygen	   atoms	   of	   helix	   α2	   of	   a	   facing	   dimer	   also	   stabilize	   Interface	   2	  
(Appendix	  Table	  10-­‐4).	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Figure	  6-­‐10.	  hPERK	  (II-­‐IV)	  tetramerisation	  
Two	  hPERK	   (II-­‐IV)	  dimers	   (purple/yellow	  and	  magenta/orange)	  come	  together	   to	   form	  closely	  packed	   tetramers	  
via	  interaction	  of	  helix	  α2	  with	  Lobe	  2	  of	  an	  interacting	  dimer.	  	  The	  structure	  is	  represented	  as	  cartoon	  (left)	  and	  
surface	  (right).	  
	   	  
	  
	  




Figure	  6-­‐11.	  hPERK	  (II-­‐IV)	  Interface	  2	  
(A)	   Packing	   of	   hPERK	   (II-­‐IV)	   in	   the	   unit	   cell.	   	   Only	   a	   few	   molecules	   are	   shown	   for	   clearer	   visualisation.	   	   The	  
tetrameric	  assembly	  in	  the	  lattice	  is	  apparent.	  
(B)	  The	  hydrophobic	  nature	  (rich	  in	  Valine,	  Isoleucine,	  Leucine,	  Methionine,	  Alanine,	  Tyrosine,	  Serine	  and	  Glycine	  
residues)	  is	  shown.	  	  These	  are	  found	  on	  helix	  α2,	  β18	  and	  β19	  that	  are	  the	  major	  contributors	  to	  Interface	  2.	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SEC	  MALS	  analysis	  showed	  that	  hPERK	  (II-­‐IV)	  appears	  to	  form	  homogenous	  dimers	  in	  solution	  
(Figure	  6-­‐9D).	  	  The	  presence	  of	  hPERK	  (II-­‐IV)	  tetramers	  was	  detected	  in	  cross-­‐linking	  and	  AUC	  
experiments.	   	   To	   investigate	   whether	   tetramerisation	   via	   Interface	   2	   could	   be	   biologically	  
relevant	  or	   if	   it	   is	   simply	   an	   artifact	   of	   crystallisation,	   targeted	  mutations	  were	   introduced.	  	  
Firstly,	   the	  conserved	  hydrophobic	  Trp165	  of	  β6	  that	  stabilizes	   the	  accommodation	  of	  helix	  
α2	   of	   an	   opposite	   dimer	   was	   mutated	   to	   a	   non-­‐polar	   Alanine	   (W165A).	   	   Secondly,	   the	  
hydrophobic	   Leu388	  of	  β18	   that	   forms	  a	  hydrogen	  bond	  with	  Arg379	  of	   the	   interacting	  α2	  
was	  mutated	  to	  a	  polar	  Asparagine	  (L388N).	  	  Finally,	  a	  truncation	  protein	  lacking	  the	  α2	  helix	  	  
(hPERK	  105-­‐384)	  was	  cloned;	  this	  will	  be	  referred	  to	  as	  hPERK	  (II-­‐IV)	  Δα2.	   	  AUC	  was	  carried	  
out	   at	   identical	   protein	   concentrations	   on	   wild-­‐type	   hPERK	   (II-­‐IV)	   and	   the	   three	   described	  
mutants	  to	  determine	  the	  dimer	  to	  tetramer	  ratio	  (Figure	  6-­‐12).	  	  hPERK	  (II-­‐IV)	  W165A,	  L388N,	  
W165A_L388N	  and	  Δα2	  proteins	  reduced	  the	  amounts	  of	  tetramer	  species	  compared	  to	  the	  
wild-­‐type	  protein.	  	  This	  confirms	  that	  in	  solution	  tetramer	  formation	  similarly	  occurs	  as	  in	  the	  
crystal	  lattice	  via	  binding	  of	  the	  α2-­‐helices	  with	  Lobes	  2	  of	  interacting	  dimers	  at	  Interface	  2.	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Figure	  6-­‐12.	  Disruption	  of	  hPERK	  (II-­‐IV)	  Interface	  2	  
(A)	  α2	  helix	  binding	  of	  dimer	  A	  (orange)	  is	  stabilized	  by	  hydrophobic	  interaction	  with	  residues	  of	  Lobe	  2	  of	  dimer	  B	  
(purple).	  	  Mutated	  Trp165	  and	  Leu388	  residues	  are	  shown.	  	  Distances	  (Å)	  of	  Trp165	  with	  α2	  backbone	  and	  of	  the	  
hydrogen	  bond	  between	  Leu388	  with	  Arg379	  are	  annotated.	  
(B)	   AUC	   analysis	   of	   hPERK	   (II-­‐IV)	   wild-­‐type,	  W165A,	   L388N,	  W165A_L388N	   and	   Δ2	  mutants	   (20	   μM).	   	   The	   c(s)	  
distribution	   is	   plotted	   versus	   the	   sedimentation	   coefficient	   (S)	   in	   Svedberg	  unit	   to	   show	   the	  distribution	  of	   the	  
different	   species	   according	   to	   their	  molar	  mass.	   	   The	  expected	  position	  of	   dimers	   (70	   kDa)	   and	   tetramers	   (140	  
kDa)	   are	   shown	   (grey).	   	   The	   dimer	   to	   tetramer	   ratio	   of	   the	   curves	   in	   ‘B’	   is	   shown.	   	   The	   change	   in	   amount	   of	  
tetramers	  compared	  to	  wild-­‐type	  hPERK	  (II-­‐IV)	  (%)	  was	  calculated.	  	  Tetramerisation	  is	  greatly	  compromised	  in	  all	  
mutant	  proteins.	  	  	  AUC	  experiments	  and	  data	  analysis	  was	  carried	  out	  by	  Dr	  K.	  Stott.	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Looking	  at	  the	  electrostatic	  potential	  of	  PERK’s	  surface,	  the	  groove	  formed	  by	  β5-­‐7	  and	  β19-­‐
20	   is	   strongly	  negatively	   charged	   (Figure	  6-­‐13).	   	  On	   the	  other	  hand,	  α2	   is	  mostly	  positively	  
charged.	   	   If	   these	   structures	   are	   not	   stabilized	   by	   tetramer	   formation,	   they	   are	   solvent	  
exposed.	   	   In	  biology,	   large	   charged	   surfaces	  are	   rarely	   solvent	  exposed	  unless	   they	   serve	  a	  
function.	   	   In	   the	   case	   of	   PERK	   Lobe	   2,	   the	   opposite	   charges	   of	   Lobe	   2	  α2	   and	   its	  β-­‐sheet	  
cluster	  allude	  to	  an	  energetically	  favourable	  ‘lock	  and	  key’	  analogy	  for	  tetramerisation.	  	  This	  
further	  highlights	  a	  probable	  biological	  importance	  of	  Interface	  2.	  	  	  
6.7.2 mPERK	  (II-­‐IV)	  
Structurally,	  the	  overall	  core	  and	  Lobe	  1	  of	  mPERK	  (II-­‐IV)	  are	  identical	  to	  those	  of	  hPERK	  (II-­‐IV)	  
(1.1	  Å	   rmsd).	   	  No	  electron	  density	  was	  observed	   for	  Lobe	  2,	  which	   is	   involved	   in	  mediation	  
tetramer	   formation	   in	  hPERK	   (II-­‐I)V,	   and	  no	   tetrameric	   assemblies	  were	   seen	   (Figure	  6-­‐14).	  	  
Crystals	  were	  washed	  and	  analyzed	  by	  SDS-­‐PAGE	  to	  confirm	  they	  contained	  the	  intact	  mPERK	  
(II-­‐IV)	  protein.	   	  The	  crystal	   lattice	  contacts	  are	  between	  antiparallel	  stacking	  of	  two	  β15	  and	  
β9-­‐β10	   interaction	   with	   β11-­‐β12	   of	   symmetry	   related	   molecules.	   	   These	   observations	  
highlight	  the	  role	  of	  Lobe	  2	  in	  mediating	  tetramer	  formation	  at	  Interface	  2.	  	  Helix	  α2	  and	  the	  
β-­‐strands	  of	   Lobe	  2	   (β5-­‐7,	  β19-­‐20)	  are	   implicated	   in	   stabilising	   tetramers	  and	  consequently	  
are	   themselves	   stabilized	   by	   tetramer	   formation	   in	   hPERK	   (II-­‐IV).	   	   In	   mPERK	   (II-­‐IV)	   these	  
regions	  are	  disordered	  because	  tetramers	  do	  not	  form	  and	  thus	  do	  not	  stabilise	  helix	  α2	  and	  
the	  Lobe	  2	  β-­‐strands.	  	  It	  follows	  that	  they	  were	  not	  observed	  in	  electron	  density	  maps.	  
	   	  
	   	  
	  
	  










Figure	  6-­‐13.	  PERK	  Lobe	  2	  electrostatic	  charge	  
(A)	   The	   electrostatic	   potential	   of	   the	   surface	   around	   Lobe	   2	   is	   shown.	   	   The	   α2	   helix,	   especially	   at	   its	   tip,	   is	  
positively	  charged	  whereas	  the	  cavity	  to	  which	  it	  binds	  to	  form	  PERK	  tetramers	  is	  strongly	  negatively	  charged.	  
(B)	  The	  cartoon	  representation	  of	  PERK	  Lobe	  2	  is	  superimposed	  on	  the	  surface	  charge	  as	  shown	  in	  	  ‘A’.	  
	   	  
	   	  
	  
	  






Figure	  6-­‐14.	  mPERK	  (II-­‐IV)	  dimeric	  structure	  
(A)	  The	  structure	  of	  dimeric	  mPERK	  (II-­‐V)	  (red)	  was	  superimposed	  onto	  that	  of	  tetrameric	  hPERK	  (II-­‐IV)	  (only	  one	  
dimer	  is	  shown)	  (grey).	  	  Structures	  are	  shown	  as	  ribbons.	  
(B)	  Crystal	  packing	  of	  mPERK	  (II-­‐IV)	  dimers	  in	  the	  unit	  cell.	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6.8 Discussion	  
This	  chapter	  presents	  the	  novel	  structure	  of	  the	  H.	  sapiens	  and	  M.	  musclus	  orthologues	  PERK	  
luminal	   domain,	   a	   major	   constituent	   of	   ER	   stress	   sensing	   and	   UPR	   signalling	   in	   higher	  
eukaryotes.	  	  The	  structures	  of	  tetrameric	  hPERK	  (II-­‐IV)	  and	  dimeric	  mPERK	  (II-­‐IV)	  were	  solved	  
by	  X-­‐ray	  crystallography	  to	  3.1	  and	  3.3	  Å,	  respectively.	  	  	  
Early	   studies	  observed	   that	   induction	  of	  ER	   stress	   resulted	   in	   the	   formation	  of	  higher	  PERK	  
and	  IRE1	  oligomers	  in	  vivo	  [76,87].	  	  Nonetheless	  to	  date,	  the	  oligomeric	  states	  of	  inactive	  and	  
active	  PERK	  and	  IRE1	  have	  not	  been	  elucidated.	  	  From	  the	  results	  presented	  in	  this	  chapter,	  a	  
biological	  role	  for	  PERK’s	  tetrameric	  assembly	  can	  be	  envisaged.	  
The	   monomer	   of	   PERK	   luminal	   domain	   is	   composed	   of	   a	   triangular	   assembly	   of	   β-­‐sheets	  
interspaced	   by	   two	   α-­‐helices.	   	   Two	   monomers	   come	   together	   to	   form	   dimers.	  	  
Superimposition	  of	  all	  known	  PERK	  and	  IRE1	  luminal	  domain	  structures	  reveals	  that	  their	  core	  
remains	  mostly	   immobile	   (Appendix	  Figure	  10-­‐9	  and	  Appendix	   Figure	  10-­‐10).	   	   In	  particular,	  
Interface	   1,	   which	   mediates	   dimerisation,	   is	   entirely	   conserved.	   	   Given	   their	   functional	  
resemblance,	  this	  is	  not	  surprising.	  	  	  
Similarly	   to	   IRE1	   structures,	   PERK	   luminal	   domain	   has	   a	   short	   α-­‐helix	   (α1)	   that	   lies	  
transversely	  along	  the	  central	  bed	  of	  β-­‐sheets	  (β8,	  β11-­‐12).	   	   In	  the	  IRE1p	  structure	  this	  was	  
postulated	   to	   mimic	   an	   MHC-­‐like	   peptide-­‐binding	   groove,	   and	   allow	   for	   direct	   binding	   of	  
unfolded	  proteins	  and	  consequently	  lead	  to	  IRE1p	  activation	  during	  ER	  stress.	  	  The	  structures	  
of	  PERK	  luminal	  domain	  do	  not	  support	  this	  mechanism	  of	  UPR	  activation	  by	  direct	  binding	  of	  
unfolded	   proteins.	   	   Firstly,	   although	   the	   secondary	   structures	   in	   this	   region	   are	   highly	  
conserved,	   DALI	   fold	   recognition	   program	   did	   not	   link	   PERK’s	   luminal	   domain	   core	   to	   any	  
known	  structural	  motif	  other	   than	   IRE1	   luminal	  domains	   [175].	   	   Secondly,	   the	  width	  of	   the	  
groove	  between	  two	  PERK	  α1	  helices	  is	  too	  narrow	  to	  accommodate	  unfolded	  proteins	  (15	  Å	  
in	  hPERK	  and	  mPERK;	  14	  Å	  in	  hIRE1;	  17	  Å	  in	  IRE1p).	  	  Thirdly,	  residues	  proposed	  to	  be	  essential	  
for	  peptide	  binding	  in	  IRE1p	  are	  Met229,	  Phe285,	  and	  Tyr301.	  	  Based	  on	  secondary	  structure	  
alignment,	   these	   correspond	   to	   Lys198,	   Lys243	   and	   Val261	   respectively	   in	   PERK.	   	   These	  
residues	  are	  all	  non-­‐conservative	  mutations.	   	   In	  addition,	  Lys198	  (on	  β8)	  forms	  a	  salt	  bridge	  
with	  Glu184	   (on	  α2)	  of	  an	  adjacent	  monomer	  and	   sterically	  occludes	  access	   to	   the	  binding	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groove.	   	  Similar	  observations	  were	  made	  for	  hIRE1	   luminal	  domain.	   	  Together	   these	  results	  
point	  away	  from	  a	  direct	  peptide	  binding	  mechanism	  for	  ER	  stress	  sensing	  by	  UPR	  sensors	  of	  
higher	  eukaryotes.	  
The	  most	  striking	  difference	  between	  PERK	  and	  IRE1	  luminal	  domain	  structures	  is	  within	  Lobe	  
2	  and	  the	  tetramerisation	  Interface	  2	  (Appendix	  Figure	  10-­‐9).	   	   In	  the	  tetrameric	  structure	  of	  
hPERK,	  the	  C-­‐terminal	  α-­‐helix	  (α2)	  of	  a	  dimer	  is	  stabilized	  against	  the	  β-­‐strand	  cluster	  of	  Lobe	  
2	   (β5-­‐7,	   β19-­‐20)	   of	   an	   interacting	   dimer.	   	   Targeted	   mutations	   of	   Interface	   2	   designed	   to	  
disrupt	   its	   hydrophobic	   nature,	   as	  well	   as	   by	   truncation	   of	  α2,	   greatly	   compromised	   PERK	  
tetramerisation.	   	   These	   results	   confirm	   that	   Interface	  2	   is	  present	   in	   solution	  and	   is	  not	  an	  
artefact	  of	  the	  unphysiologically	  high	  protein	  concentrations	  used	  during	  crystallisation.	  
Based	   on	   structural	   alignment,	   the	   region	   implicated	   in	   Interface	   2	   is	   conserved	   between	  
PERK	  and	  IRE1	  orthologues.	  	  Most	  remarkable	  is	  the	  presence	  of	  the	  hydrophobic	  C-­‐terminal	  
α-­‐helix	  as	  well	  as	   the	  VYLG-­‐X-­‐Y	  consensus	  sequence,	  where	  X	   is	  a	  positively	  charged	  amino	  
acid.	  	  These	  non-­‐polar	  residues	  are	  major	  contributors	  to	  the	  hydrophobic	  nature	  of	  Interface	  
2.	  	  ‘X’	  is	  accountable	  for	  the	  electrostatic	  forces	  that	  also	  stabilize	  α-­‐helix	  binding	  to	  Lobe	  2.	  
Interestingly,	  no	  electron	  density	  for	  the	  entire	  Lobe	  2	  was	  observed	  for	  the	  mPERK	  luminal	  
domain	   implying	   that	   it	   has	   low	   occupancy	   in	   any	   given	   orientation.	   	   In	   the	   hPERK	   (II-­‐IV)	  
structure,	  Lobe	  2	  interacts	  only	  with	  an	  adjacent	  dimer.	  	  In	  an	  isolated	  dimer,	  Lobe	  2	  would	  
be	  solvent	  exposed.	  	  Given	  that	  mPERK	  (II-­‐IV)	  adopts	  exclusively	  a	  dimeric	  arrangement	  in	  the	  
crystal	   lattice,	  Lobe	  2	   is	  probably	  mobile.	   	   It	   is	   therefore	  not	  surprising	  that	   this	   region	  was	  
not	  observed	  in	  electron	  density	  maps.	  	  	  
H.	   sapiens	   and	  M.	  musculus	   PERK	   luminal	   domains	   sequences	   share	   90%	   identity	   and	   98%	  
similarity.	   	  Differences	  occur	   almost	   exclusively	   in	   their	  most	  N-­‐terminal	   region,	  which	  was	  
not	   present	   in	   the	   PERK	   (II-­‐IV)	   constructs	   used	   for	   crystallisation.	   	   The	   C-­‐terminal	   Lobe	   2	  
region	  that	  is	  key	  for	  tetramer	  formation	  is	  100%	  conserved.	  	  Their	  different	  oligomeric	  states	  
thus	  probably	  reflect	  the	  assemblies	  in	  which	  they	  were	  trapped	  during	  crystallisation	  rather	  
than	   a	   genuine	   difference	   between	   the	   two	   species.	   	   The	   structures	   of	   hPERK	   and	  mPERK	  
luminal	   domains	   can	   therefore	   be	   used	   to	   describe	   PERK	   luminal	   domain	   tetrameric	   and	  
dimeric	  assemblies	  respectively.	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Three-­‐dimensional	   (3D)	   domain	   swapping	   was	   first	   proposed	   by	  Moore	   and	   colleagues	   to	  
explain	  the	  aggregation	  of	  RNase	  A	  after	  lyophilisation	  [181].	  	  Eisenberg	  and	  colleagues	  later	  
defined	   its	  mechanistic	   framework	   [182].	   	  Domain	   swapping	   involves	   the	   replacement	  of	   a	  
domain	  of	  a	  protein	  with	   the	  same	  domain	   from	  an	   identical	  protein	  chain.	   	  This	  can	  be	  as	  
large	  as	  a	  complete	  tertiary	  domain	  or	  as	  small	  as	  an	  α-­‐helix	  or	  β-­‐strand.	  	  Domain	  swapping	  
results	   as	   intertwined	   higher	   oligomers	   and	   serves	   as	   an	   efficient	   and	   thermodynamically	  
favourable	  means	  of	  inter-­‐converting	  between	  lower	  and	  higher	  oligomeric	  assemblies.	  	  This	  
implies	  that	  there	  are	  two	  (or	  more)	  energetically	  stable	  and	  favourable	  assemblies	  a	  protein	  
can	  adopt	  somewhat	  amending	  Anfinsen’s	  early	  thermodynamic	  theory.	  	  
3D	   domain	   swapping	   has	   been	   studied	   in	   many	   proteins	   and	   is	   often	   accompanied	   by	   a	  
change	   in	   the	   protein’s	   functionality	   [183].	   	   To	   date	   there	   are	   fewer	   than	   60	   structures	   of	  
domain-­‐swapped	   proteins.	   	   Although	   the	   interfaces	   formed	   by	   the	   lower	   and	   higher	  
oligomers	   are	   largely	   the	   same,	   this	   switch	   allows	   for	   co-­‐operativity	   between	   proteins	   or	  
formation	   of	   active	   sites	   at	   the	   interface.	   	   Variations	   such	   as	   changes	   in	   pH,	   ionic	  
concentration,	   redox	   state,	   temperature	   or	   the	   presence	   of	   co-­‐factors	   can	   favour	   one	  
oligomeric	  state	  over	  another	  and	   lead	  to	  domain	  swapping	  [184,185].	   	  Understanding	  how	  
domain	  swapping	  is	  regulated	  is	  important	  as	  it	  can	  shed	  light	  on	  the	  biological	  role	  it	  plays.	  
Domain	  swap	  can	  result	  in	  the	  formation	  of	  a	  new	  active	  site	  by	  (i)	  creation	  of	  a	  new	  interface	  
(between	   two	   RNase	   A	   dimers)	   or	   (ii)	   inducing	   conformational	   changes	   in	   distant	   catalytic	  
domains	  (α-­‐isopropylmalate	  synthase	  (α-­‐IPMS)	  dimerisation).	  	  Moreover	  it	  can	  allow	  docking	  
of	   partner	   proteins	   by	   (iii)	   changing	   the	   dynamic	   properties	   of	   binding	   regions	  
(phosphorylated	  substrates	  preferentially	  binding	  to	  dimers	  of	  the	  sucrose	  transport	  protein	  
SUC1)	   [183].	   	   Finally	   linear	   and	   ‘open	   ended’	   domain	   swapping	   (iv)	  mediates	   formation	   of	  
amyloid	   fibrils	   and	   plays	   a	   major	   role	   in	   pathologies	   associated	   with	   protein	   aggregation	  
[186].	  
Based	  on	  the	  structural	  (and	  biochemical)	  data	  discussed	  in	  this	  chapter,	  a	  biological	  role	  for	  
the	   intertwining	   of	   PERK	   (and	   probably	   IRE1)	   luminal	   domains	   via	   Interface	   2	   is	   proposed.	  	  
Although	  strictly	  speaking	  this	  is	  not	  ‘domain	  swapping’,	  it	  is	  analogous	  to	  this	  phenomenon.	  	  
Different	   models	   in	   which	   dimer	   and	   tetramer	   assemblies	   represent	   differently	   activated	  
states	  can	  be	  envisaged	  (Figure	  6-­‐15).	  	  In	  a	  possible	  scenario,	  dimers	  and	  tetramers	  represent	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inactive	  and	  active	  oligomers	  respectively.	  	  Alternatively,	  both	  conformations	  might	  mediate	  
UPR	  signalling	  but	  activate	  downstream	  pathways	  differently.	  	  
Although	  more	  experiments	  will	  be	  key	  to	  elucidate	  the	  precise	  mechanism,	  speculations	  on	  
how	  α-­‐helix	  ‘swapping’	  in	  the	  luminal	  domain	  regions	  may	  convey	  a	  divergence	  in	  PERK	  and	  
IRE1	   cytoplasmic	   signalling	   can	   be	   made.	   	   Firstly,	   it	   has	   been	   well	   established	   that	   the	  
cytosolic	   regions	   of	   PERK	   and	   IRE1	   must	   autophosphorylate	   in	   order	   to	   initiate	   eIF2α	  
phosphorylation	   and	   xbp1	  mRNA	   splicing	   respectively.	   	   Tetramerisation	   could	   allow	   for	   co-­‐
operativity	  of	  the	  cytoplasmic	  domains	  and	  increase/alter	  downstream	  signalling.	  	  Secondly,	  
tetramer	   formation	  may	   provide	   new	   surfaces	   for	   different	   co-­‐factors	   to	   bind	   and	   as	   such	  
lead	   to	   different	   physiological	   effects.	   	   This	   could	   include	   activation	   of	   Nrf2	   and	   TRAF2	  
pathways	  downstream	  of	  PERK	  and	  IRE1	  respectively.	  
Future	   experiments	   will	   be	   key	   to	   (i)	   validate	   PERK	   and	   IRE1	   oligomeric	   state-­‐dependent	  
signalling	   in	   vivo	   and	   (ii)	   appreciate	   its	   role	   in	   UPR	   signalling.	   	   This	  will	   include	   testing	   the	  
effect	   of	  mutations	   which	   compromise	   dimerisation	   and	   tetramerisation	   in	   PERK	   and	   IRE1	  
activation.	   	   The	   use	   of	   full-­‐length	   proteins	   and	   in	   vivo	   cellular	   experiments	  will	   be	   critical.	  	  
Both	   levels	  of	  phosphorylation	  of	   their	  cytoplasmic	  domains	  and	  quantification	  of	  signalling	  
(e.g.	  eIF2α	  phosphorylation	  and	  GADD34	  expression	  for	  PERK;	  xbp1	  mRNA	  splicing	  and	  TRAF2	  
binding	  for	   IRE1)	  will	  be	  important	  to	  fully	  understand	  the	  importance	  of	  dimers/tetramers.	  	  
This	   will	   shed	   light	   on	   which	   oligomeric	   state	   represents	   their	   inactive	   and	   active	  
conformation.	   	   Additionally	   it	   will	   be	   possible	   to	   appreciate	   if	   these	   are	   responsible	   for	  
detecting	   differing	   conditions/duration/strength	   of	   ER	   stress	   and	   tuning	   downstream	  
pathways	   accordingly.	   	   Together	   these	   studies	   will	   have	   great	   implications	   in	   the	  
understanding,	  and	  manipulation,	  of	  ER	  stress	  sensing	  and	  UPR	  signalling.	  	  	  
	   	  
	   	  
	  
	  







Figure	  6-­‐15.	  Model	  for	  oligomeric	  state-­‐dependent	  UPR	  signalling	  by	  PERK	  
In	  physiological	  conditions,	  PERK	  exists	  as	  an	  inactive	  monomer.	  	  In	  this	  arrangement,	  helix	  α2	  is	  unstructured	  or	  
flexible.	   	   In	   the	   presence	   of	   ER	   stress,	   two	   PERK	   monomers	   come	   together	   and	   form	   dimers	   capable	   of	   UPR	  
signalling.	  	  Elevated	  levels	  or	  prolonged	  ER	  stress	  could	  two	  PERK	  dimers	  could	  come	  together	  via	  α2	  helix-­‐Lobe2	  
interaction	   to	   form	   tetramers.	   	  α2	   is	   stabilized	   in	   the	   interaction	  with	   an	   adjacent	  dimer	   and	  adopts	   its	   helical	  
structure.	   	   This	   could	   allow	   for	   increased	   co-­‐operativity	   of	   the	   cytoplasmic	   domains	   to	   increase	   eIF2α	  
phosphorylation.	  	  Alternatively	  this	  could	  activate	  differential	  signalling	  such	  as	  Nrf2	  activation.	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7 Biophysical	  characterisation	  of	  BiP	  
interaction	  with	  H.	  sapiens	  PERK	  and	  IRE1	  
luminal	  domains	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7.1 Summary	  
This	   chapter	   presents	   the	   biophysical	   characterisation	   of	   the	   interaction	   between	   BiP	  
chaperone	   and	   the	   luminal	   domains	   of	   H.	   sapiens	   PERK	   and	   hIRE1	   in	   vitro.	   	   A	   range	   of	  
biophysical	  techniques	  including	  MST,	  ITC	  and	  pull-­‐down	  experiments	  were	  used.	  	  	  
The	   binding	   of	   BiP	   to	   the	   luminal	   domains	   is	   shown	   to	   occur	   via	   BiP’s	   NBD	   and	   luminal	  
domain	   regions	   II-­‐IV;	   with	   low	   micromolar	   affinity.	   	   This	   represents	   an	   unconventional	  
signalling	   interaction	   that	   has	   never	   been	   previously	   conclusively	   demonstrated	   nor	  
characterised.	   	   Furthermore,	   unlike	   chaperone-­‐substrate	   interaction,	   this	   interaction	   is	  
independent	   of	   nucleotide	   binding,	   reinforcing	   the	   notion	   that	   this	   is	   a	   UPR	   signalling	  
interaction	  distinct	  from	  BiP’s	  chaperone	  function.	  
In	  order	   to	   recapitulate	   conditions	  of	   ER	   stress,	   and	  as	   such	  probe	   the	  mechanisms	  of	  BiP-­‐
dependent	  UPR	  activation,	  the	  BiP-­‐luminal	  domain	  protein	  complexes	  were	  also	  analysed	  in	  
the	  presence	  of	   the	  unfolded	  protein	  mimic	  ∆EspP	  and	  the	  authentic	  unfolded	  protein	  CH1.	  	  
Although	  binding	  of	  hPERK	  and	  hIRE1	   luminal	  domains	  to	  ∆EspP	  was	  observed,	  this	  peptide	  
had	  no	  discernable	  effect	  on	  their	  oligomeric	  state	  nor	  on	  BiP-­‐luminal	  domain	  complexes.	  	  In	  
contrast,	   CH1	   bound	   specifically	   to	   BiP’s	   SBD;	   this	   is	   a	   conventional	   BiP-­‐unfolded	   substrate	  
interaction.	   	   The	   addition	   of	   CH1	   not	   only	   prevented	   the	   formation	   of	   BiP-­‐luminal	   domain	  
complexes	  but	  was	  also	  capable	  of	  disrupting	  pre-­‐assembled	  complexes.	  	  This	  indicated	  that	  
the	   ‘conventional’	   binding	   of	   unfolded	   proteins	   to	   BiP	   SBD	   is	   transduced	   to	   the	  
‘unconventional’	  BiP	  NBD-­‐luminal	  domain	  UPR	  signalling	  interaction.	  
This	   study	  elegantly	   illustrates	  how	   the	  accumulation	  of	  unfolded	  proteins	  during	  ER	   stress	  
leads	   to	  UPR	  activation	  via	  PERK	  and	   IRE1,	  with	  BiP	   chaperone	  playing	   a	  major	   role	   in	   this	  
regulation.	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7.2 Introduction	  
The	   correlation	   between	   overexpression	   of	   BiP	   and	   attenuation	   of	   UPR	   signalling	   has	   long	  
been	  established	   [79,80].	   	  Furthermore,	  many	  studies	  dating	   to	  over	  a	  decade	  ago,	  provide	  
strong	   evidence	   for	   the	   interaction	   between	   BiP	   and	   IRE1,	   PERK	   and	   ATF6	   [76,81,82].	   	   In	  
these	  studies,	  immunoprecipitation	  experiments	  using	  whole	  cell	  extracts	  were	  carried	  out	  to	  
study	  the	  protein	  complexes.	  	  These	  cellular	  studies	  have	  provided	  the	  principal	  basis	  for	  our	  
understanding	   of	   protein	   complexes	   involving	   UPR	   components.	   	   However,	   the	   direct	  
interaction	   between	   BiP	   and	   IRE1,	   PERK	   and	   ATF6	   has	   never	   actually	   been	   demonstrated.	  	  
Importantly,	  in	  part	  due	  to	  the	  experimental	  set	  up,	  these	  studies	  have	  been	  unsuccessful	  in	  
discerning	  the	  mechanistic	  events	  that	  take	  place	  in	  the	  ER	  during	  conditions	  of	  stress	  to	  lead	  
to	  downstream	  UPR	  signalling.	  	  
Several	   hypotheses	   of	   how	   the	   presence	   of	   unfolded	   proteins	   in	   the	   ER	   lumen	   lead	   to	  
activation	  of	  the	  UPR	  mediators	  have	  been	  proposed	  [77].	  	  Initially,	  a	  competition	  model	  was	  
proposed	  where	   BiP	   binds	   to	   the	   luminal	   domains	   of	   IRE1,	   PERK	   and	  ATF6	   to	   repress	  UPR	  
activation.	   	   The	   accumulation	  of	   unfolded	  protein	  within	   the	   ER	  would	   cause	   for	  BiP	   to	  be	  
titrated	   off	   the	   luminal	   domains	   and	   thus	   releasing	   the	   inhibition.	   	   More	   recently,	   a	   BiP-­‐
independent	  model	  whereby	  the	  direct	  binding	  of	  unfolded	  proteins	  to	  the	  luminal	  domains	  
of	   the	   ER	   stress	   sensors	   causes	   their	   oligomerization	   resulting	   in	   UPR	   activation.	   	   This	  
mechanism	   is	   backed	   up	   by	   the	   X-­‐ray	   structure	   of	   S.	   cerevisiae	   IRE1p	   luminal	   domain;	   this	  
model	  has	  not	  yet	  been	  linked	  to	  the	  mammalian	  proteins	  [95].	   	   In	  fact,	  based	  on	  the	  X-­‐ray	  
crystal	  structure	  of	  H.	  sapiens	  IRE1,	  although	  similar	  to	  S.	  cerevisiae	  IRE1p’s,	  it	  was	  suggested	  
that	  this	  mechanism	  is	  incompatible	  with	  the	  mammalian	  protein	  [101].	  
Clearly,	   a	   detailed	   and	   conclusive	  mechanistic	   understanding	   of	   ER	   stress	   sensing	   and	  UPR	  
activation	  remains	  to	  be	  established.	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7.3 Direct	  binding	  of	  BiP	  to	  the	  luminal	  domains	  of	  hPERK	  
and	  hIRE1	  
7.3.1 MST	  experiment	  setup	  
The	  interaction	  of	  the	  complete	  hPERK	  (I-­‐V)	  and	  hIRE1	  (I-­‐V)	  luminal	  domain	  proteins	  with	  BiP	  
was	   initially	   characterised	   using	   MST.	   	   Proteins	   were	   labelled	   with	   an	   amine-­‐reactive	   red	  
fluorescent	  dye.	   	  Preliminary	  experiments	   to	  ensure	   the	   suitability	  of	  MST	  experimentation	  
with	  the	  purified	  proteins	  were	  carried	  out.	  
Initially,	   labelled	   BiP	   FL	   was	   titrated	   with	   16	   two-­‐fold	   dilutions	   of	   unlabelled	   hPERK	   (I-­‐V),	  
samples	  were	   loaded	   into	  standard	  grade	  capillaries	  and	  a	   ‘resting	  state’	  capillary	  scan	  was	  
carried	  out	  (Figure	  7-­‐1A).	  	  Firstly,	  the	  peaks	  obtained	  are	  symmetric,	  indicating	  that	  BiP	  FL	  is	  
uniformly	  dispersed	   in	   the	   capillaries.	   	   Secondly,	   readings	  above	  200	  absorbance	  units,	   the	  
minimal	  sensitivity	  of	  the	  instrument,	  were	  obtained.	  	  This	  confirms	  that	  the	  dilution	  used	  BiP	  
FL	  produces	  sufficient	  signal	  above	  noise	  levels.	   	  Thirdly,	  the	  height	  of	  the	  peaks	  is	  constant	  
and	  independent	  of	  the	  concentration	  of	  hPERK	  (I-­‐V)	  in	  the	  samples.	  	  This	  implies	  that	  BiP	  FL	  
fluorescence	  is	  not	  quenched	  by	  hPERK	  (I-­‐V),	  and	  that	  hPERK	  (I-­‐V)	  does	  not	  cause	  BiP	  FL	  to	  be	  
irregularly	   distributed	   in	   the	   capillary.	   	   These	   factors	  were	   similarly	   checked	   for	   each	  MST	  
experiment.	  
Typical	  raw	  curves	  obtained	  for	  an	  MST	  binding	  experiment	  are	  shown	  in	  Figure	  7-­‐1	  Bi.	  	  The	  
curves	  are	  smooth	  throughout	  the	  course	  of	  the	  experiment.	  	  This	  indicates	  that	  there	  was	  no	  
sample	  aggregation	  and	  that	  the	  protein	  sample,	  buffer	  and	  experiment	  parameters	  used	  are	  
suitable.	   	  The	  curves	  were	  then	  normalized	  to	  take	  into	  account	  differences	  in	  their	   ‘resting	  
state’	  initial	  fluorescence	  (Fcold).	   	  Fhot/Fcold	  values	  were	  calculated	  for	  each	  titration	  point	  and	  
plotted	  against	  the	  concentration	  of	  the	  titrant,	  in	  a	  logarithmic	  scale	  (Figure	  7-­‐1Bii).	  
	   	  
	  
	  





Figure	  7-­‐1.	  Typical	  MST	  binding	  experiment	  
(A)	   Capillary	   scan	   of	   labelled	   BiP	   FL	   titrated	   with	   unlabelled	   hPERK	   (I-­‐V).	   	   16	   two-­‐fold	   dilutions	   from	   highest	  
concentration	  of	  500	  μM	  were	  used.	   	  Samples	  were	   loaded	   into	  standard	  grade	  capillaries	  and	  scanned	  using	  a	  
Monolith	  NT-­‐115	  instrument	  (20%	  LED;	  80%	  IR-­‐laser;	  25	  °C).	  	  X-­‐axis	  position	  values	  refer	  to	  the	  physical	  distance	  
along	   the	   tray	   in	   which	   the	   capillaries	   are	   aligned;	   capillary	   numbers	   (Cap.)	   are	   shown.	   	   The	   measured	   raw	  
fluorescence	  is	  given	  in	  absolute	  absorbance	  units.	   	  The	  peaks	  are	  symmetrical	  and	  show	  little	  variance	  in	  shape	  
and	  height	  throughout	  the	  titration.	  
(B)	   MST	   curves	   for	   labelled	   BiP	   FL	   titrated	   with	   unlabelled	   hPERK	   (I-­‐V).	   	   After	   6”	   equilibration,	   the	   LED	   was	  
switched	  on	  (100%	  power)	  for	  30”.	  	  After	  the	  LED	  laser	  was	  switched	  off,	  the	  capillary	  fluorescence	  was	  measured	  
for	   a	   further	   6”.	   	   The	   range	   of	   data	   used	   for	   Fcold	   (blue)	   and	   Fhot	   (red)	   values	   are	   shown.	   	   The	   (i)	   raw	   and	   (ii)	  
normalized	  fluorescence	  curves	  are	  shown.	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Initially,	   two	   laser	   powers	   (80	   and	   100%	   LED)	   were	   tested	   for	   the	   titration	   of	   unlabelled	  
hPERK	  (I-­‐V)	  and	  hIRE1	  (I-­‐V)	   into	   labelled	  BiP	  FL	   (Figure	  7-­‐2A).	   	  The	  KD	  values	  obtained	  when	  
using	  80%	  LED	  (KD	  =	  3.76	  µM)	  and	  100%	  LED	  (KD	  =	  2.22	  µM)	  are	  similar.	  	  The	  fit	  of	  the	  data	  to	  
the	  Boltzmann	  equation	  used	  to	  determine	  affinity	  values	  was	  determined	  (R	  square	  =	  0.74	  
for	  80%	  LED	  curve	  and	  0.99	  for	  100%	  LED	  curve).	  	  Using	  100%	  LED	  power	  gave	  a	  better	  fit	  of	  
the	   data.	   	   The	   broader	   temperature	   gradient	   induced	   by	   the	   higher	   LED	   power	   probably	  
provokes	  a	  more	  pronounced	  difference	  between	  the	  thermophoresis	  of	  BiP	  FL	  alone	  versus	  
BiP	  FL	  bound	  to	  hPERK	  (I-­‐V).	  	  100%	  LED	  was	  used	  for	  all	  subsequent	  experiments.	  	  	  
Furthermore,	   experiments	   were	   carried	   out	   using	   both	   permutations	   of	   labelled	   and	  
unlabelled	   partners	   (labelled	   BiP	   FL	   proteins	   titrated	  with	   unlabelled	   luminal	   domains	   and	  
vice	  versa).	   	   This	  ensured	   the	   results	  obtained	  were	   specific	   and	   reproducible.	   	   Figure	  7-­‐2B	  
shows	  MST	  curves	  for	  labelled	  BiP	  FL	  titrated	  with	  unlabelled	  hPERK	  (I-­‐V)	  (KD	  =	  2.37	  µM)	  and	  
the	  reverse,	  labelled	  hPERK	  (I-­‐V)	  titrated	  with	  unlabelled	  BiP	  FL	  (KD	  =	  1.99	  µM).	  	  The	  affinity	  
values	   obtained	   are	   almost	   identical.	   	   The	   first	   setup	   (labelled	   BiP	   proteins	   titrated	   with	  
unlabelled	   hPERK	   or	   hIRE1	   proteins)	   was	   chosen	   for	   all	   subsequent	   experiments.	   	   This	  
combination	   provided	   less	   variability	   between	   experiments	   allowing	   for	   more	   reliable	  
comparisons.	   	   This	   was	   especially	   of	   importance	   in	   experiments	   screening	   for	   different	  
luminal	   domain	   constructs	   binding	   to	   the	   same	   BiP	   protein	   but	   also	   for	   comparison	   of	  
identical	  experiments	  carried	  out	  with	  either	  hPERK	  or	  hIRE1.	  	  	  
	   	  
	   	  
	  
	  






Figure	  7-­‐2.	  Optimization	  of	  MST	  experiments	  
(A)	   Labelled	   BiP	   FL	   titrated	   with	   unlabelled	   hPERK	   (I-­‐V)	   using	   80%	   (green)	   or	   100%	   (blue)	   LED	   to	   induce	  
thermophoresis.	  	  KD	  values	  obtained	  are	  similar.	  	  R	  square	  values	  of	  the	  fit	  of	  the	  data	  to	  the	  Boltzmann	  equation	  
are	  shown.	  	  Using	  100%	  LED	  yields	  a	  curve	  that	  better	  fits	  the	  data.	  
(B)	   Interaction	  between	  hPERK	   (I-­‐V)	  and	  BiP	  FL	  measured	  by	  alternating	   the	   labelled	  and	  unlabelled	   species.	  KD	  
values	  obtained	  show	  no	  difference	  between	  the	  two	  experimental	  setups.	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7.3.2 hPERK	  (I-­‐V)	  and	  hIRE1	  (I-­‐V)	  binding	  to	  BiP	  sub-­‐domains	  
Although	  many	  studies	  have	  highlighted	  a	  function	  of	  BiP	  in	  the	  activation/deactivation	  of	  the	  
UPR	  sensor	  proteins,	   their	  direct	  association	  has	  never	  been	  demonstrated.	   	   Initially,	  BiP	  FL	  
binding	  to	  hPERK	  (I-­‐V)	  and	  hIRE1	  (I-­‐V)	  was	  measured	  using	  MST.	  	  BiP	  FL	  binds	  with	  similar	  low	  
micromolar	  KD	  to	  hPERK	  (I-­‐V)	  (KD	  =	  1.92	  µM)	  and	  hIRE1	  (I-­‐V)	  (KD	  =	  1.33	  µM)	  (Figure	  7-­‐3A).	  	  To	  
identify	   the	   domain	   of	   BiP	   to	  which	   the	   luminal	   domain	   proteins	   bind	   to,	   their	   association	  
with	   BiP	   NBD	   and	   BiP	   SBD	   was	   explored.	   	   MST	   measurements	   show	   that	   BiP	   NBD	   binds	  
specifically	   to	  hPERK	   (I-­‐V)	   (KD	  =	  2.05	  µM)	  and	  hIRE1	   (I-­‐V)	   (KD	  =	  1.97	  µM)	   (Figure	  7-­‐3B).	   	  No	  
binding	  to	  BiP	  SBD	  was	  observed.	  	  This	  the	  first	  time	  the	  direct	  interaction	  between	  BiP	  and	  
the	  luminal	  domain	  proteins	  has	  been	  measured	  and	  categorically	  mapped	  to	  BiP’s	  NBD.	  
7.3.3 Influence	   of	   sub-­‐regions	   I	   to	   V	   in	   hPERK	   and	   hIRE1	   interaction	  
with	  BiP	  NBD	  
The	  luminal	  domains	  of	  PERK	  and	  IRE1	  have	  been	  previously	  divided	  into	  five	  sub-­‐regions	  (I,	  
II,	  III,	  IV	  and	  V)	  [85-­‐87].	  	  The	  functional	  relevance	  of	  these	  in	  binding	  to	  BiP	  and	  UPR	  signalling	  
has	   been	   investigated.	   	   However	   so	   far,	   published	   studies	   have	   not	   given	   consistent	   and	  
definitive	  results.	  	  To	  assign	  the	  importance	  of	  the	  luminal	  domain	  sub-­‐regions	  I-­‐V	  in	  binding	  
to	  BiP	  NBD,	  affinities	  were	  compared	  using	  the	  different	  luminal	  domain	  constructs	  (I-­‐V,	  I-­‐IV,	  
II-­‐V	  and	  II-­‐IV)	  (Figure	  7-­‐4).	  	  Similar	  KD	  values	  of	  approximately	  2	  µM	  were	  obtained	  throughout	  
indicating	   that	   regions	   II-­‐IV,	   the	   core	   region	   of	   the	   luminal	   domains,	   are	   necessary	   and	  
sufficient	  for	  hPERK	  and	  hIRE1	  binding	  to	  BiP	  NBD.	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Figure	  7-­‐3.	  Interaction	  of	  hPERK	  and	  hIRE1	  luminal	  domains	  with	  BiP	  sub-­‐domains	  
(A)	  MST	  binding	  curves	  of	  labelled	  BiP	  FL	  titrated	  with	  unlabelled	  (i)	  hPERK	  (I-­‐V)	  or	  (ii)	  hIRE1	  (I-­‐V).	  	  Similar	  KD	  values	  
in	  the	  low	  micromolar	  range	  are	  obtained.	  	  
(B)	  MST	  binding	  curves	  for	  labelled	  BiP	  NBD	  (magenta)	  and	  SBD	  (teal)	  binding	  to	  (i)	  hPERK	  (I-­‐V)	  or	  (ii)	  hIRE1	  (I-­‐V).	  	  
BiP	  NBD	  binds	  to	  the	  luminal	  domain	  proteins	  with	  similar	  affinity	  as	  BIP	  FL.	  	  No	  binding	  is	  observed	  to	  BiP’s	  SBD.	  
SE	  values	  were	  calculated	  from	  KD	  of	  three	  independent	  binding	  experiments.	  
	   	  
	  
	  
	   179	  
	  
	  
Figure	  7-­‐4.	  Defining	  the	  core	  interaction	  of	  hPERK	  and	  hIRE1	  with	  BiP	  NBD	  
(A)	  Schematic	  representation	  of	  hPERK	  and	  hIRE1	  luminal	  domain	  region	  I	  to	  V	  truncation	  constructs	  used.	  
(B)	  MST	  binding	  curves	  of	  labelled	  BiP	  NBD	  titrated	  with	  various	  length	  constructs	  of	  unlabelled	  (i)	  hPERK	  and	  (ii)	  	  
hIRE1	  luminal	  domains.	  
(C)	  List	  of	  KD	  values	  (μM	  ±SE)	  for	  MST	  binding	  curves	  in	  ‘B’	  of	  BiP	  NDB	  interacting	  with	  hPERK	  and	  hIRE1	  luminal	  
domain	   constructs.	   	   The	   regions	   comprised	   by	   each	   construct	   are	   indicated.	   	   All	   affinity	   values	   obtained	   are	  
similar.	  	  Regions	  II-­‐IV	  of	  the	  luminal	  domains	  are	  necessary	  and	  sufficient	  for	  binding	  to	  BiP	  NBD.	  	  	  
SE	  values	  were	  calculated	  from	  KD	  of	  three	  independent	  binding	  experiments.	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7.3.4 ITC	  of	  BiP	  FL	  binding	  to	  hPERK	  (II-­‐IV)	  and	  hIRE1	  (II-­‐IV)	  
ITC	   was	   used	   to	   verify	   MST	   results	   as	   well	   as	   to	   gain	   additional	   information	   on	   the	  
stoichiometry	   of	   the	   complexes.	   	   hPERK	   (II-­‐IV)	   and	   hIRE1	   (II-­‐IV)	   luminal	   domain	   constructs	  
were	   chosen	   since	   they	   bind	   to	   BiP	   identically	   as	   region	   I-­‐V	   complete	   luminal	   domain	  
constructs	  but	  are	  most	  stable	  and	  express	  more	  abundantly.	  	  For	  these	  same	  reasons,	  region	  
II-­‐IV	  constructs	  were	  used	  hereon	  for	  all	  subsequent	  experiments.	  	  	  
Firstly,	   the	   heat	   of	   dilution	   of	   BiP	   FL	   was	   calculated	   by	   titrating	   BiP	   FL,	   at	   identical	  
concentration	  as	  was	  used	  for	  the	  titration	  experiments,	   into	  the	  cell	  containing	  buffer	  only	  
(Appendix	   Figure	  10-­‐11).	   	   The	  peaks	  were	   integrated	  and	  a	   straight	   line	  was	   fitted	   through	  
the	  data.	  	  This	  represents	  BiP	  FL	  heat	  of	  dilution	  (5.8	  kcal/mol).	  	  For	  binding	  experiments,	  BiP	  
FL	   was	   titrated	   into	   hPERK	   (II-­‐IV)	   and	   hIRE1	   (II-­‐IV)	   separately.	   	   The	   experimental	   data	  was	  
integrated	  and,	  after	  subtraction	  of	  the	  heat	  of	  BiP	  FL	  dilution	  values,	  they	  were	  fitted	  with	  a	  
one	  site	  binding	  model	  (Figure	  7-­‐5).	  	  BiP	  FL	  binds	  to	  hPERK	  (II-­‐IV)	  (KD	  =	  6.00	  µM)	  and	  hIRE1	  (II-­‐
IV)	  (KD	  =	  1.36	  µM).	  	  These	  values	  are	  within	  the	  same	  range	  as	  those	  obtained	  by	  MST	  (KD	  =	  
1.92	  and	  1.33	  µM	  respectively).	  	  In	  both	  cases,	  the	  data	  yielded	  a	  1:1	  binding	  stoichiometry.	  	  
The	  significance	  of	  this	  will	  be	  discussed	  further	  in	  Chapter	  7.3.7.2.	  
	   	  
	   	  
	  
	  






Figure	  7-­‐5.	  ITC	  of	  BiP	  FL	  binding	  to	  hPERK	  (II-­‐IV)	  and	  hIRE1	  (II-­‐IV)	  
(A-­‐B)	  BiP	  FL	  (500	  μM)	  was	  titrated	  into	  (A)	  hPERK	  (II-­‐IV)	  and	  (B)	  hIRE1	  (II-­‐IV)	  (55	  μM)	  (VP-­‐ITC	  MicroCalorimeter).	  	  
BiP	  FL	  heat	  of	  dilution	  (5.8	  kcal/mol)	  was	  subtracted	  from	  the	  integrated	  experimental	  data	  and	  a	  one-­‐binding	  site	  
model	  was	  fitted.	  	  The	  association	  constant	  (KA),	  changes	  in	  enthalpy	  (∆H)	  and	  entropy	  (∆S)	  and	  stoichiometry	  (N)	  
values	  obtained	  are	  shown.	  	  Dissociation	  constants	  (KD)	  were	  calculated.	  	  Both	  hPERK	  (II-­‐IV)	  and	  hIRE1	  (II-­‐IV)	  bind	  
to	  BIP	  FL	  with	  affinities	  in	  the	  same	  range	  as	  those	  obtained	  by	  MST	  experiments.	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7.3.5 Effect	  of	  nucleotides	  on	  BiP	  FL-­‐luminal	  domains	  binding	  affinity	  
Since	   BiP	   is	   a	   member	   of	   the	   Hsp70	   family	   and	   its	   ATPase	   activity	   is	   directly	   linked	   to	   its	  
chaperoning	   function	   and	   conformational	   cycling,	   the	   effect	   of	   nucleotide	   binding	   and	  
hydrolysis	  was	  investigated.	  	  	  
Firstly,	   to	   ensure	   recombinant	   BiP	   possesses	   its	   functional	   ability	   to	   bind	   nucleotides,	   DSF	  
experiments	   were	   carried	   out	   to	   measure	   changes	   in	   its	   thermal	   stability	   upon	   binding	  
different	   nucleotides.	   	   The	   normalized	   thermal	   denaturing	   curves	   indicate	   two	   separate	  
unfolding	   events	   are	   taking	   place	   (Figure	   7-­‐6Ai).	   	   This	   is	   suggestive	   of	   the	  presence	  of	   two	  
domains,	  which	  have	  very	  different	   thermal	   stabilities.	   	   In	   the	   case	  of	  BiP,	   the	   two	  melting	  
transitions	   curves	   are	   likely	   to	   represent	   the	   sequential	   denaturation	   of	   BiP	  NBD	   and	   SBD.	  	  
Only	   the	   first	   denaturing	   event	   shows	   differences	   depending	   on	   the	   nucleotide	   present.	  	  
Since	   nucleotides	   bind	   only	   to	   the	   NBD,	   these	   first	   melting	   curves	   are	   likely	   to	   represent	  
unfolding	  of	  BiP	  NBD.	   	   In	   any	   case,	   since	   all	   that	  was	  of	   interest	   in	   this	   experiment	  was	   to	  
measure	  BiP	  binding	  to	  nucleotides,	  it	  is	  not	  important	  to	  know	  which	  domain	  is	  unfolding.	  	  	  
Maximum	  and	  minimum	  values	  for	  the	  first	  transition	  curves	  were	  calculated	  and	  fitted	  with	  
a	  Boltzmann	  equation	  (Figure	  7-­‐6AiAii).	   	  BiP	  FL	  Tm	  values	  were	  obtained	  from	  the	  inflection	  
points	  of	  the	  curves.	  	  Significant	  differences	  between	  the	  apo	  (Tm	  =	  46.8	  °C),	  AMPPNP	  (Tm	  =	  
50.0	   °C),	   and	   ADP	   (Tm	   =	   55.9	   °C)	   bound	   states	  were	   observed	   (Figure	   7-­‐6AiB).	   	   Binding	   of	  
AMPPNP	  and	  ADP	  incrementally	  stabilizes	  BiP	  FL.	  	  This	  is	  consistent	  with	  the	  conformational	  
changes	   known	   to	   be	   induced	   by	   AMPPNP	   and	   ADP	   binding	   to	   Hsp70s.	   	  More	   specifically,	  
they	  promote	  a	  closed	  NBD/open	  SBD	  and	  open	  NBD/closed	  SBD	  states	  respectively.	  	  In	  the	  
ATP	  bound	  state	  (Tm	  =	  55.2	  °C)	  BiP	  behaves	  as	  in	  the	  ADP	  bound	  state	  (Tm	  =	  55.9	  °C).	  	  This	  
could	   be	   due	   to	   BiP’s	   ATPase	   activity	   or	   spontaneous	   degradation	   of	   ATP	   during	   the	  
experiment,	   both	   of	   which	  would	   result	   in	   ATP	   hydrolysis	   into	   ADP.	   	   In	   either	   case,	   these	  
results	   demonstrate	   BiP’s	   ability	   to	   bind	   nucleotides	   and	   undergo	   conformational	  
rearrangements	  upon	  doing	  so.	  	  
	   	  
	  
	  







Figure	  7-­‐6.	  Thermal	  stability	  of	  BiP	  FL	  upon	  nucleotide	  binding	  	  	  
(A)	  DSF	  was	  used	  to	  measure	  BiP	  FL	  Tm	  in	  the	  presence	  of	  5	  mM	  ATP,	  ADP,	  AMPPNP	  or	  no	  nucleotide	  (+10	  mM	  
MgCl2).	  	  (i)	  Normalized	  denaturing	  curves	  obtained	  show	  two	  melting	  transition	  curves	  (1	  and	  2).	  	  Only	  transition	  
curve	  1	  is	  affected	  by	  the	  presence	  of	  different	  nucleotides.	  	  (ii)	  	  The	  maximum	  and	  minimum	  values	  of	  transition	  
curves	  1	  were	  calculated	  and	  fitted	  with	  Boltzmann	  equations.	  	  Inflection	  points	  were	  used	  to	  obtain	  Tm	  values.	  
(B)	  Tm	  values	  obtained	  from	  the	  experiments	  in	  ‘B’	  are	  listed.	  ATP	  and	  ADP	  bound	  Tm	  are	  very	  similar	  suggesting	  
ATP	  is	  being	  hydrolysed	  into	  ADP.	  	  Nucleotide	  binding	  increases	  BiP	  FL	  stability,	  with	  highest	  stability	  achieved	  in	  
the	  ADP-­‐bound	  states.	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Next,	   the	   affinity	   of	   interaction	   of	   BiP	   FL	   binding	   to	   hPERK	   (II-­‐IV)	   and	   IRE1	   (II-­‐IV)	   in	   the	  
presence	   of	   the	   different	   nucleotides	   was	   measured	   by	   MST	   (Figure	   7-­‐7).	   	   Affinity	   values	  
obtained	   are	   comparable	   to	   those	   obtained	   in	   the	   apo	   state.	   	   These	   measurements	  
demonstrate	   that	   the	   direct	   association	   of	   BiP	   FL	   with	   the	   luminal	   domain	   proteins	   is	   not	  
dependent	  on,	  or	  at	  least	  not	  greatly	  affected	  by,	  nucleotide	  binding.	  
7.3.6 BiP	  FL-­‐luminal	  domain	  proteins	  pull	  down	  experiments	  
Pull-­‐down	  experiments	  were	  used	  (i)	  to	  confirm	  MST	  and	  ITC	  results	  and	  (ii)	  to	  have	  a	  tool	  to	  
visualize	  protein	  complexes.	  	  Negative	  controls	  where	  the	  His6-­‐tagged	  species	  were	  replaced	  
by	  buffer	  were	  included	  to	  verify	  that	  the	  untagged	  proteins	  did	  not	  bind	  to	  the	  TALON	  resin.	  	  
BiP	   chaperone	   has	   a	   proneness	   to	   bind	   charged	   molecules	   and	   surfaces.	   	   Experiments	   in	  
which	  His6-­‐luminal	  domain	  proteins	  captured	  untagged	  BiP	  were	  unsuitable.	   	  When	  this	  set	  
up	  was	  tested,	  untagged	  BiP	  bound	  to	  TALON	  resin	   in	  negative	  control	  experiments	  (results	  
not	  shown).	  	  On	  the	  other	  hand,	  the	  untagged	  hPERK	  and	  hIRE1	  proteins	  tested	  did	  not	  bind	  
to	  TALON	  resin	  (Figure	  7-­‐8	  lanes	  1-­‐4;	  Figure	  7-­‐9	  lanes	  1-­‐2).	  	  His6-­‐BiP	  proteins	  were	  therefore	  
chosen	  as	  the	  bait	  to	  capture	  the	  untagged	  luminal	  domain	  proteins.	  
When	  designing	  the	  pull	  down	  experiment,	  care	  was	  taken	  to	  allow	  for	  capturing	  of	  transient	  
and	  low	  affinity	  complexes.	   	  Firstly,	  10-­‐fold	  excess	  of	  hPERK	  and	  hIRE1	  proteins	  were	  added	  
onto	  immobilized	  His6-­‐BiP	  proteins	  to	  ensure	  concentrations	  exceeded	  not	  only	  KD	  values	  but	  
also	  reached	   levels	  where	  most	  of	   the	  complex	  would	  be	  formed.	   	  Secondly,	  multiple	  small	  
volume	  wash	  steps	  rather	  than	  fewer	   larger	  volume	  ones	  were	  carried	  out.	   	  As	  such,	   it	  was	  
ensured	   that	   the	   protein	   concentrations	   did	   not	   fall	   below	   10	   µM.	   	   At	   10	   µM	   protein	  
concentrations,	   proteins	   that	   interact	   with	   1	   µM	   KD	   can	   be	   estimated	   to	   be	   roughly	   75%	  
bound.	  	  	  
	   	  
	   	  
	  
	  








Figure	  7-­‐7.	  Effect	  of	  nucleotide	  in	  BiP	  FL	  binding	  to	  hPERK	  and	  hIRE1	  
(A)	   labelled	  BiP	  FL	  was	  titrated	  with	  unlabelled	  (i)	  hPERK	  (II-­‐IV)	  and	  (ii)hIRE1(II-­‐IV)	   in	  the	  presence	  of	  5	  mM	  ATP,	  
ADP,	  AMPPNP	  or	  no	  nucleotide	  and	  10	  mM	  MgCl2.	  
(B)	  List	  of	  KD	  values	  (μM	  ±SE)	  for	  MST	  binding	  curves	  in	  A	  and	  B	  of	  BiP	  FL	  interacting	  with	  hPERK	  (II-­‐IV)	  and	  hIRE1	  
(II-­‐IV),	  respectively,	  in	  the	  presence	  of	  ATP,	  ADP	  or	  AMPPNP	  nucleotides.	  	  All	  affinity	  values	  obtained	  are	  similar.	  	  
BiP	  FL	  interaction	  with	  the	  luminal	  domain	  proteins	  is	  not	  dependent	  on	  nor	  affected	  by	  its	  binding	  to	  nucleotides.	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In	  a	  first	  instance,	  the	  binding	  of	  the	  luminal	  domain	  complete	  (region	  I-­‐V)	  and	  core	  (region	  II-­‐
IV)	   constructs	   to	   BiP	   FL	  was	   tested	   (Figure	   7-­‐8).	   	   BiP	   FL	   binds	   to	   both	   length	   constructs	   of	  
hPERK	   (lanes	   6	   and	   7)	   and	   hIRE1	   (lanes	   8	   and	   9)	   luminal	   domains.	   	   Since	   region	   II-­‐IV	  
constructs	  are	  much	  more	  stable,	  and	  the	  data	  obtained	  throughout	  this	  study	  indicates	  that	  
it	  behaves	   identically	   to	   region	   I-­‐V	   constructs,	   at	   least	  with	   respect	   to	   interaction	  with	  BiP,	  
they	  were	  used	  for	  subsequent	  pull	  down	  experiments.	  
Using	   an	   identical	   setup,	   binding	   of	   hPERK	   (II-­‐IV)	   and	  hIRE1	   (II-­‐IV)	   to	   the	   different	   BiP	   sub-­‐
domains	  was	   tested	   (Figure	   7-­‐9).	   	   hPERK	   (II-­‐IV)	   and	   hIRE1	   (II-­‐IV)	   bind	   specifically	   to	   BiP	   FL	  
(lanes	  4	  and	  5)	  and	  its	  NBD	  (lanes	  7	  and	  8)	  but	  not	  to	  BiP	  SBD	  (lanes	  10	  and	  11).	  	  These	  results	  
are	  consistent	  with	  those	  previously	  obtained	  by	  MST.	  	  
	   	  
	   	  
	  
	  










Figure	  7-­‐8.	  His6-­‐BiP	  FL	  pull	  down	  of	  hPERK	  and	  hIRE1	  luminal	  domains	  
Pull	   down	   assay	   using	   His6-­‐BiP	   FL	   and	   untagged	   hPERK	   (lanes	   6-­‐7)	   and	   hIRE1	   (lanes	   8-­‐9)	   constructs	   spanning	  
regions	   I-­‐V	   (complete)	   and	   II-­‐IV	   (core)	   of	   their	   luminal	   domains.	   	   Both	   the	   complete	   and	   core	   luminal	   domain	  
constructs	  bind	  to	  His6-­‐BiP	  FL.	  	  In	  control	  experiments	  the	  luminal	  domains	  only	  were	  incubated	  with	  TALON	  resin	  
(lanes	  1-­‐4).	  	  The	  MW	  (kDa)	  is	  indicated.	  
	  
	   	  
	  
	  












Figure	  7-­‐9.	  His6-­‐BiP	  sub-­‐domains	  pull	  down	  of	  hPERK	  (II-­‐IV)	  and	  hIRE1	  (II-­‐IV)	  
Pull	  down	  assay	  using	  His6-­‐BiP	  FL	  (lanes	  3-­‐5),	  His6-­‐BiP	  NBD	  (lanes	  6-­‐8)	  and	  His6-­‐BiP	  SBD	  (lanes	  9-­‐11)	  with	  untagged	  
hPERK	  (II-­‐IV)	  and	  untagged	  hIRE1	  (II-­‐IV).	   	  hPERK	  (II-­‐IV)	  and	  hIRE1	  (II-­‐IV)	  bind	  to	  His6-­‐BiP	  FL	  and	  His6-­‐BiP	  NBD.	  	  No	  
binding	  is	  observed	  to	  His6-­‐BiP	  SBD.	  	  In	  control	  experiments	  the	  luminal	  domains	  only	  were	  incubated	  with	  TALON	  
resin	  (lanes	  1-­‐2).	  	  The	  MW	  (kDa)	  is	  indicated.	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7.3.7 Stoichiometry	  of	  hPERK	  (II-­‐IV)-­‐BiP	  complexes	  	  
To	  investigate	  the	  stoichiometry	  of	  hPERK	  (II-­‐IV)	  interaction	  with	  BiP,	  native	  gel	  shift	  assays,	  
chemical	   crosslinking,	   SEC,	  AUC	  and	   ITC	  were	   carried	  out.	   	   This	   thesis	   is	   a	   study	  mainly	   on	  
hPERK	  protein	  and	  thus	  only	  the	  stoichiometry	  of	  hPERK-­‐BiP	  complexes	  was	  analysed.	  	  For	  all	  
experiments,	   proteins	  were	  mixed	   in	   equimolar	   amounts	   at	   concentrations	   at	   least	   10-­‐fold	  
above	  KD	  values	  to	  ensure	  sufficient	  complex	  was	  formed.	  	  
7.3.7.1 Gel	  shift	  assays	  
To	  identify	  the	  size	  of	  the	  complex,	  gel	  shift	  assays	  were	  initially	  carried	  out.	  	  These	  included	  
native	  gels	  and	  chemical-­‐cross	  linking.	  	  hPERK	  (II-­‐IV)	  was	  incubated	  with	  BiP	  FL	  and	  run	  on	  a	  
native	   gel	   (Appendix	   Figure	   10-­‐12A).	   	   However,	   all	   bands	   in	   the	   sample	   containing	   both	  
hPERK	  (II-­‐IV)	  and	  BiP	  FL	  could	  be	  attributed	  to	  species	  also	  visible	  when	  the	  proteins	  were	  run	  
in	   isolation.	   	   This	   could	  be	  due	   to	   the	  complex	  being	   transient.	   	  Chemical-­‐cross	   linking	  was	  
then	  used	  as	  a	  means	  of	  capturing	  and	  stabilizing	  protein-­‐protein	  interactions.	  	  Experiments	  
were	  prepared	  similarly	  as	   for	  native	  gel	  shift	  assays	  but	  a	  25-­‐fold	  molar	  excess	  of	  EGS	  was	  
added	   (Appendix	   Figure	   10-­‐12B).	   	   The	  MW	  of	  BiP	   FL	   (∼65	   kDa)	   is	   a	  multiple	   of	   the	  MW	  of	  
hPERK	   (II-­‐IV)	   (∼32	   kDa).	   	   Because	   of	   this,	   it	   was	   difficult	   to	   differentiate	   between	   bends	  
belonging	  to	  protein	  complexes	  or	  those	  belonging	  to	  higher	  oligomers	  of	  either	  species.	  	  At	  
least	   as	   visible	   by	   Coomassie	   staining,	   no	   band	   corresponding	   to	   hPERK	   (II-­‐IV)-­‐BiP	   complex	  
could	  be	  discerned;	  all	   the	  visible	  bands	  could	  be	  assigned	   to	  specific	  oligomers	  of	   the	   two	  
proteins.	  
7.3.7.2 SEC	  MALS	  
BiP	  FL-­‐hPERK	  (II-­‐IV)	  and	  BiP	  NBD-­‐hPERK	  (II-­‐IV)	  complexes	  were	  analysed	  by	  SEC	  MALS	  (Figure	  
7-­‐10).	  	  When	  run	  alone	  hPERK	  (II-­‐IV),	  BiP	  FL	  and	  BiP	  NBD	  alone	  elute	  as	  homogenous	  70	  kDa	  
dimers,	   139	   kDa	   dimers	   and	   37	   kDa	  monomers	   respectively.	   	   As	   shown	   by	   the	   co-­‐elution	  
traces,	   hPERK	   (II-­‐IV)	   and	   BiP	   proteins	   come	   off	   separately	   on	   the	   SEC	   column	   and	   no	  
additional	   complex	   peak	   is	   observed.	   	   Again,	   this	   could	   be	   due	   to	   the	   complex	   not	   being	  
strong	  enough	   to	   tolerate	  diffusion	   through	   the	  Superdex	   resin.	   	  Alternatively,	   the	  proteins	  
could	   have	   been	   diluted	   to	   below	   KD	   concentrations	   in	   the	   column	   and	   as	   such	   no,	   or	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insufficient,	   complex	   is	   formed.	   	   Given	   their	   low	   affinity	   values	   this	   is	   not	   an	   unexpected	  
result.	  	  	  
7.3.7.1 AUC	  
Consequently,	   AUC	   was	   used	   as	   a	   more	   gentle	   approach	   to	   capture	   BiP	   FL-­‐hPERK	   (II-­‐IV)	  
complexes	  (Figure	  7-­‐11).	  	  Results	  show	  that	  in	  solution	  hPERK	  (II-­‐IV)	  exists	  as	  a	  dimer	  (70	  kDa)	  
and	  tetramer	  (140	  kDa);	  BiP	  FL	  exists	  as	  a	  monomer	  (∼68	  kDa)	  and	  dimer	  (140	  kDa).	   	   In	  the	  
profile	   of	   BiP	   FL-­‐hPERK	   (II-­‐IV)	   complex	   samples,	   large	   peaks	   corresponding	   to	   the	   two	  
individual	  species	  are	  clear.	   	  An	  additional	  smaller	  peak	  of	  220	  kDa	  was	  also	  detected.	   	  This	  
could	  correspond	  to	  the	  BiP	  FL-­‐hPERK	  (II-­‐IV)	  complex	  with	  a	  2:2	  ratio.	   	  However,	  due	  to	  the	  
poor	   resolution	   of	   the	   peaks,	   a	   1:1	   complex	   stoichiometry	   cannot	   be	   excluded.	   	   Such	   a	  
species	  would	  be	  of	  approximately	  110	  kDa	  and	  would	  be	  masked	  by	  the	  poorly	  defined	  BiP	  
FL	  peak	  profiles.	   	  A	  290	  kDa	   species	  was	  also	  observed.	   	   This	   could	   represent	  a	  number	  of	  
hPERK	  (II-­‐IV)	  to	  BiP	  FL	  complex	  ratios	  (2:3,	  4:2,	  6:1);	  it	  is	  not	  possible	  to	  discern	  between	  the	  
different	  stoichiometries	  from	  this	  data.	  	  Additionally,	  in	  proportion	  to	  the	  other	  peaks	  this	  is	  
very	   small	   and	   is	   likely	   to	   be	   due	   to	   aggregated	   protein	   rather	   than	   a	   biologically	   relevant	  
oligomer.	  
	   	  
	   	  
	  
	  








Figure	  7-­‐10.	  SEC	  MALS	  of	  hPERK	  (II-­‐IV)-­‐BiP	  complexes	  
(A-­‐B)	  SEC	  MALS	  analysis	  (Superdex	  200	  PC	  3.2/30)	  of	  hPERK	  (II-­‐IV)	  (100	  μM)	  and	  (A)	  BiP	  FL	  (100	  μM)	  or	  (B)	  BiP	  NBD	  
(100	   μM).	   	   The	   calculated	   MW	   (kDa)	   of	   the	   peaks	   obtained	   are	   indicated.	   	   In	   either	   experiment,	   no	   peak	  
corresponding	  to	  BiP-­‐hPERK	  (II-­‐IV)	  complexes	  could	  be	  discerned.	  
	   	  
	  
	  













Figure	  7-­‐11.	  AUC	  of	  hPERK	  (II-­‐IV)-­‐BiP	  FL	  complex	  
AUC	  analysis	  of	  hPERK	  (II-­‐IV)	  (11	  μM)	  and	  BiP	  FL	  (11	  μM).	  	  The	  c(s)	  distribution	  is	  plotted	  versus	  the	  sedimentation	  
coefficient	   (S)	   in	   Svedberg	  unit	   to	   show	   the	  distribution	  of	   the	  different	   species	   according	   to	   their	  molar	  mass.	  	  
The	  expected	  MW	  (kDa)	  corresponding	  to	  sedimentation	  coefficient	  (S)	  values	  are	  shown	  (grey).	  	  Alone,	  hPERK	  (II-­‐
IV)	  exists	  as	  a	  dimer	  and	  tetramer	  whereas	  BiP	  FL	  forms	  monomers	  and	  dimers.	  	  When	  hPERK	  (II-­‐IV)	  and	  BiP	  FL	  are	  
run	   together,	   the	   profile	   is	   poorly	   resolved.	   	   Additionally	   to	   the	   peaks	   which	   are	   also	   present	   when	   the	   two	  
proteins	   are	   run	   in	   isolation,	   a	   shoulder	   peak	   corresponding	   to	   approximately	   290	   kDa	   is	   present.	   AUC	  
experiments	  and	  data	  analysis	  was	  carried	  out	  by	  Dr	  K.	  Stott.	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7.3.7.2 ITC	  
Finally,	   ITC	   was	   used	   to	   analyse	   the	   stoichiometry	   of	   BiP	   FL-­‐hPERK	   (II-­‐IV)	   complexes.	   	   As	  
discussed	  in	  Chapter	  7.3.4,	  titration	  of	  BiP	  FL	   into	  hPERK	  (II-­‐IV)	  yields	  a	  sigmoidal	  curve	  that	  
fits	  a	  one-­‐site	  of	  binding.	   	  The	  two	  proteins	   interact	  with	  6	  µM	  KD	   in	  an	  equimolar	  ratio.	   	  A	  
stoichiometry	  of	  N	  =	  1	   in	   ITC	  cannot	  be	  used	  directly	   to	  distinguish	  between	  a	   ratio	  of	  1:1,	  
2:2,	  3:3	  and	  so	  on.	  	  As	  measured	  by	  SEC	  MALS,	  hPERK	  (II-­‐IV)	  is	  a	  dimer	  in	  solution,	  at	  least	  at	  
the	   55	  µM	  working	   concentration	   of	   the	   ITC	   experiment.	   	   If	   hPERK	   (II-­‐IV)	   dimers	   were	   to	  
break	   into	   monomeric	   species	   upon	   titration	   of	   BiP	   FL,	   an	   event	   necessary	   to	   yield	   a	   1:1	  
stoichiometry,	  it	  would	  contribute	  to	  the	  overall	  enthalpy	  of	  the	  reaction.	  	  In	  such	  a	  scenario,	  
it	  would	  probably	  difficult	   to	   fit	  a	  one	  site	  of	  binding	  curve,	  as	   this	   is	  usually	   reflective	  of	  a	  
reaction	  consisting	  of	  a	  single	  event.	  	  Although	  this	  is	  a	  first	  indication	  of	  a	  2:2	  (as	  opposed	  to	  
a	  1:1)	  hPERK	  (II-­‐IV)	  to	  BiP	  FL	  stoichiometry,	  it	  is	  not	  unambiguous	  evidence.	  	  	  
To	   further	  address	   the	   stoichiometry,	   and	   to	  gain	   further	   insight	  on	   this	   interaction,	  BiP	   FL	  
was	  titrated	   into	  hPERK	  (II-­‐IV)	  L200P	  monomeric	  mutant	   (Figure	  7-­‐12).	   	  After	  subtraction	  of	  
BiP	  FL	  heat	  of	  dilution	  to	  the	  integrated	  data,	  a	  one-­‐site	  of	  binding	  curve	  was	  fitted.	  	  The	  data	  
gave	  a	  5.92	  µM	  KD	  and	  1:1	  stoichiometry.	   	   	  The	  affinity	  value	  obtained	  is	   identical	  to	  that	  of	  
binding	   to	   wild-­‐type	   dimeric	   hPERK	   (II-­‐IV).	   	   In	   addition,	   the	   overall	   enthalpy	   of	   the	   two	  
reactions	   (BiP	   binding	   to	   hPERK	   (II-­‐IV)	   monomers	   or	   dimers)	   are	   identical.	   	   This	   strongly	  
suggests	  that	  the	  same	  reactions	  are	  taking	  place.	   	   It	  can	  be	  extrapolated	  that	  hPERK	  (II-­‐IV)	  
wild-­‐type	  and	  L200P	  mutant	  remain	  dimers	  and	  monomers	  respectively	  upon	  binding	  of	  BiP.	  	  
Together,	   the	   ITC	   data	   suggest	   that	   (i)	  BiP	   does	   not	   rely	   the	   dimerisation	   groove	  of	   hPERK	  
luminal	  domain	  for	  binding	  and	  (ii)	  BiP-­‐hPERK	  (II-­‐IV)	  complexes	  comprise	  of	  a	  2:2	  ratio.	  
	   	  
	   	  
	  
	  







Figure	  7-­‐12.	  Titration	  of	  hPERK	  (II-­‐IV)	  L200P	  with	  BiP	  FL	  
BiP	  FL	  (500	  μM)	  was	  titrated	  into	  hPERK	  (II-­‐IV)	  L200P	  (55	  μM)	  (VP-­‐ITC	  MicroCalorimeter).	  	  BiP	  FL	  heat	  of	  dilution	  
(5.8	  kcal/mol)	  was	  subtracted	  from	  the	  integrated	  experimental	  data	  and	  a	  one-­‐binding	  site	  model	  was	  fitted.	  	  The	  
association	  constant	  (KA),	  changes	  in	  enthalpy	  (∆	  H)	  and	  entropy	  (∆	  S)	  and	  stoichiometry	  (N)	  values	  obtained	  are	  
shown.	   	  Dissociation	  constants	  (KD)	  were	  calculated.	   	  At	   least	  with	  respect	  to	  affinity	  and	  enthalpy,	  hPERK	  (II-­‐IV)	  
L200P	  binds	  to	  BiP	  FL	  almost	  identically	  as	  wild-­‐type	  hPERK	  (II-­‐IV).	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7.4 Investigating	  UPR	  activation	  using	  model	  unfolded	  
proteins	  
7.4.1 ∆EspP	  unfolded	  protein	  mimic	  
7.4.1.1 ∆EspP	  binds	  specifically	  to	  hPERK	  (II-­‐IV)	  and	  hIRE1	  (II-­‐IV)	  luminal	  domains	  
As	  a	  preliminary	  screen	  for	  ∆EspP	  binding	  to	  hPERK	  and	  hIRE1	  proteins,	  DSF	  was	  carried	  out	  
at	  first	  (Figure	  7-­‐13).	  	  ∆EspP	  decreases	  the	  thermal	  stability	  of	  hPERK	  (II-­‐IV)	  and	  hIRE1	  (II-­‐IV)	  
by	  8.5	  and	  4.4	  °C	  respectively.	  	  Although	  DSF	  demonstrates	  binding,	  it	  gives	  no	  indication	  of	  
affinity	   values	   nor	   stoichiometry.	   	   MST	   relies	   on	   differences	   in	   size,	   shape	   and	   charge	   of	  
labelled	  proteins	   upon	  binding	   to	   an	  unlabelled	  partner,	  which	   changes	   its	   thermophoretic	  
properties.	   	  Association	  of	  ∆EspP	  peptide,	  with	  a	  mass	   less	   than	  3	  kDa,	   to	  macromolecules	  
larger	   than	   70	   kDa	   is	   likely	   to	   not	   result	   in	   sufficient	   changes	   to	   the	   hydration	   shell	   of	   the	  
latter	  to	  be	  measurable	  by	  MST.	  	  Therefore,	  MST	  was	  not	  deemed	  suitable	  for	  studying	  ∆EspP	  
binding	  to	  hPERK	  and	  hIRE1	  luminal	  domains.	  	  ITC	  was	  employed	  instead.	  
Firstly,	  ∆EspP	  heat	  of	  dilution	  was	  measured	  (<0.1	  kcal/mol)	  (Appendix	  Figure	  10-­‐11B).	  	  This	  is	  
negligible	  and	  thus	  was	  not	  taken	  into	  account	  in	  the	  titration	  runs.	  	  ∆EspP	  was	  titrated	  into	  
hPERK	  (II-­‐IV)	  and	  hIRE1	  (II-­‐IV)	  proteins	  separately.	   	  The	  data	  were	   integrated	  and	  fitted	  to	  a	  
one-­‐site	  binding	  model	   (Figure	  7-­‐14).	   	  ∆EspP	  binds	   to	   the	   luminal	  domain	  proteins	  with	  9.4	  
µM	  and	  6.4	  µM	  KD	   respectively.	   	  A	  1:2	  peptide	   to	  protein	   ratio	  was	  obtained	   in	  both	  cases	  




	   	  
	   	  
	  
	  






Figure	  7-­‐13.	  ΔEspP	  decreases	  the	  thermal	  stability	  of	  hPERK	  (II-­‐IV)	  and	  hIRE1	  (II-­‐IV)	  
(A-­‐B)	  DSF	  was	  used	  to	  test	  for	  ΔEspP	  peptide	  (MKKHKRILALCFLGLLQSSYSAAKKKK)	  binding	  to	  (A)	  hPERK	  (II-­‐IV)	  and	  
(B)	  hIRE1	  (II-­‐IV).	  	  Tm	  values	  indicate	  that	  binding	  of	  ΔEspP	  significantly	  decreases	  the	  Tm	  of	  hPERK	  (II-­‐IV)	  (by	  8.5	  °C)	  
and	  hIRE1	  (II-­‐IV)	  (by	  4.4	  °C).	  
	   	  
	  
	  






Figure	  7-­‐14.	  ΔEspP	  binding	  to	  hPERK	  (II-­‐IV)	  and	  hIRE1	  (II-­‐IV)	  
(A-­‐B)	  ΔEspP	  (500	  μM)	  was	  titrated	  into	  (A)	  hPERK	  (II-­‐IV)	  or	  (B)	  hIRE1	  (II-­‐IV)	  (55	  μM)	  (VP-­‐ITC	  MicroCalorimeter).	  	  The	  
data	  was	  integrated	  and	  fitted	  to	  a	  one-­‐binding	  site	  model.	  	  The	  association	  constant	  (KA),	  changes	  in	  enthalpy	  (∆	  
H)	   and	   entropy	   (∆	   S)	   and	   stoichiometry	   (N)	   values	   obtained	   are	   shown.	   	   Dissociation	   constants	   (KD)	   were	  
calculated.	   ΔEspP	   binds	   similarly	   to	   hPERK	   (II-­‐IV)	   and	   hIRE1	   (II-­‐IV)	   with	  micromolar	   affinity	   and	   a	   1:2	   ΔEspP	   to	  
luminal	  domain	  proteins	  ratio.	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To	  verify	  the	  specificity	  of	  ∆EspP	  for	  the	  luminal	  domain	  proteins,	  similar	  experiments	  were	  
carried	  out	  using	  BiP	  FL.	   	   In	  DSF,	  ∆EspP	  only	   reduced	   the	  Tm	  of	  BiP	  FL	  by	  0.4	   °C	   (Appendix	  
Figure	  10-­‐13A).	   	  This	  value	  is	  within	  experimental	  error	  values	  and	  therefore	  not	  significant.	  	  
In	  ITC,	  no	  heat	  changes	  were	  measured	  upon	  titration	  of	  ∆EspP	  into	  BiP	  FL	  (Appendix	  Figure	  
10-­‐13B).	  	  Together	  these	  results	  demonstrate	  the	  specificity	  of	  ∆EspP	  for	  the	  luminal	  domain	  
proteins	  with	  no	  binding	  to	  BiP	  FL	  observed.	  
7.4.1.2 ∆EspP	  does	  not	  induce	  clustering	  of	  hPERK	  (II-­‐IV)	  and	  hIRE1	  (II-­‐IV)	  
∆EspP	   peptide	   has	   been	   shown	   to	   induce	   formation	   of	   higher	   oligomeric	   species	   upon	  
binding	  to	  S.	  cerevisiae	  IRE1p	  orthologue.	  	  This	  ∆EspP-­‐induced	  clustering	  effect	  was	  tested	  on	  
hPERK	  and	  hIRE1	  luminal	  domains.	  	  hPERK	  (II-­‐IV)	  and	  hIRE1	  (II-­‐IV)	  were	  incubated	  with	  ∆EspP	  
and	  samples	  were	  analysed	  by	  SEC	  MALS	  (Appendix	  Figure	  10-­‐14).	  	  hPERK	  (II-­‐IV)	  and	  hIRE1	  (II-­‐
IV)	   remain	  ∼68	   and	  ∼104	   kDa	   dimers	   respectively.	   	   ∆EspP	   does	   not	   have	   an	   effect	   on	   the	  
oligomeric	  state	  of	  the	  luminal	  domain	  proteins,	  at	  least	  as	  measured	  by	  SEC	  MALS.	  
Given	  that	  ∆EspP	  does	  bind	  to	  the	  luminal	  domain	  proteins,	  its	  effect	  on	  complexes	  with	  BiP	  
FL	  was	  tested.	   	  Competition	  pull	  down	  experiments	  were	  carried	  out	  similarly	  to	  those	  with	  
CH1.	   	  Briefly,	  hPERK	  (II-­‐IV)-­‐BiP	  FL	  and	  hIRE1	  (II-­‐IV)-­‐BiP	  FL	  complexes	  were	  formed	  and	  ∆EspP	  
was	   added	   (Appendix	   Figure	   10-­‐15).	   	   This	   had	   no	   visible	   effect	   on	   protein	   complexes	  
suggesting	  ∆EspP	  has	  no	  function	  in	  the	  mechanism	  of	  UPR	  activation	  by	  hPERK	  and	  hIRE1.	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7.4.2 CH1	  authentic	  unfolded	  protein	  
7.4.2.1 CH1	  is	  a	  BiP-­‐specific	  unfolded	  protein	  mimic	  	  
CH1	  is	  a	  known	  BiP	  substrate	  and	  has	  been	  extensively	  used	  to	  study	  its	  chaperoning	  function.	  	  
MST	  was	  used	   to	   investigate	  CH1	  binding	   to	  BiP,	  hPERK	  and	  hIRE1	  proteins	   	   (Figure	  7-­‐15A).	  	  
CH1	  binds	  specifically,	  and	  similarly,	  to	  BiP	  FL	  and	  to	  its	  SBD	  in	  the	  presence	  of	  ADP	  (KD	  =	  8.67	  
and	   5.11	   µM	   respectively).	   	   No	   binding	   to	   BiP	   NBD,	   hPERK	   (II-­‐IV)	   nor	   hIRE1	   (II-­‐IV)	   was	  
observed.	  	  These	  findings	  were	  confirmed	  in	  pull-­‐down	  experiments	  (Figure	  7-­‐15B).	  	  His6-­‐BiP	  
FL	   and	  His6-­‐BiP	   SBD	  were	  able	   to	  pull	   down	  untagged	  CH1.	   	  No	  binding	  of	  untagged	  CH1	   to	  
His6-­‐BiP	  NBD,	  His6-­‐hPERK	  (II-­‐IV)	  or	  His6-­‐hIRE1	  (II-­‐IV)	  was	  observed.	  	  These	  results	  confirm	  CH1	  
as	  a	  BiP	  SBD-­‐specific	  unfolded	  protein	  mimic.	  
7.4.2.2 CH1	  prevents	  formation,	  and	  can	  promote	  dissociation,	  of	  luminal	  domain-­‐
BiP	  complexes	  
CH1	  was	  exploited	  as	   an	  authentic	  unfolded	  protein	   to	  probe	   the	   interactions	  between	   the	  
luminal	  domains	  and	  BiP	   in	  pull-­‐down	  experiments.	   	  Firstly,	  His6-­‐BiP	  FL-­‐CH1	  complexes	  were	  
formed	  and	   a	   10-­‐fold	  molar	   excess	   of	   untagged	  hPERK	   (II-­‐IV)	   or	   untagged	  hIRE1	   (II-­‐IV)	  was	  
added.	   	   As	   previously	   described,	   the	   luminal	   domain	   proteins	   normally	   bind	   to	   BiP	   FL	   in	  
identical	   pull-­‐down	   experiments.	   	   However,	   shows	   that	   if	   BiP	   FL	   is	   already	   bound	   to	   CH1,	  
hPERK	  (II-­‐IV)	  (lane	  5)	  and	  hIRE1	  (II-­‐IV)	  (lane	  7)	  do	  not	  bind	  to	  BiP	  FL.	  	  This	  was	  a	  first	  indication	  
that	   CH1	   unfolded	   protein	   has	   an	   inhibitory	   effect	   on	   BiP’s	   association	   with	   the	   luminal	  
domain	  proteins.	  
Next,	   the	   reverse	   experiment	   was	   carried	   out	   to	   test	   whether,	   in	   addition	   to	   inhibiting	  
luminal	  domain	  association	  with	  BiP,	  CH1	  was	  also	  able	  to	  disrupt	  already	  formed	  complexes.	  	  
His6-­‐BiP	  FL	  was	  complexed	  with	  untagged	  hPERK	  (II-­‐IV)	  and	  untagged	  hIRE1	  (II-­‐IV)	  and	  a	  10-­‐
fold	  molar	  excess	  of	  untagged	  CH1	  was	  added	  (Figure	  7-­‐17).	  	  hPERK	  (II-­‐IV)	  (lane	  5)	  and	  hIRE1	  
(II-­‐IV)	  (lane	  7)	  dissociate	  from	  BiP	  FL	  upon	  addition	  of	  CH1.	  	  This	  result	  demonstrates	  that	  CH1	  
can	  actively	  promote	  dissociation	  of	  BiP	  FL-­‐luminal	  domain	  complexes.	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Figure	  7-­‐15.	  Binding	  of	  CH1	  to	  BiP	  and	  luminal	  domain	  proteins	  
(A)	  Labelled	  CH1	  (+	  5	  mM	  ADP,	  10	  mM	  MgCl2)	  was	  titrated	  with	  unlabelled	  BiP	  FL	  (blue),	  SBD	  (red),	  NBD	  (*),	  hPERK	  
(II-­‐IV)	  (×)	  or	  hIRE1	  (II-­‐IV)	  (|).	  	  CH1	  binds	  to	  BiP	  FL	  and	  BiP	  SBD	  with	  similar	  micromolar	  affinities.	  	  No	  binding	  of	  CH1	  
to	  BiP	  NBD,	  hPERK	  (II-­‐IV)	  or	  hIRE1	  (II-­‐IV)	  is	  observed.	  	  
(B)	  Pull	  down	  assay	  using	  His6-­‐tagged	  BiP	  (FL,	  SBD	  and	  NBD),	  hPERK	  (II-­‐IV)	  and	  hIRE1	  (II-­‐IV)	  proteins	  with	  untagged	  
CH1	  (lanes	  2-­‐6).	   	  CH1	  only	  binds	  to	  His6-­‐BiP	  FL	  and	  His6-­‐BiP	  SBD.	   	   In	  control	  experiments	  CH1	  only	  was	   incubated	  
with	  TALON	  resin	  (lane	  1).	  	  The	  MW	  (kDa)	  is	  indicated.	  
	   	  
	  
	  










Figure	  7-­‐16.	  hPERK	  (II-­‐IV)	  and	  hIRE1	  (II-­‐IV)	  do	  not	  bind	  BiP	  FL-­‐CH1	  complexes	  
His6-­‐BiP	   FL	  was	   pre-­‐incubated	  with	   untagged	   CH1	   (+	   5	  mM	  ADP,	   10	  mM	  MgCl2)	   to	   from	   BiP	   FL-­‐CH1	   complexes	  
(lanes	   4-­‐7).	   	  Untagged	  hPERK	   (II-­‐IV)	   (lane	  5)	   and	  untagged	  hIRE1	   (II-­‐IV)	   (lane	  7)	  were	   then	   added.	   	   The	   luminal	  
domain	  proteins	  do	  not	  bind	  to	  His6-­‐BiP	  FL	  when	  it	  is	  already	  bound	  to	  CH1.	  	  In	  control	  experiments	  the	  untagged	  
proteins	  only	  were	  incubated	  with	  TALON	  resin	  (lanes	  1-­‐3).	  	  The	  MW	  (kDa)	  is	  indicated.	  
	   	  
	   	  
	  
	  









Figure	  7-­‐17.	  CH1	  promotes	  dissociation	  of	  BiP	  FL-­‐hPERK	  (II-­‐IV)	  and	  BiP	  FL-­‐hIRE1	  (II-­‐IV)	  complexes	  
His6-­‐BiP	  FL	  was	  pre-­‐incubated	  with	  untagged	  hPERK	  (II-­‐IV)	   (lane	  4-­‐5)	  or	  untagged	  hIRE1	  (II-­‐IV)	   (lane	  6-­‐7)	  to	  from	  
His6-­‐BiP	  FL-­‐luminal	  domain	  complexes.	  	  Untagged	  CH1	  (+	  5mM	  ADP,	  10	  mM	  MgCl2)	  was	  then	  added	  (lanes	  5	  and	  
7).	  	  CH1	  actively	  promotes	  the	  release	  of	  the	  luminal	  domain	  proteins	  from	  His6-­‐BiP	  FL.	  	  In	  control	  experiments	  the	  
untagged	  proteins	  only	  were	  incubated	  with	  TALON	  resin	  (lanes	  1-­‐3).	  	  The	  MW	  (kDa)	  is	  indicated.	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7.5 Discussion	  
The	   work	   in	   this	   chapter	   set	   out	   to	   investigate	   the	   interaction	   between	   the	   ER	   Hsp70	  
chaperone	  BiP	  and	  the	  luminal	  domains	  of	  H.	  sapiens	  PERK	  and	  IRE1	  proteins.	  	  The	  main	  aims	  
were	  to	  (i)	  demonstrate	  and	  biochemically	  characterise	  their	   interaction	  and	  (ii)	  understand	  
its	  importance	  in	  the	  activation	  of	  UPR	  signalling	  during	  ER	  stress.	  
To	  this	  end	  hPERK	  and	  hIRE1	  proteins	  were	  purified	  and	  their	  binding	  to	  BiP	  FL	  was	  measured	  
using	  MST	  and	  ITC	  in	  vitro.	  	  hPERK	  and	  hIRE1	  bind	  to	  BiP	  FL	  with	  ∼1-­‐2	  µM	  KD.	  	  This	  is	  the	  first	  
time	  their	  direct	  interaction	  has	  been	  demonstrated	  and	  captured	   in	  vitro.	   	  Low	  micromolar	  
KD	   values	  are	   typical	  of	  weak	  protein-­‐protein	   interactions	   that	  occur	   in	   vivo.	   	   Since	   in	   cells,	  
and	   the	   ER,	   proteins	   are	   present	   at	   low	   micromolar	   concentration	   ranges,	   affinity	   values	  
obtained	   for	   BiP-­‐luminal	   domain	   complexes	   fit	   in	  with	   the	   biology	   of	   this	   interaction.	   	   The	  
dissociation	  of	  BiP	   from	  PERK	  and	   IRE1	  as	  a	  result	  of	  ER	  stress	  has	   long	  been	  recognised	  to	  
activate	  UPR	  signalling	  pathways.	  	  It	  is	  therefore	  important	  that	  this	  interaction	  is	  sufficiently	  
strong	   to	  be	   stable	  during	  physiological	   conditions,	   so	   as	   to	   inhibit	  UPR	   signalling,	   but	   also	  
that	   it	   can	   be	   easily	   disrupted	   by	   stress	   signals	   to	   quickly	   activate	   the	  UPR	   and	   restore	   ER	  
homeostasis.	   	   Given	   a	   2	   µM	   KD,	   it	   is	   reasonable	   to	   speculate	   that	   this	   is	   a	   transient	  
interaction,	  which	  allows	  BiP	  to	  readily	  associate	  and	  dissociate	  from	  PERK	  and	  IRE1.	  
Previous	  studies	  have	  attempted	  to	  understand	  the	  functional	  significance	  of	  the	  sub-­‐regions	  
of	  PERK	  and	  IRE1	  luminal	  domains.	  	  The	  luminal	  domains	  were	  classified	  into	  five	  sub-­‐regions	  
and	   truncation	  proteins	  were	  used	   in	   functional	  assays.	   	  Published	   studies	  have	   found	   that	  
deletion	  of	  region	  V	  of	  PERK	  and	  IRE1	  led	  to	  the	  loss	  of	  association	  with	  BiP	  [85-­‐87].	  	  However	  
there	  has	  been	  ambiguity	  on	  the	  activation	  state	  of	  ΔV	  IRE1	  proteins.	  	  Whilst	  some	  of	  these	  
studies	  reported	  constitutively	  active	  UPR	  signalling,	  another	  found	  that	  this	  had	  no	  effect	  on	  
downstream	  signalling.	   	   Furthermore,	  binding	  of	  BiP	   to	  hIRE1	  proteins	   lacking	   region	  V	  has	  
been	  demonstrated	  [88,89].	   	  Clearly,	  clarification	  of	  the	  role	  of	  the	  sub-­‐domains	  has	  eluded	  
cellular	  studies	  carried	  out	  to	  date.	  	  The	  results	  presented	  in	  this	  chapter	  indicate	  that	  regions	  
II-­‐IV	   of	   hPERK	   and	   hIRE1	   are	   solely	   responsible	   for	   associating	   with	   BiP.	   	   Affinity	   values	  
obtained	   for	   constructs	   encompassing	   the	   complete	   (regions	   I-­‐V)	   luminal	   domains	   were	  
identical	  to	  those	  which	  comprised	  only	  of	  the	  core	  (regions	  II-­‐IV)	  portion.	  	  This	  demonstrates	  
that	   regions	   II-­‐IV	   are	   necessary	   and	   sufficient	   for	   binding	   to	   BiP.	   	   Regions	   I	   and	   V	   are	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dispensable	  for	  the	  direct	  binding	  of	  hPERK	  and	  hIRE1	  to	  BiP.	  	  It	  is	  possible	  that	  the	  truncated	  
proteins	   used	   in	   previous	   studies	  were	   not	   correctly	   folded.	   	   As	   such	   they	  may	   have	   been	  
unable	   to	   accommodate	   binding	   to	   BiP	   or,	   being	   unfolded	   proteins,	  may	   have	   themselves	  
acted	  as	  inducers	  of	  UPR	  activation.	  	  The	  use	  of	  folded	  recombinant	  proteins,	  as	  well	  as	  the	  
measurement	  of	   a	   direct	   interaction	  which	  precludes	   influence	  by	   the	  multitude	  of	   factors	  
which	   influence	   cellular	   experiments,	   successfully	   provided	   a	   tool	   to	   unambiguously	  
determine	  the	  role	  of	  regions	  I	  to	  V	  in	  binding	  to	  BiP.	  	  However	  these	  results	  do	  not	  elucidate	  
the	   correlation	   between	   the	   association/dissociation	   of	   BiP	   with	   the	   luminal	   domains	   and	  
UPR	  signalling.	  
The	  interaction	  of	  the	  luminal	  domain	  proteins	  was	  further	  mapped	  specifically	  to	  BiP’s	  NBD;	  
no	  binding	  to	  BiP	  SBD	  was	  measured.	  	  The	  affinity	  of	  hPERK	  and	  hIRE1	  binding	  to	  BiP	  NBD	  is	  in	  
the	  same	  range	  as	  that	  measured	  for	  binding	  to	  BiP	  FL.	   	  These	  results	  show	  that	  BiP	  NBD	  is	  
indispensable	  for	  binding	  to	  the	  luminal	  domains	  of	  PERK	  and	  IRE1.	  	  BiP	  NBD	  interaction	  with	  
a	   substrate	   domain	   is	   unprecedented	   for	   Hsp70s.	   	   This	   result	   demonstrates	   that	   this	   is	   a	  
specific	   and	   functional	   protein-­‐protein	   interaction	   rather	   than	   a	   chaperone-­‐substrate	  
interaction,	   for	  which	  binding	  to	  BiP	  SBD	  would	  be	  observed.	   	  This	  had	  eluded	  many	  of	  the	  
cellular	   based	   experiments	   of	   previous	   studies.	   	   Furthermore,	   the	   affinity	   of	   BiP	   FL	   for	   the	  
luminal	   domain	   proteins	   was	   not	   affected	   by	   the	   presence	   of	   ATP,	   ADP	   or	   AMPPNP	  
nucleotides.	  	  The	  ATP-­‐ADP	  cycle	  of	  BiP	  is	  known	  to	  be	  key	  for	  its	  chaperoning	  function.	  	  Here	  
BiP’s	  ATPase	  activity	  was	  uncoupled	  from	  its	  function	  in	  binding	  PERK	  and	  IRE1.	  	  This	  further	  
emphasizes	   that	   it	   is	   a	   specific	   UPR	   signalling	   relevant	   interaction	   rather	   than	   a	   general	  
Hsp70-­‐substrate	  chaperoning	  one.	  
PERK	  and	  IRE1	  have	  a	  distinct	  BiP	  binding	  site	  to	  that	  of	  unfolded	  proteins,	  which	  are	  known	  
to	  bind	  to	  BiP	  SBD.	  	  As	  such,	  a	  different	  functionality	  of	  these	  interactions	  can	  be	  proposed.	  	  
Whereas	  unfolded	  proteins	  target	  BiP’s	  chaperoning	  activity,	  BiP-­‐luminal	  domain	  complexes	  
probably	   play	   a	   role	   in	   ER	   stress	   sensing.	   	   This	   hypothesis	   was	   tested	   by	   using	   unfolded	  
proteins	  to	  probe	  BiP-­‐PERK	  and	  BiP-­‐IRE1	  complexes.	  	  	  
In	  a	  first	  instance,	  the	  intrinsically	  unfolded	  protein	  CH1	  was	  used.	  	  CH1	  bound	  exclusively	  to	  
BiP	  SBD	  with	  similar	  affinity	  to	  that	  obtained	  in	  published	  studies	  [22-­‐26].	  	  No	  binding	  to	  BiP	  
NBD	  or	   to	   the	   luminal	   domain	  proteins	  was	  observed.	   	   CH1	  was	  used	   as	   a	   BiP	   SBD-­‐specific	  
	   	  
	  
	  
	   205	  
authentic	   unfolded	   substrate	   to	   study	   its	   effect	   on	   the	   interaction	   between	   BiP	   and	   the	  
luminal	  domain	  proteins.	   	  Strikingly,	  the	  luminal	  domains	  were	  unable	  of	  binding	  to	  BiP-­‐CH1	  
complexes.	   	  Moreover,	  CH1	  was	   capable	  of	  dissociating	  already	   formed	  BiP-­‐luminal	  domain	  
complexes.	   	  Clearly	  the	  binding	  of	  the	   luminal	  domain	  proteins	  and	  CH1	  to	  BiP	  are	  mutually	  
exclusive.	  	  This	  confirms	  a	  negative	  regulatory	  role	  for	  unfolded	  proteins	  in	  the	  association	  of	  
BiP	   with	   PERK	   and	   IRE1	   luminal	   domains.	   	   The	   data	   presented	   supports	   a	   BiP-­‐dependent	  
mechanism	  of	  mammalian	  ER	  stress	  sensing	  by	  PERK	  and	  IRE1.	  
Similarly,	  ΔEspP,	   an	   SPR-­‐derived	   peptide	   that	   has	   been	   used	   as	   an	   IRE1p-­‐specific	   unfolded	  
protein	   mimic,	   was	   used	   to	   probe	   the	   BiP-­‐independent/direct	   unfolded	   protein	   binding	  
mechanism	  of	  ER	  stress	  sensing.	   	  ΔEspP	  bound	  exclusively	  to	  hPERK	  and	  hIRE1	  proteins;	  no	  
binding	   to	   BiP	   proteins	  was	   observed.	   	   However,	   in	   contrast	   to	   previously	   published	   data,	  
ΔEspP	  did	  not	  induce	  higher	  oligomer	  formation	  of	  the	  luminal	  domains.	  	  Additionally,	  ΔEspP	  
did	  not	  affect	  BiP-­‐luminal	  domain	  complexes.	  	  Since	  BiP	  is	  known	  to	  repress	  signalling	  when	  it	  
is	  bound	  to	  PERK	  and	  IRE1,	  even	  if	  ΔEspP	  does	  bind	  to	  the	  luminal	  domains,	  this	  is	  probably	  
not	   sufficient	   to	   activate	   UPR	   signalling	   during	   conditions	   of	   ER	   stress.	   	   Together,	   these	  
results	   point	   away	   from	   a	   BiP-­‐independent	   ER	   stress	   sensing	   mechanism,	   at	   least	   for	   the	  
mammalian	  system.	  	  
This	   study	   makes	   a	   significant	   contribution	   to	   the	   mechanistic	   understanding	   of	   BiP-­‐
dependent	  ER	  stress	  sensing	  by	  the	   luminal	  domains	  of	  hPERK	  and	  hIRE1.	   	   In	  summary,	  the	  
direct	   and	   unprecedented	   interaction	   between	  BiP	  NBD	   and	   the	   core	   region	   of	   hPERK	   and	  
hIRE1	  luminal	  domains	  was	  demonstrated.	  	  This	  interaction	  is	  not	  affected	  by	  nucleotides	  and	  
there	   is	   no	   contribution	   from	   BiP	   SBD.	   	   Together	   these	   results	   emphasize	   that	   this	   is	   a	  
genuine	   protein-­‐protein	   interaction	   rather	   than	   a	   chaperone-­‐substrate	   interaction.	   	   In	   the	  
presence	  of	  an	  authentic	  unfolded	  protein,	  which	  binds	  solely	  to	  BiP	  SBD,	  BiP-­‐luminal	  domain	  
complexes	  actively	  dissociate.	  
These	   results	   support	   an	   elegant	  model	  whereby	   BiP	   normally	   represses	   UPR	   signalling	   by	  
interacting	  with	  the	  luminal	  domains	  of	  the	  sensor	  proteins	  via	  its	  NBD.	  	  Binding	  of	  unfolded	  
proteins	   to	   BiP	   SBD	   leads	   to	   dissociation	   of	   these	   complexes.	   	   BiP	   is	   known	   to	   undergo	  
conformational	   cycling	   upon	   binding	   to	   and	   dissociating	   from	   unfolded	   proteins,	   and	  
specifically	  CH1.	   	  The	   luminal	  domain	  proteins	  bind	   to	  BiP	  only	  when	   it	   is	  not	  bound	   to	  CH1	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substrate.	   	   CH1	   binding	   to	   BiP	   causes	   dissociation	   of	   the	   luminal	   domains.	   	   Although	   no	  
definite	  conclusion	  can	  be	  made	  from	  the	  results	  carried	  out	   in	   this	  work,	  an	  allosteric	  BiP-­‐
dependent	  mechanism	  of	  ER	   stress	   sensing	  and	  UPR	  activation	  could	  be	   speculated	   (Figure	  
7-­‐18).	  	  	  
In	  the	  absence	  of	  substrate,	  BiP	  NBD	  adopts	  a	  conformation	  where	  its	  NBD	  Lobes	  IA	  and	  IIA	  
divide	  to	  create	  a	  hydrophobic	  cleft	  where	  the	  interdomain	  linker	  can	  bind.	  	  This	  also	  leads	  to	  
docking	  of	  the	  SBD-­‐α	  lid	  onto	  the	  NBD.	  	  Separation	  of	  SBD-­‐α	  and	  SBD-­‐β	  results	  in	  an	  open	  lid	  
conformation	   and	   confers	   low	   substrate	   affinity.	   	   During	   physiological	   conditions,	   the	  
luminals	   bind	   to	   susbtrate-­‐free	   BiP	   and	   maintain	   it	   in	   the	   open	   lid	   conformation/low	  
substrate	  affinity	  conformation.	  	  During	  ER	  stress,	  binding	  of	  unfolded	  substrates	  to	  BiP	  SBD	  
leads	   to	   a	   conformational	   change,	  which	   consists	   of	   	   ‘closing’	   of	   the	   SBD-­‐α	   lid	   to	   trap	   the	  
substrate	  between	  SBD-­‐α	  and	  SBD-­‐β.	   	  Substrate	  binding	  to	   the	  SBD	  of	  BiP	   is	  also	  known	  to	  
lead	   to	  conformational	   changes	   in	   the	  NBD.	   	  The	  NBD	  could	   thus	  become	  unfavourable	   for	  
binding	   to	   the	   luminal	   domain	   proteins	   and	   cause	   the	   BiP-­‐luminal	   domain	   complexes	  
dissociate.	  	  	  
Addition	  of	  different	  nucleotides	  had	  no	  effect	  on	  binding	  of	  BiP	  to	  hPERK	  and	  hIRE1.	  	  This	  fits	  
in	  biologically	   in	   that	  depletion	  of	  ATP	   in	   the	   ER	   lumen	   is	   not	   sufficient	   to	  breakdown	  BiP-­‐
luminal	   domains	   that	   would	   result	   in	   UPR	   signalling.	   	   Rather,	   the	   presence	   of	   unfolded	  
proteins	  is	  critical	  for	  this	  key	  activation	  step.	  	  
Further	   studies	   will	   be	   essential	   to	   fully	   appreciate	   (i)	   the	   interaction	   of	   BiP-­‐NBD	   and	   the	  
luminal	  domains	  of	  hPERK	  and	  hIRE1	  and	  (ii)	  the	  precise	  mechanism	  by	  which	  CH1	  promotes	  
dissociation	   of	   these	   complexes.	   	   More	   extensive	   screening	   using	   hPERK,	   hIRE1	   and	   BiP	  
truncations	   or	  mutant	   proteins	  will	   be	   essential	   to	  map	   the	   precise	   location	   and	  nature	   of	  
their	   interaction	   surface.	   	   Obtaining	   the	   crystal	   structure	   of	   the	   complexes	   will	   reveal	  
invaluable	   information	   to	   not	   only	   appreciate	   how	   the	   complexes	   physically	   form	   but	   also	  
how	   this	   relates	   to	   their	   biological	   role.	   	   It	   would	   allow	   for	   answering	   of	   the	   fundamental	  
question	  of	  how	  does	  binding	  of	  BiP	  repress	  activation	  of	  the	  luminal	  domains.	  	  For	  instance	  
is	   it	   a	   steric	   hindrance	   of	   regions	   on	   the	   luminal	   domain	   proteins	   that	   is	   important	   for	  
activation,	   or	   do	   the	   luminal	   domains	   undergo	   a	   conformational/oligomeric	   state	   change	  
upon	   binding	   to	   BiP?	   	   Additionally,	   spFRET	   and	   NMR	   studies	   could	   be	   used	   to	   study	   the	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movement	  of	  BiP	  and	  the	  luminal	  domains	  during	  complex	  dissociation.	  	  This	  would	  allow	  for	  
a	  clearer	  and	  definitive	  understanding	  of	  the	  mechanism	  of	  how	  CH1,	  or	  more	  generally	  the	  
presence	  of	  unfolded	  proteins,	  leads	  to	  dissociation	  of	  BiP	  from	  the	  luminal	  domains.	  	  	  
To	  highlight	   the	  biological	   significance	  of	   the	   findings	  by	   this	   study,	   functional	   experiments	  
using	   full-­‐length	  hPERK	  and	  hIRE1,	  or	   transfected	   cells,	   to	  measure	   autophosphorylation	  of	  
their	  cytoplasmic,	  eIF2α	  phosphorylation	  and	  splicing	  of	  xbp1	  mRNA	  as	  appropriate	  should	  be	  
carried	  out.	  	  Furthermore,	  this	  study	  could	  be	  extended	  to	  ATF6	  as	  well	  as	  IRE1p	  to	  examine	  if	  
this	   is	   a	   global	   mechanism	   of	   ER	   stress	   sensing	   and	   UPR	   activation	   or	   just	   specific	   to	  
mammalian	  PERK	  and	  IRE1	  pathways.	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Figure	  7-­‐18.	  Model	  for	  BiP-­‐dependent	  ER	  stress	  sensing	  by	  PERK	  and	  IRE1	  luminal	  domains	  
(A)	   In	   physiological	   conditions,	   BiP,	   via	   its	   NBD,	   is	   normally	   bound	   to	   the	   luminal	   domains	   of	   PERK	   and	   IRE1	  
thereby	  repressing	  them.	  
(B)	  ER	  stress	  leads	  to	  the	  accumulation	  of	  misfolded	  proteins	  in	  the	  ER	  lumen.	  
(C)	  Misfolded	  proteins	  bind	  to	  BiP	  SBD	  which	  initiates	  a	  global	  conformational	  change	  in	  BiP.	  	  This	  leads	  to	  ‘closing’	  
of	  the	  SBD-­‐α	  lid	  and	  rearrangement	  of	  the	  NBD.	  
(D)	  In	  the	  susbtrate-­‐bound	  state,	  BiP	  NBD	  exists	  in	  a	  conformation	  which	  is	  unfavourable	  for	  binding	  to	  the	  luminal	  
domains	  of	  PERK	  and	  IRE1	  and	  as	  such	  dissociates.	   	  PERK	  and	  IRE1	  are	  no	   longer	  repressed	  by	  BiP	  and	  thus	  can	  
mediate	  downstream	  UPR	  signalling.	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8 Conclusion	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8.1 Overview	  of	  findings	  
Over	   the	   last	   two	  decades	   the	  mechanisms	  underlying	  UPR	   signalling	  have	  been	   studied	   in	  
great	  detail	  in	  vivo.	  	  Research	  has	  focused	  on	  elucidating	  two	  major	  events:	  ER	  stress	  sensing	  
(ER	  luminal)	  and	  UPR	  signal	  transduction	  (cytosolic).	  	  Despite	  the	  considerable	  effort	  that	  has	  
been	   put	   into	   these	   fields,	   their	   definitive	   molecular	   mechanisms	   have	   not	   yet	   been	  
established.	   	  The	  work	  presented	   in	  this	   thesis	  provides	  evidence	  of	   (i)	  a	   functional	   role	   for	  
the	   tetrameric	   assembly	   of	   PERK	   (Chapter	   6)	   and	   (ii)	   an	   allosteric	   mechanism	   of	   BiP-­‐
dependent	  ER	  stress	  sensing	  (Chapter	  7).	  
Firstly,	   the	   structure	   of	   PERK	   luminal	   domain	   is	   described	   (Chapter	   6).	   	   The	   dimeric	   and	  
tetrameric	  assemblies	  of	  PERK	  luminal	  domain	  were	  solved	  and	  these	  can	  help	  enlighten	  our	  
understanding	  of	  UPR	  signalling.	  	  Of	  major	  importance	  is	  the	  identification	  of	  Interface	  2.	  	  Its	  
hydrophobic	   nature	   mediates	   interchanging	   of	   the	   C-­‐terminal	   α-­‐helices	   between	   two	  
interacting	  dimers	  to	  form	  stable	  tetramers.	  	  These	  are	  also	  present	  in	  solution	  and	  are	  likely	  
to	  play	  a	  functional	  role.	  	  To	  date,	  the	  oligomeric	  state	  of	  active	  and	  inactive	  PERK	  and	  IRE1	  
has	   not	   been	   conclusively	   established.	   	   Based	   on	   published	   data	   and	   the	   results	   obtained	  
from	  the	  structure	  of	  PERK	  luminal	  domain,	  two	  possible	  scenarios	  can	  be	  envisaged.	   	  PERK	  
may	  exist	  as	  inactive	  monomers	  and	  active	  dimers	  and	  tetramers,	  each	  of	  which	  represents	  a	  
differently	   activated	   state.	   	   Alternatively,	   they	  may	   function	   as	   inactive	   dimers	   and	   active	  
tetramers.	  	  Further	  experiments	  will	  be	  key	  to	  elucidate	  this.	  
Secondly,	   by	   dissecting	   the	   complex	   pathway	   of	   ER	   stress	   sensing,	   an	   elegant	   and	   novel	  
allosteric	  mechanism	   is	   presented	   (Chapter	   7).	   	  Normally,	   BiP	  NBD	   is	   bound	   to	   the	   luminal	  
domains	  of	  PERK	  and	  IRE1.	   	   It	  has	  been	  well	  established	  that	  when	  BiP	  is	  bound	  to	  the	  UPR	  
sensor	  proteins,	   their	  activation	   is	   repressed	  [76,81,82].	   	  During	  ER	  stress,	  unfolded	  protein	  
binding	  to	  BiP	  SBD	  leads	  to	  dissociation	  of	  BiP	  NBD	  from	  the	  luminal	  domains	  PERK	  and	  IRE1	  
and	   alleviates	   their	   inhibition.	   	   These	   unconventional	   events	   have	   never	   been	   previously	  
demonstrated	  and	  will	  be	  of	  major	  impact	  in	  the	  UPR	  field.	  	  However,	  how	  the	  release	  of	  BiP	  
dissociation	  leads	  to	  activation	  of	  downstream	  UPR	  signalling	  remains	  unexplained.	  	  	  
Although	   these	   results	   have	   been	   thoroughly	   discussed	   in	   their	   respective	   chapters,	   the	  
relationship	   between	   the	   two	   findings	   has	   not	   yet	   been	   examined.	   	   By	   taking	   them	   into	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consideration	  together	  a	  more	  comprehensive	  understanding	  of	  their	  important	  contribution	  
to	  the	  UPR	  field	  can	  be	  appreciated.	  	  	  
A	   scenario	   in	  which	  BiP	  NBD	  binds	   to	   inactive	  dimers	  of	  PERK	  and	   IRE1	   luminal	  domains	   to	  
inhibit	   the	   formation	   of	   active	   tetramers	   can	   be	   proposed	   (Figure	   8-­‐1A).	   	   Analysis	   of	   the	  
electrostatic	   potential	   of	   PERK	   luminal	   domain	   reveals	   that	   the	   surface,	   which	   is	   inwards	  
facing	   in	  the	  tetramer	  assembly,	  has	  a	  strong	  negative	  charge	  (Figure	  8-­‐1B).	   	  This	  surface	   is	  
solvent	   exposed	   in	   dimers.	   	   The	  outer	   surface	  of	   the	  protein	   is	  mostly	   uncharged.	   	  On	   the	  
other	  hand,	  BiP	  NBD	  has	  a	  positively	  charged	  solvent	  exposed	  patch.	   	  The	  complementarily	  
between	   these	   two	   surfaces	  makes	   them	   ideal	   binding	   partners	   in	   vivo.	   	   As	   such,	   BiP	  NBD	  
binding	   to	   the	   inner	   PERK	   luminal	   domain	   face	   would	   sterically	   hinder	   the	   formation	   of	  
tetramers.	   	   As	   such	   two	   PERK	   dimers	   would	   be	   able	   to	   come	   together	   to	   form	   active	  
tetramers	  only	  once	  BiP	  is	  released	  and	  PERK’s	  inner	  face	  is	  not	  obstructed.	  
Further	  work	  will	  be	  key	  to	  reliably	  draw	  conclusions	  on	  the	  mechanism	  by	  which	  ER	  stress	  
signals	   result	   in	   active	   UPR	   signalling.	   	   For	   instance	   to	   verify	   whether	   BiP	   inhibits	  
tetramerisation	   of	   PERK	   and	   IRE1,	   mutational	   analysis	   or	   spFRET	   experiments	   could	   be	  
carried	   out	   both	   in	   vitro	  and	   in	   vivo.	   	   Furthermore,	   obtaining	   a	   structure	   of	   BiP-­‐PERK/IRE1	  
luminal	   domains	   would	   significantly	   broaden	   the	   understating	   of	   UPR	   activation	   at	   atomic	  
detail.	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Figure	  8-­‐1.	  A	  proposed	  model	  for	  BiP-­‐dependent	  initiation	  of	  UPR	  signalling	  by	  steric	  hindrance	  of	  active	  PERK	  
and	  IRE1	  tetramer	  formation	  
(A)	  (i)	  Normally	  BiP	  NBD	  is	  associated	  with	  the	  luminal	  domains	  of	  inactive	  PERK	  and	  IRE1	  dimers.	  	  (ii)	  During	  ER	  
stress,	  the	  accumulating	  misfolded	  proteins	  bind	  to	  BiP	  SBD.	  	  This	  results	  in	  a	  global	  conformational	  change	  in	  BiP	  
that	   is	   unfavourable	   for	   binding	   to	   the	   luminal	   domains	   of	   PERK	   and	   IRE1.	   	   The	   dissociation	   of	   BiP	   relieves	   its	  
physical	  hindrance	  and	  permits	  PERK	  and	  IRE1	  active	  tetramers	  to	  form.	  
(B)	  Electrostatic	  potential	  of	  the	  surface	  of	  (i)	  dimeric	  PERK	  (Chapter	  6)	  and	  (ii)	  BIP	  NBD	  (PDB:	  3LDL)	  [45].	  	  These	  
structures	  are	  oppositely	  charged	  and	  thus	  could	  represent	  the	  interacting	  surfaces	  between	  PERK	  luminal	  domain	  
and	  BiP	  NBD.	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8.2 Implications	  for	  the	  UPR	  field	  and	  protein	  misfolding	  
disorders	  
The	  UPR	  is	  the	  major	  mechanism	  by	  which	  cells	  respond	  to	  ER	  stress.	  	  UPR	  signalling	  aims	  to	  
adapt	   the	   cells	   to	   handle	   the	   unfolded	   protein	   load	   and	   restore	   ER	   homeostasis.	   	   If	   the	  
damage	   is	   too	   severe,	   apoptotic	   pathways	   are	   activated	   instead.	   	   Impaired	   ER	   and	   UPR	  
function	   has	   been	   linked	   to	   many	   disease	   states	   including	   diabetes,	   cancer	   and	  
neurodegenerative	   disorders.	   	   Gaining	   a	   detailed	   understanding	   of	   how	   UPR	   signalling	   is	  
activated	  has	  important	  therapeutic	  potential.	  	  	  
The	   pharmacological	   modulation	   of	   UPR	   signalling	   has	   led	   to	   successful	   drugs	   against	  
important	   pathologies	   such	   as	   cancers,	   mainly	   multiple	   myeloma,	   neurodegenerative	  
diseases,	   diabetes,	   obesity,	   glaucoma	   and	   ischemia.	   	   Similarly	   ‘chaperone	   addiction’,	  
including	  that	  of	  BiP,	  in	  tumour	  cells	  has	  been	  important	  drug	  target	  [150].	  
Discovery	  of	  the	  unconventional	  model	  of	  BiP-­‐dependent	  ER	  stress	  sensing,	  and	  appreciation	  
of	   the	  precise	   role	  of	  BiP	   sub-­‐domains	   in	   the	  UPR,	   can	  be	  exploited	   for	  extremely	   targeted	  
drug	  design	  in	  cancers.	  	  Inhibition	  of	  BiP	  SBD	  would	  reduce	  the	  folding	  efficiency	  of	  the	  cell,	  
thus	  more	   quickly	   result	   in	   the	   lethal	   accumulation	   of	   unfolded	   proteins.	   	   In	   addition,	   this	  
would	  ensure	  that	  BiP	  NBD	  remains	  functional	  and	  thus	  successfully	  represses	  UPR	  signalling	  
by	   PERK	   and	   IRE1.	   	   This	   prevents	   the	   activation	   of	   resolving	   UPR	   pathways,	   which	   may	  
otherwise	   serve	   as	   a	   negative	   feedback	   loop	   to	   alleviate	   ER	   stress.	   	   Together,	   this	   would	  
quickly	   drive	   the	   cell	   towards	   apoptotic	   pathways.	   	   In	   a	   similar	   fashion,	   inhibiting	   BiP	  NBD	  
binding	   to	   the	   luminal	   domains	   PERK	   and	   IRE1	  would	   allow	   for	   constitutive	  UPR	   activation	  
and	   more	   efficient	   removal	   of	   unfolded	   protein	   aggregates	   that	   cause	   many	   of	   the	  
pathologies	  mentioned	  above.	  
The	   novel	   X-­‐ray	   structure	   of	   PERK	   luminal	   domain	   has	   shed	   light	   on	   biologically	   important	  
tetramers.	   	   Based	  on	   it,	   novel	   compounds	   that	   can	  modulate	  activation	  of	  PERK,	   and	   IRE1,	  
independently	   of	   ER	   stress	   could	   be	   designed.	   	   These	   would	   allow	   for	   the	   chemical	  
manipulation	  of	  UPR	  signalling	  independently	  of	  exogenous	  environmental	  signals.	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The	   discovery	   of	   the	   effect	   of	   protein	   misfolding,	   ER	   stress	   and	   the	   UPR	   is	   ongoing.	   	   The	  
findings	  of	  this	  thesis	  will	  clearly	  be	  of	  interest	  and	  beneficial	  for	  scientists	  in	  the	  filed.	  	  They	  
will	  also	  importantly	  provide	  powerful	  tools	  for	  the	  therapeutic	  exploitation	  of	  the	  UPR.	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Table	  10-­‐1.	  Cloning	  of	  PERK,	  IRE1,	  BiP	  and	  CH1	  proteins	  
The	  complete	  sequence	  of	  primers	  used	  for	  the	  cloning	  of	  PERK,	  IRE1,	  BiP	  and	  CH1	  proteins	  are	  shown	  (continued	  
on	  next	  page).	   	  The	  position	  (♯)	  of	   the	  5’	  N-­‐terminal	  starting	  residue,	   for	   forward	  (F)	  primers,	  and	  3’	  C-­‐terminal	  
ending	  residue,	  for	  reverse	  (R)	  primers,	  are	  indicated.	  	  Restriction	  enzymes	  used	  for	  cloning	  are	  listed.	  	  For	  primers	  
used	   for	   site-­‐directed	  mutagenesis,	   the	   target	  mutation	   residue	  and	  amino	  acid	   changes	  are	   indicated	   in	   the	  ♯	  
column.	  
	   	  
	  
	  





(continued	  from	  previous	  page)	  
	   	  
	   	  
	  
	  







Table	  10-­‐2.	  hPERK	  (II-­‐IV)	  condition	  A	  crystals	  heavy	  atom	  datasets	  
The	   total	   and	   anomalous	   outer	   resolution	   limit	   (NA	   indicates	   none	   measured),	   isomorphism	   between	   the	  
derivative	  and	  native	  datasets	  (yes	  (Y)	  or	  no	  (N))	  are	  summarised.	  	  The	  results	  are	  categorized	  into	  three	  groups:	  
(i)	  no	  heavy	  atom	  binding,	  (ii)	  binding	  but	  not	  adequate	  diffraction	  or	  (iii)	  binding	  and	  diffraction.	  	  
	   	  
	  
	  








Table	  10-­‐3.	  mPERK	  (II-­‐IV)	  condition	  D	  crystals	  heavy	  atom	  datasets	  
The	   total	   and	   anomalous	   outer	   resolution	   limit	   (NA	   indicates	   none	   measured),	   isomorphism	   between	   the	  
derivative	  and	  native	  datasets	  (yes	  (Y)	  or	  no	  (N))	  are	  summarised.	  	  The	  results	  are	  categorized	  into	  three	  groups:	  
(i)	  no	  heavy	  atom	  binding,	  (ii)	  binding	  but	  not	  adequate	  diffraction	  or	  (iii)	  binding	  and	  diffraction.	  	   	  
	   	  
	  
	  









Table	  10-­‐4.	  Hydrogen	  bonding	  of	  PERK	  luminal	  domain	  Interface	  1	  and	  2	  
The	  atoms	   involved	   in	   the	  dimerisation	   Interface	  1	  and	   tetramerisation	   Interface	  2	  of	  PERK	   luminal	  domain	  are	  
listed.	  	  Distances	  are	  given	  in	  Å.	  
	   	  
	   	  
	  
	  













Figure	  10-­‐1.	  pTWO-­‐E	  and	  pET-­‐26b	  plasmid	  maps	  
The	  pTWO-­‐E	  and	  pET-­‐26b	  plasmids	  used	   for	   cloning	  are	   illustrated.	   	   Each	   contains	   an	  origin	  of	   replication	   (Ori)	  
(red),	   lacI	   gene	   (green)	   and	   T7	  promoter	   (orange)	   region	   that	   allow	   for	   IPTG-­‐controlled	   expression	  of	   the	   gene	  
inserted	  at	  the	  multiple	  cloning	  site	  (blue).	  	  The	  His6-­‐tag,	  PreScission	  protease	  cleavage	  site	  (PreSc)	  and	  restriction	  
enzyme	   sites	   present	   in	   the	  multiple	   cloning	   sites	   are	   indicated.	   	   Their	   antibiotic	   resistance	   genes	   (purple)	   are	  
shown.	  
	   	  
	  
	  







Figure	  10-­‐2.	  Calibration	  of	  HiLoad	  16/60	  Superdex	  200	  column	  
(A)	   Thyroglobulin	   (1),	   apoferretin	   (2),	   β-­‐amylase	   (3),	   alcohol	   dehydrogenase	   (4),	   albumin	   (5)	   and	   carbonic	  
anhydrase	  (6)	  proteins	  were	  run	  on	  a	  HiLoad	  16/60	  Superdex	  200	  column.	  	  Their	  MW	  (kDa)	  and	  elution	  volumes	  
(Ve)	  are	   indicated.	   	  V0	  was	  obtained	  separately	   from	  the	  elution	  of	  Blue	  Dextran	   in	   the	  HiLoad	  16/60	  Superdex	  
200	  column.	  	  V0/Ve	  values	  used	  to	  plot	  the	  calibration	  curve	  are	  shown.	  	  	  
(B)	  V0/Ve	  values	  were	  plotted	  against	  log	  MW	  and	  a	  nonlinear	  regression	  line	  was	  fitted.	  	  The	  resulting	  function	  (y	  
=	   0.127ln(x)	   –	   0.7681)	  was	   used	   to	   estimate	  MW	   of	   samples	   from	   their	   elution	   volumes	   on	   the	   HiLoad	   16/60	  
Superdex	  200	  column.	  
	   	  
	  
	  





Figure	  10-­‐3.	  PERK	  and	  IRE1	  luminal	  domain	  sequence	  and	  secondary	  structure	  alignment	  
The	  sequences	  of	  hPERK	  (magenta),	  mPERK,	  dPERK,	  hIRE1	  (blue),	  mIRE1	  and	  IRE1p	  luminal	  domains	  were	  aligned	  
using	   the	   T-­‐coffee	   server.	   	   Residues	   are	   coloured	   according	   to	   conservation	   (red	   for	  100%	   identical;	   yellow	   for	  
>70%	   similarity).	   	   The	   known	   structural	   features	   of	   hIRE1	   luminal	   domain	   (PDB:	   2HZ6)	   are	   shown,	   and	   named	  
according	  to	  the	  published	  structure,	  at	  the	  top	  (blue)	  [95].	  	  The	  secondary	  structure	  of	  hPERK	  luminal	  domain	  was	  
predicted	  using	  Jpred3	  and	  is	  also	  shown	  (red).	  
	   	  
	  
	  







Figure	  10-­‐4.	  hPERK	  luminal	  domain	  disorder	  prediction	  
(A)	  The	  complete	  hPERK	  luminal	  domain	  sequence	  (1-­‐510)	  was	  analysed	  using	  RONN	  software	  to	  predict	  protein	  
disorder.	  	  A	  probability	  of	  disorder	  >0.5	  suggests	  disorder.	  	  	  
(B)	   hPERK	   sequence	   and	   disorder	   prediction	   for	   each	   residue	   is	   shown.	   	   ‘*’	   indicates	   disordered	   residues;	   ‘_’	  
indicates	  ordered	  residues.	   	  The	  major	  disordered	  portion	   is	   suggested	  to	  be	   the	  N-­‐terminal	   region	   (residues	  1-­‐
103).	  
	  
	   	  
	  
	  





Figure	  10-­‐5.	  Wilson	  Plot	  of	  hPERK	  (II-­‐IV)	  Condition	  A	  crystals	  diffraction	  data	  
(A-­‐B)	  The	  Wilson	  Plot	  of	  hPERK	  (II-­‐IV)	  Condition	  A	  crystals	  collected	  on	  crystals	  (A)	  without	  cryoprotection	  and	  (B)	  
after	  gradual	  dehydration	  over	  a	  final	  40%	  w/v	  PEG3500.	  
	   	  
	   	  
	  
	  






Figure	  10-­‐6.	  hPERK	  (II-­‐IV)	  and	  mPERK	  (II-­‐IV)	  SeMet	  incorporation	  
(A-­‐B)	   MALDI-­‐TOF	   analysis	   of	   (A)	   SeMet	   hPERK	   (II-­‐IV)	   and	   (B)	   SeMet	   mPERK	   (II-­‐IV)	   purified	   samples.	   	   Peaks	  
represent	  multiple	  charge	  states	  of	  component	  peptides;	  numbers	  indicate	  the	  charge	  state.	  	  The	  mass	  (Da)	  was	  
calculated	  using	   the	   equation:	  mass	   (Da)	   =	   (m/z	   value	   x	   charge	   state)	   –	   charge	   state.	   	   SeMet	  hPERK	   (II-­‐IV)	   and	  
SeMet	  mPERK	  (II-­‐IV)	  protein	  masses	  were	  34431	  and	  34221	  Da	  respectively.	   	  These	  indicate	  the	  presence	  of	  7.5	  
and	  6.9	  Se	  atoms	  per	  protein	  that	  corresponds	  to	  94%	  and	  99%	  SeMet	  incorporation	  respectively.	  
	   	  
	  
	  





Figure	  10-­‐7.	  hPERK	  (II-­‐IV)	  heavy	  atom	  binding	  	  
hPERK	   (II-­‐IV)	   was	   mixed	   with	   heavy	   atoms	   and	   samples	   were	   analysed	   on	   a	   native	   gel	   (3-­‐8%	   Tris-­‐Acetate).	  	  
Numbers	  at	  the	  top	  of	  the	  lanes	  refer	  to	  the	  heavy	  atom	  type	  (legend	  on	  the	  left).	  	  A	  significant	  shift	  was	  observed	  
for	  hPERK	  (II-­‐IV)	  in	  the	  presence	  of	  sodium	  tungstate	  dihydrate	  (lane	  15)	  compared	  to	  the	  native	  sample	  (lane	  1).	  
	   	  
	  
	  






Figure	  10-­‐8.	  Location	  of	  Na2WO4	  heavy	  atom	  sites	  
(A)	  CCall	  versus	  CCweak	  plot	  of	  MAD	  dataset	  processing	  using	  ShelxD.	  	  Correct	  solutions	  are	  clustered	  at	  high	  CCall	  
ad	  CCweak	  values.	  
(B)	  FoFc	  difference	  map	  of	  hPERK	  (II-­‐IV)	  data.	   	  A	  large	  positive	  density	  (green)	  is	  observed	  at	  the	  site	  of	  Na2WO4	  
(red).	  	  Binding	  is	  mainly	  coordinated	  by	  Trp165	  residue.	  	  Trp165	  distance	  (Å)	  to	  W	  atom	  is	  shown.	   	  
	   	  
	  
	  










Figure	  10-­‐9.	  Comparison	  of	  PERK	  and	  IRE1	  luminal	  domain	  structures	  
(A-­‐B)	  The	  crystal	  structure	  of	  H.	  sapiens	  PERK	  luminal	  domain	  (blue)	  is	  aligned	  to	  that	  of	  (A)	  H.	  sapiens	  IRE1	  (PDB:	  
2HZ6)	   (cyan)	   and	   (B)	   S.	   cerevisiae	   IRE1	   (PDB:	   2BE1)	   (purple)	   [95,101].	   	   Structures	   are	   shown	   as	   ribbons.	   	   The	  
central	  core	  portions,	  which	  include	  dimerisation	  Interface	  1,	  are	  almost	  identical.	  	  The	  most	  marked	  differences	  
occur	  in	  the	  outer	  regions	  (Lobe	  1	  and	  Lobe	  2),	  especially	  near	  the	  C-­‐terminal	  α-­‐helix.	  
	   	  
	   	  
	  
	  





Figure	  10-­‐10.	  PERK	  and	  IRE1	  structure	  alignment	  
The	  sequences	  of	  H.	  sapiens	  PERK	  (purple),	  H.	  sapiens	  IRE1	  (blue)	  and	  S.	  cerevisiae	  IRE1	  (red)	  were	  aligned	  based	  
on	  their	  secondary	  structures.	  	  Their	  overall	  features	  are	  similar,	  especially	  between	  the	  H.	  sapiens	  proteins.	  	   	  
	   	  
	  
	  











Figure	  10-­‐11.	  BiP	  and	  ΔEspP	  heat	  of	  dilution	  in	  ITC	  experiments	  
(A)	  BiP	  (500	  μM)	  was	  titrated	  into	  buffer	  K.	  	  The	  resulting	  isotherm	  was	  integrated	  and	  fitted	  with	  a	  straight	  line	  to	  
calculate	  the	  heat	  of	  dilution.	  	  A	  constant	  value	  of	  5.8	  kcal/mol	  was	  obtained.	  
(B)	  ΔEspP	  (500μM)	  was	  titrated	  into	  buffer	  K.	  	  The	  resulting	  isotherm	  was	  integrated	  and	  fitted	  with	  a	  straight	  line	  
to	  calculate	  the	  heat	  of	  dilution.	  	  A	  constant	  value	  of	  0.1	  kcal/mol	  was	  obtained;	  this	  heat	  of	  dilution	  is	  negligible.	  
	   	  
	  
	  




Figure	  10-­‐12.	  Gel	  shift	  assays	  of	  hPERK	  (II-­‐IV)-­‐BiP	  FL	  complexes	  
(A)	  Purified	  hPERK	  (II-­‐IV)	  (11	  μM)	  and	  BiP	  FL	  (11	  μM)	  were	  pre-­‐incubated	  and	  analysed	  directly	  on	  a	  native	  gel	  (3-­‐
8%	  Tris-­‐Acetate).	   hPERK	   (II-­‐IV)	   and	  BiP	   FL	  were	   run	   alone	   (+	   buffer)	   as	   controls.	   	  No	   additional	   bands	   could	  be	  
discerned	  in	  the	  complex	  sample	  compared	  to	  hPERK	  (II-­‐IV)	  (blue)	  and	  BiP	  FL	  (red)	  control	  samples.	  
(B)	  Purified	  hPERK	  (II-­‐IV)	  (11μM)	  and	  BiP	  FL	  (11	  μM)	  were	  cross-­‐linked	  with	  a	  25-­‐fold	  molar	  excess	  of	  EGS	  prior	  to	  
analyzing	  by	  SDS-­‐PAGE	  (4-­‐12%	  Bis-­‐Tris	  gel).	  	  DMSO	  was	  used	  instead	  of	  EGS	  as	  a	  control.	  	  hPERK	  (II-­‐IV)	  and	  BiP	  FL	  
were	  run	  alone	  (+	  buffer)	  as	  controls.	  	  Once	  again,	  bands	  in	  the	  complex	  lanes	  can	  be	  attributed	  to	  hPERK	  (II-­‐IV)	  
(blue)	  or	  BiP	  FL	  (red)	  proteins.	  
	   	  
	  
	  




Figure	  10-­‐13.	  ΔEspP	  binding	  to	  BiP	  FL	  
(A)	   DSF	   was	   used	   to	   test	   for	   ΔEspP	   peptide	   (MKKHKRILALCFLGLLQSSYSAAKKKK)	   (+	   5mM	   ADP,	   10	   mM	  MgCl2)	  
binding	   to	   BiP	   FL.	   	   The	   Tm	   of	   BiP	   FL	   is	   not	   significantly	   affected	   by	   the	   presence	   of	   ΔEspP	   suggestive	   of	   no	  
interaction.	  
(B)	  ΔEspP	  (500	  μM)	  (+	  5mM	  ADP,	  10	  mM	  MgCl2)	  was	  titrated	  into	  BiP	  FL	  (55	  μM)	  (VP-­‐ITC	  MicroCalorimeter).	  	  The	  
data	  was	  integrated	  and	  fitted	  to	  a	  one-­‐binding	  site	  model.	  	  The	  association	  constant	  (Ka),	  changes	  in	  enthalpy	  (∆	  
H)	   and	   entropy	   (∆	   S)	   and	   stoichiometry	   (N)	   values	   obtained	   are	   shown.	   	   Dissociation	   constants	   (Kd)	   were	  
calculated.	  ΔEspP	  does	  not	  bind	  to	  BiP	  FL.	  
	   	  
	  
	  







Figure	  10-­‐14.	  Oligomeric	  state	  of	  hPERK	  (II-­‐IV)	  and	  hIRE1	  (II-­‐IV)	  in	  complex	  with	  ΔEspP	  
(A-­‐B)	  SEC	  MALS	  analysis	   (Superdex	  200	  PC	  3.2/30	  column)	  of	   (A)	  hPERK	  (II-­‐IV)	   (100	  μM)	  and	  (B)	   IRE1	  (II-­‐IV)	   (100	  
μM)	   with	   or	   without	   ΔEspP	   (100	   μM).	   	   The	   calculated	   MW	   of	   the	   peaks	   obtained	   is	   indicated.	   	   In	   both	  






	   	  
	  
	  











Figure	  10-­‐15.	  ΔEspP	  does	  not	  induce	  dissociation	  of	  BiP	  FL-­‐hPERK	  (II-­‐IV)	  and	  BiP	  FL-­‐hIRE1	  (II-­‐IV)	  complexes	  
His6-­‐BiP	  FL	  was	  pre-­‐incubated	  with	  untagged	  hPERK	   (II-­‐IV)	   (lane	  3-­‐4)	  or	  untagged	  hRE1	   (II-­‐IV)	   (lane	  5-­‐6)	   to	   from	  
His6-­‐BiP	  FL-­‐luminal	  domain	  complexes.	  	  ΔEspP	  was	  then	  added	  (lanes	  4	  and	  6).	  ΔEspP	  does	  not	  have	  a	  discernable	  
effect	   on	   the	   association	   of	   the	   luminal	   domain	   proteins	   with	   His6-­‐BiP	   FL	   in	   pull	   down	   assays.	   	   In	   control	  
experiments	  the	  untagged	  proteins	  only	  were	  incubated	  with	  TALON	  resin	  (lanes	  1-­‐2).	  	  The	  MW	  (kDa)	  is	  indicated.	  
	  
	  
